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Abstract 
A prospective study of 1540 colorectal cancer cases aged 16 -79, diagnosed in Scotland between 
3`d January 2002 and 31s` December 2003 was conducted. 
Aims 
The main aims are: 
Report the number and proportion of cases that perceive they have a family history risk of 
colorectal cancer. 
Compare waiting time with symptoms and behaviour after development of symptoms, between 
cases that perceive a family history risk and do not perceive a family history risk. 
Report the number and proportion of cases in this cohort with a family history of colorectal 
cancer that meet Scottish clinical criteria for high or moderate family history risk. 
A secondary aim is: 
Describe the average delay time in symptom presentation and the factors contributing to delay in 
presentation of lower gastrointestinal symptoms among cases with colorectal cancer and in 
particular assess the importance of deprivation and comorbidity. 
Results 
The distribution of sex and age at diagnosis were similar to other published population -based 
colorectal cancer studies. Of the 1540 cases, 222 (14.9 %) cases perceived they had a family 
history of colorectal cancer. 
280 (18.2 %) cases out of 1540 were at a high or moderate family history risk according to 
Scottish Executive Guidelines. Of these 280 cases, 133 (47.5 %) perceived they had a family 
history of colorectal cancer. Of these 133 cases, only 51 (18.2 %) discussed this concern with their 
GP and, only 12 (4.3 %) were referred to cancer genetic services. 
Cases that perceived a family history risk of colorectal cancer were more likely to state they have 
knowledge of colorectal cancer symptoms and more likely to think that the lower gastrointestinal 
symptoms they develop are symptoms of colorectal cancer. However, this knowledge does not 
prompt them to visit the GP with less delay after development of symptoms than those cases 
with no perception of a family history risk of colorectal cancer. 
There was no association found between deprivation, comorbidity and timing of presentation 
following development of symptoms. 
The more deprived group of patients were significantly more likely to report no knowledge of 
colorectal cancer symptoms. They were also less likely not to inspect the toilet or the toilet paper 
before flushing. 
Implications for Health service 
Providing all health professionals with the knowledge and skills to take a family history and to 
follow published guidelines when assessing family history risk would share the responsibility for 
identification of individuals with a high or moderate family, improve the appropriateness of 
referrals and reduce the inequality in access to cancer genetic services. It is estimated from this 
study that each year there will be 49 families in the colorectal cancer population at high risk 
eligible for mismatch repair gene analysis and 196 of their first- degree relatives that require two - 
yearly colonoscopy. In addition there will be 446 at moderate risk and eligible for microsatellite 
testing and 1784 first- degree relatives of these cases that require a colonoscopy at age 35 and 55 
years. 
The most deprived group of patients have the least knowledge of colorectal cancer symptoms 
and the design of educational material should acknowledge this fact and ensure that it is 
appropriate for this audience. 
Conclusion 
GPs do not appear to routinely use published guidelines to assess the family history of cases with 
colorectal cancer. The most affluent group are more likely to be aware that family history is a risk 
factor for colorectal cancer and those that discuss their concern of family history risk are more 
likely to be referred to cancer genetic services. These findings suggest that inequality in access to 
the cancer genetic services exists. 
Individuals in Scotland, that perceive a family history of colorectal cancer are not prompted by 
the development of lower gastrointestinal symptoms to visit their GP more quickly, nor does this 
knowledge change their behaviour in discussing symptoms with other people, self -treating 
symptoms, inspecting the toilet and toilet paper before flushing, even though they are more likely 
to perceive that they have colorectal cancer before visiting their GP. 
There appears to be little differences in presentation and development of lower gastrointestinal 
symptoms or association with comorbidity between the most affluent and most deprived groups 
suggesting that socioeconomic status and comorbidity have little effect on behaviour after 
development of lower gastrointestinal symptoms. 
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I have been employed as a genetic nurse specialist since 1997 and have a major research 
interest in cancer genetics and the development of cancer genetic practice. I have had 
several papers published from these research projects see (Appendices 1 -5). 
Prior to this PhD research study, my main previous research experience has been in 
colorectal cancer. I recruited cases diagnosed with colorectal cancer (under the age of 
55) to the Colorectal Cancer Genetic Susceptibility study (COGS), commenced in 1999. 
I was also the lead nurse in a three -year research study, the findings which led to the 
current clinical service model implemented in SE Scotland for individuals with a family 
history of cancer. I gained further relevant research experience during another 
community -based cancer genetic research project. In this study many individuals with 
colorectal cancer and their immediate family were seen for family history consultations. 
In parallel to this research experience, as genetic nurse specialist, I have my own weekly 
nurse led cancer genetic clinic. I have continued to deliver these clinics throughout the 
period of research leading to this PhD. 
In all cases each consultand or study recruit had a detailed family history taken. It 
appeared to me that socioeconomic status might contribute to the understanding of the 
consultand's own family history risk and whether they discussed this perceived risk with 
their GP. Through my own experience and hearing the experiences of my colleagues I 
concluded that very few individuals with colorectal cancer were ever referred to the 
service, the majority of referrals being unaffected relatives of colorectal cancer cases. 
Recent changes in cancer genetic services have led to mutation analysis and gene testing 
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being available for some families; however, this is only available when there is DNA 
from an individual with colorectal cancer. 
Prior to embarking on this PhD my colorectal cancer research experience was limited in 
a number of ways: the number of cases seen, the restricted age of cases seen 
(predominantly less than 55 years of age at diagnosis) and the geographical area was 
restricted to South East Scotland. 
In defining the scope for my research I chose to focus on two main areas: 
1. Family history and perceived family history risk, discussion of perceived family 
history with GP, family history risk (as assigned by established clinical 
guidelines) that are identified by the GP and referral patterns to cancer genetic 
services. 
2. The timing of presentation with lower gastrointestinal symptoms to a GP and 
association between comorbidity or deprivation and the effect they may have 
on the waiting time with these symptoms before visiting a GP. 
I was awarded a three -year research training fellowship from the Chief Scientist Office 
at the Scottish Executive, which commenced in January 2001. During this fellowship 
the research for this thesis was undertaken. Limited research has been published on 
family history risk of colorectal cancer cases as assigned by established clinical 
guidelines, perceived family history risk and referral of the cases with high and moderate 
family history risk to the cancer genetic services. 
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A family history of colorectal cancer is a known risk factor for developing colorectal 
cancer and referral guidelines to assist GPs in making a referral to cancer genetic 
services have recently been published and disseminated. 
There is wide published literature on presentation patterns of individuals with lower 
gastrointestinal symptoms that are suspicious of colorectal cancer. Little research has 
been published on the association of comorbidity and deprivation after a diagnosis of 
colorectal cancer or the effect of comorbidity and deprivation on the reporting of 
symptoms. 
There are no large population based studies of colorectal cancer in Scotland that have 
reported on symptom presentation associated with comorbidity and relationship to 
deprivation. 
My role in this research study 
I trained a team of research nurses to recruit and collect the data for this study. I 
personally recruited 5% of the cases. Recruitment took place as part of the Study of 
Colorectal Cancer in Scotland (SOCCS). 
My contribution to this study is as follows: 
o Development of the case information sheet and consent forms for MREC 
ethics application. 
o Production and delivery of training programme for research nurses for the 
SOCCS study. 
o Visits to each Scottish hospital to ensure that key staff where aware of the 
study, (by delivery of a presentation or personally meeting key staff). 
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o Development of standard operating procedures for recruitment in each 
hospital. 
o Production of recruitment policies and data recording forms for all data 
collection in the SOCCS study. 
o Development of the following data collection tools: 
The symptom interview, 
Ethnicity and ancestry questions in the SOCCS Cancer and Lifestyle 
questionnaire, 
The medical data extraction form 
The comorbidity form for recording data relevant to the comorbidity 
index. 
o Appointment and the ongoing training of research nurses, reappointment 
and training of nursing positions throughout the time of the study. 
o Provision of additional training and supervision required by staff recruiting to 
COGS study. 
o Appointment of medical students and training of nurses and medical students 
to extract information from medical notes. 
o Liaison in all hospitals with audit and medical records departments to 
monitor ascertainment and for the medical students and research nurses to 
gain access to medical notes. 
o Ongoing management of research nursing team. This was achieved by one to 
one supervision of all nurses and regular nurse team meetings. 
o Monitoring of recruitment in each hospital and problem solving in any 
hospital where access to eligible cases was difficult or recruitment appeared 
to be below the expected numbers. 
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o Completion of the genetic risk assessment on all family histories and writing 
a risk letter to cases assigned to have at moderate or high -risk family history 
(using Scottish guidelines). 
o Overseeing the development of data scanning and data checking with the 
administrative team. 
It was key to the collection of good quality data that the nursing team were well trained, 
offered ongoing support throughout the study and encouraged to undertake a research 
academic module and a cancer genetic module to enhance their knowledge and skills. I 
undertook this management and mentoring role of the research nurses in this study. 
Data Collection 
The data collection for this study was within a large DNA sample collection (see 
methodology). 
Family history 
A research nurse collected family history information in a face -to -face interview at 
recruitment. The pedigree was drawn on a standard family history form and a minimum 
of three generations was recorded. 
Symptom interview 
The symptom data was collected using a structured interview. The family history 
information and symptom interview was completed by the SOCCS research nurses 
throughout Scotland, as follows: Sheena Ross, Alison Ogilvie, Lisa McAuley, Daniela 
Rae, Jackie Kerrigan, Eleanor Russell, Janet Chauhan, Sheila Slater, Pamela Dalrymple, 
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Lisa Ferguson, Jenny Rodgers, Catherine Johnstone, Derek Baker, Tracey Millar, Louise 
McKenna, Karen Delahunty, Elaine Pagan and Isobel Williams. 
Medical records 
The information from medical notes was extracted either by the research nurses in the 
smaller hospitals or by the following trained medical students in the larger city hospitals; 
Lisa Massie, Jennifer Browning, Lois Tait, Yen Um, Rachel Gardner, Chloe Keane, 
Kerry Hunter, Asma Kamal, Lynda Guthrie, Suzanne Price, and Sherry Zaman. 
Data Entry 
Family history 
The family history was recorded on the standard form used by South East of Scotland 
cancer genetic service. I assessed the family history risk using published Scottish 
guidelines and risk entered on to a database by Maureen Edwards or Christine 
Thompson. 
Symptom interview 
I initially designed the final symptom interview using Microsoft Word and it was then 
translated using Teleform software package into a Teleform by Maureen Edwards this 
form could then be recognised by the Teleform reader when scanned. I checked all 
symptom interviews for errors, illegible handwriting and other items that might have 
caused problems with scanning. Dorothy Thompson carried out scanning of all 
symptom interviews. Dorothy Thompson and I carried out the checking of all scanned 
data entry via Teleform software. 
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Medical records and comorbidity form 
I checked all completed medical records forms for missing data and other inaccuracies, 
prior to entry on database by Gisela Barr. 
Pathology report 
I confirmed that the case met eligibility criteria by reviewing the pathology reports when 
returned with medical records form. 
Statistical analysis 
Susan Holloway and Niall Anderson gave support with data analysis. Susan carried out 
power calculations and data analysis for the association of comorbidity and deprivation 
with symptoms waiting times. Niall developed the models for Cox Proportional Hazard 
modeling. I assisted in these analyses and independently carried out all other statistical 
tests in this thesis. 
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Chapter 1 




The initial literature search for this study was completed during January 2001 and end of 
December 2001. The development of the research questions and data collection tools 
began after the initial literature search was complete. The literature searching continued 
throughout the data collection period and the writing of this thesis. During the data 
collection period some databases became obsolete or combined with other databases. 
All databases were searched on a regular basis for new publications using previously 
created search strategies. Some database providers offer a service to run your chosen 
search strategies and email the results on a regular basis. This service was activated 
when possible. In addition, requests were made to each relevant journal to have the 
table of contents emailed as they became available. 
Literature Databases 
The following databases were searched in the initial literature search: 
o Medline from 1966 
o Web of Science from 1981 
o Cinhal from 1980 
o CancerLit from 1975 
o Embase from 1985 
o Assia Plus from 1982 
o Cochrane database from 1975 
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Where possible, database searches were limited to non- Medline references. Searches 
were limited to English abstracts and studies on humans. When it was possible 
duplicates were filtered from source. 
Key areas and Keywords 
The main key search topics in this thesis are family history, symptom presentation, 
comorbidity and deprivation. During this literature searching, all searches where carried 
out using keyword from each area and using the keywords colorectal, colon, rectal, 
bowel or colo- rectal and cancer, carcinoma or neoplasm (and all associated mesh 
headings). 
The following is an expansion of relevant keywords for each area of study. 
Family History 
o Family history, 
o Cancer family history, 
o Risk assessment, 
o Accuracy of family history, 
o Family history guidelines, 
o Family history criteria. 
Symptom presentation 
o Symptom presentation, 
o Delay in symptom presentation, 
o Delay in symptom or diagnosis, 
o Symptom reporting, 
o Duration of symptoms, 
o Guidelines, 
o Patient delay. 
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Cornorbidity 
o Comorbidity or co- morbidity, 
o Concurrent disease, 
o Comorbid disease or conditions. 
Deprivation 
o Socioeconomic or socio- economic, 
o Socioeconomic or socio- economic status, 
o Socioeconomic or socio- economic factors, 
o Socioeconomic or socio- economic position, 
o Socioeconomic or socio- economic environment, 
o Deprivation, 
o Inequalities, 
o Material deprivation, 
o Deprivation indices, 
o Demographic factors, 
o Social deprivation or class, 
o Income inequality. 
Within each search strategy all references were screened, when a paper appeared to be 
of relevance the abstract and references from that paper (if possible) were chosen and 
read. 
One relevant paper with an English abstract but full text in Dutch was translated and 
referenced in this thesis. 
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Literature search results 
The following information is the numerical results of the initial literature search from 






























Many secondary references were sources from the reference list of a paper. The 
abstracts for these new references were read (if available) and when appropriate the full 
text was read, when no abstract was available full text was sourced. These main types of 
secondary references sourced from papers and included reports, editorials poster 
presentations and newsletter articles. 
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In addition to literature searching and secondary references as a source of evidence for 
this thesis, contact was made with a UK Colorectal Surgeon with a research interest in 
colorectal cancer symptoms. Contact was made with experts in Scotland if they had 
declared a research interest in the areas of deprivation and /or inequalities in health. 
Genetic units within UK were contacted for any unpublished information on ongoing 
family history studies. Following interactions with these experts, access was granted to a 
section of a thesis examined in London University, on `colorectal cancer statistics in 
Scotland'. Two unpublished book chapters were received and permission to reference 
the material in this thesis was granted by one author, and a request not cited in my 
thesis, by the other. In addition, 2 unpublished papers were given but again 
confidentiality was requested. No material or data was received from genetic units; 
however the author is currently involved in a Scottish audit of breast, ovarian and 
colorectal cancer family history. Although the author could access these data, the data 
collection is not yet complete nor has any data cleaning been carried out. 
Selection Criteria 
Family history 
Papers were chosen for reading when an abstract indicated that a study had included any 
form of family history criteria in the data collection. Also included, were papers that 
discussed the accuracy of family history data collection. 
Symptom presentation 
Papers were chosen for reading when an abstract indicated that the study had analysed 
data on presenting to a GP with any lower gastrointestinal symptoms. Also papers were 
selected when the abstract or titled mentioned use of guidelines. 
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Deprivation 
Papers were chosen for reading when an abstract indicated that the study had a focus on 
any aspect of deprivation; non -- Scottish studies were restricted to colorectal cancer 
included in a study. When Scottish studies indicated that aspects of deprivation were 
studied this was not restricted to colorectal cancer studies only but to any site of cancer. 
Comorbidity 
Papers were chosen for reading when an abstract indicated that studies were using any 
comorbidity index and related the use of the index to any cancer site. 
Not all full text papers read were used in the final thesis. 
29 
Chapter 2 
Introduction to Incidence of Colorectal Cancer 
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Colorectal cancer incidence 
Colorectal cancer is principally a disease of economically developed populations. Low 
incidence is found throughout Central and South America, Asia and Africa. High 
incidence of colorectal cancer is found in Europe, Australia and North America. This 
high incidence has a major impact on health and use of health resources. The incidence 
of colorectal cancer increases with age and as the average life span for males and 
females is increasing the burden of disease from this condition increases accordingly. 
Concerns regarding differences in incidence and survival throughout Europe led to the 
establishment of a collaborative project. In 1990, European cancer registries agreed to 
share data in the EUROCARE' project. EUROCARE -3 now has 76 participating 
cancer registries. Eleven are National registries covering the entire populations. Sixty - 
five are regional and cover only a percentage of their country's population with coverage 
varying from 3% to 62% of the population. 
The purpose of the EUROCARE project is to estimate and compare the cancer survival 
in European populations. The current EUROCARE database contains data on 
incidence and life status of cancer patients diagnosed from 1978 -1994 with follow up 
data until the end of 1998. The EUROCARE -1 project reported on survival between 
1978 and 1985, EUROCARE -2 project reported on cancer patients diagnosed between 
1985 and 1989 and the current EUROCARE -3 project has published survival data for 
cancer patients diagnosed in 1990 -1994. The publications from this project have 
highlighted the marked differences in incidence, mortality and survival of colorectal 
I EUROCARE is a group of European epidemiologists and biostatisticians , funded by Biomed. They have collected data from 50 countries and 19 
cancer registries from 1978 -1995. 
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cancer in Europe. The EUROCARE project has been criticised for the differences in 
the data collection methods, the varied quality of data provided by the registries and the 
differing methodologies used in the analysis (Woodman et al 2001). 
Worldwide Incidence 
Internationally it is the fourth highest cause of cancer deaths in men and women. 
Figure 1 illustrates the worldwide number of cases and deaths from the more common 
cancers. 
Figure 1 World number of cases with common cancers, by sex. 












(Adapted from GLOBOCAN 2002, IRAC). 
Colorectal cancer has the 4`'1 highest incidence of common cancers in males and the 3rd 
highest incidence of common cancers in women. Figure 2 below, demonstrates that 
Scotland has a higher incidence for colon cancer than most other European countries. 
However, the incidence in Scotland is lower than in USA, Singapore, France, Germany, 
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Australia and New Zealand. Throughout the world there is a higher incidence of colon 
cancer than rectal cancer. The incidence of rectal cancer in Scotland is similar to most 
European countries and USA. 













US (SEER: White) 
France (Bas -Rhin) j 
Australia (Victoria) 
New Zealand (Non -Maori) _f 
Colon Cancer Rectal cancer 
1 
t L 
0 5 10 15 20 25 30 0 5 10 15 
Rate per 100 000 Rate per 100 000 
20 25 30 
Adapted from Cancer Incidence in Five Continents, Volume VII (1997) 
Incidence in Europe 
The EUROCARE project covers all cancers and information on colorectal cancer 
incidence, comparing Scotland with England and Wales and two Scandinavian countries 
can be seen in Table 1. 
2 Defined here as ICD10 C18 -C21 
3 The Netherlands data includes the period 1989 -92, England and Wales includes 1988 -90, Spain indudes 1986 -90 and Finland includes 1987 -92 
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Table 1 Incidence of colorectal cancer per 100, 000 based on 
cancer registration in 1995, (standardised to the world 
standard population), by sex 
Males Females 
Scotland 41.1 29.6 
Denmark 37.8 28.6 
England and Wales 35.7 27.8 
Finland 26.5 19.2 
Sweden 29.4 22.9 
(Gatta et al 1998) 
Table 1 shows that Scotland has a higher incidence than comparable European 
countries. It is recognised that cross -country comparisons are flawed and the results can 
be difficult to interpret due to variation in data quality and variation in definition of 
malignancy. Therefore, bias may be introduced by sub national cancer registration 
(Berrino et al 2001). 
Incidence in England and Wales 
Colorectal cancer is the third most common cancer in males and second most common 
cancer in females in England and Wales. England and Wales incidence, mortality and 
survival data in this thesis are taken from the Office of National Statistics (ONS 2004). 
England 
In 1997, a diagnosis of colorectal cancer was made in 28,900 individuals; it occurs more 
frequently in males and incidence has continued to increase for both sexes. Within the 
colorectal figures 63% of cases were diagnosed as colon cancer and 37% as rectal 
cancer. 
Between 1971 and 1997 the overall standardised incidence in males rose by 30% for 
colon cancer compared with an increase of 6% in rectal cancer over the same period. 
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The female colon cancer incidence is approximately twice that of rectal cancer in 
females (Quinn et al 2001). 
Wales 
In Wales, the incidence is published separately for colon and rectal cancer. The 
incidence is higher in males for both colon and rectal cancer. Colon cancer is the third 
most common cancer in both sexes. During 1992 -2001 colon cancer was responsible for 
8.4% of all male cancers and 8.5% of all female cancers. There were 640 males and 570 
females diagnosed with colon cancer in 2001. In recent years, there has been a slight 
decrease in colon cancer incidence in females but not in males. 
Rectal cancer was the fifth most common cancer in both sexes during 1992 -2001 and 
was responsible for 6.1% of all male cancers and 4.1% of all female cancers. There were 
440 males and 293 females in 2001 diagnosed with rectal cancer (Welsh cancer 
intelligence unit, 2003). 
Incidence in Scotland 
Colorectal cancer 
In Scotland, colorectal cancer (cancer of colon and rectum together) is ranked as the 
third most frequent cancer diagnosed in both sexes. Of all cancers diagnosed in 
Scotland, colorectal cancer is responsible for 15.1% in males and 12.2% in females. 
There is a higher incidence of colorectal cancer in males. During 1990 to 1999 there has 
been a 22.8% increase in male incidence and only 2.4% increase in females. Figure 3 
illustrates the number of males and females in Scotland for over this period. 
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Figure 3 Number diagnosed with colorectal cancer in Scotland 
(1990 -1999) 
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(Adapted from ISD 2003) 
Forty five percent of patients with colorectal cancer are over 75 at diagnosis and the 
population is ageing. Therefore over the next decade, the incidence of colorectal cancer 
in Scotland is not expected to decreased . 
Colon cancer 
In Scotland, colon cancer is responsible for 9.2% of all cancers diagnosed in males and 
8.7% in females. In 1999, 1,124 females and 1,083 males were diagnosed with colon 
cancer. Although females have a greater incidence of colon cancer, it has fallen by 2.8% 
in the decade 1990 -99. In contrast, male incidence of colon cancer increased by 14.9 %. 
Rectal cancer 
In Scotland, rectal cancer is responsible for 5.9% of all cancers diagnosed in males and 
only 3.5% in females. 
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Rectal cancer in males has a much higher incidence than in females and in 1999, 69% of 
cases were males. During 1995 to 1999, there has been an alarming increase in incidence 
of rectal cancer with an increase of 37.9% in males and of 17.1% in females. 
When colorectal cancer is divided into colon and rectal a different sex pattern emerges. 
Females have a higher incidence of colon cancer, although this is changing slightly due 
to falling incidence in females and a rising incidence in males. In rectal cancer there is a 
wide gap between males and females. Figure 4 shows the incidence of colorectal cancer, 
colon cancer and rectal cancer 1995 -1999. 
Figure 4 Number of cases diagnosed with colorectal cancer, colon and rectal 
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(Adapted from ISD 2003) 
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When a comparison of incidence in Scotland, England and Wales is made there are clear 
differences in incidence, as shown in table 2. 
Table 2 Crude incidences per 100,000 for England and Scotland' 
1999 and Wales in 2000' 
Cancer site 
Scotland England Wales 
Males Females Males Females Males Females 
Colon 43.6 42.- 35.9 35.8 45.1 39.8 
Rectal 27.9 17.3 24.5 16.8 32 18. ' 
(ISD 2003, ONS 2004) 
The highest male incidence of colon cancer is in Wales and highest female incidence in 
Scotland. Wales has the highest rectal cancer incidence for both sexes. 
4 Data extracted from Office for National Statistics website (www.statistícs.gov.uk) 
5 Data extracted from Scottish Cancer Registry, Information and Statistics Division (www.show.scot.nhs.uk) ISD online 
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Chapter 3 
Introduction to Mortality from Colorectal 
Cancer 
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Colorectal cancer mortality 
In most European countries mortality from colorectal cancer had been decreasing over 
recent years. Figure 5 indicates the colorectal cancer international mortality rates in 1995 
by sex. 
Figure 5 Colorectal cancer: International comparisons of mortality rates 
(world standard population), by sex: 1995 
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(Adapted from CRAG 2000) 
International comparison rates show that Scotland had a similar mortality rate to 
England, Wales, Germany and Denmark, but much greater mortality than the USA 
where the incidence is greater than most European countries. 
England and Wales 
In the year 2002, colorectal cancer was responsible for 10% of all cancer deaths in the 
UK, second only to lung cancer. It is responsible for 11 % of all cancers in men and 
10% of all cancers in women. 
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England 
When compared to all common cancers in the year 2002, colorectal cancer had the third 
highest mortality rate for males and fourth highest for females. Colorectal cancer 
mortality in both sexes has fallen steadily since the 1950s. Colon cancer mortality has 
declined by 53% in females during this period to reach a level of 12 per 100,000 in 1999. 
In the 1950s, colon cancer mortality in males was 24 per 100,000; this had dropped to 
16 per 100,000 by 1999. The decrease in mortality for males is less than for females. By 
1999, rectal cancer mortality had fallen by 56% to 9 per 100,000 in males and to 5 per 
100,000 in females. The overall decrease in mortality masks a slight rise in male 
colorectal cancer mortality in the age group 85 and over. 
Wales 
Wales has seen a reduction in colorectal cancer mortality rate for both sexes. However, 
of all cancers, colorectal cancer is the second most common cause of cancer death in 
Wales, a higher ranking than in both Scotland and England. 
Scotland 
In Scotland, colorectal cancer has shown a minimal decrease in mortality rate. The crude 
mortality rate reported for colorectal cancer in 1992 was 34.6 per 100,000 and was 34.3 
per 100,000 in 2001. Mortality rate decreased between 1960 and 1999 except for male 
rectal cancer, which after an initial fall, continued to rise to levels previously seen in the 
early 1960s (Gray et al 2002). The largest fall in colorectal cancer mortality rate is seen 
within the first year after diagnosis. 
41 
Scotland has a higher mortality rate than England and Wales in both sexes for rectal 
cancer and mortality rates are only marginally better than Wales for female colon cancer. 
These higher mortality figures in Scotland reflect the high incidence and the lower 
survival rates. Table 3 compares the crude colon and rectal cancer mortality rate per 
100, 000 for males and females in year 2000 for Scotland, England and Wales. 
Table 3 Colon and rectal cancer crude mortality rates, per 100,000 
for England, Scotland and Wales in 2000 
Cancer 
site 
Scotland England Wales 
Male Female Male Female Male Female 
Colon 21.2 20.4 19.5 18.7 26.2 21.8 
Rectal 13.3 8.4 10.5 7.5 10.7 7.7 
(ISD 2003 and ONS 2004) 
Despite decreasing mortality rates in the UK, there still remain differences between 
England, Wales and Scotland. Wales had over 6% higher mortality rate than England 
and 5% higher than Scotland for male colon cancer. Scotland has a 3% higher mortality 
in male rectal cancer than England and Wales. 
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Chapter 4 
Introduction to Survival from Colorectal Cancer 
43 
Colorectal cancer survival 
Population based survival estimates are a key indicator of the overall effectiveness of 
healthcare systems in managing cancer patients. Stage of disease at diagnosis is an 
important factor in survival (Mulcahy & O'Donaghue 1997, England et al 1998); 
therefore, every country is striving to diagnose colorectal cancer at an early stage to 
improve survival rates. 
International and European survival 
The Surveillance, Epidemiology, and End Results (SEER) Program of the National 
Cancer Institute is an authoritative source of information on cancer incidence and 
survival in the United States. The SEER Program currently collects and publishes cancer 
incidence and survival data from 14 population -based cancer registries and three 
supplemental registries, covering approximately 26 percent of the USA population. The 
SEER registries routinely collect data on; patient demographics, primary tumour site, 
morphology, stage at diagnosis, first course of treatment, and follow -up for vital status. 
Survival rates show marked differences between SEER and EUROCARE projects, for 
most cancers and in particular in the older age group. 
In colorectal cancer the survival gap by age was not as great as seen in other cancers that 
have a higher prevalence in the older age group. This implies that lower survival in 
Europe cannot be explained by age related biological factors, such as comorbidity, 
immune function and responsiveness to drugs (Coleman et al 2003). The greatest 
survival rate for colorectal cancer is seen in the first six months after treatment; 
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suggesting that there are effects from stage at diagnosis and /or access to optimal care 
(Sant et al 1995, Gatta et al 2000). 
Survival in adult cancer falls with age even after adjustment for mortality from other 
causes. Although not so marked in colorectal cancer, there is an age survival difference. 
The five -year relative survival rate of the group aged 15 -44 is 59% compared to those 
aged 75 and over who have only 42% survival rate. 
Colorectal cancer five -year relative survival rate for males diagnosed in 1990 -94 in the 
EUROCARE -3 project, have a much wider range than the areas covered in the SEER 
dataset within USA. The highest survival rate in EUROCARE -3 did not reach the 
lowest survival rate in SEER. The EUROCARE-3 range is 27 -55% and SEER range is 
60 -65% (Coleman et al 2003). It should be noted that SEER do not publish age 
standardized survival rates. 
Figures 6 and 7 show the five -year relative survival rates of colon and rectal cancer for 
people from European countries where the cancer registry coverage is 100 %, with the 
exception of England where the coverage is 63 %. These figures are compared to the 
overall European five -year survival rate. 
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Figure 6 Five -year relative survival rates ( %) of colon cancer for those 
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(Adapted from Sant et al 2003) 
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Figure 7 Five -year relative survival rates ( %) of rectal cancer for those 
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(Adapted from Sant et al 2003) 
England and Wales 
Survival in England and Wales from colon and rectal cancer has improved over time but 
only a small impact on five -year relative survival rate was achieved. Table 4 
demonstrates the increase in survival over two five -year periods. 
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Table 4 Five -year relative survival rate by site of colorectal cancer 
and by sex for England and Wales combined. 
Site 
Five year survival rate 
1991 -1995 1996 -1999 
Colon Male 42% 47% 
Female 43% 48% 
Rectal Male 40% 47% 
Female 45% 51% 
(Rowan & Brewster 2004) 
Survival from colorectal cancer has shown a smaller age difference than many other 
cancers. Five -year relative survival in 1999 from colon cancer in those aged 40 -79 was 
approximately 50% and for those age 80 -99 approximately 35% with little difference 
between the sexes in all age groups (Quinn et al 2001). 
Scotland 
Despite continued improvement in survival rates in Scotland, three in five colorectal 
cancer patients die as a direct result of their cancer within five -years of diagnosis. 
Survival rates have been improving since 1971; however, survival rate decreases with 
increasing age in both sexes. Survival rate is more favourable in young females. 
Survival at one -year for colon cancer in 1971 was 44% and increased to 66% by 1997. 
Five -year survival in 1971 was 28% and increased to 45% in 1997. Rectal cancer one - 
year survival in 1971 was 54% and increased to 71% in 1997. The five -year survival in 
1971 was 28% and increased to 44% in 1997. Six years after diagnosis, colon cancer 
patients revert to the population survival risk. However, rectal cancer patients continue 
to die from this cancer for more than 10 years after diagnosis. These figures have 
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continued to improve as shown in table 5. Females have better survival rates in all sites 
with the greatest advantage seen in rectal cancer. 
Table 5 One -year and five -year relative survival rates in Scotland 
Cancer site 
One year survival Five year survival 
Males Females Males Females 
Colorectal 
Diagnosed 1991 -95 673 65.5 44.1 45.1 
Colon 
Diagnosed 1996 -98 79.7 67.2 48.8 48.9 
Rectal 
Diagnosed 1996 -98 74.8 763 48.3 51.9 
(ISD 2003) 
In 1997, one -year survival in females with rectal cancer was marginally higher that males 
with rectal cancer. Figure 8 illustrates the one and five -year relative survival rates in 
England, Wales and Scotland, Europe. 
Figure 8 One -year and five -year relative survival rates in England, Wales, 
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(Adapted from IRAC 2000) 
Figure 8 demonstrates that England, Wales and Scotland have poorer one and five -year 
survival rates than Europe. Although survival rates are increasing in Scotland, England 
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and Wales they still remain below survival rates in many other European countries, 
which in turn, have much lower survival rates than the USA. 
Survival and tumour staging 
Colorectal cancer is given a stage to represent the extent of the disease and as an 
indicator of prognosis. There is an internationally recognised classification known as 
Dukes' staging. Sir C.E. Dukes, a British pathologist, created this in 1929 for rectal 
cancer. Simpson and Mayo modified Dukes' scheme for colon cancer in 1939. This 
system graded the tumours at three different stages, Dukes' A, B and C. Astler and 
Coller in 1967, made further modifications to include stage D, for distant metastasis and 
inoperable cancers. The Dukes' staging system and its modifications are still in use by 
many clinicians. In 1998, the Tumour, Node and Metastasis (TNM) system was 
modified to correspond with the Dukes' system. More recently, the American Joint 
Committee on Cancer updated the TMN staging system. A summary of the Dukes' and 
the TNM staging systems, used in Scottish pathology laboratories can be seen in 
(Appendix 6). 
Dukes' stage and survival 
Dukes' stage is one of the most powerful predictors of survival from colorectal cancer. 
Five -year relative survival with a tumour staged Dukes' A is 85 %, Dukes' B is 65 %, 
Dukes' C is 40% and Dukes' D is <5% (Mulcahy & O'Donoghue 1997). Therefore, 
earlier diagnosis of colorectal cancer should reduce mortality and increase survival rates. 
However, this may be difficult to achieve. The nature of colorectal cancer is such that 
some tumours may not present with symptoms until at an advanced Dukes' stage (Dent 
et al 1983). Few publications compare Dukes' stage of tumour between countries, as this 
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is not normally collected in cancer registries. The EUROCARE project is addressing 
this with the development of high- resolution studies, which have requested 
incorporation of Dukes' stage into all cancer registries. 
Distribution of Dukes' stage in Europe 
Gatta et al (2000) published data from a EUROCARE high- resolution study; this study 
comprises of a selection of 11 registries that were asked to supply a representative 
sample of at least 200 consecutive colorectal cancer patients from those diagnosed in 
1990 or over the period 1989 to 1991. The results of this study were presented with the 
Dukes' staging A and B combined into one group. 
Table 6 illustrates the highest and lowest percentages for each Dukes' stage of tumour 
found at diagnosis in European countries that are involved in the EUROCARE project. 
Table 6 Dukes' stage ( %) at diagnosis from EUROCARE 
high- resolution study on colorectal cancer 
Dukes' stage Distribution of Stage at diagnosis ( %) 
Highest Lowest 
A & B 58% Rotterdam, The Netherlands 21% Cracow, Poland 
C 25% Cote d'Or, France 18% Cracow, Poland 
D 27% Varese, Italy 14% Cote d'Or, France 
(Gatta et al, 2000) 
These figures illustrate the marked differences between European countries. There are 
numerous differences between the cancer registry populations making comparisons 
difficult to interpret (Woodman et al 2001). Gatta et al (2001) have published the 3 -year 
observed survival rate relative to Dukes' staging. It demonstrates the decline in survival 
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with more advanced Dukes' staging at diagnosis. Table 7 shows the large differences 
between countries in the initial staging of individuals at presentation. 
Table 7 Three -year survival ( %) by Dukes' stage at diagnosis from 
EUROCARE high -resolution study on colorectal cancer 
Dukes' stage Three year survival ( %) 
Highest surviving Lowest surviving 
A & B 85% Calvados, France 56% Cracow, Poland 
C 55% Cote d'Or, France 28% Varese, Italy 
D 25% Modena, Italy 6% Mersey(UK) & Cote d'Or 
(Gatta et al 2000) 
England 
Currently the distribution of Dukes' staging is not routinely published for England and 
Wales. The NHS has commissioned the development of a data set for all cancer patients 
in which Dukes' stage is included (www.nhsia.nhs.uk). 
The EUROCARE high- resolution study has shown little difference in the distribution 
of Dukes' staging in two areas of England. However, within these two areas there was a 
difference in the 3 year observed survival rates with specific reference to the unknown 
category, as seen in table 8. 
Table 8 Three -year survival in Mersey and Thames by Dukes' stage 
Dukes' stage Distribution of Dukes' stage Three years survival ( %) 
Mersey Thames Mersey Thames 
A & B 40 42 78 61 
C 23 24 48 30 
D 23 23 6 10 
Unknown 14 11 23 32 
(Gatta et al 2000 
Mersey had a higher survival rate for Dukes' stages A & B and C. Thames demonstrated 
an increased survival rate for those who did not have a staging. It is possible that 
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Thames has a high number of polyp cancers, which were not staged leading to an 
increased survival in this group and Mersey may have included these polyp cancers in 
their Dukes' stage A cancers. 
Scotland 
The Scottish Cancer Registry database includes Dukes' staging data and information was 
requested specifically for this thesis from the Information Services Division of the 
Scottish Cancer Registry. Data in this thesis may differ from other Dukes' stage 
published figures because the dataset is dynamic and changes as new information is 
received at the registry. Figure 9 indicates the colorectal cancer Dukes' stage distribution 
by year of diagnosis over a five -year period. (www.isdscotland.org) 
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(Adapted from ISD 2003) 
It can be seen from Figure 9 that over the period 1997 -2001 there was a slight increase 
in Dukes' stage A, a decrease in Dukes' stage B, little change in Dukes' stage C and an 
slight decrease from 1998 for Dukes' stage D. 
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There are a significant number of cancers with an unknown Dukes' stage. The numbers 
in the unknown stage category have increased over the years. Each year the numbers in 
the stage unknown group was higher than the number of Dukes' A tumours. The 
number with Dukes' A tumours in 2001, was 450 and the number with unknown 
staging was 601. The increased number of unknown cancers may indicate that more 
polyp cancers have been identified. This is feasible since the Faecal Occult Blood 
Testing (FOBT) pilot was introduced in the year 2000 in the Tayside, Fife and 
Grampian areas of Scotland. In the year 2000 the number of unknown staged cancers 
was 508 and this increased to 601 in 2001 and 632 in 2002. 
Summary of incidence, mortality and survival 
The incidence of colorectal cancer is increasing worldwide. Scotland has a lower 
incidence than United States of America as published by the SEER project, Australia, 
Germany and France. In the United Kingdom, Wales has the highest incidence of 
colorectal cancer in both sexes. Recent figures have shown been a decrease in incidence 
in Wales however they remian the highest incidence figures in the UK. In England, 
colon cancer incidence has increased more than rectal cancer. In Scotland, the 
incidence of rectal cancer is greater in males and the incidence of colon cancer is greater 
in females. 
In the United Kingdom, Wales has the highest mortality rate for colon cancer. Scotland 
has the highest mortality rate for rectal cancer. Throughout the UK mortality has fallen 
steadily in both sexes. England and Wales have shown a greater reduction in mortality in 
rectal cancer. Survival from colorectal cancer is increasing worldwide but there remain 
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large differences between European countries and SEER. In the United Kingdom, 
Wales has the poorest survival rates from colorectal cancer. 
The above data from the EUROCARE project include anal cancer and anal canal 
cancers, whereas the Scottish Registry data do not include anal cancers. 
Although there is a plethroa of statistics available from European and US databases on 
incidence, mortality and survival of colorectal cancer some caution should be exercised 
interpreting the results from cross country analysis for the reasons given below: 
o Data collectors Have difficulty in maintaining the quality of the data sent 
from each country. 
o The percentage of populations covered by each cancer registry varies 
between and within countries. 
o Some cancer regirsties have more robust systems of collecting cancer registry 
data from the sources of diagnosis that other countries. 




Family History of Colorectal Cancer 
56 
Inherited susceptibility to cancer 
Introduction 
In the last twenty years the developments in molecular genetics and database 
technology, have lead to greater understanding of inherited cancers and the implications 
for affected individuals and their families. This new understanding led to the 
identification and collection of large families with many cancers. Linkage analysis was 
possible in some families which lead to identification of cancer susceptibility genes and 
definition of cancer specific penetrance. These findings drove the development of 
criteria to identify families that would give the scientists the highest chance of finding 
other genes responsible for increasing risk of common cancers. When the first highly 
penetrant multi -factorial genes for breast cancer were cloned the clinical genetic 
departments responded to the demand for a service which offered family history risk 
assessment, screening recommendations, genetic testing for high -risk individuals and 
DNA storage for those not wishing testing or moderate risk family history. 
Genetics of colorectal cancer 
Familial Adenomatous Polyposis (FAP) 
Familial Adenomatous Polyposis (FAP) was first described over 100 years ago and was 
recognised as having an autosomal dominant inheritance pattern. The gene responsible 
for FAP was identified in 1991 (Kinzler et al 1991) and is known as the APC gene. FAP 
cases are responsible for approximately 1% of all colorectal cancers. 
Mutations in the APC gene are strongly associated with both inherited and sporadic 
cases of colon cancer. The APC protein, like many tumour suppressors genes, functions 
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controls the expression of genes critical in the cell division process. Inactivation of the 
APC gene, located on chromosome 5, is thought to lead to increased cell proliferation 
and contribute to the formation of colonic polyps. Several genetic alterations must 
occur during the conversion of normal colon cells into cells capable of forming 
tumours. Mutation of the APC gene is thought to be one of the early steps in the 
process of tumourigenisis. 
FAP is characterised by early onset colorectal cancer with hundreds to thousands of 
polyps. Every polyp has the potential to develop into a cancer therefore those with the 
inherited mutation are at a much higher risk of developing colorectal cancer. This 
situation is very similar to the one described for the inherited form of retinoblastoma. 
Following the identification of the APC gene, family studies identified that de novo 
mutations in the APC gene are responsible for approximately 25% of all new cases. 
There are also many extra -colonic cancers observed in cases of FAP such as; desmoid 
tumours, multiple craniofacial and long bone osteomata, epidermoid cysts and retinal 
pigmentation. 
Although the APC gene is known to cause FAP through germnline transmission, 
mutations of the APC gene are also found in over 80% of sporadic colorectal cancers. 
This finding led to a model that proposed that multiple events were required for 
tumorigenesis to complete. This model developed by comparing the mutations 
identified in cells removed at different stages of cancer development, a possible order 
for genetic mutations that led to a subset of colon cancers. In this model, the APC gene 
is mutated in the first step, producing highly proliferative cells. Those cells will then 
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form a polyp, which may develop into cancer. Figure 10 demonstrates the multistep 
process of cancer. 























Adenoma Carcinoma 4 Metastasis 
(Adapted from Fearon and Vogelstein et al 1990) 
Although presented as a linear diagram, it is now thought that these events do not need 
to follow a linear time- frame. 
Colorectal cancer, like other cancers, results from the exposure of normal cells to a 
series of toxic events that result in the accumulation of mutations in key genes that force 
the cells into proliferation. It is thought that approximately three to six different 
mutations are required for the transformation of a normal cell into a cancer cell. 
As colorectal cancer is more prevalent in the older age group, this is consistent with the 
above theory of multiple accumulations of errors, which includes inactivation of tumour 
suppressor genes and mutation activation of oncogenes for the cell to become a cancer 
cell. Having one mutated gene increases the chance of more mutations in the same cell 
due to impairment in DNA repair. It is most likely that additional interactive effects 
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between genetic and environmental factors also play a role in cancer development 
(Dicato et al 2000). 
Each mutation reduces the timescale for a cell to transform from a normal cell to a 
cancer cell and the mutation significantly increases the risk, in these individuals, of 
developing a cancer and at a much younger age, than normally seen in the general 
population. 
Family history 
Family history is a known risk factor for colorectal cancer, especially in families with 
Familial Adenomatous Polyposis (FAP) or Hereditary Non Polyposis Colorectal Cancer 
(HNPCC) mutations. Although these mutations are relatively rare, individuals with a 
known gene mutation are at a very high risk of developing colorectal cancer. 
More recently, it has been accepted that a families whose history of colorectal cancer 
does not meet the recognised high risk Amsterdam criteria also have increased risk of 
colorectal cancer, compared to the general population. Various studies have shown that 
first degree relatives of individuals with colorectal cancer are at a 2 to 3 fold increased 
risk of developing colorectal cancer (St John et al 1993, Slattery et al 1994, Johns et al 
2001). This has led to the production of risk and surveillance criteria for those with a 
moderately increased family history risk. 
It is estimated that within the general population no more than 7% have an affected 
first- degree relative with colorectal cancer (House et al 1999, Sadhu et al 2002, Wallace 
et al 2004). Despite this small percentage within the population meeting the criteria of 
one first- degree relative with colorectal cancer, if screening was implemented at this risk 
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a large number of individuals would require colonoscopy surveillance. It has therefore 
become important for moderate risk criteria to be developed to ensure that those 
individuals at increased risk are offered screening but without overwhelming the NHS. 
St Johns et al (1993) published data on risk of developing colorectal cancer as an odds 
ratio of 1.72 for any family history of colorectal cancer, 3.7 for one affected relative 
under age 45 and 5.7 for two affected relatives with colorectal cancer. Alternatively 
Houlston et al (1990) reported risk as lifetime risk of developing colorectal cancer and 
found 1:17 with any family history of colorectal cancer, 1:10 with an affected relative 
under age 45 and 1:6 for two affected relatives with colorectal cancer. 
The data can be confusing when used to relate risk to individuals in a clinical setting. A 
diagram of relative risk has been assembled produced from combining the data from St 
John et al (1993) and Johns & Houlston (2001) seen in Figure 11. This diagram is simple 
to interpret however risk expressed as relative risk is not well suited to clinical use. Risk 
of developing cancer in a particular time frame is more useful. Using one affected 
relative under age 45 and two affected relatives with colorectal cancer as the criteria the 
risk of developing colorectal cancer at the following ages is; 40 is 0.99 %, 50 is 1.15 %, 60 
is 2.78% and at age 70 is 5.00% (Scottish cancer sub group 2001). 
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Figure 11 Risk of colorectal cancer by age and family history 
Family History Category 
1. No Family History 
2. One affected first -degree relative, over 45 at diagnosis 
3. One affected first- degree relative, under 45 at diagnosis 
4. Two affected first- degree relatives 
(Permission to reproduce from Effective Health Care 2004) 
General Practitioner and Family history 
It has been suggested that GPs should have a `gate -keeping' role to cancer genetic 
services (Campbell et al 1995). GPs should have the ability to identify and refer patients 
at increased risk to cancer genetic services and reassure those at low risk, as GPs are 
strategically placed and have the potential to care for several generations of one family at 
the same time (Harper et al 1996). However, GPs must have the knowledge and the 
willingness to undertake this role for this model to succeed. 
In a randomised survey of physicians in the US, 95% self reported they take a family 
history as part of routine care (Hayflick et al 1998). Summerton and Garrod (1997) from 
62 
a postal questionnaire found that 29% of GPs stated they often /very often ask about 
family history. In a direct observational study within primary care where physicians were 
blinded to the reason for the study, Acheson et al (2000) observed that only 51% of new 
patients and 22% of established patients had family history discussed. Also, family 
history was less likely to be discussed if the patient was over age 65. This older age 
group are reported as an excellent resource of knowledge on several generations in a 
family. (Bannerman et al 1986, Aitken et al 1995). 
Fry et al (1999) sought GPs views on their role in cancer genetic services and found that 
60% of GPs were willing to take a detailed family history and make a referral to the 
regional cancer genetic services but did not feel they had the skills to assess risk or offer 
counselling based on the risk assessment. 
Cancer genetic clinics offer risk assessment and counselling with the options of genetic 
testing and /or surveillance when applicable. The testing and surveillance is offered as 
stated by local guidelines and surveillance availability in that area. These clinics also play 
a crucial role in identifying families eligible for research studies. However, the increased 
demand for this service has identified the necessity for referral to the clinic to meet high 
and moderate risk criteria of published guidelines to utilise the current cancer genetic 
services to the best advantage. 
A recent study looking at the services provided by cancer genetic services in UK 
reported: 
o An increase in referral rates, 
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o Inadequate numbers of cancer genetic staff, 
o Inequalities in cancer surveillance and genetic testing offered (Wonderling et 
al 2001). 
Wonderling et al (2001) explored the site distribution of cancer family history referred to 
22 UK cancer genetic centres. This study reported that 61% of patients were referred 
because of concerns regarding breast cancer family history and only 16% for colorectal 
cancer family history concern. Individuals referred to the cancer genetic service with a 
risk not assessed as meeting the moderate or high -risk criteria for that region varied 
from 0% to 58% for all centres and in Scotland this figure varied from 26% to 33% ( 
Presently, genetic departments have low staffing levels and the considerable increase in 
referrals of individuals with a family history of cancer, particularly those not meeting 
moderate or high risk criteria, will increase the waiting times for all genetic patients. 
In Scotland, family history criteria and guidelines have been developed to address this 
issue. 
Scottish family history guideline development 
The Scottish Cancer subgroup on cancer genetics was formed by the Scottish Executive 
in response to the increasing demands on genetic services, for the provision of a cancer 
genetic service for individuals with a family history of cancer. This group approved a 
model of Genetic Associate6 led cancer clinics previously piloted and evaluated in South 
East Scotland. The group also developed risk criteria and surveillance guidelines for use 
in the Genetic Associate led clinics and to assist other health professionals to determine 
when an individual has a relevant family history of cancer for referral to the cancer 
6 Genetic Associate - refers to a Genetic Nurse Specialist or an individual completing a Masters Degree in genetic counselling. 
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genetic services. Within these guidelines the sub group defined three levels of risk that 
can be assigned to a family history. 
The Scottish Executive published these risk criteria and surveillance guidelines and risk 
levels in March 2001 within a document `Cancer Genetic Services in Scotland: guidance 
to the implementation of genetic services for breast, ovarian and colorectal 
predisposition'. These guidelines were also published within the Scottish Intercollegiate 
Guidelines Network (SIGN) guidelines for the management of colorectal cancer in 
March 2003. Both are freely available on (www.show.scot.nhs.uk) and (www.sign.ac.uk) 
The following definitions are the three levels of risk: 
High risk: 
o At least 3 family members affected by colorectal cancer or at least 2 with 
colorectal cancer and one with endometrial cancer in at least 2 generations; 
one affected relative must be age <or =50 at diagnosis, one of the relatives 
must be a first degree relative of the other two 
o HNPCC gene carriers 
o Untested first degree relatives of known gene carriers 
Moderate risk: 
o first degree relative affected by colorectal cancer when aged <45 yrs; 
o affected first degree relatives with 1 less than age 55 at diagnosis 
o (one less than 55 years) or 3 affected relatives with colorectal cancer or 
endometrial cancer who are first- degree relatives of each other and 1 first - 
degree relative of the Consultand. 
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Low risk: 
o Anyone not fulfilling high or moderate risk. 
Table 9 lists the surveillance recommendations for those with a high and moderate risk 
family history as specified by the Scottish guidelines. 
Table 9 Scottish Executive recommended surveillance guidelines 
Surveillance recommendations for high risk 
Two yearly colonoscopy from age 30 or 5 years younger 
than the youngest affected until age 70 
Gynaecological surveillance for ovarian and endometrial 
cancer from age 35 years (research -based)? 
Two yearly upper GI endoscopy 
(from age 50 or 5 years younger than youngest onset of 
stomach cancer) 
Consideration needs to be given to surveillance for other 
cancers which may occur in specific families that are part 
of the HNPCC spectrum 
Surveillance recommendations for moderate risk 
A single colonoscopy at age 30 -35, if findings are normal 
repeat at age 55. If normal no further surveillance 
Incomplete colonoscopy should be followed by a barium 
enema preferably at the same hospital attendance. 
(Scottish Cancer Genetic Sub Group 2001) 
Colonoscopy surveillance of individuals with high or moderate family history risk has 
been shown to reduce morbidity and mortality ( Vasen et al 1998, Jarvinen et al 2000). 
In order to implement these guidelines the cancer genetic sub group in Scotland 
proposed a two -tier cancer genetic service. The service suggested was: 
o Primary care, oncologists and surgeons have a role to identify those at high 
and moderate increased risk and refer to cancer genetic services. 
7 Ovarian surveillance is offered via a National research project 
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o Cancer genetic services would provide risk assessment, referral for 
surveillance and genetic counselling for testing, if appropriate. 
This model relied heavily on the GPs, surgeons and oncologists identifying individuals 
with an increased family history and making a referral to one of four cancer genetic 
services in Scotland. 
General Practitioners and Family history risk assessment. 
The Scottish service proposal for individuals with a family history of cancer is slightly 
different than that proposed in a recent Government report for England and Wales 
(NHS 2003). This report proposes that it is the role of a GP, surgeon or oncologist to 
take a detailed family history, make an assessment of family history risk and a decision 
to discharge, screen or refer to cancer genetic services. 
In Scotland, the model implemented requires GPs, surgeons and oncologists to assess 
family history risk and make a decision to refer to cancer genetic services. 
Before the proposed Scottish model was implemented, Fry et al (1999) had shown that 
only 6% of GPs in SE Scotland felt confident on giving a risk based on family history. 
This highlights the requirement of an education programme for GPs in assessing family 
history using Scottish guidelines. When the Scottish cancer subgroup report was 
published it recommended a roll out programme of education to primary care, general 
surgeons, oncologists, gastroenterologists, radiologists and gynaecological oncologists in 
all NHS trusts in Scotland. Also, relevant bodies responsible for training of medical 
students, qualified medical staff and paramedical staff should ensure a planned 
programme of ongoing education. This report stated that the Health Depatunent would 
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provide further guidance for these activities to be set in place. These Scottish guidelines 
for breast, ovarian and colorectal cancers were issued to GPs in April 2002. 
The important topic of GP involvement in cancer genetics is only beginning to appear 
in the literature. It has been agreed by GPs that they have a role to play in cancer 
genetics (Fry et al 1999, Suchard et al 1999) although there is little agreement as to what 
that role should be or how the service for cancer genetics should develop (Watson et al 
1999, Suchard et al 1999). There is also a lack of understanding by GPs on what the 
cancer genetic services can provide for individuals with a family history of cancer 
(Watson et al 2001). 
Many studies identified that GPs had a problem with knowing when an individual 
should be referred to a cancer genetic service (Fry et al 1999, Suchard et al 1999, Rose et 
al 2001). 
GPs have identified that they do not see many individuals with a family history of 
cancer in their day to day practice. 
A GP would expect to have approximately 60 patients with a family history of a 
common cancer, for each 1000 patients, aged 30 -69 (House et al 1999). With the 
volume of patients seen by GPs on a daily basis, 60 patients is a relatively small number 
to remember to use guidelines. This highlights the need for easy accessible and user 
friendly guidelines, especially as they are not being used on a daily or even a weekly 
basis. 
Although GPs have said, that guidelines and computer aided guidelines would be 
helpful to them for assessing family history (Watson et al 2001), Rose et al (2001) 
reported less than one third of a GP study cohort was aware of family history guidelines 
which had been sent to them. 
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Suchard et al (1999) found that the number of patients discussing family history 
concerns is already affecting GP workload, and they feel that there is a lack of time to 
enable a detailed family history to be taken within an average GP consultation which 
takes approximately 8.5 minutes. 
In many of the studies carried out to assess GPs perception of their role in cancer 
genetics the majority of GPs indicated that they need more education in genetics and 
assessing family history risk. Studies suggested that the practice nurse could be offered 
training on taking a detailed family history or that a genetic nurse specialist could be 
involved with GP practices (Fry et al 1999, Watson et al 1999, Rose et al 2001, Johnson 
et al 1995, Summerton & Garrod 1997). It is clear further research is required to offer 
the optimum service to individuals with a family history of cancer. As the general public 
are now more educated in health issues the demand for information on family history 
risk will become greater. 
Lucassen et al (2001) found that when GPs were provided with an educational pack 
which included guidelines, the number of appropriate referrals improved and the quality 
of referral letter which enable the genetic service to assess the risk to triage for 
appropriate appointments. 
More general studies on changing behaviour of GPs have found that if education is 
offered it should have enabling or reinforcing strategies or there is little impact on GP 
behaviour or performance. Change is more likely if the education package is based on 
needs assessment, uses case histories, allows time for discussion, is well evaluated and is 
facilitated by a GP (Davis & Taylor- Vaisey.2000). In addition, (Wensing & Grol 1994) 
reported a combination of interventions such as peer review; feedback to GP and 
individual instruction all appear to have greater impact on changing behaviour and 
practice. 
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Other health care professionals and family history risk assessment 
Sommerton and Garrod (1997) suggest it is unrealistic for GPs to carry out family 
history taking. They propose that practice nurses (PN) or health visitors (HV) could be 
trained to do this and simple application of a sticker to patients' notes would alert a GP 
to the presence of a family history of disease. In a study carried out by Bankhead et al 
(2001) to investigate genetic knowledge of practice nurses found that 96% stated that 
they take family history as routine and 61.5 % had been asked a family history question 
in relation to family history of cancer, in past 3 months. Many practice nurses saw their 
role as `giving permission' to the patient to discuss their family history with the GP, very 
few referred the patient on to the GP for advice and /or referral to cancer genetic 
services. Bankhead et al (2001) found practice nurses over estimated family history risk 
in both breast and colorectal cancer, more so the latter where 89.5 % of the practice 
nurses overestimated the risk, using a scenario. Chorely and McDermont (1997) 
investigated senior doctors and nurses involved in all areas of cancer care and used a 
questionnaire to ask information on cancer genetic knowledge. This small survey 
showed an obvious dichotomy between wanting to provide information for future 
management and having the ability to do so. They found family history was not 
discussed due to lack of time, the criteria for testing and surveillance were not used and 
staff did not appreciate the wider issues such as impact on individual patients, their 
families and the need for confidentiality. 
Collecting cancer family history 
Large epidemiological studies for common cancers reported `family history' as a risk 
factor. The Nurses Health study (Colditz et al 1993) and Utah Population database 
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(Slattery et al 1993) reported on breast cancer; the Utah population database (Slattery et 
al 1994) on colorectal cancer. 
With family history identified as a risk factor for colorectal cancer some researchers 
have recorded family history as part of their core dataset. However, these studies had a 
main aim of validating the accuracy of family history cancer information reported. Also, 
the methodology for collecting family history varies within the studies. Table 10 
summarises the studies, which have collected family history data regarding colorectal 
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The studies shown in Table 10 all confirmed the accuracy of the family history 
information given by an individual. Table 11 shows studies that used the family history 
information given by an individual to assess population or relative risk for an individual 
of developing colorectal cancer. 
The studies in table 10 include studies from UK, Europe and USA. Within theses studies 
there are a variety of methods used to collect family history. 
There are different cohorts in these studies. These include individuals with colorectal 
cancer, individuals attending a cancer genetic centre with a family history concern and 
individuals with a known first degree relative with colorectal cancer. The majority of 
these studies had no age restriction for eligible participants. Within the studies a variety 
of family history data were collected. Four studies collected only first degree relative 
information, three studies collected information on first degree and second degree 
relatives and three studies collected information on all degrees of relatives. The latter 
cancer genetic studies were specifically in which it is mandatory to take a minimum three 
generation family history. 
There is no literature to inform the most effective method of collecting an accurate 
family history. Theis et al (1994) did note a small added benefit in accuracy of cancer site 
when family history was taken by a trained genetic nurse. Koscica et al (2001) found that 
utilising a genetic counsellor and incorporating a three- generation pedigree into a 
patient's risk assessment significantly improved detection of identifiable genetic risk 
factors. 
Results from all of the studies in table 10 showed that the accuracy of family history 
information was significantly greater in first degree relatives and became less accurate the 
further removed the relative was from the consultand. The studies carried out in cancer 
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genetic centres had a higher degree of accuracy in first degree relatives than the other 
studies. This may be explained by the fact that the individuals in the study are likely to 
have raised the family history concern with their GP and are highly motivated to find out 
family history information. 
Also of interest is that in the cancer genetic studies there were a higher proportion of 
females and these females give more accurate family history information than males in 
the same studies. 
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Accuracy of family history data 
A Consultand9 attending a cancer genetic clinic is given important information based on 
family history reported; this family history information influences: 
o Risk assessment 
o Counselling 
o Surveillance 
o Genetic testing 
If the initial family history information given is incorrect, all subsequent information 
based on the family history will be incorrect. Several authors in table 10 have described 
the accuracy of the reported malignancy in relatives, there are, however inconsistencies 
within these studies in the methodology of confirming cancers. 
Family histories of breast cancer have consistently been found to have a high degree of 
accuracy when the information was confirmed with cancer registries or medical records 
(Theis et al 1994, Anton Culver et al 1996). Love et al (1985) studied 121 consecutive 
people referred to a genetic clinic with a family history of cancer. The results showed 
93% accurately reported colorectal cancers in first- degree relatives, dropping slightly to 
84% for second and third degree relatives. An accuracy of 70% was given for other 
HNPCC related cancers which included ovarian and endometrial cancer. 
In recent studies, Douglas et al (1999) and Sijmons et al (2000) reported on cancer family 
history referrals to genetic clinics. Douglas et al (1999) compared, two UK centres and 
found the overall accuracy for all cancers reported in first- degree relatives was 86% 
(centre 1) whilst in centre 2 the accuracy was 94 %. In centre 2 a 90% accuracy of 
9 The person being seen in a clinic for genetic counselling 
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colorectal cancers were reported and an 83% accuracy of ovarian cancers reported. 
Sijmons et al (2000) reported similar results in their study; they reported 89% accuracy 
for colorectal cancers reported and 71% for ovarian cancer, in all degrees of kinship. 
Aitken et al (1995) reported a 77% accuracy of colorectal cancer information in first- 
degree relatives of individuals with adenomas found at colonoscopy. Glanz et al (1999) 
found adults with a first degree relative diagnosed with colorectal cancer, were 74.6% 
accurate in reporting colorectal cancer. Katballe et al (2001), Andrieu et al (2003) and 
Mitchell et al (2004) all reported on family history information accuracy from individuals 
diagnosed with colorectal cancer. Katballe et al (2001) identified 81.7% accuracy of 
reporting colorectal cancer, in all first and second -degree relatives. Andrieu et al (2003) 
reported accuracy of 79.1 % in all degrees of relatives, which was increased to 87.5% 
when only first -degree relatives were considered. 
However, Mitchell et al (2004) reported significantly less accuracy for all cancer sites, 
they reported 44% accuracy in first- degree relatives and 14% accuracy in second -degree 
relatives. They also gave the results on accuracy of colorectal cancer reported in relatives; 
the accuracy in first- degree relatives was found to be 56% and accuracy of reported 
colorectal cancers in second -degree relatives was 29.5 %. 
Some studies reported on the underreporting of cancers which were found when 
investigation the family. Mitchell et al (2004) and Glanz et al (1999) both found under 
reporting of cancers in first- degree relatives at 24.5% and 29% respectively. In contrast, 
Love et al (1985), Aitken et al (1995) and Douglas et al (1999) found an overestimation 
in cancer reports at 17.1 %, 22.2% and 15.3% respectively. Aitken et al (1995) and 
Katballe et al (2001) both reported cases to be more accurate than controls. It was 
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thought, that a diagnosis of colorectal cancer or adenoma was the catalyst that prompted 
them to seek more information on family history and they were more enthusiastic about 
sharing this information. However, Mitchell et al (2004) in a Scottish study found no 
difference between cases and controls in accuracy of cancers reported. Glanz et al (1999) 
and Aitken et al (1995) both reported that females were more accurate at reporting 
cancers in the family than males. Aitken et al (1995) also reported that increased age was 
positively related to the degree of cancer site accuracy. Many of the above studies also 
reported a striking drop in accuracy with increasing distance of relationship from the 
person giving information. Love et al (1985) suggested that those seen within genetic 
departments are more motivated than colorectal cancer cases within a research study 
because they sought referral or were advised to have a referral to discuss their family 
history concerns. All of the investigators reported that the time factor and the cost of 
confirming information required careful consideration when developing a research study 
or cancer genetic service. Access to information that could confirm the accuracy of the 
family history was a problem for several of the studies. Difficulties experienced were in 
accessing records due to: 
o Inability to obtain consent from case or next of kin, 
o Destroyed hospital files 
o Closed hospitals 
The validation of the cancer information given by cases and controls varied from 95% in 
a Swedish study (Olsson & Linbolm 2003) to 42% reported in a UK study (Douglas et al 
1999). 
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Genetic information and professions allied to medicine 
The field of cancer genetics is developing almost daily with new knowledge and advances 
in technology, and this new information is now reaching the public domain at the same 
time as it is available in the medical literature. It is difficult for GPs and surgeons to stay 
current with new information. Although many GPs and surgeons may be willing to take 
a detailed family history, the time factor and lack of education on the genetics of 
common diseases are barriers to the development of cancer genetic services in primary 
care (Kinmonth et al 1998 and Fry et al 2001). 
Recent literature concludes that asking family history information is not the sole 
responsibility of GPs, surgeons and oncologists as previously proposed. This knowledge 
and skill should be integrated into the role of all health care professionals. 
The white paper `realising the potential of genetics' NHS (2003) stated: 
"Over time most health professionals will need to understand how a patient's family history and 
genetic make -up affects the likelihood of developing a disease or their response to medicines. They 
will need an appreciation of how genetic technology can be used in diagnosis, prevention and 
treatment. They will need to be able to convey this information to patients and help them make 
difficult choices about whether to undergo genetic testing or to change lifestyle in the light of 
information about their genetic make -up" 047) 
Specialist genetics centres will be required to play a role in the diffusion of new genetic 
information across all professions within the NHS. The suggestion has been made that 
genetic counsellors could be attached to primary care areas to assist with the transfer of 
information and skills required to take family history and assess family history risk (NHS 
2003). However, Public Health Genetics Unit (2002) reports that education systems for 
dissemination of this information are not currently available. A rolling programme of 
educational resource development must be implemented, covering all levels of each 
professional group based on an understanding of needs and priorities. 
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If all health professionals had the skill to take a family history and assess risk, they would 
have sufficient knowledge to make a referral of those with a moderate and high -risk 
family history to genetic centres. This would reduce the workload of cancer genetic 
clinics (Wondering et al 2001 and Campbell et al 2003), improving the waiting times for 
moderate and high -risk patients. 
General population cancer family history knowledge 
Despite heightened media attention surrounding the human genome and the impact this 
new knowledge has had on cancer genetics, the general population does not appear to 
use this knowledge to assess their own family history risk or to access appropriate 
services. Cull et al (2001) found that 44% of women attending an ovarian cancer clinic 
underestimated their risk and 19% overestimated their risk. To achieve a satisfactory 
level of understanding of one's own family history risk and how to deal with this 
concern, will require less sensationalism from journalists and easy public access to 
printed media to increase awareness and understanding (NHS 2003). 
Todara et al (2001) carried out four focus groups, with a small number of individuals 
aged 30 -69; each had a first- degree relative with colorectal cancer. None of the four 
groups had heard of a genetic risk assessment. There was concern surrounding, the 
effort it would take them to collect family history information. This study and Lynch and 
Lynch (1996) found that fear of losing or loading of insurance coverage was another 
barrier to personally accessing genetic services. 
In the past, there has been limited patient and family information published by cancer 
charities offering guidance on the family history of colorectal cancer. However, new 
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information leaflets are now available with more specific information on family history 
(Beating Bowel Cancer 2003, CancerBACUP 2004) A recent publication by Cetnarskyj 
(2004) offers information to individuals in Scotland who have a concern regarding their 
family history of colorectal cancer (Appendix 7). 
A major problem for the dissemination of family history information as a risk factor is 
that individuals normally contact these charities when they have colorectal cancer and 
find out they should have been screened regularly prior to their diagnosis. 
Summary of family history 
There is little current literature regarding individuals with colorectal cancer and their 
family history of colorectal cancer. There are no published data on the number of 
individuals with an increased family history risk in the Scottish colorectal cancer 
population. 
There is no published literature on those that perceive they have a family history of 
colorectal cancer and present with lower gastrointestinal symptoms or how they perceive 
their symptoms on the background of their family history of colorectal cancer. 
Other Risk Factors for Colorectal cancer 
Colorectal cancer is a multi- factorial disease, with complex interactions between genetic 
and environmental factors. A small number of individuals are at a much higher risk of 
developing cancer due to known and yet unknown gene mutations in their family. 
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There are several other environmental factors thought to contribute to an individual's 
risk of developing colorectal cancer in addition to family history. These are: 
o Dietary factors 
o Excess Weight 
o Physical activity 
o Smoking 
o Alcohol 
The above risk factors will not be discussed further in the thesis, as it would not be 
possible to offer a succinct overview due to the vast literature in this area. 
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Chapter 6 
Socioeconomic Status and Colorectal Cancer 
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Socioeconomic status and `inequalities in health' 
For many years, there has been an awareness that a relationship between poverty and 
mortality risk exists. Today, inequality in health between the affluent and the deprived is 
high on the political agenda. Monitoring inequality in health has become an increasingly 
important task of development agencies. 
This inequality in health has not always been recognised by the government. However, 
not only are these inequalities unfair, they are also an economic burden. Improving 
health in disadvantaged groups would improve the health status of the population. 
The Black report (Townsend 1988) identified higher morbidity and mortality in deprived 
areas compared to more affluent parts of the UK, thus bringing the problem to the 
forefront of the social and political agenda. Government and Health Boards now openly 
accept and discuss the concept of inequalities in health. The lessening of inequalities in 
health and the promotion of equity in access to health care are now central to the UK 
government's Health policy (Department of Health, 1998). 
One of the major principles of the National Health Service (NHS) was to provide equal 
treatment for equal need free at the point of delivery. However, private practice was 
allowed to coexist with the NHS inevitably contributing to inequalities in health care 
between the rich and poor (Secretary of State, 1998). More than 50 years have passed 
since the beginning of the NHS and most health services remain free at the point of 
contact. However there is clear evidence that the gap is widening in health between the 
affluent and the deprived (Phillimore et al 1994, Davey Smith et al 1998). 
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This is an international problem that all governments are aiming to address. A target 
issued by the World Health Organisation in 1990 stated, 
`By the year 2000, the differences in health between countries and between groups within 
countries should be reduced by at least 25 %, by improving the level of health of the disadvantaged 
nations and groups" 
(WIIO, 1990) 
This was a very ambitious target for many countries to meet and could not be met in 
many areas of medicine. This target has driven many researchers to investigate 
discrepancies in care within their own area of health that has provided many useful 
insights into inequalities in health for those individuals living with poverty and 
deprivation. 
In the field of cancer medicine, professionals have embraced this challenge and have 
begun the development of more accurate recording and collaboration with other 
countries. The EUROCARE project is one such collaboration to develop from this 
challenge. The role of EUROCARE is to collate and disseminate cancer statistics in 
Europe. 
Poverty and deprivation 
The terms poverty and deprivation are difficult to define; they are often used 
interchangeably when discussing those who are underprivileged in some way. It has been 
argued, that there is a clear distinction between poverty and deprivation, Townsend 
(1987b) wrote, 
`Deprivation may be defined as a state of observable and demonstrable disadvantage, relative to 
the local community or the wider society or nation to which an individual, family or groups 
belong" 
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A further attempt to distinguish poverty and deprivation was made by Noble et al 
(2000); 
It can be asserted that the condition of poverty means not having enough financial resources to 
meet needs. Deprivation on the other hand, refers to unmet need, which is caused by a lack of 
resources of all kinds, not just financial." 
Townsend would not agree with these separate definitions; 
"While people experiencing some forms of deprivation may not all have low income, people 
experiencing multiple or single but very severe forms of deprivation are in almost every instance 
likely to have very little income and little or no resources": 
Further to the definitions of poverty and deprivation given, Townsend (1987a) 
elaborates on the distinction between `social' deprivation and `material' deprivation. 
Social deprivation he feels is more difficult to measure and is defines as; 
`Providing a useful means of generalising the condition of those who do not or cannot enter into 
ordinary forms of family or other relationships" 
Today, this is better known as social exclusion. He stated that to measure material 
deprivation was a much easier task as it relates to diet, health, clothing, housing, 
household facilities, environment and work. 
However poverty or deprivation is interpreted, they are a measure of social standing and 
often referred to as socioeconomic status. Mackenbach and Kunst (1997) gave the 
following definition of socioeconomic status: 
`Socioeconomic status refers to an individual's relative position in the social hierarchy and can be 
operationalised as a level of education, occupation and /or income" 
Throughout the literature deprivation and poverty are also reported as socioeconomic 
status and the term socioeconomic status will be used within this thesis to define the 
differences between individuals in higher or lower social groups. 
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Measures of deprivation 
Throughout the literature there are various instruments used to measure socioeconomic 
status, each author choosing the best method available for the population they are 
studying. The measurement tool used is also determined by the available access to the 
required information. Also the tool will be determined by the relevance of each indicator 
with respect to the culture of the population studied. 
Census -based material is the most common source of data used to calculate 
socioeconomic status, as access to these data is readily available (Kogevinas et al 1991, 
Schrijver et al 1995, Mandelblatt et al 1996, Kee et al 1992, Ionescu et al 1998, Pollock 
and Vickers 1998, Kim et al 2000, Campbell et al 2000, Brewster et al 2001). 
Although not explicit in their text, it appears that other authors use data from their own 
official National sources equivalent to the Office of National Statistics in England to 
assess socioeconomic status (Brenner et al 1991, Desoubeaux et al 1997). Some countries 
have the ability to link census data to personal records, which can then be accessed for 
research (Auvinen 1992). A small number of studies have collected the socioeconomic 
information they require at recruitment (Tavani et al 1999, Ciccone et al 2000). 
Alternatively a combination of census and personal information is used (Lynch et al 
1975). 
The variables used from census data vary greatly in each study. Table 12 illustrates the 
socioeconomic variables used by researchers, the country of the research, the study 
population and the period of data collection. 
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The above table demonstrates the many differences between research studies which can 
create difficulties when comparing results. The most common measures of deprivation 
used are Carstairs and Townsend deprivation indices, especially in the United Kingdom. 
These are discussed in more detail below. 
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Deprivation indices 
Deprivation indices are widely used within epidemiology and public health research. 
These indices are based upon the characteristics of the area of residence at the time of 
census. These indices are most often used when data relating to socioeconomic status 
have not been or cannot be directly collected during a study. Since the early 21" Century, 
there have been many attempts to produce deprivation indices of relevance to 
socioeconomic status. 
The two indices most frequently used in cancer research in the UK are the Townsend 
index and the Carstairs index. These are strongly correlated to each other as they 
measure similar factors contributing to deprivation (Morris et al 1991). The score derived 
from these indices are updated with each census and current scores available for each 
index incorporate 2001 census data, this is available on the World Wide Web, the 
Carstairs index (www.scotland.gov.uk) and Townsend index (www.wales.nhs.uk). 
There has been some criticism of census -based measures as data may be out of date 
soon after it is published (Majeed et al 1995). There are also worries about how the data 
from census should be interpreted. Many individuals in employment have a level of pay 
that is low but does not allow access to social security benefits. Their socioeconomic 
status, measured by these indices, is wrongly assessed (Beale, 2001). Beale (2001) also 
argues against the use of car ownership as an indicator of affluence, since in rural areas a 
car is an absolute necessity. In many rural areas, the most affluent group and the most 
deprived group live within a small area, which could be covered by the same ward or 
postcode. 
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A new measure of deprivation has recently been developed for UK nations and does not 
rely on census data. This index attempts to measure multiple deprivation indicators and 
produce a more dynamic index that has the ability to change more frequently than 
census data also, to assess more accurately socioeconomic status. 
This new deprivation index incorporates many more indictors of deprivation than are 
currently used in either of the Townsend or Carstairs indices. Scotland, England, Ireland 
and Wales have each tailored the indicators used in their index to reflect the known areas 
of deprivation within their own region. The Scottish index is called the `Scottish Index of 
Multiple Deprivation' (SIMD 2003). At the time of writing none of the four new 
multiple deprivation indices have been validated due to their recent publication. This 
study will use both the SIMD index and the Carstairs index for analysis and will compare 
results. 
Townsend Deprivation index 
The Townsend Index is a composite census based index, which originated from the 1981 
census data. It measures multiple deprivations by small areas known as wards, and 
incorporates four variables: 
o Unemployment - (lack of material resources and insecurity), 
o Overcrowding - (material living conditions), 
o Lack of owner occupied accommodation - (a proxy indicator of wealth) 
o Lack of car ownership - (a proxy indicator of income). 
(Townsend et al 1988) 
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Calculating the Townsend deprivation score 
The Townsend score is a sum of the standardised scores (z scores) for each variable; 
scores greater than zero indicate greater levels of material deprivation. These scores are 
available for England, Wales and Scotland for this index. 
The index score is calculated by combining four variables from the most current census 
data available (the higher the number, the greater the measure of deprivation): 
o Unemployment - unemployed residents over 16, as a percentage of all 
economically active residents aged over 16. 
o Overcrowding - households with 1 person per room and over as a percentage 
of all households. 
o No car ownership - households with no car, as a percentage of all households. 
o No home ownership - households not owning their own home, as a 
percentage of all households. 
Carstairs Deprivation index 
The Carstairs deprivation index originated in 1981 and was created by Carstairs (1982). It 
is a composite census -based index based upon postcode areas and incorporates the 
following 4 variables from the 1981 population census, 
o Overcrowding, 
o Male unemployment, 
o Low social class (population with social classes 1V &V of the Registrar 
General's social class) 
o Households with no car. 
(Carstairs, 1982) 
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These four variables are intended to represent the materially disadvantaged. The scores 
were revisited with the 1991 census and the same variables were used. Slight changes 
were made in definition of overcrowding and social class in view of the Registrar 
General's switch to an occupational basis. It was concluded that there was no substantial 
change in the scores for most areas in the 10 -year period between 1981 and 1991; those 
areas that did show a change were more likely to have a population of less than 2000. 
The 2001 Carstairs score have been derived from the same four variables used in the 
1991 score. The social class score was no longer available due to a change in Registrar 
General reporting. Special tables were commissioned from the census division of the 
General Register Office for Scotland, to maintain as closely as possible that the same 
four variables used for 1999 scores (McLoone 2003). There was little change in the score 
over the ten -year period from 1991 to 2001. 
Calculating the Carstairs Deprivation score 
The scores were derived from an unweighted combination four standardised variables 
giving a summary statistic (Z score) for an area. 
o Overcrowding - The proportion of all persons living in private households 
with a density of more than one person per room 
o Male unemployment - The proportion of economically active males seeking 
work 
o Low social class - Proportion of all persons in private households with head 
of household in social class 4 or 5 
o No Car - proportion of all persons in private households with no car 
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Using these four variables and postcode area, a score is calculated; this score is 
commonly known as the Depcat score. A postcode is available for every address in the 
UK and is commonly used in the recording of births, deaths, and marriages and is widely 
used throughout the health service for hospital admissions, discharges and similar events. 
Postcodes consist of an area of postal delivery, which in residential areas consists of 
approximately 35 people. The postcode is sectioned into area, district, sector and unit. 
The analysis for the Carstairs Depcat score is at the sector level, which is thought to 
provide reasonable reliability in respect of most health events ( Carstairs and Morris 
1991). 
Scottish Index of Multiple Deprivation 2003 
This Scottish Index of Multiple Deprivation (SIMD) (Social Disadvantage Research 
centre 2003) does not use census data, unlike Townsend and Carstairs. The score for this 
index are given at ward level but it is possible to convert to postcode areas through a 
conversion file from General Registrar's Office. This index consists of separate domains 
of deprivation, each with its specific information. The domains used in the SMID 2003 
are: 
o Income deprivation, 
o Employment deprivation, 
o Health deprivation and disability; 
o Education, skills and training deprivation, 
o Geographical access to services. 
Each domain reflects a particular aspect of deprivation and the purpose of each domain 
is as follows: 
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o Income - to capture the extent of income deprivation in an area 
o Employment - to measure enforced exclusion from the world of work 
o Health deprivation and disability - to identify areas with high proportion of 
people who are losing years of life due to premature death or whose quality of 
life is impaired by poor health 
o Education, skills and training deprivation - to measure as consistently as 
possible the key educational characteristics of the local area that might 
contribute to the overall level of deprivation and disadvantage 
o Geographical Access to services - to measure the extent to which people have 
poor geographical access to key local services. 
Within each domain, there are specific measures, for example; the Health deprivation 
and Disability indicators consists of: 
o Comparative Mortality factors for under 75s 
o Hospital episodes related to alcohol use 
o Hospital episodes related to drug use 
o Comparative Illness Factor 
o Emergency admission to hospital 
o Proportion of the population being prescribed drugs for anxiety, depression 
or psychosis 
o Proportion of live singleton births of low birth weight. 
Calculating the Scottish Index of Multiple Deprivation score 
The score is a composite of the different domains of deprivation, each dimension is 
measured independently using the best indicators available. These domains are combined 
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with explicit weighting to generate a Scottish Index of Multiple Deprivation (SIMD), 
which is an average of the component domains. The scores in this index are cumulative 
for all sections of the index and range from 1- 89, including two decimal points, 1 being 
the most affluent and 89 being the most deprived. 
Socioeconomic status, incidence and colorectal cancer 
The specific causal factors of deprivation that are important for survival from colorectal 
cancer remain elusive. 
England and Wales 
There was no difference in the incidence of colon cancer in either sex related to 
deprivation as measured using Townsend deprivation index. A clear influence of 
deprivation was noted in males with rectal cancer when a 25% increase in incidence in 
the more deprived groups was seen. 
The picture for mortality mirrors the incidence. There was a 50% higher mortality rate 
for males with rectal cancer in the most deprived group than for males in the most 
affluent group (Quinn et al 2001). This effect was not seen in females. 
Scotland 
All current ISD publications use Carstairs index 1991. Of those diagnosed with 
colorectal cancer in 1997, there were 43% in the most affluent group and 36% from the 
most deprived group for both colon and rectal cancer. The distribution of age at 
diagnosis was similar for colon and rectal patients across the deprivation groups, with a 
median age of 73 years. The incidence of colon cancer was 8% higher in the most 
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affluent group compared to the most deprived group; the same pattern was seen for 
rectal cancer with a smaller gradient (Stockton 2001). 
The incidence of colorectal cancer has also been reported to be higher in the most 
affluent group (Lynch et al 1975, Brenner et al 1991, Faggiano et al 1994, Schrijvers et al 
1995, Kee et al 1996, Tavani et al 1999, Ciccone et al 2000, Hole & McArdle 2002). This 
mirrors deprivation gradients reported from many cancer registries, although many of 
the studies cited use different measures of deprivation. Faggiano et al (1994) in an Italian 
study suggested that the lower incidence of colorectal cancer in the most deprived group 
was associated with a lower fat and higher fibre diet than more affluent group. 
Papadimitriou et al (1984) and Kim et al (2000) found that there was no trend towards 
higher incidence in the most affluent group. Auvinen et al (1992) found that the 
incidence was higher in the most deprived group, using social class as the measure of 
deprivation where census records were linked to personal files, perhaps a better indicator 
of individual socioeconomic status. 
Tavani et al (1999) noted an increase in colorectal cancer in the affluent group using 
social class as the measure of socioeconomic status and also noted that this increase was 
less for rectal cancer. Schrijvers et al (1995) found the opposite from Tavani, where a 9% 
increase in rectal cancer and a 5% increased in colon cancer incidence in the deprived 
group versus the affluent group. With a greater proportion of studies reporting an 
increased incidence of colorectal cancer, it implies that there is an association with 
increased incidence and socioeconomic status, therefore suggesting that a proportion of 
colorectal cancer may be preventable (Kee et al 1996). 
100 
Socioeconomic status and survival from colorectal cancer 
England and Wales 
There was an obvious difference in survival rate and socioeconomic status for both 
colon and rectal cancer in those diagnosed in 1986 -90. In the most deprived group one- 
year survival for colon cancer was 6% less and 7% less for rectal cancer than the most 
affluent group. Five -year survival for colon cancer was 4% less in the most deprived 
group and 5% in rectal cancer than the most affluent group. 
The survival rate gap increased between the most affluent and the most deprived groups 
for those diagnosed in 1996 -99 in both sexes. The colon cancer survival rate difference 
was 6% in males and 7% in females; for rectal cancer the difference was 9% in males and 
8% and in females (Rowan & Brewster 2004). 
Scotland 
In 1997, those registered with a diagnosis of colon cancer in the Scottish cancer registry 
showed a slight increase in the two -year survival for the most affluent group versus the 
most deprived group. For those registered with a diagnosis of rectal cancer in 1997 there 
was significantly higher survival in those from the most affluent group than the most 
deprived group. Figure 12 shows the incidence, survival and mortality of cases diagnosed 
with colorectal cancer in Scotland in 1997. 
Hole & McArdle (2002) found that of those recorded as having curative surgery the 
most deprived group had a lower survival than the most affluent group. The more 
affluent individuals had a 68% five -year survival rate versus a 62% survival rate in the 
deprived group. 
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Figure 12 Colorectal cancer in Scotland: incidence (in 1997) and two -year 
relative survival rate and mortality rate (in 1999), by deprivation 




















1 2 3 
Affluent 
4 





80 T 20 
* 
60 --- 15 





2 3 4 5 
Carstairs deprivation category Deprived 
(reproduced with permission from ISD 2003) 
Studies investigating deprivation and colorectal cancer measured survival as the main 
outcome. Survival is viewed as the best possible outcome and is often used as an 
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indicator of effective cancer care. Survival is measured as the period between diagnosis 
and death (Dickman et al 1997). 
In addition to differing socioeconomic status measures and different populations 
studied, the analysis of the data and the presentation of results are inconsistent. There 
are a variety of analytical methodologies used and therefore results are presented 
differently. Table 13 shows analysis methods used by studies reporting on survival rates. 
Table 13 Analysis methods used to present survival data 
Author Year Analysis Methods 
Kogevinas 1991 Median survival time 
Brenner 1991 Relative Hazard of Death 
Auvinen 1991 Relative survival rate 
Monnet 1993 Raw Survival 
Schrijver 1995 Relative survival rates 
Desoubeaux 1997 Observed survival rates 
Pollock and Vickers 1998 Standardise mortality rates 
Ciccone 2000 Cox proportional hazards rate 
Campbell 2000 Cox proportional hazards rate 
Kim 2000 Cox proportional hazards rate 
Polendak 2001 Cox proportional hazards rate 
Hole and McArdle 2002 Overall survival and cause specific survival 
Wrigley 2003 All cause and cause specific survival 
Kogevinas et al (1991), Auvinen et al (1992), Monnet et al (1993), Schrijvers et al (1995), 
Desoubeaux et al (1997), Pollock & Vickers (1998), Ciccone et al (2000), all found that 
survival time was shorter in the more deprived groups. Polendack (2001) found that 
survival was greater in females than in males. Monnet et al (1993) noted a poorer survival 
rate in the most deprived group existed whatever the severity of the Dukes' tumour stage 
though the difference was most marked in the less advanced tumours. Auvinen et al 
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(1992) reported a 19% greater risk of death due to colorectal cancer for the lowest social 
class than the highest social class. Stockton (2001) found, using Scottish data, that there 
were no major differences between the deprivation groups in; age at diagnosis, sex, 
tumour stage or tumour grade at diagnosis. However, deprived patients had a higher 
proportion of metastatic tumours and worse comorbidity at diagnosis. 
Socioeconomic status and health 
Many researchers have investigated the socioeconomic hierarchy, which has been 
demonstrated to influence the incidence of myocardial infarction, stroke, diabetes, 
chronic bronchitis and many other longstanding health problems. Many researchers have 
identified that as household income decreases, illness and disability increases. 
Socioeconomic status and cancer 
Many publications exist in the area of inequalities in health and cancer. It is known that 
there are factors arising from an individual's lifestyle that increase the risk of developing 
certain cancers. Examples include cigarette smoking, excess alcohol intake and poor diet. 
These factors are more often found in the lower socioeconomic groups, and form part 
of the socioeconomic divide (la Vecchia et al 1992). In Scotland, for example, it has been 
shown that there is a higher incidence and mortality rate in cancers of lung, cervix and 
oesophagus in the lower socioeconomic groups. 
In higher socioeconomic groups there is an increased incidence but no mortality 
difference in breast cancer and an increased incidence and lower mortality rate for 
colorectal cancer (ISD 2000). 
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Despite this higher incidence of breast and colorectal cancer reported in the more 
affluent socioeconomic groups (Coleman et al 2004), survival is greater than in the more 
deprived groups (Schrijvers et al 1995). 
Proposed explanations for such socioeconomic differences include; differing urban and 
rural differences resulting in unequal access to quality health care (McLeod 1999, 
Campbell et al 2001), differences in treatment (Mc Lead 1999) and late presentation with 
symptoms (Dent et al 1983, Langenbach et al 2003, Flashman et al 2004). 
Socioeconomic status and colorectal cancer 
Worldwide literature is available on colorectal cancer and the effect of socioeconomic 
status. There is specific literature relating to socioeconomic status and incidence, 
mortality, survival, staging at diagnosis and treatment variations. There are major 
differences in the reporting of these studies therefore the interpretation of results should 
be with caution especially when applying results to a different population ( Monnet et al 
1993). 
Socioeconomic status, tumour stage and colorectal cancer 
There are conflicting findings within the literature on stage of tumour and deprivation, 
Brenner et al (1991), Monnet et al (1993), Mandelblatt et al (1996), Ionescu et al (1998), 
Ciccone et al (2000), Hole & McArdle (2002), all found that the more deprived presented 
with more advanced disease. No studies found the opposite, although some studies 
found that there was no association between deprivation groups and stage of tumour at 
presentation (Auvinen et al 1992, Pollock & Vickers 1997, Kee et al 1996, Brewster et al 
2001). 
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Mandelblatt et al (1996) reported that those living in the lowest socioeconomic status 
areas were 45% more likely to be diagnosed at an advanced stage than those in the 
highest socioeconomic status areas. In two Scottish studies, Hole & McArdle (2002) and 
Ionescu et al (1998) published the distribution of tumour staging and reported the most 
noticeable difference in socioeconomic groups was in the early Dukes' staged tumours. 
Hole & McArdle (2002) reported from a Greater Glasgow study that 6% of all the 
tumours were diagnosed at Dukes' stage A. Of all of the Dukes' stage A tumours, 7% of 
were in most affluent group and 4% in the most deprived group. Ionescu et al (1998), 
reported that 15% of their Tayside cohort were found to be at Dukes' stage A and 18% 
of these were found in the most affluent group and only 9% in the most deprived group. 
Tayside region is known to have a more affluent population than Greater Glasgow. 
Socioeconomic status and treatment for colorectal cancer 
Following Dukes' stage at diagnosis, treatment is the next principal determinant of 
cancer survival (Auvinen & Karjalainen 1997). In an attempt to find out why the more 
deprived group have poorer survival, researchers have hypothesised that differences in 
treatment may be the reason. 
Emergency admissions 
It has previously been shown that emergency admissions have a poorer survival rate than 
elective admissions to hospital most likely due to surgical complications, possible 
comorbidity and more advanced stage of disease. It has been reported that individuals 
with a lower socioeconomic status have a higher proportion of emergency admissions 
(Anderson et al 1992). Pollock & Vickers (1998) found that of those admitted as an 
106 
emergency, 34% were in the most affluent group and 56% in the most deprived group. 
Wrigley et al (2003) found only a weak association between emergency admission and 
socioeconomic status. Hole & McArdle (2002) reported from a population with high 
levels of deprivation that 32% presented with emergency admissions; they found no 
association between mode of admission and socioeconomic status. 
Stockton (2001) found there was no difference in the deprivation groups for emergency 
admissions in 1997 in Scotland. 
Curative surgery 
There is some evidence in the literature that management of colorectal cancer differs in 
the more deprived group. Monnet et al (1993) used comfort10 of housing as the measure 
of socioeconomic status and found that those in no comfort or medium comfort 
housing were less likely to received curative treatment. Desoubeaux et al (1997) found 
that differences in treatment were not significant in males but were in females. 
There was no association between delay of treatment and social class but there was a 
difference in the numbers receiving surgical treatment (Auvinen et al 1992). In the 
highest social class 54% received surgery compared to only 44% in the lowest social 
class. The largest difference found was in the group with distant metastases, where 10% 
of those in the high social class received surgery versus 2% of those in the lowest social 
class. 
10 No comfort housing - no indoor toilet or bathroom. Medium comfort housing - has toilet but no bathroom. Comfortable housing - toilet and 
bathroom 
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Access to treatment 
Auvinen et al (1992) reported a shorter delay in the more affluent group after presenting 
with symptoms. However, there was no difference in delay of treatment within 
socioeconomic status groups, once diagnosis had been made. 
Some studies have questioned the equality of access to treatment and the treatment 
provided to those in rural areas. Campbell et al (2001) reported little differences in those 
receiving surgery, chemotherapy or radiotherapy by socioeconomic status or by living in 
rural areas in Scotland. There was a trend towards a lower likelihood of receiving 
radiotherapy the further the person lived from a cancer centre. Auvinen et al (1992) 
reported social class differences in those who received chemotherapy and radiotherapy. 
Another Scottish study, (McLeod 1999) found that chemotherapy was less likely to be 
given to the most deprived group compared to the most affluent group. 
Wrigley et al (2003) found that survival was not linked with socioeconomic status but 
was strongly associated with a specialist surgeon, concluding that access to a specialist 
surgeon is not a problem for the deprived. 
Summary of socioeconomic status 
Within the current literature most studies report that there is an increased incidence of 
colorectal cancer in the most affluent group, this would suggest that there is an 
association between socioeconomic status and colorectal cancer. 
There is a consistent one and five year higher survival rate in rectal cancer than in colon 
cancer, through the UK. There are conflicting results published in the literature 
regarding an association with socioeconomic status and the Dukes' stage of tumour. The 
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majority of studies report that the most deprived group present with a more advanced 
stage of tumour than the most affluent group. The literature has some discussion 
regarding inequality and access to treatment resulting in a more advanced stage of 
tumour at diagnosis. However, there is little published evidence to suggest this is true. 
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Comorbidity 
Comorbidity is the presence of one or more medical conditions at the time of diagnosis 
of subsequent disease. With an ageing population there is likely to be an increase in the 
absolute number of such conditions in the population. The existence of comorbid 
conditions and their treatment may influence a doctor's decision on further treatment or 
surgery. 
Research has focused upon validity of the measurement tool used in a particular disease 
population and /or the usefulness of the measurement tool to measure outcome for the 
disease or diseases under study. Feinstein (1970) was first to report that the coexistence 
of various chronic illnesses had an important impact on the management and prognosis 
of cancer patients. 
In the past 15 years, there has been a greater research interest in comorbidity and the 
impact on various outcomes, particularly mortality or quality of life. There is consensus 
in the literature that comorbidity is an increasingly important factor that all research 
studies concerned with outcome measurements, should attempt to collect (Ogle et al 
2000, Mandelblatt et al 2001). 
The following is an overview of comorbidity literature in the key areas of research. 
Methods of collecting comorbidity data 
There is considerable debate regarding the optimum measuring tool and optimum 
method of collecting comorbidity data. Currently, the most frequent method of data 
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collection is to use data extractors to access medical records (Yancik et al 1996, 
Newschaffer et al 1997, Schrivjers et al 1995, De Marco et al 1999, Coebergh et al 1999, 
Vaeth et al 2000, Gonzalez et al 2001). 
Administrative databases are mainly used in large population studies and only a few 
countries have this resource available. Many data entry errors have been found when 
using administrative databases, compared with other methods of extracting comorbidity 
data (Newschaffer et al 1998, Extermann 2000, Humphries et al 2000). 
Some studies use self -reported or personal interview to ascertain comorbidity (Silliman 
and Lash 1999, Fillenbaum et al 2000, Ogle et al 2000, Mandelblatt et al 2001). One 
study used a physician to record comorbidity information but the number of cases was 
relatively small (Munro and Bentley 2004). 
Criticism of data extraction from medical notes has focused upon the accuracy of 
information extracted and the interpretation by extractors. Satariano and Ragland (1994), 
De Marco et al (1999) and Coebergh et al (1999), re- extracted comorbidity information 
from a sample of their own study populations and found 80 -95% accuracy. Self -reported 
comorbidity is limited by the ability to recall by the participants. Silliman and Lash (1999) 
and Mandelblatt et al (2001) found women with breast cancer accurately provided 
information about their disease and related symptoms, this information correlated well 
with the information extracted from medical records. 
One advantage of the interview or questionnaire methodology for self reported 
comorbidity is that it can be used in research studies where access to medical records is 
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not available through lack of staff or where financial resources prohibit other 
methodologies. 
The option of a doctor collecting the comorbidity data has major resource implications 
for any research study and to date has been limited. 
Measuring comorbidity 
There are 13 different measures of comorbidity used in clinical research, recently 
reviewed by de Groot et al (2003). Four of the most commonly used indices in cancer 
research have been peer reviewed for validity and reliability in clinical research. The 
other nine measurement indices have not accrued sufficient data to assess their validity 
and reliability. The four most common indices are: 
1. Charlson index - CCI (Chanson et al 1987a) 
2. Index of coexistent disease - ICED (Greenfield et al 1987, Greenfield et al 1993) 
3. Cumulative Illness Rating Scale - geriatric - CIRS G (Linn et al 1968, Miller et al 
1992) 
4. Kaplan (Kaplan and Feinstein 1974) 
Many studies compare results from different indices on their study population 
( Mandelblatt et al 2001, Extermann et al 1998, Extermann 2000). The four most 
common will be discussed in more detail. 
Chanson Comorbidity Index 
The Charlson Comorbidity Index (CCI) was developed using data from a series of 
medial admissions to an urban teaching hospital and their one -year mortality rates. The 
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comorbid conditions used in this index were extracted from medical notes and subjected 
to a multivariate analysis, yielding a summary severity index of 19 chronic conditions. 
Each category has an associated weight of zero to six based on the adjusted risk of one - 
year mortality. The overall comorbidity score reflects the cumulative increased likelihood 
of one -year mortality; the higher the score the more severe the burden of comorbidity. 
This index also correlates with specific outcomes of postoperative complications, length 
of stay in hospital and discharge to nursing home (Deyo et al 1992). 
The CCI index has been validated in studies that extract comorbidity information from 
medical notes using a pre-designed form with a list of conditions. 
Index of coexistent disease 
The Index of Coexistent Disease (ICED) estimates the severity of 14 comorbid 
conditions and provides an assessment of the functional disability caused by each. It is a 
significant predictor of functional status at 1 year. It includes two dimensions: 
1. The severity of each of the 14 coexistent medical conditions - the Index of 
Disease Severity (ICED - DS) 
2. The degree of physical impairment or overall functional severity caused by the 
comorbidity - the Index of Functional Severity (ICED - FS) 
These two dimensions are combined to form four levels according to increasing severity 
of co- existent disease and functional severity. The final index is a global measure of 
comorbidity. 
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Cumulative Illness Rating Scale 
The Cumulative Illness Rating Scale (CIRS) classifies 13 comorbid conditions by organ 
system and each condition is graded from zero (signifying no problems found) to four 
(severely incapacitating or life -threatening). This scale was slightly adapted by Miller et al 
(1992) for use on the elderly population who developed guidelines to enhance reliability, 
using the name CIRS - Geriatric or CIRS -G scale. 
Kaplan Index 
The Kaplan index uses two forms of classification; one is the type of comorbidity 
whether vascular or non - vascular and the second is the severity of the pathophysiology. 
This is rated on a four -point scale from zero (no comorbidity or easy to control) to three 
(recent exacerbation of a comorbid condition). The rating of the most severe comorbid 
condition is the overall comorbidity score. 
Information extracted from medical records is unlikely to give any indicator as to the 
effect these comorbid conditions have on individual's quality of life, mobility or 
functionality. Therefore, the method of data collection and index used to measure 
comorbidity should reflect the outcome measures of each research study (de Groot et al 
2003). Although these indices have been studied for many years, it appears that no one 
index will fit all purposes and possibly a combination of indices are required for some 
outcome measures ( Mandelblatt et al 2001). 
Comorbidity and treatment 
Comorbidity is frequently reported in individuals aged over 65 (Balducci and Extermann, 
2000). It is therefore not surprising that this is the target age group reported in the 
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comorbidity literature. The number and severity of comorbid conditions increases with 
age ( Yancik et al 1998, Yancik et al 2001 (b)). Few comorbidity studies compare people 
with cancer under age 65 to those over 65 ( Yancik et al 1998, De Marco et al 1999 and 
Coebergh et al 1999). 
Eligibility criteria for most clinical oncology trials require prior good health in the trial 
population. Many individuals aged 65 and over are excluded from these trials and 
therefore the study findings cannot be generalised to this age group, in the cancer 
population. As comorbidity increases with age, a greater proportion of the cancer 
population will be excluded from oncology trials. Existing comorbidity may mean that 
individuals are not offered standard treatment for their cancer. Havlik et al (1994) and 
Newschaffer et al (1997) showed this in their studies of women with breast cancer, as did 
Smith et al (1995) in a lung cancer study. Schag et al (1994) found that patients with prior 
comorbidity and lung and prostate cancer were less likely to be offered surgery. 
There are some appropriate reasons for deviation from standard treatment. The toxicity 
of treatment may be harmful with certain chronic conditions or may affect independent 
living. In a recent study, Extermann and Balducci (2003) found that older cancer patients 
tolerate chemotherapy, even though they may experience some degree of toxicity. It had 
little impact on their independence, their comorbid condition or their quality of life. 
It has been argued that the true effect of treatment in a range of comorbid conditions 
will not be known unless more individuals with comorbidity are offered entry into trials 
or given standard treatments and surgery ( Extermann 2000, Gijsen et al 2001, Yancik et 
al 2001 (a)). Mandelblatt et al (2001) noted in her cohort of women with breast cancer 
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that the life expectancy, even for the more sick patients, was eight years and stated fears 
that older patients with comorbidity are being under treated. 
Comorbidity and outcome 
Survival 
The current literature is highly focused on the impact of comorbidity on survival. 
Chanson et al (1987) developed an index of 19 comorbid conditions weighted for their 
impact on mortality. Later, Chanson et al (1994) developed a combined age -comorbidity 
score. The Chanson index has become the most frequently used scale in measuring the 
impact of mortality in cancer studies (de Groot et al 2003). Virtually all research studies 
using the Charlson index found it to be a valid and reliable predictor of mortality. 
The following researchers have used the Charlson index, for breast cancer studies 
(Chanson et al 1987, West et al 1996, Ballard -Bash et al 1996, Newschaffer et al 1997), 
prostate cancer (Zincke et al 1994), head and neck cancer (Singh et al 1999), colorectal 
cancer (Munro and Bentley 2004) and also a study with various cancers, which included 
many of the above (Gonzalez et al 2001). 
The above studies addressed a variety of cancer sites but only a limited number have 
reported on survival in colorectal cancer patients. Gonzalez et al (2001) showed that 
following a diagnosis of colorectal cancer; survival was poorer for those patients with 
comorbid conditions, compared to those with no comorbidity. Munro and Bentley 
(2004) demonstrated that comorbidity has an important influence upon the overall 
survival and the cause specific survival in patients with colorectal cancer. Stockton 
(2001) found comorbidity was strongly correlated with survival rate. Future studies 
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reporting on survival rate in the future should therefore include a measure of 
comorbidity. 
Functionality or Quality of life 
Also of interest to researchers are the effects of comorbidity on functional status of 
people with cancer (Extermann et al 1998). It is felt that this should also be measured 
along with the number and severity of comorbid conditions. The Kaplan index, 
described in more detail above, measures both comorbidity and functionality. 
However, there are other measures of functional status that can be used along with an 
independent comorbidity index. It has been shown that comorbidity measures appear to 
be statistically independent of performance status and functional scales (Extermann et al 
1998). At present there appears to be an agreement that no one comorbidity index can 
cover all aspects of the effect of comorbidity. 
Delay in diagnosis 
It has been suggested that individuals with serious comorbidity are less likely to be 
informed of surveillance recommendations for cancer, as they have a more urgent 
conditions requiring the attention of the GP (Jaen et al 1994). Cooper et al (1997) in a 
study of GP referrals for colorectal surveillance found that both doctors and patients felt 
that cancer surveillance has less value when there are other competing causes of 
morbidity present. 
There is little literature relating to comorbidity and the effect it has on an individual 
reporting new symptoms to their doctor. There is some suggestion from earlier literature 
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by Crawford and Cohen (1984) that comorbidity may mask early symptoms and lead to 
later diagnosis. Conversely, there is a theory that individuals with chronic comorbid 
conditions attend their GP more frequently and therefore may be more likely to be sent 
earlier for investigations, with a possibility of being diagnosed at an earlier stage of the 
disease. Satariano and Ragland (1994) and West et al (1996) found that in women with 
breast cancer there was a trend towards earlier diagnosis of women with increased 
comorbidity. Neither of these studies used multivariate analysis, thus limiting the 
interpretation of their findings. 
Gonzalez et al (2001) conducted a study in colorectal cancer, prostate cancer, breast 
cancer and melanoma and hypothesised that patients with more comorbidity would be 
diagnosed at a later stage of the disease. This study had a large cohort in each cancer site 
(8,933 colorectal cancer cases). 
Multivariate analysis found overall that, taking all cancer sites together, a patient with any 
comorbid condition was more likely to have cancer diagnosis at a later stage of disease. 
However, further analysis of individual cancer sites suggested that this is true only for 
prostate and breast cancer. It was not found in colorectal cancer or melanoma. 
Porta (1996) incidentally found in a small Spanish sample of 110 individuals diagnosed 
with colorectal cancer, 20 with oesophageal cancer and 52 with stomach cancer that 
those with more comorbidity presented to their GP sooner than those with no current 
medical illness at diagnosis. 
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Comorbidity, socioeconomic status and colorectal cancer 
The influence of comorbidity on survival has had little attention in colorectal cancer 
studies and even less in studies combining colorectal cancer, socioeconomic status and 
comorbidity. 
Polendack et al (2001) and Wrigley et al (2003) found that those with comorbid 
conditions had poorer survival than those without. They suggest that this may be a 
reflection of the choice of treatment for those with higher comorbidity. They used 
different measures of comorbidity, Polendak using the Chanson comorbidity index, and 
Wrigley making a simple count of condition in the medical notes, as the measure of 
comorbidity. 
Stockton (2001) reported that comorbidity did not explain the deprivation -specific 
gradient in risk of death whereas, Wrigley et al (2003) found comorbidity was only 
associated with all cause survival. There remains no clear reason to why there is poorer 
survival in colorectal cancer for more deprived individuals. It is certain that increasing 
age, Dukes' stage of tumour and receiving curative surgery all have a positive impact on 
survival, but these factors do not fully explain the differences between socioeconomic 
status groups. 
It has been suggested that in the most deprived group tumour biology is more aggressive 
which may be the result of nutritional, immune or comorbidity status (Auvinen 1992). 
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Summary of comorbidity 
The current literature remains highly focused upon comparing comorbidity data 
collection indices and the outcome measures of these indices. However the Chanson 
comorbidity index was developed in 1987 and remains in use today and is the most 
commonly used index in UK literature. A proportion of this comorbidity literature also 
reports on the methodology of data collection and demonstrates that the most frequent 
methodology is using trained data collectors to extract data from medical notes. 
As comorbidity is known to be more common in the age group over 65 years there are 
few studies report on individuals below 65 years. A section of this literature deals with 
the concern that many research studies exclude individuals with comorbidity and in 
doing so exclude a large proportion of the group aged over 65. Therefore results from 
these studies cannot be generalised to those over age 65. The literature concludes that 
researchers should include cases with comorbidity in their cohort in order to understand 
comorbidity and the interaction with common cancer treatments. 
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Lower gastrointestinal signs and symptoms 
This chapter reviews the published literature on lower gastrointestinal signs and 
symptoms. A large proportion of the literature relates to reporting rectal bleeding to a 
GP and in particular rectal bleeding in the community. This literature is included in this 
thesis as it is closely linked with a diagnosis of colorectal cancer. 
Lower gastrointestinal symptoms that can prompt a visit to the General Practitioner 
(GP) are rectal bleeding, change in bowel habit, abdominal discomfort or abdominal 
pain. All of these symptoms are reported frequently in primary care, and the task for 
GPs is to decide if the presenting signs or symptoms suggest a diagnosis of colorectal 
cancer. 
A very extensive literature exists on all aspects of lower gastrointestinal symptoms and 
colorectal cancer and is dominated by the following areas: 
o Rectal bleeding 
o Delay in presentation 
o Stage at diagnosis 
o Delay in diagnosis 
o Delay and mortality 
Recent research has focused upon the combination of symptoms in the development of 
guidelines. The current literature on signs, symptoms and their outcome has primarily 
been in publications from a group of researchers in UK. 
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Rectal bleeding 
Rectal bleeding is a symptom associated with colorectal cancer. Many studies have 
reported that rectal bleeding occurs in a large percentage of the general population, on 
most occasions, it is self -limiting and the large majority of cases do not seek medical 
advice. 
Rectal bleeding is also prevalent in other colorectal diseases such as, haemorrhoids 
(Goulston et al 1986, Korkis and McDougall, 1995) and irritable bowel syndrome Gones 
and Lyeard, 1992). This can make it very difficult for GPs to distinguish between rectal 
bleeding from a potential colorectal cancer and from other causes. There is a very fine 
balance between missing a diagnosis of colorectal cancer and subjecting large numbers of 
people to complex investigations, which are not without risk. These investigations can be 
anxiety provoking and physically uncomfortable for their patients. There is an added 
danger of overloading an already stretched NHS system by investigating individuals with 
a low risk of colorectal cancer. 
Rectal bleeding in general population 
The prevalence of rectal bleeding is reported as being present in between 18 and 20% of 
those aged 20- 80years in the UK, (Jones and Lyeard 1992, Crossland and Jones 1995, 
Thompson et al 2000) and present in 15.5% to 20% of the Australian population (Dent 
et al 1986, Byles et al 1992, Talley and Jones 1998). 
Few studies report on whether this bleeding was seen for the first time in the previous 
year or whether it had happened on previous occasions. The prevalence of rectal 
bleeding seen in the previous year was reported at 8.8% (Ferraris et al 2004) and 19% 
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(Crossland and Jones 1995) in the UK population. In the Australian population, Byles et 
al (1992) found only 4.5% had bleeding in previous year. 
Another important factor for consideration when assessing rectal bleeding is the age at 
which individuals present. Crossland and Jones (1995), Talley and Jones (1998) and 
Thompson et al (2000) all found that rectal bleeding appeared to be more common in 
adults that were younger than age 50. 
Three population based studies in the UK reported that only a few individuals ever seek 
medical advice for rectal bleeding, the following results were found 18% (Farquharson 
and Heald 1994), 28% (Thompson et al 2000) and 41% (Crossland and Jones 1995) this 
was also true for those individuals who have a family history of colorectal cancer that 
would increase their risk and yet do not seek advice. 
Crossland and Jones (1995) reported that 66% of those reporting rectal bleeding were 
under age 50; much lower figures of 14% were found in Australia; these cases were age 
65 and under (Talley and Jones 1998). 
Thompson et al (2000) reported a positive predictive value of 1 in 709 for colorectal 
cancer from those reporting rectal bleeding in the community. This figure is similar to 1 
in 1000 that reported by Fijten et al (1993) who estimated that only 7 per 1000 with 
rectal bleeding ever consult a GP and of these 2 per 1000 are deemed to have clinically 
important bleeding. 
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Reasons for not seeking advice on rectal bleeding 
The percentage of people seeking advice for rectal bleeding varies across studies, in 
differing populations. The reasons given for not seeking advice are: not perceiving 
symptom to be serious (Crossland and Jones 1995), certainty that the bleeding is from 
haemorrhoids (McAdam et al 1979, Byles et al 1992, Crossland and Jones 1995) and 
hope that it would clear up ( Byles et al 1992). 
Haemorrhoids have been reported to be the most common cause of rectal bleeding in 
the general population. Goulston et al (1986) reported that haemorrhoids were 
confirmed as the source of rectal bleeding in 73% of the study sample, however, it was 
reported that 63% of those with haemorrhoids also had a concurrent colon lesion (not 
all colorectal cancer). 
Rectal bleeding in those reporting to a GP Practice 
Although rectal bleeding is common in the general population, few people ever report 
this to their GP; this has been referred to as the `tip of the iceberg' (Thompson et al 
2000). If everyone with rectal bleeding did attend his or her GP the system would be 
overloaded. Therefore, the public health message regarding rectal bleeding in the general 
population should be very specific and clear. 
Individuals who do present to their GP with rectal bleeding are often eligible for 
research studies. This group of individuals is possibly an easier population to access for 
research purposes, as it provides the opportunity of follow -up to ascertain a diagnosis 
for the source of bleeding. 
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These studies vary in many important respects such as, the country of study population, 
sample size, ascertainment of the sample and age group included in sample. Not all 
studies specify whether rectal bleeding was an isolated symptom or if other 
gastrointestinal (GI) symptoms were also present in those diagnosed with colorectal 
cancer, thus making comparisons difficult. 
Results from studies of rectal bleeding presenting to a GP and the results of follow up to 
diagnosis or discharge are shown in Table 14 
Table 14 Percentage of individuals diagnosed with colorectal cancer 
after presenting to their GP with rectal bleeding. 
Author and 
Year Country Sample size Age 
% diagnosed with 
colorectal cancer 
(number) 
Goulston et al 
1986 
Australia 145 >40 10.3% (15) 
Fijten et al 
1995 




USA 102 - <50 0% 
Douek et al 
1999 
UK 91 with isolated 
bleeding 
84 with rectal bleeding 
and other symptoms 
All ages 2.2% (2) 





Denmark Study 1- 208 
Same data collected 2 
years later from 
different GPs 
Study 2 -209 
>40 15.3% (32) 
12% (22) 
Dodds et al 
1999 
UK 8438 All ages 5.6% (471) 
0.56% 
With rectal bleeding 
only 
Wauters et al 
2000 
Belgium 386 All ages 7% (27) 
Branagan et al 
2004 
UK 16,487 All ages 6.4% (690) 
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The most consistent reported result from studies interested in rectal bleeding is the 
prevalence of colorectal cancer. Most rectal bleeding studies accept those with rectal 
bleeding and other gastrointestinal symptoms in their inclusion criteria. 
There were few studies that reported on rectal bleeding in isolation. Douek et al (1999) 
found that 20% presented with isolated rectal bleeding and 2.2% of these were 
diagnosed with colorectal cancer. Dodds et al (1999) found a prevalence of 0.56% for 
those with isolated rectal bleeding. 
Studies reporting rectal bleeding and other associated symptoms, reported on the 
proportion found to have colorectal cancer. Goulston et al (1986) found 10.3 %, Fijten et 
al (1995) reported 3.3 %, Norrelund & Norrelund (1996) reported they found 15% and 
10% in two cohorts in different time periods, in the one study, Wauters et al (2000) 
found 7.7% and Branagan et al (2004) reported 6.4% with colorectal cancer. 
Rectal bleeding in isolation is not a good predictor of colorectal cancer and is common 
in the younger age group. The chance of a colorectal cancer diagnosis increases as a 
person makes their way through the NHS system. The lowest positive predictive value 
(PPV) is in those with rectal bleeding in the community, increasing in those presenting to 
GPs with rectal bleeding and the highest in those referred for investigations. Researchers 
have suggested that cumulative symptoms may be a more accurate guide to determine an 
individual's risk of colorectal cancer in the presence of rectal bleeding (Fijten et al 1995, 
Mant et al 1989, Norrelund & Norrelund 1996, Thompson et al 2000). This is supported 
by the recent research i.e. that a combination of symptoms may guide more appropriate 
referral for investigation (Thompson et al 2000, Selvachandran et al 2002) 
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Rectal bleeding and associated symptoms 
There are several other symptoms that are associated with positive prediction of 
colorectal cancer. Norrelund & Norrelund (1996) found that age greater than 40 years 
and change in bowel habit are associated with an increased risk of colorectal cancer. 
Fijten et al (1995) reported that older age and palpable mass had an increased risk of 
colorectal cancer and Mant et al (1989) reported an association with dark red blood 
mixed with stool and absence of haemorrhoids. 
Despite these findings by other researchers, Thompson et al (2000) cautions against the 
positive prediction of symptoms such as painless rectal bleeding, dark red bleeding and a 
change of bowel habit. They reported that these symptoms were all present in a high 
percentage of individuals in the community who also reported rectal bleeding to their 
GP and did not have colorectal cancer. They suggest that painless rectal bleeding without 
anal symptoms is a better indicator of colorectal cancer in this population. 
Summary of rectal bleeding 
Rectal bleeding is common in the community especially in the younger age group and in 
majority of cases it is self -limiting. Only a small proportion of those experiencing rectal 
bleeding ever seek medical advice for this symptom. 
Differences in study methodology and reporting make the overall comparisons of these 
studies difficult. It appears that rectal bleeding alone is not a good predictor of colorectal 
cancer, although it was shown by Armstrong James et al (1997) that those with rectal 
bleeding as the only symptom at diagnosis were more likely to have a Dukes' stage A 
tumour. 
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Delay in presenting with symptoms 
Delay in presenting with GI symptoms remains a regular topic of publication. 
The literature presents the length of delay in various ways: delay from first symptom 
until presentation to a GP, delay from first symptom to diagnosis or delay from first 
symptom until surgery. 
There are inconsistencies in data presentation within the literature on this sub -group. 
1. Studies often give a breakdown on tumour site within the large bowel such as, 
rectal cancer and colon cancer. However, these are often inconsistent. Some 
studies report right -sided colon cancer and left sided colon cancer and may give 
no definition of where the right or left sided start and stop. Some studies report 
right sided and left sided as proximal and distal colon cancer. Some give the 
definition of the inclusions for these sites, which highlights these sub -sites vary 
between studies. Some studies include the sigmoid colon in the proximal colon 
and others do not. The definition of rectal cancer is sometimes cancer of the 
rectum only and, in other studies, rectal cancer includes the rectum and the 
recto -sigmoid junction. 
2. When discussing delay it may be presented as mean delay or median delay, rarely 
both and with no reference to normality of distribution. 
3. Timescale of delay differs through the literature and can be presented in days, 
weeks, months or in blocks of time such as > 1 month, > 3months or < 3months, 
without raw data this makes comparison very difficult. 
Table 15 gives an illustration of the data presented in the literature for delay in 
presentation with gastrointestinal symptoms. Only studies reporting on delay until 
presentation at GP are included in this thesis. 
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Table 15 Reported delay time from first symptom until presentation 
to GP 
Author 
Year Mean delay for 
Colon cancer 




Shallow et al 1954 Site of colon dependent 
35 -42% waited 
< 6 months - 
47% waited 
< 6 months - 
750 
Shallow et al 1954 Site of colon dependent 
20 -24% waited 
> 6 months - 
31% waited 




12.7 weeks 16.2 weeks 
200 
McAdam 1979 Site of colon dependent 
14 -22 weeks 17 weeks 
150 
Ratcliffe et al 1989 Site of colon dependent 
60 - 62 days 90 days 
332 
Wheeler et al 1998 1979 -12.7 weeks 16.2 weeks 100 colon 
100 rectal 
cancers 
Wheeler et al 1998 1995 - 9.6 weeks 20.8 weeks 
Aimstrong James 
et al 
1997 Site of colon dependent 





93 days 157 days 
70 
Mean delay for 
Colorectal Cancer 
Dixon et al 1990 Site of colon dependent 




Curless et al (b) 1994 Site of colon dependent 
13 -26 weeks 
273 




Roncorni et al 1999 10.8 weeks 100 
Majumdar et al 1999 26 weeks 194 
Gonzalez- 
Hermoso et al 
2004 50% waited< 3 months 
50% waited > 3 months 
660 
Site of colon dependent - information given for right and left sided of colon, however, 
some left sided include; the rectum and some rectal cancers include the sigmoid colon or 
recto -sigmoid junction. 
*Median delay 
Table 15 demonstrates the diversity of data presentation from studies concerned with 
delay with gastrointestinal symptoms. It is apparent from studies published over a period 
of 50 years, that there has been little change in the length of time people wait with 
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symptoms, before they present to their GP. Most studies report a mean delay of three 
months or more. 
Wheeler et al (1999) collected data 16 years apart and found that the delay time for those 
with colon cancer improved and those with rectal cancer delayed almost twice as long as 
16 years ago. The conclusion by the authors was that there is a lack of public knowledge 
associated with colorectal cancer. Table 15 presents information separately on colon and 
rectal cancer and provides evidence that those diagnosed with rectal cancer delay longer 
than those with colon cancer. The marked difference in time of delay is striking in some 
studies. In addition, it is reported that males delay longer in reporting symptoms 
(Hansen et al 1997, Potra et al 1996). 
There was a variation in the methodology of data collection between studies although 
most studies collected data via interviews with the patients. Three studies used hospital 
records to collect their data (Shallow et al 1955, Majumdar et al 1999 and Gonzalez - 
Hermoso et al 2004). Data collection from medical notes has been criticised due to GPs 
selecting clinical data to write their referral letters and hospital doctors selectively 
recording infotniation given to them by the patients. 
Reasons for delay 
Holliday & Hardcastle (1979), Porta (1995) and Wheeler et al (1998) asked individuals 
diagnosed with colorectal cancer why they waited a significant time before presenting to 
their GP. The results are presented in Table 16. 
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Hardcastle Porta Wheeler 
Not concerned 
about symptoms 45% 44.3% 35% 
Not serious 
enough to report 43% 23.5% 46% 
Not serious 
disease or cancer Not reported 88.5% 81% 
Langenbach et al (2003) also asked the same question and his cohort responded 
differently, as follows; 50% `feared unpleasant investigations', 40% hoped `the symptoms 
would just resolve themselves with no need to report to a GP' and 10% had `no reason 
at all for delaying to report symptoms'. 
The reasons for delay in reporting symptoms that were given by those who had 
colorectal cancer are similar to the reasons given in a population -based study for not 
reporting rectal bleeding. Dent et al (1990) found that 13% with rectal bleeding assumed 
they had haemorrhoids, Byles et al (1992) found that 13% `did not want unpleasant tests' 
and only 4% `thought it could be cancer'. Kocher and Saunders (1999) found 27% 
thought `not serious' and 27% `hoped bleeding would stop'. The perceived seriousness 
of the symptom for that individual is the deciding factor, in reporting symptoms to their 
GP Qones et al 1993). 
Overview of studies reporting on symptom delay 
Studies consistently reported a slightly higher number of males. On average the 
distribution is approximately 52% males to 48% females. This would match with registry 
data. The mean age range in these studies is 60 -72 years. Most studies are in small 
populations, restricted to one hospital site. The majority of studies are from the UK with 
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a reasonable contribution from Australia, Netherlands and United States of America. 
The sample sizes vary from 44 to 750 recruits. Only a few studies focus on an age range, 
most have no age restriction. 
Site distribution 
The site distribution varies throughout the studies, most showing a slightly smaller 
proportion of rectal cancers. Shallow et al (1955) found the opposite with 63% rectal 
cancer and 37% colon cancers. 
There are an increasing number of males diagnosed with rectal cancer (McSherry et al 
1969, Bassett et al 1979, Ratcliffe et al 1989) and more females with right -sided colon 
cancer (Alley & McNee, 1986 and Stebbing and Nash 1995). 
Alley & McNee (1986) reported a greater number of females in the >75 age group, but 
cautioned this may be because there are significantly more females, in this age group. 
Dukes' stage distribution 
Dukes' stage distribution is topical in many studies that report on delay in presentation. 
As the Dukes' staging definitions have been modified over time, there is a difference 
between the studies. The reporting of Dukes' stage of tumour will be dependent on the 
pathology department's criteria in use at time of study. Table 17 shows the distribution 
of Dukes' stage in published literature. 
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Table 17 Distribution of cases with colorectal cancer by Dukes' stage 
Author Year 
Dukes' stage 
A B C D Unknown 
McSherry et al 1969 24.4 24.8 12.7 38.1 
Bassett et al 1979 17 28 27.5 
Robinson et al 1986 5 49 28 18 
Stubbs & Long 1986 7 39 26 26 2 
Ratcliffe et al 1989 8.7 48.1 27.4 5 
Kyle et al 1991 10 42 23 25 
Anderson et al 1992 3 30 28 30 8 
Curless (b)et al 1994 <70 9 33 25 31 
>70 14 31 23 27 
Hansen et al 1997 12 43 43 2 
Roncorni et al 1999 17 30 39 14 
Young et al 2000 6 56 38 
Kiran & Glass 2002 A & B 53 C & D 47 
Diagnosis of Dukes' C tumours has increased in recent years and Dukes' D tumours 
were found in greater than 20% in many studies. 
Curless et al (1994b) found that there was a trend towards the elderly not reporting 
symptoms and in particular change in bowel habit. However they found that those < 70 
years had a higher percentage of Dukes' D tumours and those >70 year presented with 
more Dukes' A tumours. 
Scott et al (2004) presented information from a single hospital in UK, over the period 
1995 to 2003. Dukes' A tumours were reported at 18% in 1995 and to 9% in 2003 and 
Dukes' D tumours were reported at 24% in 1995 increasing to 32% by 2003; this 
increase was evident from the year 2000. 
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Dukes' stage and delay in presentation 
The Dukes' stage of tumour at diagnosis will determine the outcome in terms of surgery, 
treatment and survival. Few studies investigating delay in presentation with symptoms 
found any correlation of any variable with Dukes stage at presentation. 
Vineis et al (1993), Roncorni et al (1999) and Langenbach et al (2003) found a positive 
correlation between time delay in presentation and stage of tumour. Robinson et al 
(1986) reported a statistically significant correlation in rectal cancer only. 
A more favourable Dukes' stage was found to be associated with longer presentation 
delay in some studies. Ratcliffe et al (1989) reported Dukes' B subjects delayed for 90 
days and Dukes' C subjects delayed for 60 days. Similarly, Kyle et al (1991) found that of 
those who presented in under 12 weeks, 33% had Dukes' A versus 61.5% of those with 
Dukes' D. Wheeler et al (1999) and Bassett et al (1979) also found that the more 
advanced the tumour, the less delay. Wheeler et al (1999) reported that delay was greater 
in rectal cancer for Dukes' A and C tumours. 
Although it is counterintuitive, Mulcahy & O'Donaghue (1997) reported that the longer 
the duration of symptoms, the more favourable the prognosis for recovery. There was a 
trend towards longer symptom duration in younger patients. The longest symptom 
duration was observed in rectal cancer patients, the shortest in patients with tumours of 
the left colon. 
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Family history 
As family history is a known risk factor attempts were made to collect these data in some 
studies. In the majority of studies the definition of a positive family history was having 
one first degree relative with colorectal cancer. The following studies reported the 
prevalence of family history; McSherry et al (1969) found 5.1 %, Ratcliffe et al (1989), 
16% and Kiran and Glass (2002) 6.8% in their cohorts. 
Ratcliffe et al (1989) and Kiran and Glass (2002) found a longer delay time of those with 
the knowledge of family history versus those not reporting knowledge of family history. 
In a study of reported rectal bleeding to GP (Mant et al 1989) 15 individuals were 
diagnosed with colorectal cancer and 10 had a family history. 
Nichols et al (1999a) reported a weak association of family history and colorectal cancer 
in symptomatic patients. Family history was reported by 3.3% of those aged <65 and 
11.8% of those >65. This is in contrast to other findings where hereditary colorectal 
cancer is more common in patients <65. This association may be stronger if guidelines 
are used as these have been found more accurate in identifying those at increased risk 
(Dunlop & Campbell 1997). 
Other factors involved in delay 
Other reported factors have been found to influence delay in reporting symptoms. 
Those who discussed their symptoms with family or friends were more likely to present 
sooner. The relationship to the person did not influence reporting and closeness of 
relationship was not found to be important (Holliday and Hardcastle 1979). 
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Dent et al (1983), Flashman et al (2004) and Langenbach et al (2003) reported that the 
more affluent had a shorter delay in presenting with symptoms. Langenbach et al (2003) 
also noted that those with private health insurance had least delay and those on welfare 
had the longest delay. Also those who were married reported symptoms sooner than 
those who were single, divorced or widowed. This supports the data published by 
Holliday and Hardcastle (1979). 
Vines et al (1993) reported that advanced disease was commoner in those who were well 
educated, than those with fewer years of education. 
Emergency admission 
It is often assumed that those who present as emergency admissions have delayed in 
reporting symptoms to their GP and that the stage of disease is advanced. 
The literature does not support an association between delay and advanced Dukes' stage. 
There is little statistically significant evidence that those presenting as an emergency have 
more advanced stage of tumours (Holliday & Hardcastle 1979 and Stebbing & Nash 
1995). The advanced stage of tumour, together with the risks of emergency surgery, 
increases the risk of mortality. Table 18 identifies the percentage of individuals diagnosed 
with colorectal cancer that presented as an emergency within the various studies. 
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Table 18 Percentage of colorectal cancer patients with emergency 
admissions from published reports 
Author Year 
Admitted as 
emergency ( %) Comments 
Holliday& 
Hardcastle 
1979 42.0 76% had consulted GP 
concerning symptoms 
Stubbs & Long 1986 26.0 Mean duration of symptoms 
2.7months 
Ratcliffe et al 1989 26.0 
Kyle et al 1991 23.0 20% had symptoms for longer 
than 1 month 
Anderson et al 1992 36.0 
Curless et al (b) 1994 25.0 No difference in age 
Stebbing & Nash 1995 33.0 
Mulachy & 
O'Donoghue 
1997 23.4 2.7 emergencies for perforation 
20.7 those presenting with 
obstruction 
Roncorni et al 1999 18.0 
Wheeler et al 1999 26.6 1.5 Presented at A &E 
25.1 acute presentations 
Young et al 2000 15.0 
Kiran & Glass 2002 28.9 
The smaller percentage of emergency admissions found by Mulcahy and O'Donoghue 
(1997) and Wheeler et al (1999) are the number admitted via accident and emergency 
only. The higher percentage included those presenting with acute obstruction which is 
similar to the other studies. Interestingly, Anderson et al (1992) in a study of patients 
admitted to a Glasgow hospital reported that 36% presented as an emergency. 
Emergency admission and Dukes' staging 
There were a higher proportion of individuals with advanced Dukes' staged tumours 
admitted as an emergency, but this distribution was not significantly different from those 
admitted for elective surgery (Holliday & Hardcastle 1979 and Stebbing & Nash 1995). 
Anderson et al (1992) reported the proportion with tumours not staged was much 
greater in the emergency admissions (15% versus 6% in the elective admissions). Many 
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tumours have no stage because they are not removed, for a variety of reasons. Those 
admitted as an emergency and having no stage recorded at diagnosis are unlikely to be 
due to cancer within a polyp. 
Emergency admission and delay in reporting symptoms 
There is strong evidence that those who are admitted as emergency admissions do not 
delay longer than those with early stage disease. Stubbs & Long (1986) reported that 
mean duration of symptoms for the 55 (26 %) admitted as emergency admissions, was 
2.7 months but 40% of these individuals had symptoms for less than 2 weeks. Ratcliffe 
et al (1989) and Kyle et al (1991) also reported shorter symptom duration in cases 
admitted as an emergency admission. 
Holliday & Hardcastle (1979) found that of the 42 (42 %) cases admitted as emergency 
admissions, 76% had previously consulted their GP about symptoms. Of this 76 %, 12% 
were currently under investigation at hospital outpatients. 
Curless et al (1994 (b)) reported that cases >70 years were no more likely to present as 
emergencies than those <70 years. Anderson et al (1992) reported differently, with a 
higher proportion of age 75 and over admitted as an emergency. Emergency admissions 
are less likely to be rectal cancer, as noted by Anderson et al (1992). 
Emergency admission and mortality 
Anderson et al (1992) found that the 30 -day mortality rate was significantly greater in 
emergency admissions and reported 28% mortality in emergency admissions versus 9% 
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in elective admissions. Stebbing and Nash (1995) confirmed this finding and reported 
20.7% for emergency admissions and 3% for elective admissions. 
Delay in referral for investigation 
The issue of delay is commonly discussed in the literature and, in particular, there has 
been some debate regarding where in the process the longest delay existed, and where in 
the process the delay was most important in terms of affecting outcome. Not all studies 
report delay in presentation in a stepwise progression, some studies report an overall 
delay from onset of symptom until diagnosis or surgery. 
McArthur & Smith (1984) and Curless et al (1994 (a)) have shown the delay by GPs to 
be the same as patient delay. All other studies found the patient delay to be greater than 
the medical delay. In one exception, Roncorni et al (1999) reported the mean patient 
delay to be 10.8 weeks with medical delay 19.5 weeks. 
There is concern in the literature that simple procedures are not carried out on patients 
reporting gastrointestinal symptoms, citing: 
o Abdominal and rectal examinations, 
o Routine haemoglobin levels and proper investigations as to the source of 
anaemia, 
o Proper attention paid to number and relation of presenting symptoms. 
Abdominal and rectal examination 
There is a high probability that colorectal cancer will be diagnosed if an abdominal or 
rectal mass is found during a physical examination. The palpation of an abdominal or 
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rectal mass should prompt a speedy referral for further investigations. However, the 
literature suggests that these routine examinations are not being carried out in the GP 
surgery. 
McSherry et al (1968), McArthur & Smith (1984) and Langenbach et al (2003) reported 
only 29 %, 32% and 23% of cases had abdominal examination at first visit to GP. 
McArthur & Smith (1984) noted that presentation with abdominal pain was the greatest 
prompt for GP to perform an abdominal examination. 
McSherry et al (1968) reported 39% of rectal cancers were found by rectal examination, 
but did not indicate if this examination was carried out by the GP before referral. Bassett 
et al (1979), Holliday & Hardcastle (1979), Dixon et al (1990) and Wheeler et al (1999) 
reported that 90 %, 77 %, 70% and 78% of rectal cancers did have a rectal examination by 
GP before referral. Bassett et al (1979), Dixon et al (1990) and Wheeler et al (1999) 
found GPs correctly diagnosed a rectal cancer in a percentage of the cases examined, 
53 %, 47% and 50% respectively. 
McArthur & Smith (1983) reported that only 34% of colorectal cancer patients were 
given a rectal examination on the first visit; this figure rose to 38 % after a second visit, a 
figure much lower than other studies. They also noted that when abdominal and /or 
rectal examinations were carried out there was a delay of no more than 3 days for 
referral. For those individuals not examined by a GP, 48% had not been referred after 3 
months. 
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Dixon et al (1990) found that in individuals referred for treatment of haemorrhoids, 12% 
were found to have a palpable rectal cancer; however they had no examination by a GP. 
This alone resulted in delay of diagnosis. Wheeler et al (1999) found that in 22 patients 
who did not have a rectal examination by a GP 45% had a palpable tumour found at 
outpatient appointment. Results have shown that a high number of abdominal and rectal 
cancers were found by GPs when an examination was carried out. Adherence to 
protocols may prevent delays in referral to hospital. 
Hennigan et al (1990) carried out a survey of GPs practice on rectal examinations and 
concluded that the reasons given for not carrying out a rectal examination on 
symptomatic patients were: 
o Reluctance of patient 
o Knowledge that the examination would be repeated again at outpatient 
department 
o Lack of time 
o No chaperone available 
Iron Deficiency Anaemia 
Iron deficiency anaemia is the most common cause of anaemia and affects approximately 
1% of the population in the United Kingdom. The most common causes are bleeding 
from the gastrointestinal tract or uterus, and it can be a sign of underlying serious 
disease. 
The quality of investigation and treatment for iron deficiency anaemia is questioned in 
the literature. Logan et al (2002) carried out a study in the community of individuals 
who were found to have iron deficiency anaemia. GPs were randomised to control or 
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intervention arms; the intervention arm received a prompt with prescribing details, 
follow up details and advice to investigate the cause. The results of this study improved 
appropriate prescribing but failed to impact on investigation. Of the individuals in this 
study, 7% were diagnosed with colorectal cancer within 12 months, 25% had no further 
tests and of these 40% did not have a normal haemoglobin level, within 12 months. 
As has been previously reported, iron deficiency anaemia is present in a high percentage 
of individuals with right sided colon cancer. Ria et al (2004) investigated the role of iron 
deficiency anaemia as part of a surveillance programme. Haemoglobin estimations were 
carried out on all those under going flexible sigmoidoscopy. The aim was that left sided 
colon cancer would be identified by sigmoidoscopy and right sided colon cancer would 
be identified by iron deficiency anaemia. This study reviewed the 194 individuals with 
right sided colon cancer and iron deficiency anaemia, levels were set at <11g /di in men 
and <10g /dl in females. Results showed that 44% of males and 57% of females had iron 
deficiency anaemia and concluded that iron deficiency anaemia alone is a poor predictor 
of right sided colon cancer. 
Till and Grunduran (1997) investigated the role of iron deficiency anaemia in the 
diagnosis of colorectal cancer, using a reference of <10g /dl for males and females. On 
reviewing notes 3 years later, 15% had a diagnosis of colorectal cancer. In a similar study, 
Stewart et al (2004) found 6.4% to have colorectal cancer, at time of initial investigations; 
no follow up period was reported. Archer et al (2003) studied the diagnostic delay in 
colorectal cancer within a group of individuals with iron deficiency anaemia. The study 
found that 38% of the cohort had iron deficiency anaemia at diagnosis, 12 % had this 
diagnosed for 6 months or more before diagnosis. There were significantly more right 
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sided colon cancers (65 %) with iron deficiency anaemia, but no significance was found 
between iron deficiency anaemia and Dukes' stage of tumour. 
The percentage of individuals with iron deficiency anaemia in colorectal cancer studies is 
given in table 19. In common with other inconsistencies in the colorectal cancer 
literature, the reporting of iron deficiency anaemia also varies between studies. Many 
studies do not publish the reference value used for anaemia, and, those who do, often 
use different base levels, possibly accounting for the wide range of results shown in 
Tables 19 to 23. 
Haemoglobin levels are often extracted from medical notes, where it is recorded at time 
of diagnosis or surgery, while other studies record haemoglobin levels at time of referral 
from GP. 
Shallow et al (1969), Alley & McNee (1986), Stebbing & Nash (1994) and Till & 
Grundman (1997) all found an excess of right sided colon cancer with iron deficiency 
anaemia. Goodman & Irvin (1993) report an excess of females, with right sided colon 
cancer. Also reported is that right sided colon cancers often present with iron deficiency 
anaemia a significant time before any other symptoms that are suggestive of colorectal 
cancer. 
Goodman & Irvin (1993) and Roncorni et al (1999) both stated that the failure to 
investigate iron deficiency anaemia was the most common reason for GPs to delay 
referral and these people were more likely to have a delay of greater than 12 weeks. 
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Delay in referral and number of visits to GP prior to referral 
The literature offers some insight into how many times a person visited the GP before 
referral to hospital for further investigation. Holliday & Hardcastle (1979), McArthur & 
Smith (1984), Jones et al (1993) and Wheeler et al (1999) reported 30 %, 32 %, 47% and 
51.5% of patients respectively were referred to hospital, at the first visit. However, the 
same researchers found that a higher proportion of their study cohorts visited their GPs 
three or more times before referral to hospital. 
These results have identified the difficulties that a GP encounters when he has a patient 
reporting symptoms that are common in the general population. 
Number of symptoms at presentation 
Little research has been carried out into importance of the total number of symptoms 
present at first visit to a GP. Two studies examining number of symptoms reported 
found at least three symptoms at first visit (McArthur & Smith 1984, Majumdar et al 
1999). 
Summary of delay 
There is a wide representation of studies from UK, Europe and USA in the literature 
concerning delay in presentation with gastrointestinal symptoms. It is interesting that 
despite the different country of origin and likely culture differences, the delay time was 
consistently three months or more before presenting with symptoms and the vast 
majority of studies found an even greater delay. The length of patient delay has changed 
relatively little over the past 50 years, demonstrating that habits are difficult to change. In 
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contrast, in recent years, GPs have been referring more quickly, signifying an increase of 
knowledge and awareness of colorectal cancer symptoms. 
The answer to the prolonged delay may lie in the fact that the mean age of the study 
cohorts are predominantly greater than 65 years and most studies report a higher 
proportion of males. It may be difficult for older individuals to discuss their toilet habits 
with their GP. 
Delay in presenting with symptoms was found not to be associated with a more 
advanced Dukes' stage at diagnosis. Current guidelines emphasise the importance of 
early presentation to a GP and prompt referral for investigations. The benefits may be 
prevention of an emergency admission and the increased mortality that accompanies 
emergency surgery and prevention of increased anxiety if other symptoms develop. In 
addition, a symptomatic person's overall general health may deteriorate with prolonged 
delay in referral; this may complicate the postoperative period. 
It has often been reported that individuals diagnosed with advanced disease have a short 
symptomatic period. However, a GP who manages his symptomatic patients expectantly 
may be blamed for delay, if cancer is later found. 
Thompson (1999) reported that 14% of individuals may benefit from an earlier diagnosis 
of colorectal cancer and Armstrong James et al (1999) felt that 28% would benefit as 
their tumour could have been diagnosed at a less advanced stage. 
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Reporting of symptoms 
Many factors may influence when and why a person may report symptoms that are 
suggestive of colorectal cancer. 
Symptoms reported by colorectal cancer patients 
Several studies collected detailed information on symptoms reported. Similar to the 
other colorectal cancer literature, the results are published in a variety of formats. Results 
are presented for the whole cohort with colorectal cancer or for rectal and colon cancer 
separately. Others present results as right sided and left sided colon and rectal cancer or 
proximal and distal cancer. This lack of consistency adds to the difficulty in ascertaining 
a combination of symptoms, which may assist as predictors for colorectal cancer. 
Symptom combinations indicating a possible site of colorectal cancer may also assist in 
the most appropriate first line surveillance method, for that patient. The results of these 
studies are given in tables 21, 22 and 23. 
In addition to the differences in the site of cancer within the colon, lack of detail on 
reported symptoms also gave cause for concern due to the lack of clarification reported 
in each study. The most common symptoms reported in these studies are, rectal 
bleeding, change in bowel habit, abdominal pain, weight loss, abdominal or rectal mass 
and anaemia. 
Rectal bleeding is either seen or not seen. Some studies give more detail on the colour 
of bleeding and whether it is mixed with stool or on the stool. Details of rectal bleeding 
will be discussed later. 
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Change in bowel habit is recorded but the type of change is rarely defined by most 
studies, limiting comparability. Interestingly, the study published by McSherry et al 
(1969) did give a definition of change in bowel habit as constipation or diarrhoea, or a 
combination of both, the classic presentation accepted for colorectal cancer at that time. 
In recent studies the change in bowel habit that has created most interest, is a change to 
looser, more frequent stools (Depat<hient of Health 2000). 
Abdominal pain is reported regularly by studies, with no definition of whether this is 
acute abdominal pain or abdominal discomfort. A few studies do give more details as to 
the position of the pain in the abdomen. Several studies report high numbers of 
individuals presenting with abdominal pain. 
Weight loss is probably the easiest symptom to detect but the methodology is important 
to exclude weight loss related to diet reduction or dietary changes. 
Abdominal or rectal mass is commonly reported by studies, but not all studies 
reporting colorectal cancer differentiated between whether the mass is in the abdomen 
or rectum. 
Anaemia is reported frequently with a great degree of inconsistency in the baseline 
measurement. Even where the baseline is given, it can vary between studies and some 
do not make any differentiations of levels for males and females. After the publication of 
NHS guidelines `referral for suspected cancer' (2000), recent studies have been 
consistent in using the guidance. 
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Excess tiredness is sometimes reported as a separate symptom, and other studies 
combine anaemia and symptoms suggestive of anaemia, together. 
Wind and bloating are symptoms collected by some studies; again inconsistencies 
appear when they are reported as individual symptoms, whereas most studies report 
them together, as one figure. 
Table 19 shows percentages of cases with symptoms present on first visit to GP and 
table 20 shows all of the symptoms reported at any time before diagnosis. 














Basset et al 
1979 
51 58 39 
Kyle et al 
1991 
44 56 41 17 11 7 
Hansen et al 
1997 
64 75 43 36 50 14 
Young et al 
2000 
36 16 26 20 
Kiran & 
Glass 2002 
37 48 34 24 16 2 
Tablel9 demonstrates that those diagnosed with colorectal cancer present with three 
common symptoms, rectal bleeding, change in bowel habit and abdominal pain. 
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Table 20 Percentage of patient with colorectal cancer who report 












bloating Tiredness Mass Tenesmus 
McSherry 
et al 1969 
51 73 65 57 3 12 29 
Curless 
et al 1994 
(a) 
52 71 51 47 40 43 36 
Hansen 
et al 1997 
43 52 58 67 
Roncorni 
et al 1999 
38 65 45 15 50 
Gonzalez 
et al 2004 
47 19 17 7 0.6 1.6 
Table 20 illustrates that there are two common symptoms that individuals commonly 
report before diagnosis; rectal bleeding and change in bowel habit. In addition, a high 
percentage of individuals report abdominal pain and weight loss. 
Tables 21 and 22 represent the symptoms reported by individuals with colon cancer 
divided by left and right sided cancer and table 23 shows symptoms reported by 
individuals with rectal cancer. 
Table 21 Percentage of patients with right sided colon cancer who 
















et al 1955 
29 57 35 77 70 31 6 30 55 5.1 
McAdam 
1979 
14 82 54 91 40 59 
Curless 
et al 1994 
(a) 




11 22 38 74 54 
Majumdar 
et al 1999 
43 56 46 70 31 4 
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Table 22 Percentage of patients with left sided colon cancer who 
















et al 1955 
41 73 28 68 45 5 15.3 11 43 5 
McAdam 
1979 
43 84 70 68 43 48 
Dixon et 
al 1990 
59 74 44 12 4 2 14 
Curless 
et al 1994 
(a) 
44 70 20 70 48 33 48 23 
Majumdar 
et al 1999 
70 88 34 47 12 
In the following table 23 a breakdown of symptoms for rectal cancer is given, but these 
studies sometimes include the sigmoid colon or the recto- sigmoid junction. 
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Table 23 Percentage of patients with rectal cancer who report 















Shallow et al 
1955 









77 84 54 30 39 
McArthur & 
Smith1984 
68 22 28 
Curless et al 
1994 (a) 




Site within colon and comparison of symptoms 
When comparing the above symptoms with site of cancer, it must be remembered that 
there will be an overlap between rectal cancers and left sided cancers, due to the 
differences in division points in the colon and some left sided cancers in these studies 
include the rectum. The division point of right sided and left sided colon cancer was 
inconsistent in many of the studies. 
Rectal bleeding 
Rectal bleeding was a more common symptom in left sided colon cancer and rectal 
cancer. The range for left sided colon cancer is 71 -84% and rectal cancer had a range of 
53 -77 %. Right sided colon cancer had a much lower range of 14 -29 %. 
Change in bowel habit 
A significant proportion of individuals with left sided colon cancer and rectal cancer 
reported a change in bowel habit. The range is 57 -88% for left sided colon cancer, 40- 
81% rectal cancer and 11 -82% for right sided colon cancer. In right sided colon cancer, 
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11% and 82% are the two extremes. Most studies found a change in bowel habit in 
slightly more than 50% of their cohort. 
Pain 
Pain as a symptom cannot be compared between rectal cancer and colon cancer, as the 
studies did not specify the site of the pain especially in studies reporting rectal cancer. 
However, in comparison to right sided colon cancer, left sided had a much lower range 
of pain recorded. 
Reporting of rectal bleeding, changes in bowel habit and pain are common to virtually all 
studies. The following symptoms are only reported in some studies. The more detailed 
reporting of symptoms reflects the aims of the research study. 
Nausea 
Nausea is a rare symptom in those who are diagnosed with rectal cancer. A range of 20- 
70% is reported for left sided colon cancer and 33 -54% for right sided colon cancer. 
Only two studies reported nausea in rectal cancer at 4% and 10 %. 
Weight Loss 
Similarly to nausea, weight loss is more common in ride right colon cancer. Studies 
reporting weight loss showed a range of 30 -46% for rectal cancer, 12 -48% for left sided 
colon cancer and 30 -70% for right sided colon cancer. 
Anaemia 
Anaemia is rare in rectal cancer and more common in right sided colon cancer. Right 
sided had a range of 31 -74 %, left sided 5 -47% and only one study reported anaemia for 
rectal cancer at 4.7 %. 
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Excess tiredness 
Tiredness is reported independent of anaemia by some studies, although excess tiredness 
can be the result of anaemia. However, consistent with the findings of anaemia, reports 
show a range of 13 -39% for rectal cancer, 11 -48% for left sided colon cancer and 30- 
68% for right sided colon cancer. 
Tenesmus 
Tenesmus is unlikely to be a symptom reported by cases with right sided colon cancer. 
Tenesmus is reported in rectal cancer studies with a range of 11 -55 %, 5 -23% for left 
sided colon cancer and 5 -8% for right sided colon cancer. 
Wind and bloating 
Rectal cancer cases are unlikely to report wind and bloating as a symptom (not shown in 
table) Wind and bloating figure are reported together, left sided colon cancer 20 -32% 
and 29 -42% for right -sided colon cancer. Rectal cancer was reported by one study at 
14 %. 
Mucus 
Those diagnosed with right sided colon cancer do not often give passing of mucus as a 
symptom. Passing mucus was reported 15 -33% with colon cancer, 13 -44% for rectal 
cancer and only 6 -8% of right sided colon cancer. 
Abdominal and rectal mass 
The reporting of the site of a mass was very unclear in some studies. Rectal mass was 
reported in 53 -72% of rectal cancer studies. Abdominal mass was reported as 2 -43% for 
left sided colon cancer, 54-55% for right sided colon cancer. It is not possible to make 
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any assumptions about these results as it is unclear, from the literature whether the 
figures given were at the time of referral or after examination by a physician or surgeon. 
Specific characteristics of symptoms 
In recent years, researchers have attempted to identify more specific details of some 
symptoms or to create a combination of symptoms which may guide referral for 
investigation. 
Rectal bleeding 
The colour of rectal bleeding has been reported as a predictor for a diagnosis of 
colorectal cancer. Researchers investigated whether the bleeding was bright red or dark, 
if the blood was mixed with the stool or on the stool. Fijten et al (1995) found colour of 
bleeding was of little value in predicting colorectal cancer. Mant et al (1989), Ellis et al 
(1999b), Chave et al (2000) and Branagan et al (2004) found that presenting with dark 
red bleeding as opposed to bright red was a slightly higher predictor for colorectal 
cancer. 
Change in bowel habit 
The term, `change in bowel habit' is used throughout the literature and is commonly 
cited as highly prevalent and an important symptom in the diagnosis of colorectal cancer. 
The most common oversight of authors in the literature is that they fail to give a 
definition of the change in bowel habit. Without this clear definition it is not possible to 
make comparisons. Some of the more recent literature has addressed change in bowel 
habit and investigated if any specific changes have a higher predictive value. 
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In a community study of those presenting with rectal bleeding, Ellis et al (1999b) 
reported that those with a change to increased frequency and /or looser stool had a 
higher probability of a colorectal cancer diagnosis; this is compared to those reporting a 
change to less frequent stools and /or harder stools. Chave et al (2000) also had the same 
results in a study of those referred to hospital for investigations. 
Anal symptoms 
Until recently, in studies from the UK, the presence or absence of anal symptoms was 
uncommonly reported in the literature. In 1989, Mant et al reported a negative 
association with anal protrusion and Fijten et al (1995) reported that anal pain, anal itch 
or prolapse were not significantly associated with colorectal cancer. More recently, 
reports by Ellis et al (1999a), Ellis et al (1999b), Chave et al (2000) and Branagan et al 
(2004) have shown if any anal symptoms are present, this is a low predictor for 
colorectal cancer. Nichols et al (1999b) found that the combination of rectal bleeding 
without anal symptoms had an 11°A positive predictive value, painless rectal bleeding 
alone had a 5% positive predictive value. 
Combination of symptoms 
Mant et al (1989) was the first to attempt using combinations of symptoms to predict the 
probability of colorectal cancer diagnosis. It was concluded that the signs and symptoms 
did not satisfactorily aid the decision on whether to proceed to full colonic 
investigations. 
Fijten et al (1995) developed a model to predict those who should proceed to colonic 
investigations and those who have a low probability of colorectal cancer. They 
concluded that age over 60, rectal bleeding with blood on stool or mixed with stool and 
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a change in bowel habit, had a higher probability of colorectal cancer diagnosis. This 
study had only nine cases with colorectal cancer. 
Majumdar et al (1999) also developed a symptom combinations model to predict the site 
of the cancer within the colon. The symptoms given for proximal cancer are; anaemia 
and the presence of any one of anorexia, nausea, vomiting, abdominal pain or fatigue. 
Symptoms for distal cancer given are; rectal bleeding, altered stools and the presence of 
any one of diarrhoea, mucus, rectal pain or tenesmus. This model had a sensitivity of 
93% and a specificity of 47 %. Other models have been developed in UK studies have 
specific guidance on the type of bleeding and characteristics of change in bowel habit. 
Dodds et al (1999), Ellis et al (1999a) and Ellis et al (1999b) and Thompson et al (2000) 
have concluded that a combination of dark red rectal bleeding and change of bowel 
habit, to looser more frequent stools, have a high predictive value in the diagnosis of 
colorectal cancer. In the following studies the rectal bleeding and change in bowel habit 
is as referenced above. Dodds et al (1999) reported in those referred to outpatients with 
rectal bleeding, that rectal bleeding and change in bowel habit together identified 54% of 
all cancers, with a predictive value of 1 in 8. Ellis et al (1999b) refined this further, noting 
that 84% of patients with rectal /sigmoid tumours presented with change in bowel habit 
some with and some without rectal bleeding, 89% had a change in bowel habit to 
increased frequency and /or looser stools. These research studies played a major role in 
the development of Government guidelines on referral for suspected cancer (NHS 2000) 
these guidelines state that those who are suspected of having cancer should not wait 
more than 2 weeks for a hospital appointment. 
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Selvachandran et al (2002) also used a combination of symptoms derived from the NHS 
guidelines and developed questionnaire and a computer based programme. Patients 
completed the questionnaire before endoscopy assessment, and data from the 
questionnaire and the referral letter, together were entered into the computer program. A 
weighted numerical score was derived from weighting of primary symptoms and 
symptom complexes, and was calculated automatically. 
Using this program of a combination of symptoms than did not require Consultant 
input, it was found that there was no difference in cancer detection rate from the NHS 
guidelines (p= 0.34), but that the NHS guidelines led to a higher rate of urgent referrals. 
Pre -symptomatic colorectal cancer 
In 1983 Dent et al published their theory on the progression of a colorectal 
adenocarcinoma through the Dukes' stages. Figure 13 illustrates that it is possible for a 
tumour to be at an advanced Dukes' stage before onset of symptoms. It is universally 
accepted that the more advanced the Dukes' stage at diagnosis, the poorer the prognosis 
and shorter survival time (Mulachy & O'Donoghue, 1997). This theory is now accepted 
and there is consensus that to improve overall survival from colorectal cancer the cancer 
should be identified before the onset of symptoms. In recent years the government has 
been addressing this. 
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Figure 13 Dukes' stage progression of an adenocarcinoma 
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The Depaitment of Health has provided funding for a pilot study of faecal occult blood 
testing (FOBT) in three sites within the UK. The aim is to identify colorectal cancer at 
an early Dukes' stage and remove a cancerous polyp or pre -cancerous polyps by 
colonoscopy, if possible. Some early tumours, Dukes' stage A, would require surgery but 
no chemotherapy minimising the physical cost of treatment for patients and the financial 
treatment costs to the health service. Those diagnosed at an early stage have a very high 
one -year and five -year survival rate (Mulachy & O'Donoghue, 1997). 
Summary of reporting symptoms 
There are some important indicators from the literature on lower gastrointestinal 
symptoms. A change in bowel habit is an important symptom in association with rectal 
bleeding. Many cases with right sided colon cancer may have iron deficiency anaemia for 
some time before the first gastrointestinal symptom is present and /or an abdominal 
mass is felt. Those with right sided colon cancer are more likely to present with pain. 
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Rectal cancers have a high probability of being found by rectal examination and 
individuals diagnosed with rectal cancer are more likely to have rectal bleeding and 
change in bowel habit but less likely to present with pain. 
The complexities of lower gastrointestinal signs and symptoms suggest that, identifying 
symptoms that may be suspicious of colorectal cancer is a very difficult task for any GP. 
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Chapter 9 
Development of Referral Guidelines for 
Suspected Colorectal Cancer 
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Referral guidelines 
Guidelines were developed to assist GPs in the decision making process and unify care 
in the UK. 
A committee derived from the Association of Coloproctology of Great Britain and 
Ireland, Royal College of General Practitioners and British Society of Gastroenterology, 
has reviewed published literature on signs, symptoms and outcomes. Following this 
review, The UK referral guidelines for Suspected Cancer' (Department of Health 2000) 
have been published. These were disseminated to all GPs in 2000. These guidelines are 
to assist GPs in deciding which patients are at high risk and which at lower risk, when 
presented with symptoms that are suggestive of colorectal cancer. They have not been 
designed to diagnose colorectal cancer in primary care. 
The literature on lower gastrointestinal signs and symptoms in colorectal cancer, 
demonstrates the need for referral criteria in primary care. O'Riordan & Clifton (1999) 
carried out a study to produce criteria that would be sensitive and specific to significant 
colorectal disease, not only cancer. These criteria are as follows: 
o Patients at 50 years of age or over with recent change in bowel habit; 
o Any patient with recent change in bowel habit AND a strong family history of 
colorectal cancer 
o Any patient with a carcinoma palpable on rectal examination. 
o Patients with rectal bleeding AND another symptom. 
In this study, all local GPs were sent the inclusion criteria and informed that all patients 
meeting the above criteria would be seen within one week of referral. The criteria were 
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deemed to be sensitive and specific to colorectal disease. Only 17% of new colorectal 
cancers diagnosed during the study period were identified by GPs using the criteria, 
despite the publicity given to this study. 
Published referral guidelines 
Colorectal cancer guidelines were published in a document called `Improving outcomes 
in colorectal cancer' by the Department of Health (1997). This document has now been 
updated and published by the National Institute for Clinical Excellence (NICE) 
www.nice.org.uk (2004). 
In response to a previous document The new NHS - Modern, Dependable.' 
Department of Health (1997) the NHS published a document `referral guidelines for 
suspected cancer' (NHS 2000), which outlines the referral guidelines for several cancers. 
This document states that all patients meeting the criteria should be seen in clinic within 
two weeks, the `two week wait standard'. It specifies high -risk criteria for colorectal 
cancer that would warrant an urgent referral to a fast track clinic. 
Referral guidelines for suspected colorectal cancer in England and 
Wales 
The guidelines shown in table 24 are divided into two levels; high -risk for fast track 
referral and a low risk for referral through the outpatient process. 
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Table 24 Referral guidelines for suspected colorectal cancer NHS 
2000 
Referral guidelines criteria for suspected colorectal cancer Age 
Threshold 
Rectal bleeding WITH a change in bowel habit to looser stools 
and /or increased frequency of defecation persistent for 6 weeks 
All ages 
A definite palpable right -sided abdominal mass All ages 
A definite palpable rectal (not pelvic) mass All ages 
Rectal bleeding persistently WITHOUT anal symptoms 
(* see below) 
Over 60 yrs 
Change in bowel habit to looser stools and /or increased 
frequency of defecation, WITHOUT rectal bleeding and 
persistent for six weeks 
Over 60yrs 
Iron deficiency anaemia WITHOUT an obvious cause 
(Hb <11 g /dl in men or <10 g /dl in postmenopausal women) 
NB. Patients with the following symptoms and no abdominal or rectal mass are at very 
low risk of cancer: 
o Rectal bleeding with anal symptoms* 
o Change in bowel habit to decreased frequency of defaecation and harder 
stools. 
o Abdominal pain without clear evidence of intestinal obstruction. 
*Anal symptoms include soreness, discomfort, itching, lumps and prolapse, as well as pain. 
These were the guidelines in use during the data collection of this study, however NICE 
plan to update these published guidelines, following a commitment in the NHS cancer 
plan. 
NICE has commissioned the National Collaborating Centre for Primary Care to develop 
new referral guidelines for suspected cancer, to be used in the NHS of England and 
Wales. These are not expected to be available until mid 2005 (www.nice.org.uk). These 
165 
guidelines will incorporate any new published research and audit results since the 
publication of the previous guidelines. 
Since the publication of the NHS suspected cancer guidelines that included the `two 
week wait standard' for any individual suspected of having cancer, there have been many 
publications questioning (Sikora et al 2000, Willis 2000) and supporting their necessity 
(Suinmerton et al 2003). Audits carried out in the UK by Harinath et al (2002), Davies et 
al (2002) and Flashman et al (2004) confirm the validity of the high -risk guidelines for 
their diagnostic yield in colorectal cancer cases. 
Harinath et al (2002) assessed 50 consecutive colorectal cancers and applied the high -risk 
criteria to them and found that 82% would have been eligible for fast track referral. 
Although the specificity was high, they felt that the sensitivity was too low for safety and 
recommended changes and a new addition to the criteria. They recommended changing 
the age threshold from 60 to 50. This would make the guidelines the same as the Scottish 
Executive guidelines. 
They recommended adding abdominal pain with weight loss, even though using this is a 
criterion is very non -specific for colorectal cancer. Previous literature has shown these 
symptoms are found in high percentage of individuals diagnosed with colorectal cancer. 
Flashman et al (2004) reported on effectiveness and efficiency of the referral guidelines 
for suspected cancers. It was found that 39% of referrals to the fast track clinic did not 
meet the criteria. They were disappointed that over 50% of those who did meet criteria 
were not referred to a two -week standard clinic. Of all colorectal cancer diagnosed in the 
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time of the study, 85% met the high -risk criteria. This study reported that there was no 
staging difference of Dukes' stage between those attending the two -week standard clinics 
and routine clinic. 
Davis et al (2001) reported that 53% of colorectal cancers were diagnosed in the fast 
track clinic. Compared to 17% in the previous year when 48% of the colorectal cancer 
were diagnosed within two weeks. There was also a reduction in the number of 
emergency admissions from 40% to 30% for colorectal cancer. 
A report from Soo et al (2001) reviewed case notes of 78 patients referred to one 
surgeon without using guidelines and applied the two -week rule guidelines to these cases. 
A significant benefit in terms of treatment times for colon cancer would have been 
experienced if the two -week guidelines were enforced. However for those with rectal 
cancer due to prolonged waiting time for staging and for pre -operative radiotherapy, 
there would be little benefit. 
Moreea et al (2001) reported that the two -week waiting time standard was met but at the 
cost of a substantial increase in waiting time, an average of 30 days, for those attending 
the routine clinic. 
Warwick et al (2004) reported that the two -week waiting time standard has changed 
clinical practice in their hospital. Before publication of the new guidelines, individuals 
were seen for a consultation, followed by investigations, if appropriate. This practice has 
been replaced with direct referral for flexible sigmoidoscopy and discharge on exclusion 
of colorectal cancer. These studies highlight the positives and the negatives of the new 
high -risk guidelines and the effect of two -week waiting time standard on clinical services. 
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Scottish referral guidelines for suspected colorectal cancer 
The Scottish Intercollegiate Guideline Network (SIGN) published their first guidelines 
for management of colorectal cancer in 1997. Updated guidelines were published in 
March 2003. Within this publication are GP guidelines for referral. Before the updated 
version of the SIGN guidelines were published in 2003, the Scottish Executive Health 
Department (SEHD) published urgent referral guidelines `Scottish referral guidelines for 
suspected cancer' in April 2002 for (www.show.scot.nhs.co.uk /sehd). These guidelines, 
shown in table 25, are similar to the `referral guidelines for suspected cancer `in the NHS 
2000 document. Unlike the NHS guidelines for England and Wales, Scottish guidelines 
suggested urgent referrals should be referred to routine clinics labelled as urgent rather 
than utilising the specified two week model. 
Table 25 Colorectal Cancer: Guidelines for Urgent Referral 
(SHED 2002) 
Referral guidelines criteria for suspected colorectal cancer Age 
Threshold 
Rectal bleeding WITH a change in bowel habit to looser stools 
and /or increased frequency of defecation persistent for 6 weeks 
All ages 
A definite palpable right -sided abdominal mass. All ages 
A definite palpable rectal (not pelvic) mass All ages 
Rectal bleeding persistently WITHOUT anal symptoms 
(* see below) 
Over 50 yrs 
Change in bowel habit to looser stools and /or increased 
frequency of defecation, WITHOUT rectal bleeding and 
persistent for six weeks 
Over 60 yrs 
Iron deficiency anaemia WITHOUT an obvious cause 
(Hb <11 g /dl in men or <10 g /dl in postmenopausal women) 
NB. Patients with the following symptoms and no abdominal or rectal mass are at very 
low risk of cancer: 
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o Rectal bleeding with anal symptoms* 
o Change in bowel habit to decreased frequency of defaecation and harder 
stools. 
o Abdominal pain without clear evidence of intestinal obstruction. 
*Anal symptoms include soreness, discomfort, itching, lumps and prolapse as well as pain. 
Scottish Intercollegiate Guidelines Network for colorectal cancer 
Patients over the age of 50 years with any of the following symptoms over a period of 
six weeks should be urgently and appropriately investigated: 
o Rectal bleeding with a change in bowel habit to looser stools and /or increased 
frequency 
o Rectal bleeding without anal symptoms 
o Palpable abdominal or rectal mass 
o Intestinal obstruction 
o All patients with Iron deficiency anaemia (Hb < 11 g /dl in men or < 10 g /dl 
in postmenopausal women) without overt cause should be thoroughly 
investigated for colorectal cancer. 
Scottish GPs have access to both sets of Scottish of guidelines, which differ slightly in 
the age for referral; this may be confusing for GPs and any group who may be auditing 
the referral guidelines. 
Implementation of clinical practice guidelines 
Over the past decade, there has been an abundance of evidence based clinical practice 
guidelines produced for use in primary care. However, the current literature suggests that 
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GPs to do not implement guidelines readily. The continued proliferation of guidelines 
being produced requires the reasons behind poor implementation of guidelines to be 
understood. 
Clinical practice guidelines have been defined as `recommendations for patient management that 
identify one or more strategies for treatment'. It is thought that as guidelines can be applied to all 
aspects of patient care such as; disease management, referrals, prescribing and 
preventative medicine, they can standardise and improve the quality of patient care (Grol 
1992, Onion et al 1996). It is not possible for GPs to keep up to date with all the current 
research literature available for the many conditions seen in their daily practice. 
Therefore, it would appear that the simplest way forward for GPs would be to use 
evidence based guidelines. 
Studies have attempted to understand the barriers to the implementation of clinical 
practice guidelines. In a qualitative study of GPs from several UK practices (Cranney et 
al 2001) found that the main barriers were shortage of time and pressure of work. Other 
reasons given were: 
Guidelines where developed on a motivated trial group of patients and not on 
the typical patient seen every day, 
GPs lacked ownership of the guidelines and therefore were not committed as not 
locally developed, 
Guidelines were not readily accessible. 
Langley et al (2001) reported that GPs wanted local development and involvement with 
guidelines. Silagy et al (2002) found that when local guidelines were adapted from 
National guidelines they differed very little from the National guideline. This study used 
more than one method of introducing the guidelines to the groups and found that the 
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knowledge and practice had changed in both groups, suggesting that a multifaceted 
approach was important to effective implementation, rather than the changes to the 
actual guideline. This multifaceted approached was supported by Onion et al (1998) who 
also found that this use of multi educational approaches sustained the change in practice 
for at least 12 months. 
It was also suggested that the guidelines need not be locally adapted but that locally 
known individuals working within the field of guideline to be implemented could be 
used in the dissemination process. This study reported that it is extremely costly to adapt 
National guidelines and the investment of time and money would be better utilised in the 
implementation process. 
Other researchers have had similar results to the above studies and, in addition, found 
that to successfully implement guidelines, adequate support and time resources are 
required (Flottrop et al 2003), and as the most frequent reason for diversion from 
guidelines was patient pressure, the development of educational material for patients may 
help adherence to guidelines (Kerry et al 2000). 
Despite the current issues surrounding the implementation and adherence to guidelines, 
they remain the way forward. With the introduction of clinical governance, a policy 
emphasising quality of care is required as a necessity to standardise many areas of patient 
care. Therefore, further research is required to optimise the implementation and use of 
guidelines. 
There is little published information on the uptake of guidelines. The literature 
concentrates on the barriers to implementation and methods of implementing guidelines. 
The SIGN guideline report on auditing the implementation of the guidelines, 
predominantly in secondary care, reported that after implementing a local guideline, 
evaluation through re -audit was rare as was baseline audit (Millard 1998). Keaney and 
171 
Lorimer (1999) found minimal changes in the audit processes of implemented SIGN 
guidelines and concluded, that there was much work to be done, to embed clinical audit 
in the process of implementation. 
In a UK randomised control trial of X -ray referrals in primary care, the intervention 
group were given updated, short and user friendly guidelines. When the guidelines were 
audited, a 20% reduction in referral for some x -rays was seen, compared to the standard 
arm. 
There have been several audits on the referral guidelines for colorectal cancer, many 
reporting that high numbers of referral for `two week rule' were inappropriate. Eccersley 
et al (2003) found that 45% of referrals did not comply with the guidelines and 38% non 
compliance was reported by Debnath et al (2002). 
However, the audit of family history guidelines produced more positive results. Lucassen 
et al (2001) developed new guidelines using a local multidisciplinary team and 
disseminated these to GP practices. When audited, an improvement was seen in that 
27% more referrals met guidelines. 
There appears to be a message in this literature that the success of the guideline will be in 
the subject matter and the implementation process. 
Knowledge of colorectal cancer symptoms, in the community 
Guidelines can only be implemented if individuals with gastrointestinal symptoms 
present to their GP for assessment. There are small but significant number of 
individuals, who would benefit from an early presentation of their colorectal cancer. 
Research into public awareness of the signs and symptoms of colorectal cancer has been 
published. Yardley et al (2000) carried out a telephone survey of the public and found 
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that only 31°/0 were able to correctly state a symptom of colorectal cancer. Those most 
likely to know this information were older, female and from a higher social class. Those 
most unlikely to know a symptom of colorectal cancer were males under 25, of lower 
socioeconomic status. 
Pullybank et al (2002) conducted a study of individuals attending a one -stop breast or 
rectal bleeding clinic. Each group were asked information on both breast and colorectal 
cancer, 47% of females were able to name a symptom of colorectal cancer against 27% 
of males; this was not statistically significant. Of these, 44% attending the breast clinic 
could state a symptom of colorectal cancer and only 37% of those attending the 
colorectal clinic could state a symptom of colorectal cancer. 
Hughes et al (2004) circulated a questionnaire to those aged 50 -80. Returned 
questionnaires were analysed for significant symptoms and subjects offered further 
assessment, if appropriate. To promote this study, a campaign was implemented to 
promote an awareness of colorectal symptoms. The 84.4% response rate reported was 
much greater than expected for a study of this methodology. The prevalence of 
symptoms in this study was 43.9 %. Despite public health campaigns for colorectal 
cancer, the knowledge of the general population appears not to have improved 
dramatically. The study by Hughes et al (2004) has identified that small targeted health 
promotions can be successful without overloading the health system. 
173 
Chapter 10 
Aims of the study 
174 
Background 
Funding had been awarded by the Medical Research Council (MRC) for a very large 
collection of DNA and environmental exposure data from colorectal cancer cases in 
Scotland. The study for this thesis was undertaken within this DNA sample collection. 
The DNA samples were collected from individuals with colorectal cancer, age 16 -79, 
diagnosed after September 2001 and normally resident in Scotland. This MRC study is 
known as the Study Of Colorectal Cancer in Scotland (SOCCS). 
This prospective cohort study of individuals diagnosed with colorectal cancer gave the 
opportunity to record family history information from all recruited cases and to 
investigate the presentation patterns with lower gastrointestinal symptoms in relation to 
comorbidity and deprivation. 
Literature 
There is little literature reporting on family history pattern among a large series of cases 
with colorectal cancer. The current literature in this field concentrates primarily on the 
accuracy of the family history information given by the case against the information 
confirmed by cancer registry and medical records. This published literature lacks 
consistency in the definition of what constitutes a family history. The most common 
definition of a family history in this literature is `one first degree relative with colorectal cancer'. 
There are no published data investigating how a perceived family history of colorectal 
cancer influences; waiting time with symptoms, consideration of cancer before diagnosis, 
inspecting the toilet or toilet paper before flushing or the association with comorbidity 
or deprivation. There is little literature, particularly with a large cohort that report on the 
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proportion of cases with colorectal cancer and a high or moderate family history that is 
assessed using published clinical guidelines. 
There is vast literature relating to delay in presenting with lower gastrointestinal 
symptoms but few published papers on the association with comorbidity and 
deprivation. 
My professional interest in cancer genetics together with the lack of literature on 
colorectal cancer cases and family history (either perceived or assigned using guidelines) 
and the research opportunity afforded by the SOCCS study led to the following primary 
and secondary research questions. 
Research questions 
Primary questions 
1. What proportion of individuals with a diagnosis of colorectal cancer perceived 
themselves to have a family history of colorectal cancer? 
2. What proportions of individuals with a diagnosis of colorectal cancer are 
assessed to have an actual family history risk, (assigned using published 
guidelines)? 
3. How does the number of cases with a perceived family history risk compare to 
those with an actual family history risk? 
4. Does a perceived family history of colorectal cancer modify behaviour with 
respect to: 
o The knowledge of colorectal cancer symptoms? 
o The surveillance of toilet habits? 
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o Concern that lower gastrointestinal symptoms are symptoms of cancer 
before diagnosis? 
o Shortened waiting time before presentation to GP with lower 
gastrointestinal symptoms? 
5. Do GPs recognise family history as a risk factor in individuals diagnosed with 
colorectal cancer? 
Secondary questions 
1. Is waiting time with lower gastrointestinal symptoms among cases with colorectal 
cancer associated with: 
o Socioeconomic status? 
o Comorbidity? 
o Knowledge of colorectal cancer symptoms? 
2. Do Scottish patients with colorectal cancer present with different symptoms or 
do they delay longer with lower gastrointestinal symptoms than other colorectal 
cancer population? 
Aims 
The primary and secondary aims of this thesis are: 
Primary aims 
o Ask information on family history and draw pedigree using only information 
given by the case, (no confirmations of cancers will be made). 
o Ascertain and recruit the highest number of all cases, aged 16 -79, diagnosed 
with colorectal cancer and normally resident in Scotland, as possible, over 24 
months. 
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o Report the number and proportion of cases that perceive they have a family 
history risk of colorectal cancer. 
o Describe waiting time with symptoms and any behavioural differences in 
dealing with symptoms between those cases that perceive a family history risk 
and those not perceiving a family history risk. 
o Report the number and proportion of cases in this cohort with a family 
history of colorectal cancer meeting Scottish clinical criteria for high or 
moderate family history risk. 
o Report on the numbers referred to cancer genetic services and the numbers 
referred that meet Scottish clinical criteria for high or moderate family history 
risk. 
Secondary aims 
o Investigate any association between deprivation categories (using two 
deprivation indices) and the following: 
Family history 
Symptom presentation, 
Waiting time with symptoms, 
Comorbidity, 
o Describe the symptom presentation and waiting time pattern of 1540 cases 
aged 16 -79 diagnosed with colorectal cancer. 
o Explore the role of comorbidity and delay in presentation of symptoms. 
o Describe the percentage of the 1540 cases recruited that meet at least one 
referral criterion for suspected colorectal cancer. 
178 
Sample size 
The projected sample size for this study was based upon pilot data gathered during the 
first three months of the SOCCS study. This recruitment approximated 50 cases per 
month. This study collected data for 24 months. A recruitment rate of 50 cases per 
month would give a total of 1200 cases. It was considered reasonable to assume that the 
recruitment figures would increase as the study became established and 25% was added 
to give a target total of 1500 cases. 
Power 
The pilot data for this study showed that 25% of cases perceived they had a family 
history of colorectal cancer and 18% of cases were assigned a high or moderate family 
history risk using published guidelines. 
We based power calculations on the primary research questions that related to perceived 
family history, and those with an assigned high or moderate family history based on 
Scottish guidelines. In order to obtain estimates of the power to detect differences in 
proportions between groups, we considered 2 pairs of groups based on the above data 
from the pilot study. 
These were those who were (n =270) or were not (n =1230) assigned a high or moderate 
family history risk and those who did (n =375) or did not (n =1125) perceive that they 
had a family history of colorectal cancer. Tables 26 and 27 below give each grouping and 
show the power to detect a significant (p <0.05) difference between the proportions in 
these pairs of groups for given true proportions. The results in the two tables are very 
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similar. These tables show that, for the above sample sizes and most comparisons there 
is a power of over 80% to detect a true difference in the proportions of 10% or more, 
and low power to detect smaller differences. 
Since I considered this to be a difference which would be important to detect and was of 
a plausible magnitude, I concluded that the projected recruitment in the SOCCS study 
would permit a study of family history that would have sufficient power to be able to 
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Eligibility for study 
All cases aged between 16 and 79 years of age with colorectal cancer diagnosed after 
September 2001 and normally resident in Scotland were eligible for this study. 
Exclusion criteria 
Not eligible to be included in study 
o Not normally resident in Scotland 
o Squamous cell carcinoma of anus 
o Melanoma of rectum 
o Carcinoid tumours of colon 
o Recurrent disease 
Eligible - cannot give informed consent 
o Too ill to give informed consent 
o Mental health problems 
o Learning difficulties 
o Dementia 
Ethical approval 
MREC approval (approval number MREC /01/0/5) the local research ethics committee 
(LREC) approval was successfully obtained. Management approval was requested and 




Consultant surgeons in all Scottish hospitals were asked permission for their eligible 
patients to receive information on the SOCCS study. Each consenting surgeon was 
offered an option for the author to visit them personally, or meet with the nursing staff 
involved in the care of their colorectal cancer patients. This visit would involve: 
o Discussion and planning of how patients would be given the information 
packs, 
o Discussion of the most appropriate way for SOCCS research nurses to liaise 
with the nursing team in that hospital. 
Two surgeons in Scotland refused to allow their patients to be informed of the SOCCS 
study. One surgeon (who carried out emergency colorectal cancer surgery only) failed 
to respond after many reminders and the other was a colorectal surgeon. 
Patients registered with either surgeon did not receive information on the SOCCS study 
and were recorded as non -participants. 
During the course of this study, patients were identified with the diagnosis of a polyp 
cancer that did not require surgery. For these patients the Consultant Physician was sent 
a letter asking permission to offer their patients SOCCS study information and no 
refusals were received. It was the role of the research nurse to inform the SOCCS 
administration office of any consultant surgeons newly appointed within their hospitals 
of responsibility. New Consultants were then sent a letter, before any of their patients 
were offered information on SOCCS study. 
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All surgeons who perform surgery outwith the NHS were asked for consent to 
approach their private patients with study information and all agreed. When it was 
necessary to access information from audit and pathology departments, these 
department managers often requested a copy of the signed consent given by the 
Consultant surgeon. 
Study awareness in hospitals 
The most common method for dissemination of study information in hospitals was a 
presentation delivered by the author. This presentation was repeated several times to 
enable as many of the nursing and medical staff as possible to hear information on the 
study. Following this presentation a recruitment protocol was developed for each 
hospital. 
In 23 hospitals that had a Colorectal Cancer Nurse Specialist, they became the main 
contact for the study, and a recruitment protocol was developed to suit their working 
practice. 
Recruitment Protocols 
Recruitment to the SOCCS study began in 36 NHS and Private funded Scottish 
hospitals, during September 2001. Each hospital had a recruitment strategy developed 
to ascertain eligible patients and provide them with the SOCCS information pack. In 
addition, a non -participant form was developed (Appendix 8) to record information on 
individuals eligible for the study, but unable for various reasons, to be offered the study 
information. The research nurses used this non -participant form to record individuals 
that had returned a reply slip indicating that they did not wish to take part. They also 
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recorded on this form those that did not reply within two months of having the 
information pack. 
It is necessary to record minimum data to enable monitoring of ascertainment but it is 
deemed unethical to record identifying information on non -consenting individuals 
therefore the data recorded in this study for non -participants are: 
o Sex 
o Age at diagnosis 
o Consultant 
o Health Board where treated 
o Reason for non -participation, if given 
o Surgery - curative or palliative 
Staff recruitment and training 
The author developed the job descriptions for each post. Eight research nurses were 
initially appointed for eight geographical areas. Throughout the course of the study 
these geographical areas changed to meet the recruitment requirements. 
The eight original research nurses attended a 3 -day training session designed by the 
author. The principal investigators, project co- coordinator and the author delivered the 
training programme. All research nurses were given further one to one training with 
cases by the author. 
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During the first year of the SOCCS study research nurse meetings were held three 
monthly. Each meeting incorporated a session on the data collection specifically 
required for this study. These meetings were reduced to 4 -6 monthly after the first year. 
Case ascertainment and recruitment 
Each research nurse activated the recruitment protocol initially agreed for the hospitals 
in their own area of responsibility. The initial plan for the SOCCS study was that the 
research nurse would visit patients in the last few days of their stay in hospital to recruit 
to the study if requested. 
During development of the recruitment protocols, no members of nursing staff raised 
any objection to this proposal. Soon after recruitment commenced, a new discharge 
policy was implemented in most hospitals in Scotland. Colorectal cancer patients were 
discharged from hospital within 4 -6 days of surgery in most cases, and this was not an 
appropriate time to recruit individuals to the study, as pathology reports had not been 
confirmed or the patient was distressed by their pathology result. 
In many hospitals the research nurses met significant resistance from the nursing staff, 
as they were reluctant to inform patients of their eligibility for the study. Many nurses 
were unsure if the patients had been informed of their diagnosis. The study recruitment 
was least problematic in hospitals that had a colorectal cancer nurse specialist (CCNS). 
These problems resulted in a change of recruitment protocols and cases were recruited 
in their own homes. 
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Data collection for this study 
Family history data 
If the case was willing to give family history information, a three- generation family 
history was taken at recruitment. The information was recorded on a family history 
sheet to assist with consistency of information collected (Appendix 9). All research 
nurses had pedigree drawing training, using the universal nomenclature. Each family 
history was assigned a risk assessment using risk levels published in the Scottish 
Executive cancer genetic guidelines for colorectal cancer (Scottish Cancer Group 2001). 
The guidelines were chosen as they are used in all four Scottish Genetic Centres. 
The following is the criteria for moderate and high risk: 
Moderate risk: 
o One first degree relative affected by colorectal cancer when aged <45 yrs; 
o Two affected first degree relatives with one less than age 55 at diagnosis 
o Three affected relatives with colorectal or endometrial cancer who are first 
degree relatives of each other and one a first degree relative of the 
Consultand 
High risk: 
o At least three family members affected by colorectal cancer or at least two 
with colorectal cancer and one with endometrial cancer in at least two 
generations; one affected relative must be age <or =50 at diagnosis, one of 
the relatives must be a first degree relative of the other two 
o HNPCC gene carriers 
o Untested first degree relatives of known gene carriers 
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Low risk: 
o Anyone not fulfilling any of the above 
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Figure 14 Procedure for obtaining a family history 
All research nurses were trained and 
observed for competency in taking a family 
history and drawing a pedigree 
The information sheet states that family history information 
will be requested at the visit. Research nurses call the case to 
arrange an appointment to recruit them to the study. During 
this call, the nurse informs the case that information on 
family members will be asked and in particular members with 
cancer. 
Nurse visits case as 
arranged. Family history 
is taken and pedigree 
drawn 
If case refused family 
history, no further action 
is taken. 
The pedigree drawn is sent 
for risk assessment 
T 
Research nurse will leave a 
contact number. If case wishes 
to add more information to 
family history, they can call this 
number. 
If new family history 
infoiniation is received a 
new risk assessment to be 
mad. 
Low Risk 
No further action 
High and Moderate Risk 
Case is sent a letter advising that they 
and /or members of their family are 
eligible to attend a genetic centre for 
further advice on surveillance. 
This letter also gives information on how 
to access this appointment. 
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Risk assessment 
Any person assigned a moderate or high -risk family history was sent a letter. This letter 
informed case of the risk assessment and included instructions on how they and relevant 
family members can access a cancer genetic clinic. 
Genetic referral 
High -risk cases are eligible for HNPCC mutation analysis testing and their first- degree 
relatives over age 30 (or five years younger than youngest affected relative) are eligible 
for surveillance by colonoscopy ever two years. In addition they are eligible for upper 
endoscopy every two years from age 50 (or five years younger than youngest stomach 
cancer if present in family history). Female relatives are eligible for discussion on 
ovarian and endometrial surveillance. Case would also be eligible for this surveillance 
after discharge from surgical follow -up. 
Moderate risk cases are eligible for Microsatellite Stability Testing (MSI) of the tumour, 
their adult children and siblings over age 35 are eligible for asymptomatic colonoscopy 
surveillance at age 35 and, if normal, another colonoscopy at age 55. 
Symptom data 
An administered structured interview (Appendix 10) was the chosen methodology for 
symptoms data collection. The first draft of the symptom interview was piloted 
between March 2001 and June 2001. The first draft was mailed to known experts for 
comment. This process generated a number of interesting comments, and the second 
draft was developed to incorporate these. 
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The second draft was piloted on cases between September 2001 and December 2001 by 
the research nursing team. Amendments made for the final draft were based on 
comments from the research nurses about the layout, ordering of questions and the 
actual space provided for text. Throughout the study, the author personally recruited 
5% of all recruits and supervised recruitments throughout the training process of each 
research nurse. 
Question development 
This structured interview comprised a combination of closed, semi- closed and open 
questions. A few questions have rating scales where appropriate. No appropriate 
existing measuring tool for the whole study could be found. However, communication 
with Mr. M Thompson, Consultant Colorectal Surgeon, during the draft phase of the 
questionnaire this resulted in sharing of information on a similar study of lower 
gastrointestinal symptoms on patients referred to a hospital outpatient clinic in the UK. 
The results of this study were not published at that time. 
The questions from the data collection tool from Mr. Thompson were used for the 
development of Questions 4 and 5 `symptoms experienced prior to first visit to GP' It 
was intended that part of this study would replicate the work carried out by Mr 
Thompson's research team. 
Other questions were designed using the Scottish Intercollegiate Guidelines (SIGN) for 
the management of colorectal cancer (1997). 
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Question 10 was added `Looking at the contents of the toilet before flushing,' in 
response to several colorectal surgeons stressing to the author the importance of 
patients observing their own bowel movements. 
Comorbidity data 
This study collected comorbidity data using a recognised measurement tool. However, 
Professor D. Hole advised collecting information on hospital admissions in the previous 
two years would add further useful information on comorbidity. Therefore a question 
on previous two years hospital admissions was therefore added. 
Family History data 
The family history question was included due to the lack of literature in cases with 
colorectal cancer. This question was designed not to provoke anxiety during 
recruitment. Therefore the positioning of this question was important. During a visit to 
recruit a case it is more natural to ask about other aspects of their symptoms and care 
before discussing their family history risk as this may have biased their response to 
symptom questions. The final version of the symptom interview was ready for data 
collection in January 2002. The recruitment period for this study was 3rd January 2002 
through to 31st December 2003. 
It would have been good practice to re- administer a random sample of the symptom 
interviews for consistency and accuracy. However, the ethical approval for the SOCCS 
study did not allow re- contact with the subject after the initial contact visit. 
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Data entry 
The symptom interview was designed using Teleform software version 7. The designed 
Teleform questionnaire enabled completed symptom interviews to be scanned and then 
read by the Teleform. Each completed symptom interview was scanned using a duplex 
scanner and imported into the Teleform package. All symptom interviews were checked 
for the quality of the ink markings before the scanning process. It is known that 
Teleform performs more accurately if the ink markings in boxes are firm through the 
centre of the box. 
The symptom interviews were also checked for illegible handwriting that Teleform 
software would find difficult to read. This was made legible if possible, but most free 
text boxes were retyped at verification stage. 
Teleform software verifies the data and verification can be set at different levels. Each 
symptom interview was verified using Teleform software and verification was set to 
stop at any unrecognisable letters or numbers in free text fields for each field. The 
verified data were exported into SPSS version 11.5, in preparation for data analysis. 
Once data were exported into an SPSS file, cleaning of these data were carried out by 
author. 
Medical Record information 
Specific consent was taken at recruitment to allow access to medical information stored 
in written or electronic form (Appendix 11). Infoi nation required by this study from 
medical records was included in a data collection form (Appendix 12). 
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All medical record managers in each hospital were contacted to discuss access to the 
medical notes of a recruited case. Each hospital had its own policy of allowing access to 
the medical records. Research nurses and medical students viewed the medical records 
that were available to them at each visit to medical records depai nent. Each completed 
medical record form was checked for missing data before entry. The Charlson 
comorbidity index (CCI) (Charlson et al 1987) was incorporated into the medical 
records form (Appendix 12). 
Data extraction from medical records 
Each nurse or medical student involved in data extracting from medical notes was 
trained to extract this information by the author. Notes not available were re- requested 
each time a data extractor was attending that medical records department. For 
uniformity of collection they were asked to extract the data from the admission sheet, 
anaesthetic and surgical recording sheet, discharge letter and pathology reports. 
For comorbidity data the CCI index sheet included a free text box for data extractors to 
write down any condition that was recorded in the notes but not on the list. They also 
had a comments box to write their own interpretation of anything they were unsure 
about. 
It was not possible to record whether the conditions recorded were currently being 
treated. It was assumed if a doctor recorded a condition in the medical notes it was 
important enough to mention for ongoing management. The comorbidity index was 
checked for completeness before data entry. Data collection from medical records 
ceased on 31st July 2004. Many problems were experienced when accessing medical 
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records. Initially notes were requested three months after surgery to optimise the chance 
of availability. However, in year two this was changed to one month after surgery as it 
was found that even at three months, difficulty was experienced in getting access to 
medical notes. At one month it was possible the notes were in file awaiting first review 
appointment, which is normally at six week in many hospitals. 
Comorbidity data 
The Charlson comorbidity index is the most commonly used index in the literature. As 
the CCI index was developed for mortality outcome each condition is weighted. 
However, for this study the outcome measured was the total number of comorbid 
conditions prior to a diagnosis of colorectal cancer. 
This study has used a simple count of CCI conditions named within the index. Two 
other conditions that were frequently noted in free text box were depression and alcohol 
abuse these have been included in the score of cases where recorded. 
Deprivation data 
Each person was allocated a deprivation scores derived from two independent 
deprivation indices, both allocated according to postcode at time of diagnosis. The 
indices chosen to measure socioeconomic status in this study are Carstairs deprivation 
index 2001 and Scottish Index of Multiple Deprivation 2003 (SIMD 2003). 
Carstairs Deprivation index 
Carstairs Deprivation index is categorised into 7 groups, 1 the most affluent and 7 the 
most deprived. 
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For this study, the scores have been condensed using methodology in common with 
other published literature. It is common in published literature using this index to have 
5 groups or 3 groups, more commonly 3 groups are used. The 3 groups used in this 
study are condensed as follows: 
o Group 1 = 1 & 2, 
o Group2 =3,4 &5 
o Group 3 =6 &7. 
Scottish Index of Multiple Deprivation 
The SIMD 2003 index is a new deprivation index and at time of writing there are no 
published papers. Therefore it has not been validated nor is there guidance on 
generating groups for least deprived to the most deprived unlike the Carstairs index. 
The statistician responsible for developing this index was contacted and asked advice on 
defining the groups using this studies data. However they could not advise. The scores 
in this index range from 1- 89; 1 is the most affluent and 89 is the most deprived. 
The three groups defined in this study were assigned based on limited information in 
the report of the SIMD index. The report gave the top 100 most deprived regions and 
the scores ranged from 47.5 to 89. This range was used to define the most deprived 
group in this study. Groups 1 and 2 were derived from the equal divisions of the 
remaining scores into three groups; Group 1 is the most affluent and using the 
condensing principle applied in the Carstairs index. Groups 2 and 3 were condensed to 
define Group 2. 
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The SIMD group in this study are as follows: 
o Group i = 0.00 to 8.66 
o Group 2 = 8.67 to 47.49 
o Group 3 = 47.50 to 89 
All analyses carried out in relation to deprivation in this thesis report for both 
deprivation indices and are indicated in the text. 
Three deprivation groups using Carstairs and SIMD deprivation categories are: 
o Group 1 - least deprived, 
o Group 2 - intermediate 
o Group 3 - most deprived. 
Pathology data 
Only adenocarcinoma of the colon and rectum were included in the study, this 
information was confirmed from the pathology report. Information on Dukes' stage of 
disease, tumour, node and metastasis status were also gained from pathology reports, 
the minimum data set form or from a letter written in the medical notes. 
Scottish pathology departments do not record the tumour staging information in a 
standard manner. Therefore, if elements of the staging data were not found, a request 
letter with patient consent was sent to the pathology department requesting the 
information required. Due to time constraints and problems accessing all medical 
records, this information was available for only 1212 of the 1540 cases. 
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Some individuals had no Dukes' staging was recorded for the following reasons: 
1. A polypectomy was performed at colonoscopy and excision was complete 
2. Surgery was not indicated due to other health problems 
3. Palliative surgery performed tumour not excised for pathology 
4. Radiotherapy was given before surgery and patient had a complete response and 
no residual tumour available for pathology. 
Qualitative data 
Almost all of the questions within the symptom interview had a free text box as a part 
of the question. After scanning and checking that all text fields had been read and the 
qualitative data interpreted properly by the Telefoi reader, the data was taken into 
SPSS 11.5 for analysis. The author cleaned the data in each free text field and for each 
text field common categories were developed. This was then entered in to SPSS by 
recoding the data. The recoding of the data allowed this qualitative to be analysed using 
quantitative analysis methodology. 
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Chapter 12 
Results: Ascertainment and Recruitment 
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Ascertainment 
From 3rd January 2002 until 31st December 2003, a total of 3,761 individuals were 
identified with colorectal cancer, living in Scotland. Of this total 2,138 (57 %) did not 
participate in the study. Of the total number not participating 856 are recorded as 
`unable to take part''' and 1,223 cases recorded as `did not want to take parti12 in the 
study (reasons given table 29). 
A further 33 cases gave no reason for not taking part and may have been in either 
`unable to take part' or `did not want to take part' group and a further 26 cases were 
patients of two non -consenting surgeons13 that did not give consent for their patients to 
be approached. Further details of the ascertainment are shown in figure 15. 
Table 28 shows a comparison of the two groups `unable to take part' and `did not want 
to take part' by sex, median age, surgery and their Health Board of residence at 
diagnosis. 
11 Unable to take part' -eligible but decision made not to give study information 
12 'Did not want to take part' not want to take part' - given study information and chose not to take part. 
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Table 28 Distribution of non -participants by Health Board of 
residence 
Did not want to take part Unable to take part 
1223 ( %) 856 ( %) 
Males * 689 (56.5) 489 (57.1) 
Females* 531 (43.5) 366 (42.8) 
Median age ** 69 70 
Inter -quartile range 63 -74 63 -76 
Surgery 
Yes 806 (65.9) 433 (50.6) 
No 42 (3.4) 79 (9.2) 
Unknown 375 (30.7) 344 (40.2) 
Surgery Type 
Curative 394 (48.8) 70 (16.2) 
Palliative 138 (17.1) 241 (55.6) 
Surgery type not 
recorded 












Argyll and Clyde 90 (39.5) 50 (21.9) 
Ayrshire 77 (30.3) 76 (29.9) 
Borders 10 (13.9) 20 (27.8) 
Dumfries & Galloway 50 (41.3) 24 (19.8) 
Fife 76 (36.4) 36 (17.2) 
Forth Valley 78 (39.0) 33 (16.5) 
Grampian 132 (28.3) 67 (14.3) 
Greater Glasgow 269 (38.0) 195 (27.6) 
Highland 41 (28.7) 41 (28.7) 
Lanarkshire 103 (30.5) 104 (30.8) 
Lothian 168 (30.2) 147 (26.5) 
Orkney 2 (22.2) 1 
1 
(11.0) 








(28.8) Western Isles 
*For the group `did not want to take part', the sex was missing for three cases and for those 
`unable to take part' for one case. 
** Age was missing for 15 cases that `did not want to take part' and 12 cases that were `unable to 
take part'. 
Table 28 shows that in the `unable to take part' group there was a greater proportion of 
cases that had undergone palliative surgery. 
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Unable to take part 
There were 91(10.6 %) individuals in this group that could not give informed consent, 31 
had dementia, 47 had learning difficulties and 13 had mental health problems. 
Table 29 lists the main reasons, if available, why a person was `unable to take part' in the 
study. Those `unable able to take part' were not given the study information to make the 
choice to take part. 
Table 29 Reasons given by health professional why individuals were 
`unable to take part' 
Reason 856 ( %) 
Advanced Disease 204 (23.8) 
Deceased 277 (32.3) 
Dementia 31 (3.6) 
Learning difficulties 47 (5.5) 
Mental health problems 13 (1.5) 
Unaware of diagnosis 11 (1.2) 
Various other 86 (10.4) 
No reason given by nurse 187 (21.8) 
Table 29 shows that the two main reasons for cases `unable to take part' are: the case 
died before receiving the information or the colorectal cancer nurse specialist made the 
decision that their disease was too advanced to give them the study information. 
Of these 856 cases, 433 (50.6 %) cases had surgery, 79 (9.2 %) cases had no surgery was 
performed, 344 (40.2 %) cases had no information available on surgical status. Of the 
433 cases that had surgery, 70 (16.2 %) of these had curative surgery, 241 (55.7 %) had 
palliative surgery and for 122 (28.1%) the surgery type was unknown. Within the 79 
cases where no surgery was performed, 41 (51.8 %) were receiving palliative care and no 
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information was given why surgery was not performed for the remaining 38 (48.1 %) 
cases. 
When comparing these surgery data with the participants of the study, the surgery data 
were available for 1046 participants. Of these only 99 (9.5 %) had received palliative 
surgery with the remaining 947 (90.5 %) cases receiving curative surgery. 
Did not want to take part 
Of the 1223 cases that `did not want to' take part the reason was not recorded for 1055 
(86.2 %) as the information was not given to the research nurse by the CCNS. For the 
remaining 168 (13.8 %) the reasons given were: 
o 56 (4.6 %) were not interested, 
o 28 (2.3 %) had advanced disease, 
o 2 (0.1%) died after getting information, 
o 7 (0.6 %) were too anxious 
o 75 (6.1%) various reasons were given. 
The source of the reason for a case not taking part was the CCNS or consultant surgeon 
and only in a small number of cases was the reason given directly by the case to the 
research nurse. Of all cases not participating in the study there was a statistically 
significant (p <0.001) difference within the proportions in each age group. In the age 
group 16 -54 years 139 (6.7 %), group 55 -64 years 466 (22.4 %) and in the group 65 -80 
1479 (71%) did not participate. 
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Participant 
The total number of cases ascertained during the study period was 3761 and the number 
that initially consented to the study was 1623 (43 %). Eighty three (5 %) were not 
available for analysis as; 65 refused to answer the symptom interview, 13 withdrew their 
consent, 5 died before blood could be taken to complete recruitment. The final number 
of cases eligible for analysis is 1540 (41% of those ascertained). 
For 328 (21.2 %) of the 1540 cases, we were unable to obtain data from medical records, 
as they were not available in the medical records department at time of requesting. 
There was no difference amongst the cases with missing medical records in respect of 
age, sex or deprivation groups using both deprivation indices. The exact number of 
cases available for analysis for each variable is indicated in the text where applicable. 
Sex and age of participants 
Amongst the 1540 cases there were 901 (58.5 %) males and 639 (41.5 %) females. The 
median age of participants is 65 years, the 25± centile is 57 years and 75th centile is 71 
years. Table 30 shows the distribution of cases by age groups and sex. 
Table 30 Distribution of recruited cases by age groups and sex 
Cohort 
Age Groups 
Total 16 -54 years 55 -64 years 65 -80 years 
All 309 (20.1 %) 441 (28.6%) 790 (51.3 %) 1540 
Males 162 (18 %) 274 (30.4 %) 465 (51.6 %) 901 (100 %) 
Females 147 (23 %) 167 (26.1 %) 325 (50.9 %) 639 (100 %) 
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The distribution of participants by Health Board of residence at time of diagnosis is 
given in Table 31. 





% of all cases 
ascertained 
Argyll and Clyde 88 38.6 
Ayrshire 101 39.8 
Borders 42 58.3 
Dumfries & Galloway 47 38.8 
Fife 97 46.4 
Forth Valley 89 44.5 
Grampian 267 57.2 
Greater Glasgow 243 34.4 
Highland 61 42.6 
Lanarkshire 131 38.7 
Lothian 239 43.1 
Orkney 6 66.7 
Shetland 3 27.3 
Tayside 123 42.0 
Western Isles 3 21.4 
Table 31 shows that overall; Health Boards with large city hospitals have a higher 
proportion of cases participating in the study. 
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Table 32 Comparison of patients with colorectal cancer who were 
eligible for the study by consent status 
Gender & Age 
Did not consent to 
take part 
Consenting cases 
2079 ( %) 1540 ( %) 
Males 1178 56.8 901 58.5 
Females 897 43.2 639 41.5 
Median Age 70 65 
Interquartile range 63 -75 57 -71 
Surgery 
Yes 1239 59.6 1174 76.2 
No 121 5.8 20 1.3 
Unknown 719 34.6 346 22.5 
Surgery Type 
Curative 460 37.1 941 80.1 
Palliative 316 25.5 100 8.5 
Not recorded 463 37.4 133 11.3 
Health Board Total 
identified 
during study 
Argyll and Clyde 222 140 61.4 88 38.6 
Ayrshire 254 153 60.2 101 39.8 
Borders 72 30 41.7 42 58.3 
Dumfries & Galloway 121 74 61.2 47 38.8 
Fife 209 112 53.6 97 46.4 
200 111 55.5 89 44.5 
Grampian 466 199 42.7 267 57.3 
Greater Glasgow 707 464 65.6 243 34.4 
Highland 143 82 57.3 61 42.7 
Lanarkshire 338 207 61.2 131 38.8 
Lothian 554 315 56.9 239 43.1 
Orkney 9 3 33.3 6 66.7 
Shetland 11 8 72.7 3 27.3 
Tayside 293 170 58.0 123 42.0 
Western Isles 14 11 78.6 3 21.4 
Table 32 represents a comparison of age, sex, surgery and the type of surgery performed 
and Health Board of residence for the total 2079 that did not consent to take part and 
1540 that did consent to the study. This table demonstrates that cases not consenting to 
the study for any reason had more advanced disease than those consenting to the study. 
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Grampian Health Board had the highest number of consenting cases. This Health 
Board also had a low rate of `unable to take part' and within that group a low rate of 
cases receiving palliative care. 
Comparing those `unable to take part' and those participating in the study, participants 
were more likely to have curative surgery than non -participants. The information on 
curative or palliative surgery was available for 1046 participants, of these 99 (9.5 %) had 
palliative surgery and 947 (90.5 %) had curative surgery. 
There were 36 hospitals involved in this study, of these 21 had a colorectal cancer nurse 
specialist (CCNS) at start of the study, 4 hospitals appointed a colorectal cancer nurse 
specialist during the study and 11 hospitals had no CCNS. In the hospitals with a 
CCNS, the ascertainment of cases was over 75% of that expected. It was significantly 
less in hospitals without a CCNS. Although, it was noted that in 2 hospitals where there 
was no CCNS ascertainment was above 75 %. 
Recruitment by hospital 
The following table 33 shows the percentage of the expected number of cases 
ascertained in each hospital. The expected numbers are based on ISD Cancer registry 
data for colorectal cancer diagnosed in 1999. 
210 
Table 33 Percentage of the expected numbers from 15 selected 
hospitals 
Hospital Percentage ascertained 

















Table 33 presents data from a sample of 15 hospitals to demonstrate the range of 
ascertainment. In all 36 hospitals, the ascertainment figures varied from 45% to 134% of 
the expected number. 
Ancestry and ethnicity 
Eligibility for this study required the case to be normally resident in Scotland; no 
specification was given that the case should be born in Scotland. It was of interest to 
know the percentage of cases that were born in Scotland and those with Scottish 
ancestry. On completion of this study, 1295 (84 %) of the total 1540 cases had given 
information on ancestry and ethnicity. 
1290 (99.6 %) of cases reported themselves to be white Caucasian. The 1166 cases 
answered all of the ancestry questions and it was found that number of cases born in 
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Scotland and had parents or grandparents born outside of Scotland was relatively small. 
Figure 16 illustrates the number of cases that answered all of the ancestry questions and 
were born in Scotland. Of those born in Scotland, the number that had Scottish born 
parents and grandparents are shown. 
It is important to note that the results of this study can only be generalised to 
populations of white Caucasians due to the very high percentage in this cohort and the 






































































Figure 16 shows that 979 (82.9 %) were born in Scotland and of those 872 (74.8 %) had 
both parents born in Scotland. Of those cases with both Scottish parents, 815 (69.9 %) 
had both maternal grandparents and 835 (71.6 %) had both paternal grandparents born 
in Scotland. 
The remaining 183 (14 %) of these cases were born in other parts of UK and 39 (3 %) 
outside of the UK. Those who answered `other' to place of birth of their parents and /or 
grandparents ranged from 3% to 6 %. Within this group there were a high proportion of 
parents and /or grandparents born in Ireland. 
Distribution of deprivation scores 
The Carstairs index and the SIMD index are the deprivation indices used in this thesis. 
Group 1 is most affluent; group 2 moderately affluent and group 3 is the most deprived. 
There was one Carstairs score missing for a case and two SIMD scores missing for two 
cases. 
Table 34 shows the distribution of Carstairs scores and SIMD score for this study. 
Table 34 Carstairs and SIMD deprivation scores for participants 
Deprivation Carstairs score 2001 SIMD score 2003 
group ( %) ( %) 
1 (most affluent) 417 (27.1) 470 (30.6) 
2 912 (59.2) 942 (61.2) 
3 (most deprived) 210 (13.6) 126 (8.2) 
Table 34 shows that there is some difference in the proportions within each group 
between the two indices 
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Table 35 compares the distribution of deprivation groups in the Scottish population for 
2001 and the all reported cases of colorectal cancer diagnosed in Scotland during 2000 
and this study population using Carstairs index. The Scottish data given in table 35 is 
from Information Services Division (ISD) of the Scottish Cancer registry. 
Table 35 Carstairs deprivation score distribution for the Scottish 
population, cases register with colorectal cancer in 






cancer population 2000 
Study 
Population 
(all ages) 2001 (16 -79) (16 -79) 
1 (most affluent) 25.8% 22.3% 27.1% 
2 59% 62.8% 59.2% 
3 (most deprived) 15.2% 14.9% 13.6% 
Table 35 shows that the study population has a similar percentage of the most affluent 
and most deprived group as those registered with colorectal cancer in Scotland. 
Comorbidity 
The comorbidity score was derived from information given in the medical notes and 
reflects conditions present before the diagnosis of colorectal cancer. The Charlson 
comorbidity index was used with the addition of 2 conditions, depression and alcohol 
dependence. The scores are a total count with no weighting or measure of 
functionality14. The comorbidity score was available for 1208 cases. 
The total scores range from 0 to 6, numbers and percentages are listed below in Table 
36. 
14 Some comorbidity scores have the ability to measure the effect of a comorbid disease on functional status. 
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719 ( %) 489 ( %) 
0 505 (41.8) 314 (43.7) 191 (39.0) 
1 342 (28.3) 195 (27.1) 147 (30.0) 
2 219 (18.1) 122 (16.9) 97 (19.8) 
3 85 (7.0) 56 (7.8) 29 (5.9) 
4 35 (2.9) 19 (2.6) 16 (3.2) 
5 16 (1.3) 11 (1.5) 5 (1.0) 
6 6 (0.5) 2 (0.2) 4 (0.8) 
This table shows that 847 (70.1 %) of cases had zero or one comorbid condition at time 
of diagnosis of colorectal cancer. 
Further analysis of comorbidity scores was carried out using a variable code for those 
with no comorbidity and those with comorbidity. There was no statistically significant 
difference between male and females, age groups or deprivation groups (using both 
indices) in the proportions of those with or without comorbidity. Within each category 
with or without comorbidity the percentage of cases was higher in the older age group. 
Table 37 shows the results of this analysis for both deprivation indices and those with 
and without comorbidity at time of diagnosis. 
Table 37 Deprivation groups and cases with and without 
comorbidity at diagnosis. 
With comorbidity Deprivation 
groups 
No comorbidity 
Carstairs SIMD Carstairs SIMD 
193 (27.5 %) 201 (28.7 %) 1 145 (28.7 %) 169 (33.5 %) 
407 (58.0 %) 442 (63.1 %) 2 298 (59.0 %) 294 (58.2 %) 
102 (14.5 %) 58 (8.3 %) 3 62 (12.3 %) 42 (8.3 %) 
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There was no statistically significant difference between the groups with comorbidity or 
without comorbidity and the proportion in each Dukes' stage at diagnosis. 
Type of admission to hospital 
The medical notes were available for 1212 cases, 970 (80 %) were elective admissions 
and 242 (20 %) were emergency admissions. 
There was no statistically significant difference in the proportion within the age groups, 
sex, deprivation groups or comorbidity of those admitted electively or as an emergency 
admission. 
Cross tabulation of Carstairs index and type of admission to hospital was possible for 
1185 cases and 1184 cases when using the SIMD index. 
Analysis using the Carstairs index found no statistically significant difference in type of 
hospital admission between proportions in the deprivation categories. Although not 
statistically significant, there were a greater proportion of emergency admissions in the 
more deprived group. Emergency admission was recorded for 35 (25.2 %) of the 
deprived group and 63 (17.8 %) of the most affluent group. 
Using the SIMD index, there was no statistically significant difference in type of hospital 
admission. Although not statistically significant, the emergency admission number was 
20 (22.5 %) in the most deprived group and was 77 (18.8 %) in most affluent group. 
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Analysing the Dukes' stage and mode of admission to hospital there was a statistically 
significant difference (p <0.001) between those admitted as an elective admission or 
emergency admission and Dukes' stage of tumour. The results are shown in table 38. 
Table 38 Dukes' stage of tumour and mode of admission to hospital 
Admission to hospital 
Dukes' stage Emergency ( %) Elective ( %) 
A 20 (8.5) 225 (23.7) 
B 91 (38.6) 348 (36.6) 
C 105 (44.5) 327 (34.4) 
D 16 (6.8) 29 (3.1) 
N /A* 4 (1.7) 21 (2.2) 
*N /A- no staging available as no surgery was performed 
This table demonstrates that there is a large percentage difference in those presenting 
with Dukes' stage A tumours by mode of admission to hospital. There was a statistically 
significant difference (p <0.001) between proportions with colon cancer and rectal 
cancer and the mode of admission to hospital. In the group of cases admitted as an 
emergency 196 (82.7 %) had colon cancer and 41 (17.3 %) had rectal cancer. 
Analysis of delay in presentation with symptom and mode of admission to hospitals is 
shown in table 39. 
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Table 39 Median delay time and mode of admission to hospital 
Symptom 
Median wait time 
(weeks) 
Emergency Elective 
Change in bowel habit 8 12 
Rectal bleeding 4 6 
Weight loss 12 13 
Marked loss of energy 13 13 
Wind and bloating 8 13 
Loss of appetite 8 13 
Mucus 8 13 
Tenesmus 12 13 
Abdominal Discomfort 5 10 
Pain 2 5.2 
Nausea 2 8 
Vomiting 1 1.5 
Table 39 clearly demonstrates the shorter wait time with most symptoms in cases 
admitted as an emergency, with the exception of marked loss of energy, which has the 
same wait time as for elective admissions. 
There was a statistically significant (p <0.001) difference between the proportions of 
cases with rectal and colon cancer and the mode of admission to hospital. 
Of the cases admitted as an emergency 196 (82.7 %) had colon cancer and only 41 
(17.3 %) had rectal cancer. 
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Chapter 13 
Results: Family History 
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Family history 
Of the 1540 colorectal cancer cases, 31 (2 %) cases refused or were unable to give their 
family history for a variety of reasons. The main reason given was that the case was no 
longer in touch with their family. Therefore a total of 1509 cases were available for risk 
assessment. Of these, a total of 280 (18.6 %) cases in this study were assigned a high or 
moderate family history risk, based on Scottish guidelines. The remaining 1229 (81.4 %) 
cases were assigned a low family history risk. A proportion of cases assigned a low 
family history risk will have a close relative with colorectal cancer but they do not meet 
the specified guidelines. Throughout this section the family history risk assigned by the 
guidelines will be referred to as assigned family history risk. 
The assigned family history risks are given in Table 40. 





High15 27 (1.8) 
Moderate16 253 (16.8) 
Low17 1229 (81.4) 
Total 1509 100 
Family History Data Analysis 
The data in this section relate to questions 13 and 13b of the symptom interview 
(Appendix 10). Each case was asked `would you say you have a family history of 
15 High risk -families with three or more relatives with colorectal cancer over two generations who are 1st degree relatives to each other and one under 
age 50 at diagnosis. 
16 Moderate risk -families who have a case under age 45 and are a 1st degree relative or two cases with one under 55 or three cases with colorectal 
cancer. 
17 Low risk - families not meeting high or moderate risk 
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colorectal cancer ?' The term `family history' was chosen for the question, as it is the 
terminology used in health insurance documentation, it is also used by hospital doctors 
and General Practitioners (GP). By adulthood, most people have had some experience 
of GPs or hospital doctors or insurance documentation asking them about their family's 
medical history. Therefore, the term family history, in the above context, is understood 
by the general public to mean other people in their family with the condition of 
reference. No reference to risk was used or choice of risk given as the overall aim was to 
investigate how an individual would interpret their current family history situation. 
It was assumed that many people understand that if they have a family history of certain 
conditions their insurance premium will be greater than for someone without such a 
family history. Therefore, having a family history in some circumstances may imply an 
increased risk for that person. For this analysis, each case was assigned a high, moderate 
or low risk assessment based on their family history, using the Scottish guidelines 
(Scottish Cancer Genetic Sub Group 2001). 
Of the 1509 with family history data, 48 cases were assigned a moderate risk family 
history assessment because they were diagnosed with colorectal cancer under the age of 
45. However, each of these 48 cases were the only person in the close family to be 
diagnosed with colorectal cancer and they would therefore answer `no' to the question 
`do you have family history of colorectal cancer ?' Because of this they were omitted 
from the analysis. Therefore in total, 79 were omitted, leaving 1461 cases to be included 
in the remaining analysis. 
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Only 27 (1.8 %) cases were assigned a high risk therefore, high and moderate risk cases 
have been combined creating two variables; those with a family history and those with 
no family history. 
Another 5 cases did not respond to the question about the perceived presence of family 
history question and table 41 below, gives the distribution of 1456 cases by family 
history risk and perceived presence of a family history. 





Perceived family history 
( %) 
YES NO Don't Total 
Know 
High or 133 84 18 235 
moderate (59.9) (7.3) (20.0) 
Low 89 1061 71 1221 
(40.1) (92.7) (80.0) 
222 1145 89 1456 
There was a statistically significant (p <0.001) difference between the cases in the three 
groups; those that did perceive they had a family history of colorectal cancer, those that 
did not perceive they had a family history of colorectal cancer and those that did not 
know if they had a family history of colorectal cancer and the assigned family history 
risk using Scottish guidelines. 
Of those who did perceive they had a family history, 133 (59.9 %) were assessed as 
having a high or moderate family history risk. In contrast, those who did not perceived 
18 Perceived presence of family history - the perception of whether the case thou3ht they had a family history of colorectal cancer 
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they had a family history, 84 (7.3 %) cases were assessed as having a high or moderate 
family history risk, of cases who answered that they did not know if they had a family 
history 18 (20 %) did have a high or moderate family history risk. 
The same analysis was repeated for males 855 (58.4 %) and females 606 (41.6 %) 
separately and the findings were similar to those described above. The 89 cases that 
answered `don't know' to presence of a family history have been excluded in what 
follows leaving 1367 cases included in the analysis. 
Deprivation scores 
Table 42 below compares the relationship between the perceived presence of a family 
history and assigned family history risk in the 408 most affluent cases and 152 most 
deprived cases according to Carstairs deprivation index. 
Table 42 Distribution of the perceived family history and family 





Perceived presence of family history 
( %) 
YES NO 
1 Most affluent Moderate or 38 25 
High (50.0) (7.5) 
Low 38 307 
(50.0) (92.5) 
3 More deprived Moderate or 17 8 
High (68.0) (6.3) 
Low 8 119 
(32.0) (93.7) 
19 Table 42 are the results using Carstairs deprivation groups 1 and 3 
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Of the most affluent group 38 (50 %) cases perceived they had a family history of 
colorectal cancer but did not have an assigned high or moderate family history risk. 
However, only 8 (32 %) cases in the most deprived group fell in to this category. 
The same analysis was carried out using the SIMD index and the results were very 
similar. 
Perceived presence of family history 
The 222 cases that perceived presence of family history were asked if they discussed 
their family history concern with their GP. 215 cases answered this question and 7 cases 
omitted to answer. It was found that 76 (35.3 %) cases had discussed their perceived 
presence of family history with their GP and 139 (64.7 %) did not. Of the 76 cases 
discussing their concerns with their GP, 51 (67.1%) had a high or moderate family 
history risk assigned. 
There was no statistically significant difference between males and females as to whether 
they discussed their concerns with a GP. Of the 117 cases that did discuss their 
concerns 60 (25.6 %) were female and 57 (19.7 %) were male. 
Considering those with a perceived presence of family history, there was no statistically 
significant difference between the three deprivation categories ( Carstairs index) in the 
proportion that discussed their concerns with their GP. Although statistically non 
significant, there was a trend using both deprivation indices, for the most affluent group 
to discuss their family history concerns with their GP. Using Carstairs index, 27 (35.5 %) 
of the most affluent group and 7 (30.4 %) of the most deprived group, and using SIMD 
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index 31 (36.9 %) of the most affluent group and 5 (33.3 %) of the most deprived, 
discussed their concerns. 
Assigned family history risk 
The family history results that have most clinical importance are those cases assigned a 
high or moderate family history risk (defined by the Scottish guidelines). These are an 
important group because the case is eligible for mutation analysis or microsatellite 
instability (MSI)2° testing and their first- degree relatives eligible to enter a surveillance 
programme. 
In this analysis there were a high proportion of cases with an assigned high or moderate 
family history not referred to a cancer genetic service. In this study 280 cases were 
assigned a high or moderate family history risk and were eligible for referral to cancer 
genetic services. Of the 280cases a total of 266 (95 %) were not referred. Of these 280 
cases, 147 (52.5 %) did not perceive they had a family history, 83 (29.6 %) of the 280 
cases did perceive they had family history risk but did not discuss it with the GP. 
Of the 280 cases with a high or moderate family history risk, 133 (47.5 %) perceived they 
had a family history. Of these 133 cases that perceived a family history, 51 (18.2 %) 
discussed their concerns with the GP. In the whole cohort, 6 other cases were referred 
to clinical genetics. However they all had a low risk family history. 
20 Microsatellites sequences, short (1 -6 nucleotide) sequences repeated tens to hundreds of times, occur normally in DNA. However, where DNA 
repair systems are abnormal, as when there are mutations in mismatch repair genes, abnormally long or short microsatellite sequences tend to 
accumulate. This phenomenon is termed microsatellite instability or MSI 
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Figure 17 demonstrates the numbers with family history and the final numbers referred 
to genetics. 
Figure 17 280 cases with an increased family history risk of colorectal cancer 
and referral to cancer genetic services 
147 (52.5 %) 
Did not perceive a 
family history 
2 (0.7 %) 
Cases not perceiving 
risk were referred to 
cancer genetics 
280 
Cases with assigned 
moderate or high 
family history risk 
82 (29.6 %) 
Did not discuss 
family history with 
GP 
14 (5 %) 
Referred to cancel- 
genetic service 
133 (47.5 %) 
Did perceive family 
history 
51 (18.2 %) 
Discuss their family 
history with GP 
12 (4.3 %) 
Referred to cancer 
genetic service 
Referral to genetic department by GP 
The 51 cases with a high or moderate family history risk that perceived a family history 
risk and had discussed the concern with their GP should have expected a referral to a 
cancer genetic clinic. When these cases were asked if they had been referred only 12 
(23.5 %) of the 51 cases with a high or moderate family history risk stated that they has 
been referred to a cancer genetic service. 
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When the relationship between assigned family history risk and referral to cancer genetic 
services was investigated, more females were referred. However, there was no 
statistically significant difference between sex and the proportion of those referred to 
cancer genetic services. Of those cases assigned a high or moderate family history risk 
and who perceived a family history risk 8 (13.8 %) were females and 4 (6.6 %) male. 
There was a statistically significant (p <0.001) difference found between the proportions 
of cases referred to cancer genetic services in the different age group. Cases in the 
youngest age group (16 -54) were most likely to be referred to cancer genetic services. In 
the younger age group, 8 (18.6 %) cases were referred, in the middle age group 2 (6.5 %) 
were referred and 2 (4.4 %) in the older age group were referred. However it is 
acknowledged that the numbers of cases in each age subgroup are very small. 
There was no statistically significant difference found between the proportions referred 
to cancer genetics services and the deprivation groups using both deprivation indices. 
Of those cases with an assigned high or moderate family history risk referred to the 
cancer genetic services 5 (11.1%) are in the most affluent group, 6 (8.7 %) in the 
moderate group and 1 (20 %) in the most deprived group using Carstairs deprivation 
index. Using the SIMD deprivation index and the group of cases with an assigned high 
or moderate family history risk referred to the cancer genetic services, 6 (10.9 %) are in 
the most affluent group, 6 (9.7 %) in the moderate group and 0 (0 %) in the most 
deprived group. It is acknowledged that the numbers are small and there is low power 
to detect a difference. 
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Dukes' Staging 
Relationship analysis was carried out to identify any differences in Dukes' staging and 
cases with an assigned high or moderate family history risk, No statistically significant 
difference between cases with a high or moderate family history and the Dukes' stage of 
tumour at diagnosis was found. The results shown in table 43 are for total number of 
1140 cases that had Dukes' staging available for analysis. 
Table 43 Cases with an assigned high or moderate family history 
risk and Dukes' stage at presentation 
Family history 
risk 
A B C D 
High or 45 72 80 8 
Moderate 
(22.6) (34.0) (37.0) (3.8) 
Low 196 357 345 37 
(20.6) (37.5) (36.2) (3.9) 
There was no statistically significant difference between those with a hi h or moderate 
family history risk and those that a perceived family history risk in the proportions 
referred to hospital after one or more than one visit to GP. 
Perceived presence of colorectal cancer family history 
As not all of the cases with a high or moderate family history risk perceived a family 
history of colorectal cancer, the following analysis was carried out using only the 222 
cases that did perceive a family history of cancer. The analysis was to ascertain if a 
perceived family history of colorectal cancer initiated a different behaviour pattern than 
those cases with no perceived family history risk. 
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There was a statistically significant (p <0.001) difference between the proportion of cases 
with a perceived family history of colorectal cancer and those not perceiving a family 
history colorectal cancer stating `some knowledge of colorectal cancer'. Those with a 
perceived family history of colorectal cancer were more likely to state `some knowledge' 
of colorectal cancer symptoms than those not perceiving a family history. In the group 
perceiving a family history of colorectal cancer 130 (56.8 %) had `some knowledge' of 
colorectal cancer symptoms and those with no perceived family history risk 521 (43.1%) 
stated they had some had `some knowledge' of colorectal cancer symptoms. 
There was a statistically significant (p <0.001) difference between the proportion of cases 
with a perceived family history of colorectal cancer and those not perceiving a family 
history colorectal cancer when asked about whether they considered that they had 
cancer before their diagnosis. Of the cases that perceived a family history risk 119 (52 %) 
considered cancer before diagnosis and of those not perceiving a family history risk 443 
(36.9 %) considered cancer before diagnosis. There was no statistically significant 
difference between cases with a perceived family history of colorectal cancer and those 
not perceiving a family history colorectal cancer and the waiting time with symptoms or 
likelihood of self medicating for symptoms or discussing symptoms with another person 
before visiting their GP. Table 44 shows the mean waiting time for each symptom of 
those cases perceiving and not perceiving a family history of colorectal cancer 
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Table 44 Median waiting time with symptoms of cases perceiving 
and not perceiving a family history of colorectal cancer 
Symptoms Median wait time 
for cases perceiving 
family history 
(days) 
Median wait time 




Change in bowel habit 84 61 
Rectal bleeding 61 42 
Weight loss 121 90 
Marked loss of energy 91 91 
Wind and bloating 91 70 
Loss of appetite 61 61 
Mucus 56 61 
Tenesmus 28 61 
Abdominal discomfort 61 61 
Pain 30 21 
Nausea 60 21 
Vomiting 43 7 
It can be seen in table 44 that although not statistically significant those cases not 
perceiving a family history risk of colorectal cancer were more likely to visit the GP 
sooner than those that did perceived they had a family history risk of colorectal cancer. 
There was no statistically significant difference between the response of those cases that 
did and did not perceive a family history of colorectal cancer to the question asking if 
they discussed their symptoms with anyone prior to visiting the GP. Of the cases that 
did perceive a family history 137(14.3 %) did discuss their symptoms with someone and 
69(14.4 %) cases did not discuss their symptoms with anyone. 
There was no statistically significant difference between the response of those cases that 
did perceive a family history risk of colorectal cancer to the question asking if they had 
taken any over the counter medication for any symptom prior to visiting the GP and the 
cases that did not perceive a family history of colorectal cancer. Of the cases that did 
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perceive a family history 39 (12.8 %) did take medication for a symptom and 167 
(14.9 %) cases did not take medication for any symptom prior to visiting their GP. 
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Chapter 14 
Results: Symptom presentation 
233 
Lower gastrointestinal symptom 
Cases were asked if they had visited their GP to discuss the presenting symptom that 
concerned them. A total of 1533 responded to this question. Of the 1533 cases 1212 
(79.0 %) did visit a GP to discuss their symptom, another 112 (7.3 %) cases stated that 
they had gone to their GP for another reason and mentioned that they had a lower 
gastrointestinal symptom and 87 (5.7 %) cases did not visit a GP and were referred for 
further investigation from another hospital appointment or diagnosed with colorectal 
cancer whilst attending another hospital appointment. A further 122 (8.0 %) did not visit 
their GP with symptoms, as they did not think they had symptoms requiring a visit to a 
GP. 
Of these 122 cases that did not a visit to a GP with symptoms, 100 cases were 
investigated for colorectal cancer during a faecal occult blood testing (FOBT) pilot (48 
of these cases did report having symptoms to research nurse) and 22 were a mixture of 
just feeling generally unwell when they visited the GP or were admitted after a collapse 
but reported no symptom. Of the total 199 that were referred from another hospital 
appointment or did not present to a GP, 115 had symptoms and are included in table 
46. 
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A total of 1324 case did discuss symptoms with their GP. The main presenting 
symptom is given in table 45. 




1324 ( %) 
Rectal bleeding 492 (37.2) 
Change in bowel habit 349 (26.4) 
Abdominal pain 220 (16.6) 
Marked loss of energy/ 
breathlessness 
139 (10.5) 
Family history 87 (6.6) 
Weight loss 20 (1.5) 
Tenesmus 3 (0.2) 
Other 14 (0.7) 
This table illustrates that rectal bleeding and change in bowel habit are the two most 
common symptoms that prompt presentation to the GP. 
After asking the question on the main symptom that prompted their visit to the GP, all 
1540 cases were asked by the research nurse to state whether they had experienced any 
of a list of symptoms before visiting their GP. For each symptom reported they were 
asked how long it had been present when they first visited their GP. Many cases 
presented with several symptoms at the first GP visit therefore, the total number with 
symptoms in table 46 is higher than the total number of cases. 
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Number in cohort 
with symptom 
( %) 
Change in bowel habit 1501 805 (53.6) 
Rectal bleeding 1491 768 (51.5) 
Weight loss 1491 256 (17.2) 
Marked loss of energy 1489 603 (40.5) 
Wind and bloating 1501 506 (33.7) 
Loss of appetite 1499 246 (16.4) 
Mucus 1490 296 (19.9) 
Tenesmus 1484 324 (21.8) 
Abdominal discomfort 1499 346 (23.0) 
Pain 1489 332 (22.3) 
Nausea 1333 159 (11.9) 
Vomiting 1337 123 (9.3) 
Table 46 shows that greater than 50% of cases in the whole cohort were experiencing 
either rectal bleeding or a change in bowel habit when they first presented to a GP. 
Change in bowel habit, rectal bleeding and marked loss of energy were the 3 symptoms 
experienced by the highest percentage of individuals in the whole cohort and by site of 
cancer. There was no statistically significant difference between males and females in the 
frequency of those experiencing rectal bleeding or a change in bowel habit. Of 603 
experiencing a marked loss of energy, there was a statistically significant difference 
(p <0.001) between the sexes and the numbers reporting this symptom. Females were 
more likely to report having marked loss of energy, 299 (48.1 %) females reported this 
and 304 (35 %) of males. 
There was no statistically significant difference between the age groups in the 
proportion of those with or without a change in bowel habit. There was a statistically 
significant difference between the age groups and the reporting of rectal bleeding 
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(p <0.001) and marked loss of energy (p <0.05) where the youngest age group (16 -54) 
were more likely to report these symptoms. 
In the youngest age group (16 -54) rectal bleeding was reported by 191 (63.9 %) cases and 
reported by (46.7 %) in the older age group (65 -80). Marked loss of energy was reported 
by 140 (47.3 %) of the younger age group and 294 (38.5 %) of the oldest age group (65- 
80). 
There was no statistically significant difference between those with or without rectal 
bleeding, change in bowel habit and marked loss of energy within the deprivation 
groups using both indices. When the same analysis was carried out using colon and 
rectal cancer data separately the results remain statistically non significant for both. 
Other symptoms 
All cases were asked if they had any other symptoms they would like to mention that 
were not included on the list. 184 (11.9 %) of all cases stated they had another symptom. 
The more common symptoms reported are listed below: 
o Breathlessness 37 (20.1%) 
o Indigestion 24 (13.0 %) 
o Dizzy 13 (7.1%) 
o Thinner stools 11 (6.0 %) 
o Foul smelling stools 8 (4.3 %) 
o Felt a lump 7 (3.8 %) 
o Back pain 6 (3.3 %) 
o Various other symptoms 78 (38.6 %) 
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Site of cancer 
The site of cancer was available for 1199 cases. Of the 1199 cases, 44 (3.6 %) had a 
double primary tumour. There were 697 (58.1 %) cases with colon cancer and 502 
(41.9 %) with rectal cancer. Rectal cancers include the recto - sigmoid cancers. 
The sex distribution in colon cancer was 55.4% male and 44.6% female. There was a 
statistically significant difference (p <0.05) between distribution of sex and site of cancer. 
Of those with rectal cancer there were 312 (62.2 %) males and 190 (37.8 %) females. 
There was no statistically significant difference between site of cancer and age groups or 
different deprivation groups (using both deprivation indices). There was a trend that the 
most affluent group were more likely to be diagnosed with rectal cancer and the most 
deprived group diagnosed with colon cancer (using both deprivation indices). Table 47 
is the results of cancer site and Carstairs deprivation index. 
Table 47 Site of cancer and Carstairs deprivation groups 
Colon Rectum 
Deprivation group number ( %) number ( %) 
1 205 (59.4) 140 (40.6) 
2 387 (55.7) 308 (44.3) 
3 89 (66.4) 45 (33.6) 
Table 48 presents a comparison of symptoms at presentation to a GP by rectal and 
colon cancer, some cases had more than one symptom. The table also presents the 
difference in the proportions (all calculations relate to rectal cancer from colon cancer). 
The 95% confidence intervals (CI) given in table 48 are the confidence intervals for the 
difference in proportions. 
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Table 48 Site of cancer and symptom presentation 
Symptom 






Interval of the 
difference 697 ( %) 502 ( %) 
Change in bowel 
habit 
317 (45.5) 307 (61.2) -0.15- -0.212 to -0.100 
Rectal bleeding 237 (34.0) 370 (73.7) -0.397 -0.447 to -0.343 
Weight loss 132 (18.9) 73 (14.5) 0.044 0.001 to 0.086 
Marked loss of 
energy 
310 (44.5) 152 (30.3) 0.142 0.087 to 0.195 
Wind & bloating 232 (33.3) 168 (33.5) -0.002 -0.056 to -0.052 
Loss of appetite 143 (20.5) 51 (10.2) 0.104 0.063 to 0.143 
Mucus 99 (14.2) 130 (25.9) -0.117 -0.142 to -0.071 
Tenesmus 113 (16.2) 141 (28.1) -0.119 -0.167 to -0.071 
Abdominal 
discomfort 
177 (25.4) 83 (16.5) 0.089 0.042 to 0.134 
Pain 194 (27.8) 67 (13.3) 0.145 0.099 to 0.189 
Nausea 92 (13.2) 28 (5.6) 0.076 0.043 to 0.108 
Vomiting 74 (11.0) 14 (2.8) 0.078 0.051 to 0.106 
This table demonstrates the differences in symptom presentation with the site of 
colorectal cancer. The most common symptom for colon cancer is change in bowel 
habit. Also noted is the high proportion with marked loss of energy in colon cancer 
cases. In cases with rectal cancer, rectal bleeding was the most common symptom. 
There was no statistically significant difference between delay in presentation with 
symptoms and site of cancer. However there was a difference in the delay pattern and 
site with most symptoms. Table 49 presents the results of each symptom and waiting 
with symptoms less than six weeks and greater than six weeks. 
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Table 49 Delay time reporting symptoms and site of cancer 
Symptoms 
Site of Cancer Site of Cancer 
Colon 
< 6 weeks 
Rectum 
< 6 weeks 
Colon 
> 6 weeks 
Rectum 
> 6 weeks 
Change in bowel habit 118 (39.3) 93 (32.3) 182 (60.7) 195 (67.7) 
Rectal bleeding 128 (54.9) 175(47.6) 105 (45.1) 193 (52.4) 
Weight loss 23 (18.3) 19 (27.1) 103 (81.7) 51 (72.9) 
Marked loss of energy 78 (25.4) 35 (23.2) 229 (74.6) 116 (76.8) 
Wind & bloating 66 (30.0) 48 (29.6) 154 (70.0) 114 (42.5) 
Loss of appetite 53 (39.3) 17 (33.3) 82 (60.7) 34 (66.7) 
Mucus 35 (37.2) 55 (45.8) 59 (62.8) 65 (54.2) 
Tenesmus 38 (35.5) 45 (33.8) 69 (64.5) 88 (66.2) 
Abdominal discomfort 68 (42.8) 25 (33.8) 91(57.2) 49 (66.2) 
Pain 107 (63.3) 33 (57.9) 62 (36.7) 24 (42.1) 
Nausea 52 (59.1) 13 (50.0) 36 (40.9) 13 (50.0) 
Vomiting 52 (70.3) 9 (69.2) 22 (29.7) 4 (30.8) 
Six weeks was chosen for this analysis because is the time scale stated in the referral 
guidelines `for suspected colorectal cancer' that key symptoms should be present in an 
individual before being referred for further investigation. 
Low haemoglobin levels and colorectal cancer site 
There was a difference in the distribution of low haemoglobin levels and site of 
colorectal cancer. In male colon cancers 80 (77.6 %) had haemoglobin levels less than 
11g /dl and only 23 (22.4 %) of rectal cancers. Of females with colon cancer 51 (87.9 %) 
had haemoglobin levels less than 10g /d1 and 7 (12.1 %) with rectal cancers. All females 
with low haemoglobin levels are included in this analysis, not only post -menopausal 
women. 
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This table shows that weight loss, marked loss of energy, wind and bloating were the 
three symptoms present for the longest time at first visit to a GP. 
Cases with colon cancer waited a shorter time that those with rectal cancer. Rectal 
cancer cases with rectal bleeding wait 8 weeks and those with a change in bowel habit 
waited 11 weeks before visiting a GP. Colon cancer cases waited 8.7 weeks with rectal 
bleeding and 4.3 weeks with a change in bowel habit. 
Figure 18 visually illustrates the median waiting time with each symptom. 







loss of appetite 
wind & bloating 
Excess loss energy 
weight loss 
rectal bleeding 
Change of bowel habit 
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Median waiting time in weeks 
The cumulative numbers and percentages of cases waiting various times with each 
symptom are shown in table 51. The number of cases with the symptoms, shown in 
table 40 differs slightly from those who gave the waiting time as, some cases failed to 
give a waiting time although the symptom was present. 
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It was interesting to look at the cumulative waiting time with symptoms before visiting a 







































































































































































































































This table illustrates that on average 25% of cases waited up to 24 weeks to visit their 
GP with symptoms. No statistically significant difference between waiting time with 
symptoms and sex, age, with or without comorbidity, deprivation groups (using both 
deprivation indices) were detected using Spearman's rank correlation. 
Analysis was carried out on the site of cancer and waiting time with rectal bleeding, 
change in bowel habit and weight loss because the median wait time differed by site for 
these symptoms. The results showed no significant difference for any of the analysis 
with the exception of rectal bleeding and age. The younger the age of person with rectal 
bleeding the longer they wait to report symptoms. 
Multivariate analysis 
In addition to the above analysis, a multivariate model was built using Cox proportional 
hazard modelling. The models were built and fitted to the data to investigate differences 
between age, sex, comorbidity and deprivation, to determine the likelihood that 
someone would present to the GP with rectal bleeding, change in bowel habit or 
marked loss of energy. For each symptom two models were created for each of the 
deprivation indices together with age, sex and number of comorbidities. None of the 
variables were associated with the likelihood of presenting with rectal bleeding. For 
change in bowel habit there was a positive association with age (p= 0.006). For an 
increase in age of 10 years, the hazard of presenting with change in bowel habit was 
increased by a factor of 1.12 (95% CI 1.03, 1.22). For marked loss of energy there was a 
difference between the sexes (p= 0.003) the male to female hazard ratio was 0.76 (95% 
CI 0.63, 0.91). Therefore, males are 25% less likely to present with marked loss of 
energy. Models were built using cases with rectal and colon cancer separately and the 
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analysis results were identical to those described above. Following these results using the 
more common presenting symptoms a decision was taken not to proceed further with 
more multivariate analysis. 
Total number of symptoms at first visit to GP 
The total numbers of symptoms at presentation to a GP was not normally distributed 
and a median of 3 symptoms present at first visit to a GP was found, inter- quartiles (1- 
4). Of the 1540 cases, 99 reported no symptoms and 48 were cases found at FOBT 
pilot, the remaining 51 cases were a combination of cases found at a surveillance 
appointment for previous colorectal cancer, ulcerative colitis and polyps. In addition 
some patients were already inpatients for other reasons and underwent a colonoscopy. 
This figure differs from those who did not present with symptoms to their GP as 23 
cases not visiting their GP reported having symptoms before any investigation. Figure 
19 shows the total number of symptoms at presentation. 
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Figure 19 Distribution of recruited patients with colorectal cancer by number 
of lower gastrointestinal symptoms at presentation 
Figure 19 shows that the majority of cases presented with between 1 and 3 symptoms. 
The following analysis was carried out after classifying the cases into 2 groups according 
to whether they had 1 -3 symptoms or 4 -11 symptoms. There was a statistically 
significant (p <0.001) difference between the sexes in the proportions that has 1 -3 
symptoms and those that had 4 -7 symptoms at presentation to GP. Males were more 
likely to be in the group with a higher number of symptoms. Results show that there 
were 255 (42.5 %) females in the group with 1 -3 symptoms and 267 (32.4 %) males in 
this group. 
There was no statistically significant difference between the age groups or deprivation 
groups in the proportions of those with 1 -3 symptoms at presentation to GP or those 
with 4 -11 symptoms at presentation to GP. 
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Of the 333 cases presenting to GP and reporting only one symptom, the highest 
percentage consisted of rectal bleeding (162 (48.6 %)), marked loss of energy (67 
(20.1%)) and change in bowel habit (57 (17.1%)) the remaining 47 (14.1%) cases 
presented with only one symptom from the other nine possible remaining symptoms. 
Developing new symptoms after referral to hospital 
Cases were asked if they developed any new symptoms in the time between their GP 
referring them to hospital for further investigations and getting their hospital 
appointment. In total 490 (31.8 %) did develop a new symptom. Cases were also asked if 
they reported any new symptoms to their GP. Many of the 490 cases develop more than 
one new symptom after referral to hospital accounting for the total number in table 52 
being greater than 490 cases. Table 52 shows the number that developed each symptom 
and the number of the 490 cases that discussed the new symptom with their GP. 
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Table 52 New symptoms developing after referral to hospital and the 
number reporting new symptoms to GP 
New symptom 
Number with new 
symptom ( %) 
Number reporting 
new symptom to GP ( %) 
Change in bowel habit 125 (25.5) 77 (61.6) 
Rectal bleeding 94 (19.1) 63 (67.0) 
Marked loss of energy 93 (19.0) 40 (43.0) 
Weight loss 78 (15.9) 40 (51.2) 
Wind & bloating 68 (13.9) 30 (44.1) 
Loss of appetite 65 (13.2) 29 (44.6) 
Mucus 60 (12.2) 32 (53.3) 
Tenesmus 55 (11.9) 28 (50.9) 
Abdominal discomfort 50 (10.9) 27 (54.0) 
Pain 93 (19.1) 65 (69.8) 
Nausea 52 (10.6) 36 (69.2) 
Vomiting 52 (10.6) 38 (73.0) 
This table shows that approximately one third of cases developed new symptoms whilst 
waiting for a hospital appointment. Of those with new symptoms, 48 (38.4 %) cases 
with change in bowel habit, 31 (33 %) with rectal bleeding and 53 (57 %) with marked 
loss of energy did not report these to their GP. There was no statistically significant 
difference in sex of cases between those reporting new symptoms to their GP and not 
reporting symptoms. There was a statistically significant (p <0.05) difference between 
age groups in those reporting new rectal bleeding. There was a statistically significant 
(p <0.01) difference between age groups in those reporting new change in bowel habit 
and a statistically significant (p <0.001) difference between age groups in those reporting 
new marked loss of energy. The results of this analysis are shown in Table 53. 
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Table 53 Percentage within each age group that reported new 
symptoms to GP after referral to hospital 
Age group 
Percentage in age groups reporting new symptoms 
Rectal bleeding 
(p <0.05) 
Change in bowel habit 
(p <0.01) 
Marked loss of energy 
(p <0.001) 
16 -54 13 (68.4 %) 19 (70.4 %) 14 (60.9 %) 
55 -64 21 (50.0 %) 25 (152.1%) 10 (30.3 %) 
65 -80 31 (40.3 %) 33 (38.4 %) 17 (20.5 %) 
This table shows that a higher proportion of young people who develop a new 
symptom reported this to their GP. 
Anal symptoms 
Cases were asked if they experienced any symptoms in their anal region such as; itching, 
soreness, lumps, discomfort, pain or anything prolapsed and 1347 responded. Of those 
who responded, 1094 (81.2 %) had no anal symptoms and 289 (18.8 %) had anal 
symptoms. 
Of the 289 who did have anal symptoms, 253 gave the symptom they had experienced: 
o Soreness 78 (27.5 %) 
o Itching 118 (41.5 %) 
o Lumps 43 (14.8 %) 
o Discomfort 75 (25.7 %) 
o Pain 59 (20.1%) 
o Prolapse 14 (4.6 %) 
Itching was the most common symptom experienced by 118 (41.5 %) cases. A number 
of cases had more than one anal symptom. 
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Of the 768 cases with rectal bleeding, 512 (66.7 %) had no anal symptoms. These 
represented 512 (35.6 %) of cases from the 1439 that answered both questions on rectal 
bleeding and anal symptoms. 
Specific information on change in bowel habit 
Of the 1540 cases, 805 (53.6 %) cases reported having a change in bowel habit. These 
cases were asked to give more specific information on the frequency and consistency of 
this change. Of those with a change in bowel habit, 743 cases gave information on 
change of frequency, 473 (63.7 %) had increased frequency, 200 (26.9 %) decreased 
frequency and 70 (9.4 %) reported having both increased and decreased frequency. 
Cases with increased frequency were asked about consistency and 430 case of the 473 
replied. Of the 430 cases, 416 (89.1 %) cases reported that with the increased frequency 
they also had looser stools. 
Of 805 cases reporting change in bowel habit, the total number with change to 
increased and /or looser stools was 549 (68.2 %) cases. 
Self treatment 
Cases were asked if they had self -treated for any symptom before visiting the GP, 1127 
responded to this question. Of these, 305 (27 %) stated they had taken medication for a 
symptom. Of the 305 that did self -treat, 298 stated which symptom they had treated and 
these are shown in table 54. 
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Table 54 Number and (percentage) of patients with colorectal cancer 
that self treated before presentation by specific symptom 
Symptom 
Cases that self treated symptoms 
N =298 (%) 
Change in bowel habit 137 (46.0) 
Pain 52 (17.4) 
Piles 48 (16.1) 
Wind 20 (6.7) 
Itching 15 (5.0) 
Indigestion 11 (3.4) 
Nausea 5 (1.7) 
Other 10 (3.7) 
This table shows that the most common symptom to self -treat was a change in bowel 
habit. 
There was no statistically significant difference between the percentages of males and 
females that self -treated or within deprivation groups. There was a statistically 
significant difference (p <0.001) between the proportion in the age groups and those 
self -medicating. Of all three age groups, the youngest age group (16 -54) was more likely 
to take medication for a symptom. Of those who stated that they self -treated there were 
82 (26.5 %) in the younger and 130 (16.5 %) in the oldest age group (65 -80). 
Discussion of symptoms with other people 
Cases were asked if they discussed their symptoms with anyone before visiting the GP. 
1397 responded and 963 (68.9 %) stated that they had discussed their symptoms with 
someone. If they had discussed their symptoms they were asked the relationship of the 
person they discussed symptoms with and 945 gave the relationship of the person. Of 
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these, 689 (72.9 %) stated they had discussed symptoms with their spouse or partner, 
232 (24.6 %) with another family member and only 10 (1 %) with a health professional 
such as a pharmacist or nurse. 
There was a statistically significant difference (p <0.007) in the proportion of males and 
females discussing their symptoms with someone. Males were more likely than females 
to discuss their symptoms. The number of males discussing symptoms with someone 
were 582 (69.5 %) compared to 381 (62.8 %) females. Younger cases were more likely 
that older cases to discuss their symptoms with someone but this was not statistically 
significant. In the younger age group 207 (71.3 %) discussed their symptoms compared 
to 474 (64.1 %) of the older age group. 
Waiting time with any symptoms. 
At commencement of this study the referral guidelines for the management of colorectal 
cancer available to GPs in Scotland stated if a symptom was present for more than 4 
weeks the patient should be referred for investigations (SIGN 1997). 
If the case had waited more than 4 weeks with any symptom, the research nurse asked 
the case if there was any reason why they waited more than 4 weeks. 
For 411 cases it was not applicable to ask the question, as they did not have any 
symptom for more than 4 weeks. Of 1129 asked a total of 952 gave a reason or made a 
statement. The responses for waiting more than 4 weeks with a symptom are shown in 
table 55 
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Table 55 Reasons given for waiting more than 4 weeks with 
symptoms before reporting to GP 
Reason for waiting > 4weeks 
Number 
952 ( %) 
Thought had piles 140 (14.7) 
Symptoms vague, intermittent 109 (11.4) 
Hoped symptom would go away 94 (9.9) 
No reason really 70 (7.4) 
Did not think it was serious 54 (5.7) 
Inflammatory bowel disease 52 (5.5) 
Ageing process 34 (3.6) 
Did not want to bother GP 30 (3.2) 
Too Frightened or embarrassed 28 (2.9) 
Too busy 21 (2.2) 
Caring for a dying close relative 18 (1.9) 
Not aware being tired could be a symptom 
of anything 
18 (1.9) 
Constipation before 15 (1.9) 
Other 269 (28.3) 
Table 55 demonstrates that there are a wide variety of reasons for cases waiting with 
symptoms before visiting their GP. The most common reason for waiting was that 
people believed that their symptoms to be related to having piles. 
There was a statistically significant (p <0.05) difference between the age groups and 
those waiting more than 4 weeks before visiting a GP with symptoms, and those not 
waiting more than 4 weeks before visiting a GP. In the younger age group 198 (77.3 %) 
cases presented after 4 weeks opposed to 483 (68.1%) of the older age group. This 
younger age group were also more likely to associate their symptoms to piles than the 
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older age group, In the younger age group the number thinking they had piles was 36 
(18.2 %) and in the older age group 59 (12.2 %). 
Inspecting the toilet before flushing 
Cases were asked if, before their diagnosis of colorectal cancer, they looked down the 
toilet before they flushed and also asked, if they looked at the toilet paper before 
flushing. The responses to these questions are shown in Table 56. 
Table 56 Number and (percentage) of patients with colorectal cancer 
who inspected the toilet and toilet paper by frequency of 
inspection 
Frequency 
Looking down toilet Looking at toilet paper 
N =1080 ( %) N =1055 ( %) 
Every time 668 (61.9) 683 (64.7) 
Once a week 38 (3.4) 33 (3.1) 
Once a month 3 (0.3) 5 (0.5) 
Sometimes 371 (34.4) 334 (31.7) 
This table shows that a high proportion of individuals do inspect the toilet and the toilet 
paper before flushing. 
Inspecting down the toilet 
There was a statistically significant difference (p <0.01) in the proportion of males and 
females that inspect the toilet before flushing. Males were more likely to inspect the 
toilet than females, 662 (73.7 %) males reported inspecting the toilet and 425 (66.5 %) of 
females. There was also a statistically significant difference (p <0.001) between the 
proportions in the age groups inspecting the toilet before flushing. The younger age 
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group (16 -54) were more likely to do so; 243 (78.9 %) of the younger age group did 
inspected the toilet compared to 533 (67.5 %) of the older age group (65 -80). 
There was a statistically significant difference (p <0.05) between the deprivation groups 
and inspecting the toilet. Using both deprivation indices the most affluent group were 
more likely to inspect the toilet before flushing than the most deprived group. The 
analysis results using the Carstairs index found that in the most affluent group 309 
(74.5 %), the middle deprivation group 647 (71 %) and only 130 (61.9 %) in the most 
deprived group inspected the toilet before flushing. Using the SIMD index 352 (75.2 %) 
of the most affluent group, 651 (69.2 %) of the middle group and only 82 (65.1%) of the 
most deprived group inspect the toilet before flushing. 
Inspecting the toilet paper 
There was no statistically significant difference between the proportions of males and 
females inspecting the toilet paper before flushing. There was a statistically significant 
difference (p <0.001) in proportions within the age groups inspecting the toilet paper; 
the younger age group were more likely to inspect the toilet paper before flushing. 
There were 249 (81.1%) of the younger age group and 524 (67.1%) of the older age 
group who inspected the toilet paper before flushing. 
There was a statistically significant difference (p <0.001) between the deprivation 
categories and those inspecting the toilet paper before flushing. Using both deprivation 
indices the most affluent group were more likely than the most deprived group to 
inspect the toilet paper before flushing. Using the Carstairs index it was found that of 
the most affluent group 316 (76.5 %), the middle group 620 (69 %) and most deprived 
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group 127 (60.5 %) inspected the toilet paper before flushing and using the SIMD index, 
of the most affluent group 357 (76.6 %), the middle group 622 (67.7 %) and the most 
deprived group 77 (61.1 %) inspect the toilet paper before flushing. 
Number of visits to GP before referral to hospital 
Cases were asked to state how many visits they made to see their GP before they were 
referred to hospital for further investigations. A total of 1327 cases replied, 723 (54.5 %) 
were referred after their first visit, 440 (33.2 %) after 2 or 3 visits, 93 (7.0 %) after 4 or 5 
visits and 71 (5.4 %) were referred after more than 5 visits to the GP. 
Classifying the cases into two groups according to whether they were referred to 
hospital after one visit to GP or more than one to GP, there was no statistically 
significant difference between the sexes, the age groups, the deprivation groups, the 
knowledge groups or those with comorbidity or without comorbidity in the proportions 
referred to hospital after one visit to GP. Although not statistically significant, there 
were a greater number of cases in the most affluent group (using both deprivation 
indices) that were referred on their first visit to their GP than the most deprived group. 
Results for both deprivation indices are shown in table 57. 
Table 57 Referral to hospital on first visit to GP by deprivation group 
Deprivation Index 
Deprivation group Carstairs SIMD 
1 (most affluent) 192 (56.8 %) 224 (56.9 %) 
2 439 (54.9 %) 440 (53.9 %) 
3 (most deprived) 92 (48.9 %) 59 (51.8 %) 
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Using the data from table 57 chi square for trend was carried out and the results 
remained statistically non significant. 
Knowledge of colorectal cancer symptoms 
Cases were asked to describe their own knowledge of colorectal cancer symptoms 
before their diagnosis. 1529 responses were as follows in Table 58. 
Table 58 Knowledge of colorectal cancer symptoms before 
diagnosis 
Responses Number 0/0 
None 847 (55.4) 
A little 518 (33.9) 
Good 121 (7.9) 
Very good 37 (2.4) 
Expert 6 (0.4) 
Table 58 notes that 55% of cases in this study stated they had no knowledge of 
colorectal cancer symptoms before their diagnosis. 
There was no statistically significant difference between proportions in age groups; 
however the older age group were more likely than the younger age group to state they 
had no knowledge of colorectal cancer symptoms. There were 451 (57.1%) of the older 
group stating no knowledge and 162 (52.4 %) in the younger group. 
There was a statistically significant difference (p <0.001) between the knowledge of 
colorectal cancer before diagnosis and sex of cases. Males were more likely to state they 
had `no knowledge' of colorectal cancer symptoms before their diagnosis than females. 
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There were 532 (59 %) males reporting `no knowledge' and 315 (49.3 %) of females 
reporting `no knowledge' of colorectal cancer symptoms. Table 59 shows the numbers 
and percentages within the deprivation groups for both deprivation indices and 
knowledge of colorectal cancer symptoms. 
Table 59 Knowledge of colorectal cancer before diagnosis with 
deprivation groups 
Deprivation group 
No Knowledge of symptoms 
Carstairs ( %) SIMD 
( %) 
1 (most affluent) 199 (47.7) 217 (46.2) 
2 492 (53.9) 533 (56.6) 
3 (most deprived) 155 (73.8) 96 (76.2) 
Was cancer considered before diagnosis? 
Cases were asked if they considered having cancer before their diagnosis. Of the total 
1540 cases, 1530 answered this question, 605 (40 %) did consider cancer and 925 (60 %) 
did not consider cancer. 
Of cases the 605 cases that considered they had cancer before diagnosis, 589 cases 
reported at which stage before their diagnosis this was considered. The responses were 
as follows: 
o 298 (50.6 %) thought this before they attended their GP, 
o 125 (21.2 %) after tests were carried out, 
o 108 (18.3 %) on referral to hospital, 
o 58 (9.8 %) answered `other'. 
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The main time for the group responding `other' was when they realised that their 
symptoms did not improve after they had visited their GP for the first time. 
There was no statistically significant difference in sex when considering cancer before 
diagnosis. There was a statistically significant (p <0.01) difference between the 
proportion of cases in each age group and those considering a diagnosis of cancer. The 
younger age group were more likely than the older group to consider cancer before 
diagnosis. Those considering cancer before diagnosis are 141 (46.1%) in the younger age 
group and 279 (35.6 %) in the older age group. 
There was no statistically significant difference between the proportions considering 
cancer before diagnosis in the different deprivation groups (using both deprivation 
indices). There was a tendency for the more affluent group to consider cancer before 
diagnosis. The results of both indices are given in Table 60. 




Group 1 Group 2 Group 3 
69 (34.0) Carstairs 163 (40.0) 363 (40.9) 
SIMD 191 (41.5) 360 (39.3) 44 (36.1) 
The 925 cases that did not consider cancer, were asked what they felt could be wrong. 
Of the 925 cases, 853 answered the question and table 61 shows the responses given. 
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Table 61 Reasons given for current symptoms 
Reason for symptoms 
Number 
853 % 
Don't Know 202 (23.7) 
Piles 205 (24.0) 
Inflammatory bowel disease 105 (12.3) 
An infection 36 (4.2) 
Ulcer 34 (4.0) 
Polyps (not cancer) 31 (3.6) 
Constipation 31 (3.6) 
Gallbladder problems or Hernia 25 (2.9) 
Ageing process 12 (1.4) 
Appendicitis 10 (1.2) 
An abscess 5 (0.6) 
Indigestion 4 (0.5) 
Other 153 (17.9) 
This table shows that 24% of cases delayed in visiting a GP as they thought that piles 
caused their symptoms. 
Analysis was carried out for all cases that did not consider they had cancer before 
diagnosis. The cases were classified into two groups; those thinking they had piles and 
those thinking other reasons for their symptoms. 
There was a statistically (p <0.05) significant difference in the sexes and the proportions 
thinking they had piles and those thinking some other reason. Males were more likely 
than females to think they had piles. In the group thinking they had piles there were 71 
(20.2 %) females and 134 (26.7 %) males. 
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Dukes' Staging 
Figure 20 shows the Dukes' stage distribution from the latest available 24 months, as 
provided by ISD, from the Scottish colorectal cancer population and for 24 months 
recruitment to this study. 

















The Dukes' stage data was available for 1188 cases, in i i medical notes no Dukes' stage 
was recorded. Included in the numbers with Dukes' stage A are 20 cases that had a 
polypectomy and pathology results showed no need for further surgery. Included in the 
numbers with Dukes' stage D are 19 cases that had no surgery, due to advanced disease. 
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A further 14 rectal cancer cases had preoperative radiotherapy, which resulted in 
eradication of the tumour and no tumour material was available to stage at surgery and 
is shown as CH in figure 21. The distribution of Dukes' staging at diagnosis from this 
study is: 
Dukes' stage t_ = 247 
Dukes' stage B = 439 
Dukes' stage C = 432 
Dukes' stage D = 45. 
Percentages of the Dukes' stage can be seen in Figure 21. 
Figure 21 Dukes' stage distribution for study cohort 
Waiting time and Dukes' Staging 
To identify if Dukes' staging was affected by waiting time, an analysis of waiting time 
with each symptom and each Dukes' stage was carried out. Table 62 shows the median 




































































































































































































































Table 62 shows that the median wait time for Dukes' stage D with change in bowel 
habit, weight loss, marked loss of energy and abdominal discomfort are all shorter wait 
times than for Dukes' stage A. 
However within the Dukes' stage D group the 75th centile wait time is much greater for 
change in bowel habit, rectal bleeding; marked loss of energy, mucus in stool and 
tenesmus than in the 75th centile for any of the other Dukes' stages for these symptoms. 
Figure 22 shows the median waiting time in weeks, the 25`h and 75th centiles for change 
in bowel habit, rectal bleeding and marked loss of energy. 
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Figure 22 Median, 25th and 75th centile for wait time for with change in bowel 
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Table 63 shows the proportion of Dukes' stage for colon and rectal cancer 




A B C D CH21 N /A22 
Colon 108 (15.7) 293 (42.5) 261 (37.8) 25 (3.6) 0 3 (0.4) 
Rectum 135 (27.8) 144 (29.6) 167 (34.4) 18 (3.7) 14 (2.9) 8 (1.6) 
Table 63 shows that the proportion of Dukes' stage A tumours in rectal cancer were 
greater than the proportion of Dukes' stage A tumours with for colon cancer in this 
cohort. There was a statistically significant difference (p <0.001) between the Dukes' 
stage at diagnosis and the site of cancer in the large bowel. 
There was no statistically significant difference between sex, age groups, and deprivation 
groups, knowledge of colorectal cancer symptoms or perceived family history in the 
proportions with different Dukes' stage at diagnosis. 
21 Cases with rectal cancer that have had pre operative radiotherapy and no residual tumour left for staging. 
22 Cases that had no surgery and therefore staging is not available. 
267 
Rectal examination 
Cases were asked if they had a rectal examination carried out at the first visit to their 
GP, 1311 gave a response. Rectal examination was carried out on 639 (48.7 %) cases and 
672 (51.3 %) did not have rectal examination at the first appointment. The 672 cases 
that did not have a rectal examination at this first appointment were then asked if at any 
time before referral to hospital, they had a rectal examination by their GP. A further 97 
(14.4 %) did have a rectal examination before referral to hospital. Therefore, 736 (56 %) 
of cases had a rectal examination at sometime before referral to hospital. 
Of the 522 cases with rectal cancer, 442 answered the question on having a rectal 
examination at the first visit to a GP. Of these, 297 (67.3 %) replied yes and 145 (32.7 %) 
replied no to rectal examination at first visit to a GP. The 145 cases answering that no 
examination was carried out at first visit to GP were asked if they had a rectal 
examination at any time before referral to hospital. Of these, 138 cases replied, and a 
further 33 replied yes. Therefore a total of 330 (74.6 %) of the 442 rectal cancers had a 
rectal examination before referral to hospital. 
Analysing the 768 cases that presented with rectal bleeding to a GP, there was a 
statistically significant (p <0.05) difference between the proportions in the three age 
groups and those having a rectal examination at first visit to GP. In the younger age 
group 98 (56.6 %) cases and 227 (69.8 %) in the older age group had a rectal examination. 
There was a statistically significant difference (p <0.05) between the sexes and the 
proportions having a rectal examination at first visit to GP. Females were less likely than 
males to be given a rectal examination by their GP. In the group reporting rectal 
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bleeding 174 (60.8 %) females and 280 (69.1%) males had a rectal examination at first 
visit to GP. 
In the whole cohort, there was a statistically significant (p <0.05) difference between 
those with comorbidity and those without comorbidity and the proportion having a 
rectal examination at first visit to GP. Those cases with comorbidity were more likely to 
have a rectal examination at first visit to GP than those with no comorbidity. Of those 
with comorbidity 313 (52 %) were given a rectal examination at first visit to a GP and 
those with no comorbidity 196 (45.8 %) were given a rectal examination at first visit to 
GP. There was a statistically significant (p <0.05) difference between cases with no 
knowledge of colorectal cancer symptoms and some knowledge and the proportion 
having a rectal examination at first visit to GP. Those with `some knowledge' of 
colorectal cancer symptoms were more likely to be given a rectal examination at first 
visit to GP than those with no knowledge. Those with some knowledge 315 (53.3 %) 
were given a rectal examination at first visit to GP and those stating no knowledge of 
colorectal cancer symptoms 324 (44.9 %) had a rectal examination at first visit to GP. 
Referral letters 
Referral letters were accessed from the medical notes and information on abdominal 
mass and rectal mass were extracted from the referral letter. Of 1212 medical notes 
accessed 204 (16.8 %) cases had no referral letter or emergency admission letter in file 
and a further 89 (7.3 %) cases were referred direct from the faecal occult blood testing 
study with no letter. 
269 
Information from the referral letter should indicate the level of urgency of the referral. 
Of the 919 with a referral letter 154 (16.7 %) cases were referred as routine, 477 (51.9 %) 
cases were referred as urgent and for 288 (31.3 %) cases there was no indication given in 





Colorectal cancer referral guidelines 
The Association of Coloproctology of Great Britain and Ireland (ACPGBI) (Thompson 
2002) published a reference paper with the evidence to support the NHS 2000 
guidelines for suspected colorectal cancer. The following analysis is a comparison of the 
data collected retrospectively from colorectal cancer patients and the data present by 
ACPGBI. The ACPBGBI data was primarily derived primarily from individuals 
referred to hospital for further investigations after presenting to GP with symptoms. 
This study cohort is individuals with colorectal cancer giving their symptoms 
retrospectively. 
Table 64 and table 6523 illustrate the evidence according to the site of the cancers. 










Meeting (95 %) 
guideline 
criteria 
Both rectal bleeding and change in 
bowel habit 
50 -60% 39.2% (35.8 -42.8) 
Rectal bleeding no anal symptoms 50 -60% 49.6% (45.9 -53.3) 
Rectal mass present on examination 
of rectal cancers 
40 -60% 11.4% (9.4 -13.9) 
Palpable mass on left sided for 
sigiuoid cancers 
20% N/A N/A 
Change in bowel habit is to looser 
and /or increased frequency 
>90% 50% (46.2 -53.8) 
23 Table 64 & 65 represent the range from published data meeting each criterion with guidelines and study population meeting guidelines. 
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Table 65 Caecal and Descending colon cancers and symptom 
criteria analysis 




Present with iron deficiency anaemia 30 - 75% 27.9% (23.4 - 33.0) 
Haemoglobin level below 10g 54% 84% 
Present with abdominal mass 40 - 55% 9% (6.6 - 2.1) 
Present with intestinal obstruction 10 - 30% 9% (6.6 - 2.1) 
Tables 64 and 65 considered 1199 cases where the site of cancer was known. 
The medical notes data collection tool in this study did not request the site of abdominal 
mass.. 
Low haemoglobin levels 
The first haemoglobin level recorded in the hospital notes as close to the referral letter 
date or emergency admission date was used for this analysis. This information was 
available for 1212 cases. 161 (13.5 %) cases were found to have haemoglobin levels 
below 10g/á1 for women and below 11g /dl for males. There were 58 (36 %) females 
with haemoglobin levels below 10g /di (of these 10 were below the age of 50) and 103 
(64 %) males who met low haemoglobin level criteria. 
The criterion for low haemoglobin levels does not consider those women under age 50 
(50 considered the age of menopause) with a haemoglobin level below 10g /dl. In this 
cohort 10 females had a haemoglobin level below 10g /d1 but were not included in the 
analysis for the low haemoglobin level criterion as the referral (NHS 2000) guidelines 
specify postmenopausal women. 
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Abdominal mass 
In the 1212 medical notes reviewed 68 (5.6 %) of GPs reported in their referral letter 
that a palpable abdominal mass was found. These 1212 case were asked `did they have 
an abdominal examination'? those who said yes, were asked what the GP told them after 
the examination and 14 (1%), stated that they were informed by their GP that they had a 
lump or mass in their abdomen. 
Rectal mass 
In the 1212 medical notes reviewed, 5 (0.4 %) GPs reported in the referral letter finding 
a rectal mass. However with further investigation of the referral letter in a further 88 
cases the GP noted a suspicion of rectal cancer. A rectal mass was recorded or it was 
recorded that rectal cancer was suspected for 93 (18.5 %) of all 502 rectal cancers cases. 
The data collected on rectal mass and abdominal mass was not considered reliable due 
to the small numbers of rectal mass and abdominal mass reported and the great 
difference in results when compared with the ACPGBI findings. There is also sample 
bias due to very few Duke's stage D cancers recruited to this study. This combination 
of events resulted in no comparison being carried out between the referral guidelines 






This study is one of the largest population based studies of colorectal cancer which 
evaluates family history information in a systematic manner. Few population -based 
studies have reported on the proportion of colorectal cancer cases which meet modified 
Amsterdam family history (also referred to as HNPCC family history) criteria, even 
fewer such studies have reported on the proportion which meet criteria defined as 
moderately increased family history. No studies have published family history risk data 
on the Scottish colorectal cancer population in relation to family history. 
The methodology used in this study also gave the opportunity to collect data on 
symptom presentation and waiting time with symptoms and to analyse these data with 
respect to deprivation and comorbidity. This the study also aimed to report on the 
proportion of individuals within this cohort that had symptoms meeting at least one of 
the high -risk criteria within the published guidelines for suspected colorectal cancer. The 
following outlines some of the main strengths and the limitations of the study. 
Strengths 
1. The study has a large sample size of individuals with colorectal cancer and family 
history; this was prospectively ascertained and has sufficient power to detect 
modest differences between groups defined by family history criteria. 
2. The family history was taken and the pedigree drawn by a trained research nurse 
in a face -to- face interview. Information on at least three generations was 
recorded and universal nomenclature was used in the drawing of the pedigree. 
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This is equivalent to the level of family history recording in a clinical cancer 
genetic setting. 
3. The methodology was found to be highly acceptable to participants. This was 
confirmed by the results of a small acceptability sub -study. A short report of this 
study can be found in Appendix 13. 
Limitations 
1. The methodology of the study resulted in the cohort being biased by the small 
number with Dukes' D stage cancers participating. However this bias in this 
cohort is not expected to affect the family history analysis with respect to 
assigned family history risk. However the sample will be biased regarding referral 
to cancer genetic services. 
2. Access to medical notes was found to be problematic resulting in 21% of 
medical notes being unavailable. These problems arose from access by research 
staff to medical records departments and medial notes not actually being in the 
medical records department once access had been granted. 
3. The data collected from referral letters within medical notes was found to be 
incomplete. There was lack of symptom detail and examinations carried out by 
GPs recorded in referral letters. 
4. Although the number of primary research questions (related to the influence of 
family history) was limited I did carry out multiple statistical tests investigating 
other aspects of the data. These analyses were exploratory and results cannot be 
considered robust since multiple testing was performed. 
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5. The analysis has shown that the results can only be generalised to white 
Caucasians due to the high percentage within this cohort and the few cases from 
other ethnic groups. 
6. Data presented in this thesis are a case cohort and no control data has been 
reported. 
Changes to study 
The changes that the author would make to this study if it was to be repeated: 
1. Would aim to recruit research nurses on a seconded basis, and in particular, 
those working within areas where colorectal cancer cases are cared for. This 
would possibly increase ascertainment figures. 
2. Set up access to audit and medical records departments prior to recruitment of 
cases. 
3. Establish a more robust system to collect reason for cases not participating in 
study. 
4. Request ethical approval to contact cases sent a high and moderate risk letter to 
follow up, if they or their family had activated a referral to genetics department. 
If they had attended a genetic department seek consent to access this final risk. 
5. More research nurses may have increased ascertainment and recruitment. 
Ascertainment and recruitment of cases 
This study was conducted within the SOCCS study that recruited people throughout 
Scotland with colorectal cancer. In a 24 months data collection period, 3761 individuals 
were identified. 
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The Information Statistic Division of Scottish Cancer Registry (ISD 2003) publishes 
incidence figures for colorectal cancers in Scotland. Data for 1997 were available at start 
of this study. For the age group 16 -79, 2566 cases were registered with ISD. Therefore, 
approximately 5132 cases could be anticipated during the 24 months of data collection. 
At the time of writing, colorectal cancer registrations were available for the year 2000. 
The data presented in the result section for ascertainment related to the year 2000 
published data. There were 2726 cases in the target age group, an absolute increase of 
160 cases compared with 1997. Ascertainment of cases in the study was therefore 
between 69% and 73% of that expected throughout Scotland. 
The Scottish Cancer registry data has been found to have high levels of accuracy and 
completeness (Brewster et al 1994, Brewster et al 2002) 
During this study there was a reorganisation of colorectal cancer services by which 
several hospitals changed admission for surgery to feed into nearest city hospital with 
the aim of developing centres of excellence. We found ascertainment in hospitals to 
range from 45% to 134% (see table 33) of the numbers expected based upon published 
colorectal cancer registrations for 1999. This reorganisation of services may explain why 
ascertainment figures from some hospitals were greater than expected. Alternatively, 
these increased figures may reflect an accurate ascertainment with increasing numbers 
diagnosed with colorectal cancers in that hospital. 
Reasons for lower ascertainment and recruitment to the study may have been due to the 
following: 
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o We relied on the colorectal cancer nurse specialist (CCNS) in hospitals to 
identify patients eligible for the study. The CCNS would then give the 
patient information about the study. The patient would inform the CCNS (if 
still in hospital) whether they would like to be contacted by the research 
nurse for recruitment. In some hospitals the CCNS was not informed of all 
cases of colorectal cancer, thus lowering the likelihood of accurate 
ascertainment. 
o In hospitals with no CCNS, ascertainment of eligible patients relied on the 
surgical ward staff informing the research nurse of eligible patients. A lack of 
continuity in staff led to sub -optimal referral of eligible patients despite 
educational input and operating protocols that were discussed and agreed 
with ward staff. The ascertainment in these hospitals was lower than 
expected. 
o Ascertainment was also pursued through audit data in most hospitals. 
However, in most audit departments there is a substantial delay in entering 
data. This resulted in the research nurse identifying eligible cases many 
months after their diagnosis. These cases were sent a letter with information 
about the study by the Consultant surgeon or CCNS (if they felt it was 
appropriate). Recruitment in cases approached by this method was lower, 
possibly due to late ascertainment. 
o A confirmed diagnosis of colorectal cancer was required for recruitment to 
the study. The timing of the approach and the age of patient at diagnosis may 
have been important. The decision to take part in a research study soon after 
diagnosis may be affected by age. There was a difference between the age 
groups (16 -54, 55 -64 and 65 -79) and the proportion of non -participants and 
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the participants. Of the non -participants 7.1% were in the younger age group 
and 70% in the older age group compared to those participating where 20.10/0 
were in younger age group and 51.3% in older age group. In this study, older 
cases were less likely to participate. 
o Socioeconomic status may play a role in decision making to take part in any 
research study. There was a high level of non -participation in the Greater 
Glasgow Health Board area in the study. This area is highly populated and 
has a higher proportion of the most deprived group (ISD 2003). It has been 
found by other studies that socioeconomic status was a predictor of 
participation in research studies. McCaffery et al (2002) found a low 
recruitment rate of the more deprived group in Greater Glasgow in a study 
of individuals being offered sigmoidoscopy surveillance. 
o It is possible that employment of more research nurses would have increased 
the ascertainment and recruitment. It was demonstrated in the study that if a 
nurse only recruited from one hospital and /or was known staff member 
ascertainment and recruitment were higher compared to a research nurse 
who had to ascertain and recruit cases from several hospitals. The staffing 
for the study employed the equivalent of 5.5 full time nurses to ascertain and 
recruit cases and in addition also to recruit controls and many unaffected first 
degree relatives. 
o As ascertainment to the study was exclusively through surgical teams 
individuals with polyp cancer, treated by endoscopy alone, were picked up on 
audit data and therefore approached several months post treatment. This is 
likely to have reduced participation in the study. 
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Ascertainment and recruitment was affected by the time it took for each hospital to 
become confident with the study procedures and to build a working relationship with 
the research nurse designated to their hospital. Of the 1540 cases, 597 (38.8 %) were 
recruited in the first year and 943 (61.2 %) in the second year of the study. This may 
reflect an increase in the confidence of the CCNS and other nurses in the designated 
research nurse. This fact underscored the importance of retaining staff for the duration 
of the study. 
In hospitals with a CCNS the ascertainment was usually 75% and above, but elsewhere 
it was generally well below 75 %. In three hospitals with no CCNS, ascertainment was 
above 75 %, however in these hospitals the research nurse was also a part time member 
of staff or on secondment to the study from that hospital. This would suggest that the 
ward staff were more confident in communicating with their own colleagues about the 
study than to a research nurse previously unknown to them. 
Alternative study methodologies may have led to increased ascertainment and 
recruitment. The use of audit in a Scottish study of this type would rely on every 
hospital collecting the same dataset and this is currently not fully operational in 
Scotland. 
Alternatively, individuals presenting to an outpatients department with lower 
gastrointestinal symptoms may offer the prospect of increased recruitment. A major 
disadvantage of recruiting individuals in this way is that they require to be followed 
through to diagnosis and the majority of these cases will not have colorectal cancer. This 
may be a more feasible methodology in a study of a single hospital. Another 
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disadvantage of using this alternative methodology is that a family history would be 
taken for all recruited cases, many not with colorectal cancer. Taking family history in 
this manner is likely to identify individuals with a family history of breast and ovarian 
cancer as well as family histories with colorectal cancer. 
Future population studies of colorectal cancer in Scotland might be able to make better 
use of audit data and pathology databases to ensure high levels of case ascertainment. 
Once these systems are well established nationally, careful attention must be paid to 
ethical and data protection guidelines. 
In view of the higher ascertainment and recruitment where the research nurse was 
known to hospital staff, future research studies may want to locate the research nurse 
within the nursing team. This may be a seconded member of staff or a new member, 
integrated into the surgical team.. In Scotland this model has been proposed for both 
breast and colorectal cancer through the National Translational Cancer Research 
Network (NTRAC). In this model, one research nurse will have responsibility to make 
contact with each eligible case. Following consent they will collect a core dataset and 
inform patients about other research projects for which they are eligible and could 
consider participation. 
In the past nurses have tried to protect their patients from research studies. Poor 
professional development may have led to an individual's lack of research knowledge, 
which may be shown in a lack of enthusiasm and interaction with research studies. 
Recently there has been a drive by the Scottish Executive to widen nurses' knowledge of 
research methodology, data collection and to involve more nurses in research planning 
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and development. This study was active before the Scottish Executive initiative was fully 
implemented. Ascertainment could have been affected by the lack of research 
knowledge in some hospitals. This was most evident in the early stages of developing 
the recruitment process when some ward nurses refused to inform the research nurse of 
cases eligible for the study. 
The role of CCNS in Scotland evolved with little strategic direction. Each post 
developed differently with the result that each CCNS post has a wide range of different 
skills and responsibilities. Only recently work has begun to assign core competencies for 
these posts both in terms of skills and academic requirements. The role of interacting 
with research studies within hospitals has been devolved to CCNS in each area. 
However, many of the CCNS post do not have a nurse with the academic knowledge to 
fully understand the implications for a research study of incomplete data. 
It was stressed by several CCNS in the study that the time at which cases were 
approached with study information appeared to be important. The study tried to 
acknowledge this with guidance from the CCNS and allowed them to give out the 
information about the study. Despite this approach many older cases chose not to take 
part and eligible patients approached some months after diagnosis had lower 
recruitment rates. 
It is possible that the older generation are still suspicious of research studies and choose 
not to take part. Cases that have their diagnosis and treatment complete before being 
approached with study information may not want to think of themselves as someone 
with colorectal cancer. 
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The study was conducted within a larger study and it may have been that this adversely 
impacted on recruitment since the larger study involved collecting a blood sample and 
gathering additional information. It is also likely that smaller studies within single 
hospitals may be able to achieve higher ascertainment and recruitment rates. In a 
population based colorectal cancer study by Katballe et al (2001) the recruitment rate 
was 1200 (80 %) of 1514 ascertained, this study only collected family history information 
and did so via the patient's own surgeon. A French Population based colorectal cancer 
study collected more detailed information including family history and blood samples 
and reported their recruitment as 767 (56.8 %) of 1351 cases ascertained (Audrieu et al 
2003). A Southern Californian study reported recruitment of 1431 (57 %) from 2489 
cases ascertained (Peel et al 2000). These two studies compared more favourably with 
the 41% recruitment of those ascertained in this study. Both of these studies ascertained 
their cases from a pathology database. 
Participants 
A large cohort of 1540 participants was recruited to this study (41% of all eligible 
patients). This study is the largest UK and possibly European, prospective cohort of 
colorectal cancer that has data on (three- generation) family history. Three other large 
colorectal cancer cohorts have been published. Katballe et al (2001) from a cohort of 
1200 cases collected family history information on first- degree relatives of cases and 
second -degree relatives if the case was under age 50 at diagnosis. Audrieu et al (2003) 
and Peel et al (2000) collected information on all first and second -degree relatives. 
Analysing the distribution of participating cases by Health Board, it was found that a 
higher number of cases were recruited from large city hospitals. This was expected as 
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many Scottish city hospitals are establishing centres of excellence for colorectal cancer 
care. Many of the recruited cases were diagnosed at district hospitals but had their 
surgery in a city hospital. Larger hospitals in Glasgow were an exception, with relatively 
fewer participants recruited. 
Comparing the non -participant group with the participants the median age of the 
participants in the study was 65 years, whilst that of the non -participant group was 70 
years. 
The 1999 published data for Scottish colorectal cancer registration in the age group 16- 
79 reported the male: female ratio as 55.4% males and 44.6% females (ISD 2003) which 
is similar to the 58.5% males and 41.5% females in this study cohort. 
There were 309 (20.1%) cases in this study under age 55 at diagnosis; other published 
studies report lower proportions in this age group. Higher participation in this study 
may be due to cases under age 55 being offered mutation analysis for three mismatch 
repair genes regardless of family history risk. Those over age 55 years were not offered 
any form of gene testing. 
Conclusion 
This study recruited a large prospective population -based cohort of cases with colorectal 
cancer with derailed family history information. There is a small age bias in the cohort, 
participants being marginally younger than the non -participants and there was a small 
difference in the proportions of males and females compared to the latest published 
colorectal cancer data. There is a bias in the study as the proportion of cases with more 
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advanced disease (by Dukes' stage) was lower than expected. However these biases are 
unlikely to have a major effect on the results of the main research questions related to 
family history with the exception of generalisability of the results due to the cohort 
being almost exclusively white Caucasian. 
Non -participants 
Limited data are available for the cases not recruited to the study due to restrictions 
placed on data collection for ethical reasons. A total of 2079 cases identified with 
colorectal cancer did not participate in the study. The non -participants fall into two 
distinct groups: those `unable to take part,' 856 (41%) cases and those that `did not want 
to take part,' 1223 (59 %) cases. All information collected on the non -participants was 
within the ethical approval guidelines. 
Non Participant data is extremely important to any study. This data will be combined 
with the recruitment data and will complete the overall ascertainment figures. This data 
is also equally important in order to ascertain any bias within the study. 
`Unable to take part' group 
Cases recorded as `unable to take part' were never given information about the study to 
enable them to choose whether to take part. The CCNS and some Consultant surgeons 
(CS) made the decision whether, and at what stage, an eligible case would be given 
information about the study. Many CCNS would only give information on age and sex 
of eligible patients as they felt that the research study had no need to know more 
information on non -participants. This reluctance to give more information resulted in a 
large number of cases with limited data. 
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The proportion of those `unable to take part' in relation to the numbers ascertained 
varied greatly between Health Boards. This ranged from 9% in Shetland to 30.8% in 
Lanarkshire. These cases were never informed of the study and the differences are likely 
to be due to the subjective nature of decisions made by each nurse responsible for 
giving information to patients about the study. This decision is likely to be based on a 
number of factors such as years of practice at a senior level, the depth of research 
knowledge, workload pressures, their personal views on research studies, and personal 
feelings on other professionals interacting with their patients. This information is 
important to be aware of the bias that could be introduced to the study. 
`Did not want to take part' 
Cases recorded as `did not want to take part' were given information about the study 
and chose not to participate. The ascertainment protocol in the majority of hospitals 
stated that the CCNS would give the study information pack to eligible patients. 
There were several methods for the research nurse to know whether a case wished to be 
recruited to the study. It was very common for the patient to inform the CCNS whether 
or not they wished to take part and this information was passed on to the research nurse 
by the CCNS. On some occasions the case would return the patient reply form given in 
the information pack, indicating that they did not wish to take part and no further 
information was given or requested. Other eligible patients agreed that the research 
nurse could contact them but then told the research nurse that they did not wish to take 
part, in some instances the cases volunteered the reason. Other eligible patients that had 
been given an invitation failed to reply. 
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The proportion of cases not wanting to take part ranged from 13.9% in Borders to 
63.6% in Shetland. In larger Health Boards it ranged from 28.3% in Grampian to 39.5% 
in Argyll and Clyde (see table 28). 
There was no difference in sex or age distribution between those that `did not want to 
take part' and those `unable to take part'. In the group `did not want to take part' more 
information was available on whether surgery was performed and the type of surgery 
performed than for the group `unable to take part'. 
When surgery information was available, a higher proportion in the `did not want to 
take part' group had curative surgery performed. These results appear to show that the 
patients `unable to take part' were more ill at diagnosis than those choosing not to take 
part. 
Information that was collected on non -participants included; sex, age, Health Board 
area, was surgery performed and was it curative or palliative and the reason that the case 
was unable to take part. It is not possible to compare the socioeconomic status of those 
not participating in the study. The ethical committee ruled that individual postcodes 
may enable identification of patients, so should not be recorded for non -participants. 
The only information available that would indicate any measure of socioeconomic status 
was the Health Board area. In both non -participant groups a higher proportion were in 
the Greater Glasgow Health Board area (which has a high proportion of deprived 
individuals) than in others. 
Of the eligible patients identified for the study, 57% did not consent for a variety of 
reasons. A more robust methodology for collecting reasons for non -participation may 
289 
have yielded data that would be valuable in the design of future research studies. 
Possibly if the CCNS were given a non -participant sheet to complete (containing a 
choice of reasons for being unable to take part) more data on non -participants may have 
been gathered. However, asking them to complete a sheet and return to the office 
would have added to their workload. 
The methodology used by Katballe et al (2001), Audrieu et al (2003) and Peel et al 
(2000) to collect data from pathology databases and write to the eligible cases resulted in 
a higher recruitment than this study suggesting that the decision by the nurses not to 
give the information to certain individuals and excluded some cases that would have 
chosen to take part. 
Conclusion 
A substantial proportion of cases did not consent to the study that resulted in 
recruitment bias. There was a small age bias as a higher proportion of older cases did 
not participate and, from the data provided, a higher proportion of the more ill patients 
did not participate. 
Data collection 
Family history 
Family history was requested at recruitment and of the 1540 cases participating in the 
study, 31 (2 %) were unable or refused to give family history information. 
The data included all family members over a minimum of three generations. Pedigrees 
were constructed and recorded on a standard family history form (Appendix `) to the 
290 
quality expected within a clinical genetic setting, using universally recognised 
nomenclature (Bennett et al 1995). 
Other large studies have used questionnaires or a combination of questionnaire and 
telephone interview to collect family history data. These methodologies have been used 
successfully by many studies that collect only first and second -degree relative 
information. However, to collect the more in -depth family details necessary for this 
study the use of a family history questionnaire would require a very complex form. 
There is little published evidence on the most accurate method of taking a family 
history. However, clinical genetics services throughout the UK continue to take and 
record family history in a face -to -face interview believing this to be the best available 
method. 
Other studies collecting family history information from colorectal cancer cases did so 
with the aim of investigating the accuracy of the family history data given not to assess 
risk. In many cases this was felt to be most accurate for first- degree relatives and slightly 
less for second -degree relatives (Love et al 1985, Douglas et al 1999, Simons et al 2000). 
However, Mitchell et al (2004) found a much lower degree of accuracy. The family 
history in that study was taken and recorded by a genetic nurse but the data were 
collected many years before publication and it may be that understanding of family 
history of colorectal cancer as a risk factor was much less advanced, or was not 
discussed within families at that time. Alternatively it may be that discussing cancer 
within families was still taboo or it was still common for individuals not to be informed 
of their cancer status. 
291 
In this study I did not aim to assess the accuracy of the family history, but to assess GP 
knowledge of family history in relation to published guidelines and to assess the extent 
to which GPs had also identified family history risk. Therefore, family history reported 
by the cases at recruitment was that to which a risk was assigned following Scottish 
criteria. No attempt was made to confirm cancer diagnoses in relatives. This is the same 
method GPs could apply to assess risk. I also aimed to assess if individuals with 
colorectal cancer perceived a family history risk. 
Incidentally, within the study, there was a crude way of assessing the quality of family 
history given by each case. As part of the larger study, siblings and /or parents of the 
cases were recruited into a parallel study. The baseline was the original family history 
taken from the case and with consent from the case it was extended by any further 
information from the family. Each family history was then reassessed. After 
interviewing 309 relatives, new information was often added, but only two families 
showed a change in risk category from low to moderate risk, and only one family from 
moderate to high risk. In no instance was the risk reduced. It appears that the family 
history given initially by cases was as accurate as the information known within the 
family. However, this sample may be biased towards those families that speak to each 
other and enjoy a close relationship. 
The family history information in this study was collected at recruitment and there was a 
mean recruitment time of 21 weeks from diagnosis until recruitment. We asked what 
information the case was aware of at time of recruitment. The information sheet 
indicates that we will ask information on family history and when the case was 
contacted to arrange a home visit this was discussed again. Each case had the same 
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opportunity to seek out family history information and to discuss it with GP or other 
health professional before recruitment. 
The study collected data to assess if high or moderate family history was identified by 
the GP. Data discussed later in this thesis clearly illustrate that many cases with 
knowledge of cancer in their family did not discuss this with their GP and that the GP 
does not routinely ask information on family history to assess risk. 
Conclusion 
No other published study with a large population based cohort has collected such 
detailed data on family history collected in a systematic manner. Mitchell et al (2004) 
used a similar methodology in a relatively small sample. 
Family history information in this study was gathered to inform risk assessment using 
published Scottish guidelines and to assess the number and proportion of cases with a 
family history requiring referral to cancer genetic services. The recruitment biases 
reported above in this cohort should not affect the validity of these results. 
Symptom data 
Data on symptoms experienced prior to reporting to a GP were collected from cases 
through a structured symptom interview. This method carries a number of advantages: 
o It is an effective way of ensuring a response when collecting data from a large 
number of individuals over a wide geographical area, as data are recorded at 
the meeting and no postal return is required. 
o Asking a set of predetermined, precise questions in the same way and in the 
same order can increase the reliability of the data. 
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o As the research nurse is present to clarify and assist with the meaning of the 
questions, the responses are likely to be more valid. 
o There is the assurance that data are given by the case, which cannot always be 
guaranteed with self -completed postal questionnaires. 
o This methodology can overcome literacy problems that may be experienced 
by the case, reducing the bias of the sample. 
Although not an advantage over postal questionnaires, carrying out the interview in the 
privacy of someone's own home reduces the fear of others overhearing personal 
responses. One disadvantage with regard to an administered structured interview is that 
the researcher may not elicit the true answer that is willingly divulged to a self - 
administered questionnaire. 
Data from medical notes 
Of the 1540 cases recruited to this study, the medical notes were accessed for 1212 cases 
by June 2004. The process of accessing medical notes was very bureaucratic and caused 
significant time delays in many hospitals, particularly in the West of Scotland. Many 
medical records departments insisted that a request letter was sent to either the medical 
director or the Caldecott guardian and a reply received before re- contacting the medical 
records department. On many occasions, the medical director or the Caldecott guardian 
was the same person that had signed the trust management approval letter for the study, 
but medical records managers would not give access to records until this procedure was 
followed. Access could have been simplified if the trust management team giving 
approval for the study had notified all the departments likely to be involved with the 
study. Alternatively, as the Research and Development departments are credited with 
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the study as research activity within their hospital they could be the co- ordinators with 
departments to gain permission to access the data required with consent forms. 
Once procedures were in place for accessing medical notes, further problems were 
encountered with their availability. It was often found that medical records staff were 
not available to have notes accessible or the notes were in the hospital system and not in 
the records department. 
On some occasions the staffing problem was solved by payment for notes to be made 
available. The problem encountered with unavailable medical notes was more difficult 
to resolve and in order to circumvent it; notes were requested 3 months after 
recruitment. It was thought that notes would be more available three months after 
discharge than before the first outpatient appointment, normally at six weeks. However 
this was not found to be the case. The lag time in requesting notes was reduced to one 
month and produced similar results to waiting 3 months. 
A total of 328 notes were unavailable at first request. This may be the result of internal 
audit on colorectal cancer patients or many simply reflect the fact that some hospitals 
take longer to return medical notes to medical records departments. The Research and 
Development department should inform research studies of current audits, if data 
collection relies on access to medical notes. An example of good practice was found in 
two hospitals, where a medical records officer was responsible for all notes being 
available to both research and audit projects. In these hospitals 96% of notes were 
available when requested for the first time. This compares to the situation in the 
hospital with the highest deprivation only 9% of notes were available at first request. 
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Other studies using medical notes to access required data have acknowledged that they 
had a degree of difficulty. This resulted in a number of individuals recruited to their 
studies having incomplete data (Aitken et al 1995, Douglas et al 1999) as was 
experienced in this study. 
Conclusion 
Although 21 °/0 of the medical notes were not accessed for data collection there was no 
difference in the age, sex or deprivation categories that would result in bias of the 
cohort for analysis using medical note data. 
The medical notes when available are an excellent source of objective data. In this study 
these data included information on haemoglobin levels (as laboratory results were clearly 
documented and dated). In most, but not all hospitals, Dukes' stage and the Tumour 
Nodes and Metastatic (TNM) status was recorded on pathology form or in a minimum 
dataset form. This study also required data from the GP or doctor's referral letter, these 
data on symptoms at presentation and examinations performed by GP were found to be 
less reliable and on many occasions not available. Future studies requiring these data 
should consider employing the use of a standard referral form by GPs for data capture. 
Deprivation Indices 
The deprivation index used by the ISD on Scottish population and colorectal cancer 
data is the Carstairs index. The latest data published on deprivation and the Scottish 
population are for the year 2001 and report on all ages. These data show that 25.8% of 
Scottish individuals are in the most affluent group (as defined in this study). In the 
colorectal cancer population in the year 2000 and in age group 16 -79, 22.3% were in the 
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most affluent group; compared to 27.1% in this study. Similarly the proportions in the 
most deprived group are 15.2% in the Scottish population, 14.9% in the colorectal 
cancer population and 13.6% in this study. 
The incidence of colorectal cancer has been increasing more rapidly among the more 
affluent group in Scotland resulting in a widening of the "deprivation gap" between the 
most affluent and the most deprived groups. Therefore, the increased percentage in the 
most affluent group in the study may be an accurate representation of the current 
colorectal cancer population. However, this cannot be confirmed until the data for the 
years 2002 and 2003 are available. 
The Scottish Index of Multiple Deprivation (SIMD) has only been published recently 
and was the second deprivation index used (a detailed discussion of the Carstairs and 
SIMD indices are presented in the methods section). The deprivation groups in this 
index were more difficult to compile but followed a similar method to that employed in 
forming groups defined by the Carstairs index. The distribution was 29.5% in the most 
affluent group and 11.5% in the most deprived group. It was not possible to compare 
deprivation between the Scottish population and the colorectal cancer population, as no 
data have been published using the SIMD index. 
Indices used in the study are derived from different datasets. The SIMD index data are 
derived from multiple sources of live data and it aims to be a dynamic source of data. 
The Carstairs index is created from the latest census data that is only updated every 10 
years. The Carstairs index is often criticised in the literature for being out of date by the 
time the census data are available. Most analysis carried out involved an investigation on 
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the effect of deprivation and both indices where used. In all of the analyses the results 
were similar. 
Conclusion 
The Scottish Executive identified inequalities in various aspects of health and has 
invested in numerous projects that will generate more detailed information on the 
reasons for inequalities in health and areas of inequalities that could inform public 
health campaigns. 
Published data from ISD show that in Scotland the incidence of colon and rectal cancer 
is greater in the most affluent groups and the deprivation gradient is steeper in those 
diagnosed with colon cancer. There is little difference between the deprivation groups 
and mortality. However there is an inverse survival (especially in rectal cancer) among 
most affluent groups (ISD 2003). In this study there was little to suggest that the most 
affluent group are treated any differently from the most deprived group by GPs or that 
the groups differ greatly in behaviour when lower gastrointestinal symptoms are present. 
We found no differences in waiting time with symptoms, taking medication for 
symptoms, discussing symptoms with other people, or in the number of visits before 
referral for investigations. These findings were robust to method of categorising the 
deprivation groups. 
The Carstairs index is considered by some not to be an accurate measure of deprivation 
due to the limited measures of deprivation used to comprise the total score. The SIMD 
index used more current and possibly more accurate data for assessing deprivation 
status but in this study it gave similar results to the Carstairs score. This means that both 
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indices using different datasets arrived at comparable total scores. The new SIMD 
index allows more specific areas of deprivation to be included and an advantage of this 
index may be seen in studies wishing to investigate specific aspects of deprivation. 
Comorbidity 
Comorbidity data were collected from medical notes. The data collection tool used was 
the Charlson index (Charlson et al 1987), one of the most commonly used in UK 
research. We investigated if there was any association with comorbidity and delay in 
presenting with symptoms. We postulate that those cases with greater comorbidity 
might be more frequent visitors to the GP and might either report new symptoms of 
any kind more quickly or alternatively that they may delay in reporting as they have 
other more serious symptoms of other conditions. Cases with higher levels of 
comorbidity may not visit their GP as since often as they are maintained on medication 
for chronic conditions by repeat prescriptions and any new symptom may be interpreted 
as an effect of medication. 
Comorbidity data in this cohort were available for 1208 cases and analysis of these data 
has shown that 505 (41.8 %) cases had no comorbidity at the time of diagnosis of 
colorectal cancer. A further 342 (28.3 %) cases had one comorbid condition and 361 
(29.1%) cases had more than one comorbid condition. The number of cases in the study 
with comorbidity scored by Charlson index was much higher than that reported in a 
thesis by Stockton (2001). Stockton found only 15% of colorectal cancer in Scotland at 
the time of diagnosis to have any comorbidity at diagnosis using the Charlson index. 
The reason for this large deficit cannot be easily understood since information was not 




The information we have available on the non -participants suggests that patients with 
more comorbidity were more likely to be excluded from the study by the CCNS. In 
addition, individuals with more comorbidity may present with a poorer prognosis than 
those consenting to the study, although data to explore this are not available. It had 
been previously found that cases with higher levels of comorbidity are excluded from 
oncology research projects (Schag et al 1994) and it is reasonable to believe that this also 
happened in this study. 
Dukes' stage of tumour 
Dukes' stage in colorectal cancer identifies the severity of disease at diagnosis. Analysis 
carried out using Dukes' stage and total number of comorbid conditions did not show 
any statistically significant difference between Dukes' stage and number of comorbid 
conditions at diagnosis. 
There is little literature on the relationship between comorbidity in colorectal cancer and 
delay in presenting with symptoms. Porta (1996) did find that cases with colorectal 
cancer and comorbidity did present sooner with symptoms than those with no 
comorbidity, but this was a small sample of 110 cases. 
Analysis of the study data did not show any association with delay in presentation with 
symptoms and the number of comorbid conditions present at diagnosis (resulting in no 
difference in median waiting time for those with or without comorbidity). The results 
from this study would suggest that comorbidity status at diagnosis of colorectal cancer 
has little association with the presentation of symptoms or Dukes' stage at presentation. 
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This result should be interpreted with caution for those diagnosed with Dukes' stage D, 
as the sample of cases in this category was relatively small. 
Data for all ages were available from ISD for Dukes' stage for cases registered in the 
year 2000 and 2001. Comparing these data to the 24 months study data there is a clear 
deficit of cases with Dukes' stage D in the study population. 
Conclusion 
Comorbidity was not associated with delay in presenting with symptoms or with the 
Dukes' stage at diagnosis. However, the cohort consisted of relatively few cases with 
Dukes' D stage tumours that may affect our power to detect such differences. 
Family history of colorectal cancer 
Until recently family history had been overlooked as an important risk factor in 
colorectal cancer. However in the past few years in Scotland, Scottish cancer genetics 
recommendations have recognised the importance of evaluating a family history of 
cancer and have drawn up appropriate clinical guidelines. 
In 1995 the Department of published a report on, The advances in the genetics of 
common diseases, the implications for the NHS'. 
This report stated: 
"If the potential benefits of this progress are to be achieved a carefully planned programme of 
research and development will need to be implemented, with service organisation and development 
involving ongoing formal evaluations and integration of primary care into genetic services" 
Demand for cancer genetic services has increased since this time. However this increase 
in demand has primarily been from those individuals with a family history of breast 
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cancer (Wonderling et al 2001). The ongoing National breast screening programme for 
women age 50 and over may have led to a higher public recognition of the availability of 
breast cancer surveillance. The knowledge that a family history of breast cancer 
increased the risk of breast cancer may have driven a demand among women younger 
than age 50 for breast surveillance. 
Due to regular breast awareness campaigns, many women realise when they reach 50 
year of age they should attend for regular mammography through a surveillance 
programme. Many women will have experience of female relatives attending the 
surveillance programme and have relatives and /or friends with a diagnosis of breast 
cancer. 
Breast cancer has a high public profile and has enjoyed the benefits of media attention 
through regular public health campaigns, abundance of public targeted information 
leaflets, breast cancer awareness month and women's journals regularly featuring breast 
cancer and more recently family history of breast cancer. 
Colorectal cancer has no National surveillance programme equal to the breast 
surveillance programme. Colorectal cancer is not so widely publicised or bowel habits 
discussed publicly unlike the symptoms of breast cancer. The stigma of having a 
colostomy following a diagnosis of colorectal cancer has made colorectal cancer less 
socially accepted (MacDonald & Anderson 1984). In recent years there have been 
changes in surgery and treatment that have lessened the need for permanent colostomy. 
There has been limited research carried out on family history in patients with colorectal 
cancer. The evidence in support of recommended management strategies for individuals 
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with a family history meeting modified Amsterdam criteria (also known as high risk 
family history or HNPCC family history) is from observation studies and not 
randomised trials in families with high numbers of cancer cases. The available evidence 
suggests that surveillance management can prevent a colorectal cancer. However larger 
National or international studies are required to provide more robust evidence. The 
evidence for management of cases with a lesser degree of family history is not evidence 
based and is based on consensus of expert opinion. 
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Scottish guidelines for family history risk assessment 
Scottish guidelines24 for those with a family history of colorectal cancer have been 
developed and implemented. These recommend an assessment of family history with an 
individual level of risk that would give recommendations on the timing and frequency of 
surveillance that is offered to the individual. The levels of risk and the thresholds for 
surveillance recommended by the Scottish guidelines have varying degrees of evidence 
for their development and implementation, as noted above. 
This study reports the proportion of cases with colorectal cancer that have a high or 
moderate family history. However, it is not possible to discuss such cases in isolation 
from their first- degree relatives. When a case meets the criteria for high or moderate 
risk due to family history they are informed that all first- degree relatives (age dependent) 
are `at risk' and will be eligible to enter a surveillance programme to prevent colorectal 
cancer. 
The criteria used to assign a high -risk to a family history in Scotland are the modified 
Amsterdam criteria, (which are used internationally to identify families that should be 
offered mismatch repair gene mutation analysis). These criteria were developed at a 
consensus conference hosted in Amsterdam by the International Collaborative Group 
on Hereditary Non Polyposis Colorectal Cancer (ICG- HNPCC) (Vasen et al 1999). 
They are applied Internationally, including the UK, to assign a high -risk to a family 
history of colorectal cancer. 
24 Scottish guidelines are criteria for assignment of family history risk and surveillance recommendations. The risk assignment is detailed as high, 
moderate and low risk. 
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Patients with a family history that does not meet the high -risk criteria are assessed for a 
lower criterion that categorises them as having a moderate risk family history. This 
categorisation has a less firm evidence -base than the modified Amsterdam criteria. A 
UK consensus for moderate risk criteria for family history has not yet been reached 
within cancer genetic services. There is little published literature to provide the evidence 
required for efficacy of surveillance, the optimum number of screens required and the 
criteria to assess family history into this moderate risk group. Each cancer genetic 
service outwith Scotland varies slightly in moderate risk criteria, and the recommended 
surveillance infoinied by the risk criteria also varies. 
The lifetime risk in Scotland of developing colorectal cancer is 1 in 16 for males and 1 in 
20 for females (ISD 2004). 
There are two Scottish family history critera for a moderate risk of developing colorectal 
cancer: 
One first degree relative with colorectal cancer under age 45 at diagnosis, 
Two first degree relatives with colorectal cancer, one diagnosed under the age 
of 55. 
These criteria would equate to an approximate lifetime risk of 1 in 4, for a person 
meeting this family history criteria. 
This lack of consensus between centres does not instil confidence in other health 
professionals who are asked to apply the criteria and offer appropriate surveillance to 
their patients. The publication of the Scottish guidelines aimed to address this lack of 
consensus. These guidelines are used in all four Scottish cancer genetic centres and 
applied to all cancer family histories assessed. 
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The assignment of a low risk to a family history will include some individuals that do 
have a family history of colorectal cancer but do not have a family history that meets 
moderate risk criteria as defined by these guidelines. This can be confusing for patients 
to understand especially if family members living outside Scotland are offered 
surveillance. Not all health professionals will feel confident to deal with this scenario 
and may refer to cancer genetic services inappropriately. 
The results of this study have shown that 27 (1.8 %) of 1509 cases giving their family 
history were assessed as high risk, 253 (16.8 %) moderate risk and 1229 (81.4 %) low risk, 
using Scottish guidelines. As the high -risk criteria of the Scottish guidelines are the 
modified Amsterdam criteria, two other studies which have published data from a 
colorectal cancer cohorts and assessed the number of cases with a family history that 
meet modified Amsterdam criteria are directly comparable. Andrieu et al (2003) found 6 
(0.8 %) families and Katballe et al (2001) reported 18 (1.5 %) families meeting the criteria. 
Neither of these studies offered criteria that could be compared to the moderate risk 
family history of the Scottish guidelines to enable a comparison. 
Family history eligible for referral to cancer genetic services 
Following Scottish guidelines the 280 (18.6 %) cases with a high or moderate family 
history should have been offered a referral to cancer genetic services. Of these 280 
cases, 14 (5 %) were correctly identified at increased risk and referred to cancer genetic 
services prior to recruitment to the study. Of the 14 cases referred with an increased 
family history, 8 (66.7 %) were in the age group 16 -54 years. It is relatively unusual for 
the GP to have a young patient diagnosed with a colorectal cancer and this may prompt 
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GPs to explore reasons for this and undercover information about genetic risk which 
can be associated with cancers at a younger age. 
Published results from many cancer genetic studies encourage the referral of younger 
cases to cancer genetic services. However, the case diagnosed later in life may be the 
person that changes a family history from low to moderate risk or moderate to high risk 
highlighting the importance of enquiring about family history in all colorectal cancer 
cases. 
Many of the family histories assessed in the study did not meet high or moderate risk 
status until after the diagnosis of the recruited case. There was a mean time interval of 
21 weeks from diagnosis to study recruitment and during this period cases had contact 
with some or all of the following; GP, colorectal cancer surgeon, oncologist or CCNS. 
These professionals had the opportunity during the 21 weeks to identify a high or 
moderate risk family history. 
When a patient presents to the GP with symptoms suspected to be due to colorectal 
cancer, it is most important to deal with the current symptoms. However there should 
be a mechanism for the family history to be addressed following any diagnosis because 
there are surveillance implications for both the cases and their first- degree relatives. 
Although surveillance to prevent colorectal cancer is important for `at risk' relatives, 
mutation analysis and microsatellite instability (MSI) testing can only be offered to 
affected individuals who should be offered the opportunity to discuss this further in a 
cancer genetic clinic. 
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Interestingly, for cases with a high or moderate family history risk (as assigned by 
Scottish guidelines) there was no association found with sex, site of cancer, and Dukes' 
stage at diagnosis, comorbidity or deprivation. 
Conclusion 
The results of this study show that 18.6% of cases have a family history that requires 
referral to cancer genetic services (according to Scottish guidelines) and that a very small 
percentage of these cases were actually referred to cancer genetic services. 
Of the 280 cases with high or moderate family history, there was no association with 
any variable analysed with the exception of the age of referrals made to cancer genetic 
services. This suggests that families with a moderate or high family history risk are 
broadly similar to other colorectal cancers cohorts with no assigned family history risk. 
These results highlight that more education is necessary to enable GPs and other health 
professionals to apply the guidelines to family history. This education should provide a 
basic understanding of assessing a family history and making an appropriate referral to 
cancer genetic services. 
Perceived colorectal cancer family history risk 
This study examined whether a diagnosis of colorectal cancer increased an individual's 
perception of their family history risk and how they dealt with that perceived increased 
risk. All cases were asked if they thought they had a family history of colorectal cancer. 
Of 1456 cases25, 222 (15.2 %) perceived that they did have a family history. In order not 
25 53 cases of the 1509 were the only person in the family with colorectal cancer; as they were diagnosed under age 45 their family history is deemed at 
moderate risk. They would not have been expected to answer yes to perceiving a family history of colorectal cancer and were excluded from analysis. 
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to bias the replies, they were neither asked to specify their concept of a family history, 
nor to justify the reply. No guidelines were given on moderate or high risk of colorectal 
cancer and perceived levels of risk were not challenged. 
Of the 222 cases declaring a perceived family history 23 (10.5 %) had a high risk, 110 
(49.5 %) moderate risk and 89 (40.0 %) low risk family history, as assessed using Scottish 
guidelines. 
Having a perceived family history risk of colorectal cancer varied by deprivation group, 
in the most deprived group 68% of cases that perceived a family history did have a 
family history meeting high or moderate risk criteria opposed to 50% of the most 
affluent group. It may be that those in the most deprived group are more likely to know 
more accurate details on their extended family. The number of cancers in their family 
may therefore appear higher which may cause them to think more about their risk. The 
more affluent cases may have moved away from their family for career development and 
have less detailed knowledge of their extended family history or alternatively they may 
have a greater awareness that family history is a risk factor for colorectal cancer but not 
be aware of the risk criteria. 
In contrast more affluent women with a family history of cancer appear to actively 
request that GPs refer to cancer genetic services (Holloway et al 2004). It has also been 
found that a higher proportion of women attending family history clinics with a 
perceived risk of breast cancer are in the more affluent group (Fraser et al 2003) and are 
more educated (Brain et al 2000). 
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From the 280 cases with a high or moderate family history there were 147 (52.5 %) cases 
that did not perceive a level of family history risk when questioned. This result is not 
surprising as in a study of women it was found that 25% of them did not know that 
family history was a risk factor for breast cancer. This is similar to findings of a number 
of studies on perceived risk for breast cancer that found many women estimated their 
risk of breast cancer as low (Murabito et al 2001). In a study of women attending a 
breast cancer family history surveillance programme 27% of the women enrolled felt 
their risk of developing breast cancer was either none or very small (Kash et al 1992). 
Two cases in the study answered that they did not perceive themselves to have a family 
history risk but the GP informed them that they should be referred to cancer genetic 
services. 
Conclusion 
These results suggest that the most affluent group are more aware that family history is 
a risk factor for colorectal cancer as previously identified for individuals with a breast 
cancer family history. They also suggest that the more deprived group know more about 
their family history but only when they have several members with cancer do they 
perceive a risk. 
The results have shown that GPs do not routinely enquire about family history and 
previous research has shown that more affluent individuals request referral by their GP. 
Referral to cancer genetic services 
If a case responded yes to a perceived family history of colorectal cancer they were then 
asked if they had discussed this with their GP. Of the 222 cases that responded `yes' to 
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having a family history, 76 (34.2 %) cases had discussed their concern with their GP and 
51 (22.9 %) of these cases had a high or moderate risk status assigned by the Scottish 
guidelines. Of the 222 cases that perceived a family history risk, a total of 14 (6.7 %) 
cases were referred to the cancer genetic services. In 2 of the 14 cases the family history 
was assessed as low risk using the Scottish guidelines. The other 12 (5.4 %) cases were 
referred to cancer genetic services and were appropriately referred. 
These findings from this study appear to indicate that GPs do not routinely ask about 
family history of cancer. This may be a result of their lack of confidence in assessing the 
risk as found by Fry et al (1999) or due to time constraints (Suchard et al 1999). 
Alternatively many GPs may not be aware of the existence of guidelines for family 
history of common cancer (Rose et al 2001). The results also suggest that they are not 
encouraged to investigate the best course of action when a patient raises a concern 
about family history. 
It appears that a concern about family history risk is not sufficient for most individuals 
to raise the concern with their GP. A higher proportion of cases in the most affluent 
group (35.5 %) compared to the most deprived group (30 %) discussed concerns with 
their GP. The existence of this study is unlikely to have any bearing on the decision 
making of the GP to refer to cancer genetic services. GPs were only informed about the 
study after the case had been recruited. In contrast knowledge that the study would 
identify those with a family history requiring referral could be an explanation as to why 
there were few referrals from the surgical and oncology teams as they were fully aware 
of the study. The surgical team in each hospital identified eligible cases and informed 
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the study team. They knew that a family history would be taken and cases at increased 
risk sent information on their risk assessment. 
It was not possible to collect information from non -participants with a family history of 
colorectal cancer on whether they were referred to cancer genetic services. Of the 14 
(5 %) cases of a potential 280 cases that were referred to cancer genetic services 12 
(4.3 %) had discussed their concern with their GP. 
High -risk family history 
A total of 27 cases had a high family history risk, 17 (62.9 %) of these perceived an 
increased risk and discussed their concern with the GP but only three (11.1%) were 
referred to cancer genetic services. An individual with colorectal cancer and a high -risk 
family history should ideally be identified before surgery. This enables the surgeon to 
discuss with the case, more radical surgery to remove more of the colon, because of the 
increased risk of metachronous tumours (Van Dalen et al 2003). A high -risk family 
history should also alert the surgeon to the need for continuing endoscopic surveillance 
(as the Scottish guidelines,) rather than being discharged at 5 years post -operatively. 
Individuals at high risk should also be offered referral to the cancer genetic service, as 
they are eligible for mismatch repair gene analysis and advice on surveillance for other 
cancers such as endometrial, ovarian and stomach cancer (Vasen et al 1999). 
When a case is identified with a high -risk family history, the first- degree relatives 
become `at risk' relatives. The Scottish guidelines focus on the `at risk' individual's 
requirements for surveillance however, to begin the process of identifying a gene 
mutation in a high -risk family, the focus shifts to the person with colorectal cancer. 
That person requires genetic counselling on mutation analysis, discussions on what the 
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outcome of mutation analysis could mean for them and their immediate family, and the 
options available to gene carriers, before consent can be taken for mutation analysis. 
The obvious aim of a HNPCC surveillance programme is to prevent colorectal cancer in 
potentially many other family members. It is important that the individual with 
colorectal cancer is fully aware of the implications of a positive mutation analysis result, 
and the change in risk to their first- degree relatives if a gene mutation is found. That 
person also needs to be aware that if no mutation is found, the family remains at high 
risk and surveillance of the case and `at risk' relatives should remain in place. 
Moderate risk family history 
In the study 253 cases were assigned a moderate risk family history of colorectal cancer 
and should be offered referral to cancer genetic services. Each case can be offered MSI 
testing of tumour material, It has been found that >90% cases with a known mismatch 
repair gene mutation also have microsatellite instability in their tumour Gass et al 1998) 
and only 10 -15% of sporadic colorectal cancer tumours demonstrate MSI (Ionov et al 
1993). These finding have led to the development of triage testing by cancer genetic 
services. In Scotland, cases that are living, had colorectal cancer in the past and have a 
moderate risk family history are offered testing of their tumour material. Those cases 
shown to have microsatellite instability through MSI testing are then offered mismatch 
repair gene analysis. 
Cases not wishing to be tested but who would be happy for testing to be available to 
family after their death can have DNA stored by the cancer genetic services. This may 
be discussed with the cases at time of family history assessment. All first- degree relatives 
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over age 35, of a case with a moderate risk family history, are eligible for enrolment into 
a cancer surveillance programme. The surveillance for those at moderate risk is less 
intensive than high -risk families. It is important that these individuals are made aware of 
their risk and that the cancer genetic services can offer a service to discuss their risk and 
the surveillance available to them. 
In this study 253 cases had a moderate risk family history and in total 9 (3.5 %) cases 
were referred to cancer genetic services. There is a great potential to improve this 
referral rate. 
The results from this study have shown that the publication and dissemination of 
referral guidelines alone has not achieved appreciation in routine medical practice that 
family history is an important risk factor. This is not an unusual finding as this has been 
reported for many published guidelines even when adapted for local use. This would 
suggest that innovation is required to successfully implement these guidelines and audit 
is necessary to monitor the effectiveness of them. 
It appears from the results of this study that there is a lack of knowledge in most health 
professionals and the general public regarding family history risk and availability of 
cancer genetic services. This lack of knowledge has resulted in those eligible for cancer 
genetic services not being identified. 
Cancer genetic services could also foster closer links with the relevant teams in each 
hospital. A procedure could be developed to make referral to cancer genetic services 
simple but effective for surgery, oncology and cancer genetic services. 
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Surveillance recommendations for high and moderate risk 
individuals 
The risk category assigned to a family history determines first whether surveillrnce is 
appropriate. For those with a high or moderate risk family history the risk category also 
determines the frequency of endoscopic surveillance offered both to cases and their `at 
risk' family members. 
Colonoscopy is the recommended surveillance in individuals with an increased family 
history of colorectal cancer ( Vasen et al 1998, Jarvinen et al 2000). There are currently 
long waiting lists for colonoscopy for those with lower gastrointestinal symptoms in 
Scotland. Resources are not yet in place to meet the additional workload of a 
surveillance programme for the asymptomatic `at -risk' population. Currently surveillance 
colonoscopies for individuals with a family history of colorectal cancer are carried out 
within the routine colonoscopy clinics. 
In contrast, the population breast -surveillance and familial breast -surveillance 
programmes are operated separately from symptomatic breast clinics in the breast units. 
Therefore the pressure of surveillance asymptomatic women does not impact upon the 
breast units seeing symptomatic women. Furthermore the population breast -surveillance 
programme for women age 50 -65 is funded separately from the symptomatic breast - 
surveillance services in Scotland. 
The interval between colonoscopy and other cancer surveillance may differ throughout 
UK. Surveillance intervals recommended in Scotland for high risk individuals differ 
greatly from the surveillance intervals recommended for moderate risk individuals. This 
study found that 27 (1.8 %) cases were assigned a high risk. Cases could be offered 
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testing and first degree at risk' relatives would also be eligible for two -yearly 
surveillance. Data from ISD has shown that 2726 individuals, age 16 -79, in Scotland had 
a diagnosis of colorectal cancer in the year 2000 (ISD 2003). Assuming that the findings 
of this study can be generalised to all cases with colorectal cancer in Scotland, and 
applying the figure of 1.8% to individuals diagnosed in Scotland would result in 49 
families having a high risk of colorectal cancer. These would require referral to cancer 
genetic services for mutation analysis; cases and first- degree relatives would also require 
two -yearly colonoscopy surveillance whilst awaiting the result of the mutation analysis. 
This surveillance would continue for all mutation carriers if direct gene testing was 
available to the family and for all first- degree relatives and cases where no mutation is 
identified in the family. 
It has been reported that an average of four first- degree relatives will be `at risk' per 
increased risk colorectal cancer family excluding parents (Rose et al 2001). Thus 196 `at 
risk' individuals will qualify for two- yearly colonoscopy using figures from this study. In 
addition, female cases and female `at risk' individuals will require surveillance for ovarian 
and endometrial cancer, and some of these may opt for prophylactic surgery. In addition 
Scottish guidelines recommend upper endoscopic surveillance every two years after age 
50 even if there is no gastric cancer in the family. 
A further 253 (16.8 %) cases in the study were at moderate risk when assessed using the 
Scottish guidelines. Assuming as above that this figure can be generalised to all cases in 
Scotland in the same age group and applying the figure of 16.8% to the number of 
individuals diagnosed in Scotland in the year 2000, 458 cases would be eligible for 
microsatellite instability testing (MSI). If each case has four first- degree relatives that 
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are eligible and interested in endoscopic surveillance 1832 asymptomatic individuals 
would require a surveillance colonoscopy in a year. 
It is possible that the proportion with high and moderate family history is inaccurate due 
to under or over reporting of cancers in a family. Nevertheless, these are the best data 
available of this kind and could serve as a basis from which to estimate the cost 
associated with these recommendations. This in turn could inform any future economic 
assessment. There is evidence that surveillance of `at risk' individuals from the high -risk 
group may prevent colorectal cancer Qarvinen et al 2000). In contrast the surveillance 
recommendations in Scottish guidelines for the moderate risk group are not based on 
robust evidence and no cost -effectiveness analysis has been performed. 
As cancer genetics is a relatively new discipline, many individuals are currently being 
screened by colonoscopy but have had no formal risk assessment made on their current 
family history. There is evidence that the number of colonoscopies carried out for 
family history concern would be reduced (Brampton et al 2002) if a formal family 
history assessment were made. In many parts of the UK surveillance for a moderate 
family history risk is offered 3 -5 yearly. This was the situation in Scotland until the 
implementation of the Scottish guidelines, now surveillance for a moderate family 
history risk is offered at the age 35 (or current age before 55 years when attending the 
cancer genetic service) and if this colonoscopy is clear another is suggested at age 55 
years. This a major change with the new guidelines being based on age and risk relative 
to the population (Dunlop 2002). It is unlikely that a randomised controlled trial will be 
carried out in this group of people, so it is important that data is recorded systematically 
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from individuals undergoing surveillance and from cases with moderate risk family 
history so that a future evaluation of these guidelines can be made. 
There is evidence that screening individuals at high risk using colonoscopy can prevent 
them developing colorectal cancer. The cost of screening these individuals (at 2005 
costs) every two years from age 30 until age 70 would be L4,600. The basic cost of 
colorectal cancer surgery, chemotherapy and 5 year basic follow -up costs is 
approximately L 36,000 (www.dh.gov.uk). This does not include management of any 
complications of surgery or infection nor any other further surgery or treatment for 
metastasis. 
There is little evidence on the merit of surveillance screening for the moderate group of 
individuals. However, the cost of colonoscopy screening, on two occasions, for 
moderate risk individuals in Scotland is approximately L600, significantly less than the 
cost of basic colorectal cancer surgery. Approximately 60 moderate risk individuals 
could be screened for one person developing colorectal cancer and requiring surgery. 
This is a very conservative estimate as the overall cost of caring for a person with 
colorectal cancer and the consequences of the disease is likely to be far greater than 
£36,000. 
Implementing Scottish family history guidelines 
When the Scottish guidelines for colorectal cancer family history were published, the 
target population was asymptomatic `at risk' individuals with a family history of 
colorectal cancer and not individuals diagnosed with colorectal cancer. These guidelines 
pay inadequate attention to individuals with colorectal cancer and the impact that a 
diagnosis may have on their family history status. In addition to the lack of direction 
given in the guidelines for cases with colorectal cancer, they have not been updated to 
reflect the changes in cancer genetic services that can be offered to the case. Scottish 
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genetic centres now offer MSI testing on tumour material from living cases with 
colorectal cancer that have a moderate risk family history. The individual with colorectal 
cancer is seen within cancer genetic services to give consent to access tumour material 
and normal tissue stored within pathology departments at time of surgery. If this request 
is successful the specimens are sent to the laboratory for MSI testing. This service is 
clearly biased towards individuals that are aware of family history of colorectal cancer 
and are well enough to attend the cancer genetic services. Many cases with colorectal 
cancer will never be well enough or survive long enough to visit a cancer genetic service 
and a more systematic approach is required to capture these cases. 
Many problems are currently experienced by cancer genetic services in Scotland 
regarding access to tumour material in pathology departments. Normally an individual 
`at risk' attends cancer genetic services for a consultation on family history risk and is 
informed that MSI testing is available if an affected family member can give informed 
consent. If the MSI testing is found to be positive the normal practice is to obtain blood 
DNA for mutation analysis and in families with no living affected relative this cannot be 
offered. When MSI testing is negative, family history guidelines for family surveillance 
remains in place, whether high or moderate risk. Similarly, if an MSI positive result is 
found and mutation analysis does not identify a gene change, family surveillance remains 
in place. 
The results of this study have shown the lack of use and interpretation of published 
guidelines for individuals with a family history of colorectal cancer. It appears that when 
an individual is diagnosed with colorectal cancer, this does not increase the likelihood 
that the guidelines are used. 
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When the Scottish guidelines were developed and published, the Scottish Executive 
funded five cancer genetic associates in Scotland to provide the genetic associate -led 
model suggested in the document. This was to provide a service for individuals with a 
family history of breast, ovarian and colorectal cancers throughout Scotland. As 
previously discussed, the cancer genetic services have had an increase in referrals 
predominantly for breast cancer. Wonderling et al (2001) reported from UK genetic 
departments that 61 % of patients were referred because of concerns about breast cancer 
and only 16% and with a concern about colorectal cancer family history, and that there 
were almost twice as many referrals and consultations per million population in Scotland 
than in the rest if the UK. In Scotland the population risk for a woman to develop 
breast cancer is 1 in 11, and for both men and women to develop colorectal cancer it is 
1 in 20. Using this data you would expect the referral rates for breast and colorectal 
cancer to approximately the same. 
An improvement in the service for access to cancer genetic services for individuals with 
colorectal cancer and a high or moderate family history risk is required. The most 
important task for the improved service is the development of an education programme 
for GPs and other health professionals involved in the care of cases with colorectal 
cancer. This could involve the investment of a genetic counsellor on secondment to 
deliver the education programme. In a community trial of two models to manage breast 
cancer family history referrals (involving the author of this thesis) Campbell et al (2003) 
reported that during the two -year study period, there was enhanced communication 
between GPs and genetic nurses. Guidelines were issued to all GPs in South East 
Scotland who were involved in the study and presentations made to some GP practices. 
Referral rates to the regional clinical genetic department during this time increased by 
48 %, indicating the benefit of an education programme. Referral rates were greater in 
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the trial arm that deployed a clinical genetic nurse to work more closely with general 
practice. 
GPs should not be the only professionals responsible for identifying a family history 
indicating increased cancer risk. This should be the responsibility of every professional 
that is involved in the care of individuals with cancer (Burton 2003). In the early stage of 
cancer diagnosis and treatment, an individual with cancer will have more contact with 
other health professionals than with their GP. All health professionals should have the 
skill to take a family history. 
Public awareness of family history 
The study has shown that all of the cases referred to cancer genetic services had raised 
the concern about family history themselves with the GP. This confirms the findings of 
Fraser et al (2003) and Campbell et al (2003). Of the 280 cases identified as having a 
high or moderate family history, 133 (47.5 %) cases had a concern regarding their family 
history. However, only 51 (18.2 %) actually discussed their family history concerns with 
the GP and 12 (4.3 %) were referred to cancer genetic services. The remaining 147 
(52.5 %) cases with a high or moderate family history did not perceive they had any 
increased risk. 
Recently there have been some bowel cancer awareness campaigns, with leaflets 
primarily focused on the awareness of symptoms. Only in recent years have the 
colorectal cancer charities published specific information on family history as a risk 
factor for colorectal cancer, the first patient information leaflet that detailed family 
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history risk for breast, colorectal and ovarian cancer was published by the Cancer 
Research Campaign in April 1998. This leaflet was specifically on cancer family history 
and would only be requested by individuals that are aware they had or perceive they had 
a family history. However, the charity advisors have noted that most individuals in 
contact with the colorectal cancer charities have had a diagnosis of colorectal cancer or 
are the relatives of the person with colorectal cancer and are coming with questions on 
cancer and cancer care rather than concerns on family history (personal 
communication). More recently, one charity has addressed this within a booklet on 
colorectal cancer with a section giving detailed information on family history risk 
(Cancer Bacup 2004). The aim of this booklet is that users will read the section on 
family history risk. 
A mass media awareness campaign on family history of cancer may assist the general 
public in recognising a relevant family history. However there is a potential that anxiety 
would be raised by an awareness campaign. Recent research has shown that it would be 
possible to raise awareness for all and not increase anxiety in those with or without an 
increased family history (Leggatt et al 2000). 
Such campaigns are a common method of disseminating health information to a large 
amount of people. However the NHS Health Development Agency recognises they 
have limited success and to maintain awareness levels requires continuing investment 
and continued short bursts of mass media activity. 
As no awareness campaign on family history of cancer has been attempted within 
Scotland, it is not possible to comment on how successful this may be in meeting 
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objectives. However, it would be possible to develop material for a campaign in 
Scotland using current family history guidelines. The foiniat should be comprehensible 
to the general public, without raising undue anxiety. 
A family history awareness campaign would aim to improve the numbers recognising a 
relevant family history. An awareness campaign may also aim to increase the confidence 
of the public to discuss their concerns regarding family history of cancer with the GP. A 
family history information leaflet may help GPs to explain why a person can be or 
should not be referred to cancer genetic services. However, this is unlikely on its own 
bring about a significant change in referral practices and will need to be considered as 
part of a wider plan of action. 
A recent information leaflet published in Scotland (Appendix 7) is an appropriate 
example of assisting the general public to understand what constitutes a relevant family 
history of colorectal cancer. 
Although cases with an increased family history are only a small percentage of all cases 
with colorectal cancer, they give an opportunity to identify small numbers of early 
colorectal cancers or prevent a colorectal cancer developing. The identification of ̀ at 
risk' individuals and their entry into surveillance programmes may in the future make a 
small but significant impact by the early identification colorectal cancer or reduction in 
incidence. 
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Family history risk and lower gastrointestinal symptoms 
In this study, family history assessment was conducted after recruitment and after 
recording data on symptom presentation so should not have biased symptom reporting. 
The behaviour of the group that perceived they had a family history of cancer was 
analysed as it could be thought that perceiving a family history risk of colorectal cancer 
in relationship to lower gastrointestinal symptoms might change actions and thoughts 
when experiencing lower gastrointestinal symptoms. 
There was no statistically significant difference between those perceiving and those not 
perceiving a family history risk, with respect to sex, discussing their symptoms with 
other people, inspecting the toilet or toilet paper before flushing. 
Those perceiving a family history risk were significantly more likely to be in the younger 
age group, to think they had cancer before they were diagnosed, and to state that they 
had some knowledge of colorectal cancer symptoms. Surprisingly, they did not use this 
knowledge, or their suspicion they had cancer to visit the GP sooner than those not 
perceiving a family history risk. There was no difference in the median waiting time with 
symptoms of those perceiving a family history risk; this median waiting time was exactly 
the same as the waiting time of the whole cohort. 
Conclusion 
Of 222 cases perceiving a family history risk analysis of knowledge and behaviour 
variables related to lower gastrointestinal symptoms failed to identify any differences 
from cases not perceiving a family history. This would suggest that the worry of family 
history is not considered high priority as patients do not visit their GP more promptly 
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for advice nor do they make their concerns about family history more frequently known 
to their GP. Making the concern on family history known to a GP was found in this 
study to increase the likelihood that a referral to cancer genetic services would be made. 
Despite the Scottish Executive developing guidelines to assist GPs in assessing family 
history risk, these appear to be under- utilised. It is possible that GPs and other health 
professionals have not yet realised there are NHS services available to individuals with a 
family history of colorectal cancer. A concentrated effort is required to increase GPs 
and other health professionals' knowledge of genetics in colorectal cancer, and to 
develop skills to record family history information. There is a need to develop health 
professionals' ability to assess and refer those at increased risk and reassure those who 
are not. 
A public health campaign may increase the public's understanding of an appropriate 
family history of colorectal cancer resulting in more appropriate referrals to cancer 
genetic services. This study found that 52.5% of cases with a family history that met 
Scottish criteria for high or moderate risk were completely unaware of their family 
history risk. It is possible that information for the general public on colorectal cancer 
family history risk would increase the confidence to discuss their family history risk 
concerns with their GP. 
Symptom Presentation 
A secondary aim of this thesis was to describe lower gastrointestinal symptoms that 
were present at the first visit to GP. 
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This section of the discussion concentrates on the descriptive analysis presented in the 
results. Although a great number of published papers present similar data, there is no 
literature presenting these data for the Scottish colorectal cancer population. There are a 
few studies of colorectal cancer cases in specific areas of Scotland, but the current study 
represents 1540 cases diagnosed throughout Scotland. It is important to investigate 
whether the Scottish population differ from other colorectal cancer populations, given 
the high incidence in Scotland. 
Admission to hospital 
Information on admission to hospital was abstracted from hospital medical records, 
irrespective of whether or not a case had emergency surgery. In this study, 242 (20 %) 
cases were admitted as emergencies. This is within the range found in other studies but 
may not be an accurate representation of the proportion admitted as an emergency in 
the Scottish population due to the recruitment bias noted. 
These data have shown a statistically significant difference between tumour stage and 
mode of presentation with a greater percentage of Dukes' stage D tumours presenting 
as emergencies than electively. In this cohort, 16 cases (6.8 %) of emergency admissions 
had a Dukes' stage D tumour compared to 29 (3.1 %) in the elective group. 
Cases not participating in the study were sicker than the participants; a higher 
proportion received palliative surgery because of more advanced cancer. Other studies 
have reported the trend towards the presentation of Dukes' stage D tumours as 
emergency rather than elective admission, but have not reported this to be statistically 
326 
significant. The statistically significant result in this study may be explained by the large 
sample size giving the power to detect more modest differences. 
There was a trend in this study for the most deprived to be more likely to be admitted as 
an emergency. Similar findings have been reported by other published studies. It was 
also found that the median waiting time with symptoms was shorter in cases admitted as 
an emergency than in those admitted electively. This finding again confirms previously 
published results of other research groups in other study populations. 
Symptom presentation is widely reported in the literature and the results from this study 
mirror other published studies, where it was possible to make comparisons. In this 
study each case was asked which symptom prompted them to visit their doctor. They 
were then asked if they had any of twelve symptoms were present before they reported 
to a GP. 
A large proportion of this study cohort consistently reported only a few symptoms. 
These are rectal bleeding, change in bowel habit, and to a lesser extent marked loss of 
energy. At presentation to a GP, most cases had several symptoms, some of which were 
of longer standing than the symptom that prompted them to see their GP. The main 
symptoms reported at first visit to their GP were rectal bleeding, (in 492 (37.2 %) cases) 
and change in bowel habit, (in 349 (26.4 %) cases). 
When considering all symptoms reported to be present at first visit to a GP, the most 
common symptoms were; change in bowel habit, (in 805 (53.6 %)), rectal bleeding (in 
768 (51.6 %)), and marked loss of energy (in 603 (40.5 %)). The same three symptoms 
were also found to be the highest percentages in colon and rectal cancer. Rectal cancer 
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cases were found to have rectal bleeding in 370 (73.7 %) cases, change in bowel habit 
307 (61.2 %) and 152 (30.3 %) marked loss of energy. Colon cancer cases were found to 
have rectal bleeding in 237(34.0 %), change in bowel habit 317 (45.5 %) cases and marked 
loss of energy 310 (44.5 %). 
Of the 333 cases that visited a GP with only one symptom, 162 (48.6 %) cases had rectal 
bleeding, 67 (20.1 %) cases marked loss of energy and 57 (17.1 %) had change in bowel 
habit. 
The finding that a high proportion of colorectal cancer cases presented with both rectal 
bleeding and a change in bowel habit is consistent across all published studies. 
Published NHS guidelines for referring a patient with suspected colorectal cancer 
concentrate on rectal bleeding and changed bowel habit as symptoms. These guidelines 
mainly focus on cases having no anal symptoms with rectal bleeding and a change in 
bowel habit to more frequent and looser consistency of stools. Within this cohort 1094 
(81.2 %) had no anal symptoms. Of the 768 cases with rectal bleeding, 512 (66.7 %) had 
no anal symptoms. The 33.3% of cases with rectal bleeding that did experience anal 
symptoms had soreness, itching, could feel a lump, had discomfort in the anal region or 
were experiencing anal pain. Of 805 cases reporting a change in bowel habit, 743 cases 
gave information on change of frequency and in 473 (63.7 %) cases had increased 
frequency. Only 430 cases answered the question about consistency and of these 416 
(89.1%) cases reported that with the increased frequency they also had looser stools. 
The group below 55 years of age were more likely than the two older age groups to 
report rectal bleeding. In the cancer referral guidelines the age threshold for referral is 
60 years in England and 50 years in Scotland. These results show that some younger 
cases would be missed using these guidelines. 
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Marked loss of energy is most likely to be present in those cases with a low 
haemoglobin level. This study demonstrated that those most likely to report marked loss 
of energy were female and in the younger age group. It may be that younger people 
feeling excessively tired are aware that it is abnormal and are likely to report to the GP, 
whereas older people may accept this as part of the ageing process. 
Delay in presentation with lower gastrointestinal symptoms 
The study aimed to investigate which factors affect the time individuals have lower 
gastrointestinal symptoms before presenting to a GP, with special attention given to 
deprivation and comorbidity. There is a wide literature on this topic but little on the 
effect of comorbidity and deprivation. The median waiting times for the whole cohort 
show that the longest waiting time with any symptom was 13 weeks for weight loss and 
marked loss of energy. The median waiting times for pain, nausea and vomiting were 
shortest, consistent with their impact on daily living. For the majority of symptoms the 
median waiting time before seeing a GP was 8 -9 weeks, with the exception of rectal 
bleeding, where it was 6 weeks. The three symptoms, which show a statistically 
significant difference in waiting time from the median of the whole cohort is rectal 
bleeding, change in bowel habit and weight loss. 
Cases with rectal cancer waited longer before presentation with a change in bowel habit 
and rectal bleeding than those cases with colon cancer. Where there was weight loss, 
colon cancer cases waited longer than those with rectal cancer. 
These results give further evidence that rectal bleeding is the main presenting symptom 
and appears to be the `decision -making' symptom that prompts a visit to a GP. The 
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results also indicate that change in bowel habit is not considered a priority symptom, as 
the waiting time is the same as most other symptoms included in the symptoms list. 
Change in bowel habit with change in frequency and consistency is one of the main 
symptoms for consideration in making an urgent referral. These data suggest that 
individuals are not aware that change in bowel habit is important once present for 6 
weeks. This may be an area for a health campaign to focus upon. 
Interestingly, of the symptoms which individuals in this study self -treated, change in 
bowel habit was the most common. The 137 (46 %) cases self -treating had a change in 
bowel habit. This may have contributed to the relatively long waiting time before seeing 
a GP. 
There was no association between median waiting time with symptoms and any Dukes' 
stage of tumour at diagnosis. However, for Dukes' stage D tumours the 75th centile of 
the median wait time with rectal bleeding, change in bowel habit, marked loss of energy, 
mucus in stools and tenesmus was much greater than the 75th centiles of any other 
Dukes' stage. In this group, it is possible that earlier presentation may have changed the 
Stage at diagnosis in some cases. Cumulative data on waiting time demonstrated that at 
24 weeks 178 (27 %) cases with change in bowel habit, 179 (23 %) of cases with rectal 
bleeding and 192 (31%) with marked loss of energy had not reported their symptoms to 
a GP. Further analysis of waiting time and Dukes' stage at diagnosis support findings 
previously published that longer the waiting time with symptoms were associated with 
less advanced Duke's Stage at diagnosis (except for rectal bleeding which showed the 
opposite relationship). 
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The study found no evidence that age, sex, deprivation or comorbidity had any effect on 
the length of time an individual waits with symptoms before visiting a GP. Although no 
overall association was found in waiting time and gender. Symptomatic females were 
more likely to have visited their GP at four weeks with symptoms than males. 
Presentation factors in colorectal cancer 
Number of symptoms at presentation 
The number of symptoms that were present at the first visit to the GP ranged from 1 
through to 11 symptoms. The majority of the cohort had between 1 and 4 symptoms 
with a median of 3 symptoms at presentation. Further analysis of those cases with 1 -3 
symptoms and 4 -11 symptoms showed that males reported more symptoms at 
presentation than females. 
Development of new symptoms after referral to hospital 
The referral guidelines for suspected colorectal cancer indicate that if an individual 
presents with symptoms meeting referral criteria they should be referred urgently, where 
as others should be referred for a non -urgent appointment. In Scotland there is no 
definition of urgent appointment, unlike the two -week wait in England. Those referred 
for non -urgent appointments can wait for several months to be seen at an outpatient 
department. In 581 (47.9 %) referral letters in this study there was no indication of 
urgency. Therefore it is important that these individuals are encouraged to report any 
new symptoms that develop after their referral to hospital to their GP. They should 
understand that any new symptom that develops could indicate a greater risk. 
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This study showed that 490 (31.8 %) of cases did develop new symptoms and the 
percentage reporting these to their GP varied. The symptoms that would have made a 
difference to risk for urgent referral are change in bowel habit, rectal bleeding and 
marked loss of energy. In this cohort, 48 (38.4 %) cases developed change in bowel 
habit, 31 (33 %) rectal bleeding 53 (57 %) marked loss of energy but did not report these 
to their GP. 
There was no difference in the sex distribution of those reporting new symptoms during 
the waiting time, but a statistically significant difference in age groups with a greater 
proportion of younger cases than older cases reporting each of these three symptoms. 
This may reflect a change in the attitude of younger people and how they use the GP 
service. 
Age 
The study found that younger cases were more likely to wait longer than 4 weeks with 
their symptoms, (77.3% of this younger group waited greater than four weeks opposed 
to 68.1% in the older age group). This could be due to the younger age group being 
more likely to think that piles were the cause of their rectal bleeding. Of those waiting 
more than 4 weeks 18.2% of the younger age group thought they had haemorrhoids 
compared to only 12.2% in the older age group. The younger age group were also more 
likely to discuss their symptoms with other people, (71.3% of the younger age group 
compared to 64.1% of the older age group discussed symptoms with another person). 
Other studies have found the most common reason given for not attending a GP with 
rectal bleeding was the certainty that the cause was haemorrhoids (Byles et al 1992, 
Crossland & Jones 1995). 
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When questioned on knowledge of cancer symptoms before diagnosis, the younger 
cases were also more likely to state that they had some knowledge of colorectal cancer 
symptoms than the older age group. This younger age group were also the most likely 
group to consider that they had cancer before their diagnosis (46.1% in the younger 
group thinking they had cancer compared to 35.6% in older group). This is surprising as 
the older age group would be more likely to have experienced friends or relatives with 
colorectal cancer than the younger group. 
The younger age group were also more likely to inspect the toilet and the toilet paper 
before flushing. It may be that the older group was less honest in answering this 
question. 
Younger individuals reporting rectal bleeding were less likely to have a rectal 
examination by the GP on the first visit (56.6% of the younger group with this 
symptom had a rectal examination compared to 69.8% of the older group). The GP may 
consider a diagnosis of cancer less likely in a younger person as rectal bleeding is 
relatively common in the younger population in the community (Thompson et al 2000). 
Gender 
Females were significantly less likely than males to have had a rectal examination by 
their GP when reporting rectal bleeding, (280 (69.1%) of males and 174 (60.8 %) of 
females with this symptom had a rectal examination). Possible reasons for this have 
been published; lack of an available chaperone, lack of time or recent publicity of alleged 
sexual assaults on patients. 
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Females were more likely to report some knowledge of colorectal cancer symptoms 
before diagnosis, perhaps being more aware of health campaigns due to the high profile 
of breast cancer campaigns. 
Males were more likely than females to inspect the toilet and the toilet paper. However, 
on finding rectal bleeding, they did not present any sooner to a GP than females. 
Deprivation 
Cases in the most deprived group were less likely to say that they had any knowledge of 
cancer symptoms before their diagnosis and less likely to inspect the toilet paper or 
down the toilet paper before flushing. These latter results are consistent with not 
knowing about symptoms of colorectal cancer and thus being less likely to look for 
bleeding in your stools. The study found a few other differences between the most 
affluent and most deprived groups but none of these differences were statistically 
significant. The most affluent group were referred after only one visit to GP more often 
than the most deprived group. This may be as a result of the most affluent group having 
more knowledge of colorectal cancer symptoms or being more likely to insist on earlier 
referral. The influence of private medical insurance may also be a factor. Although data 
on private medical insurance were not collected systematically, the research nurses 
commented that privately insured cases that visited their GP with symptoms that may 
be interpreted as colorectal cancer symptoms were referred immediately for 
investigations. 
There was trend in this cohort (not statistically significant) for those in the most affluent 
group to be diagnosed at Dukes' stage A than those in the most deprived group. 
Younger cases were more likely than older cases to be diagnosed with advanced 
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tumours. This was not associated with waiting time with symptoms or deprivation 
group. The behaviour of tumours in the younger group may be more aggressive, raising 
the possibility of different tumour aetiology in younger cases. 
The most affluent group were more likely to have rectal cancer and the most deprived 
group to have colon cancer, and this mirrors the data published for the Scottish 
colorectal cancer population by ISD in 2004. 
Comorbidity 
Comorbidity was not found to be associated with any of the variables studied with the 
exception of having a rectal examination. Cases with more comorbidity were more likely 
to have a rectal examination at first visit to GP than those with no comorbidity. 313 
(52.0 %) with comorbidity having a rectal examination compared to 196 (45.8 %) cases 
with no comorbidity that had a rectal examination. 
Conclusion 
There were no differences in the presenting symptom or the symptoms present at first 
visit to GP, waiting time with symptoms and various other aspects of symptom 
behaviour prior to diagnosis of colorectal cancer with respect to age, gender, deprivation 
groups and comorbidity in cases. 
Guidelines for referral of suspected colorectal cancer 
At the development stage of this study, the referral guidelines available to all Scottish 
GPs were the SIGN guidelines for the management of colorectal cancer (1997). These 
differed significantly from the NHS (2000) guidelines for England and Wales. In April 
2002, the Scottish Executive Health Department (SEHD) issued new referral guidelines 
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for suspected colorectal cancer. (SEHD 2002) The SEHD guidelines were very similar 
to the National Health Service (NHS) 2000 guidelines, but with the key additional 
recommendation to refer cases urgently if they met the high -risk criteria. NHS (2000) 
guidelines set a `two -week standard' for high -risk cases being seen at outpatients. A 
secondary objective of this study was to provide information on cases meeting the 
Scottish referral guidelines and to collect data on the development and reporting of new 
symptoms. However, the lack of near complete case ascertainment, recruitment and 
missing data limited the ability of this study to report on this topic. 
The data required to meet this aim were collected through a structured symptom 
interview and extracted from medical notes. Reported symptom data were available 
from 1540 cases and medical notes data from 1212 cases (due to problems accessing 
medical notes). 
The problems with eligible cases not being offered the study information and thus only 
41% of ascertained cases being successfully recruited to the study were not predicted. 
The study methodology that is most likely to achieve near complete case ascertainment 
in a large Scottish study is identification of cases through audit framework. This would 
require the systematic and prospective collection of data that is of acceptable quality for 
all colorectal cancer through out Scotland. 
In 2002, the Association of Coloproctology of Great Britain and Ireland (ACPGBI.) 
published a reference paper with evidence to support the development of referral 
guidelines. Within this paper a range was given for the percentage of cases meeting 
specific referral criteria as reported in published studies. 
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A similar analysis by site of cancer by specific referral criteria was carried out in this 
study following the ACPGBI methods. Of the 1212 cases that had their medical notes 
accessed, 1199 cases had information on cancer site. Of these, 778 (64.9 %) cases had 
rectal and sigmoid cancers and 421 (35.1 %) cases had caecal or descending colon 
cancer. 
The ACPGBI reference paper gave five referral criteria for rectal and sigmoid cancers 
and three criteria for caecal or descending colon. Of the eight criteria, five relied on 
access to medical notes for data on abdominal mass, rectal mass, haemoglobin levels 
and intestinal obstruction. 
Rectal or sigmoid cancer 
In those with rectal or sigmoid cancer there were three referral criteria that related to 
data on symptoms at presentation and two relied on data from the referral letter. 
o `Rectal bleeding with no anal symptoms' was found in 50 -60% of cases 
assessed by the ACPGBI and 49.6% of this cohort. 
o `Rectal bleeding and change in bowel habit' was found in 50 -60% of cases 
assessed by the ACPGBI and 39.2% of this cohort. 
o `Change in bowel habit to looser and /or increased frequency' was reported in 
>90% by the ACPGBI and was found in 50% of cases in this cohort. 
There are reasons why such a wide discrepancy is seen: 
o Cases in this study may have underreported their symptoms, due to recall 
bias. 
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a A high proportion of the advanced cancers in other studies displayed these 
symptoms and this group is under represented in this study. 
o Hospital doctors have more experience in eliciting symptom information. 
The research nurses in this study simply asked the question and explained the 
meaning of some symptoms, if required. 
`Rectal mass' was found in 40 -60% on rectal examination and in this cohort it was 
found in 11.4% of the cohort. 
`Left sided abdominal mass' was found in 20% of sigmoid cancers but there were no 
comparable data available in this study. 
Cancers of the caecal and descending colon. 
In those cases with caecal and descending colon cancers, three referral criteria were 
given that relied on data from medical notes. 
The ACPGBI criteria predicted that a range of 30 -75% of cases would have iron 
deficiency anaemia and 54% would have a haemoglobin level below 10g /d1. 
In this study the data on haemoglobin level was available for 1212 cases. Haemoglobin 
level recorded the closest time to the referral letter or admission to hospital, if 
emergency admission was recorded. Adopting this approach reduced the bias that might 
be caused if an individual received a blood transfusion prior to surgery or soon after an 
emergency admission. 
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Iron deficiency anaemia was not defined in this section of the ACPGBI guidelines. This 
study analysed using a definition of Hb < 11 g /dl in men or < 10 g /dl in 
postmenopausal women, as given in the NHS 2000 guidelines. Of the cases in this study 
27.9% had iron deficiency anaemia, and 84% of these had a level below 10g /d1. 
`Abdominal mass' was given a range of 40 -55% and this study found that abdominal 
mass was recorded for 9% of cases in this group. `Emergency cases presenting with 
intestinal obstruction' was given as 10 -30 %, and 9% was found in this study cohort. 
Results from this analysis confirm that the information on rectal and abdominal mass 
data taken from the referral letters cannot be assumed to be accurate. Much of the 
literature on which the ACPGBI paper was based was from hospital studies. There is a 
high probability that their data may represent the range of signs and symptoms elicited 
by specialists rather than GPs. 
The uncertain quality of data from the GP referral letter limits the validity of the results. 
Detailed results on the proportion of this study cohort meeting at least one of the 
referral criteria (in the high -risk referral guidelines) are not presented in this thesis. 
Conclusion and recommendations 
The data collected for this section of the thesis were biased due to recruitment bias and 
uncertain validity of the data quality within the referral letters. The latter illustrates that 
an improvement in data capture from GP referral letters will be required if the 
assessment of referral guidelines is to be effective. 
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Using a standard proforma that incorporates the referral guidelines for patients with 
suspected colorectal cancer may have achieved better quality data. An example of a 
referral proforma for suspected colorectal cancer is included in (Appendix 15). This may 
have a role in reminding GPs of the referral guidelines and would assist in providing the 
accurate information required to assess the referral. This proforma may also reduce 
administrative time rather than producing an individual letter for each patient. 
As GPs have previously stated that easy accessible, simple format guidelines would 
encourage implementation, this simple format may appeal to them. With current 
technology available to most GPs, it is feasible that this proforma could be completed 
on screen and emailed direct to surgical department. Alternatively, it could be completed 
on screen and printed out or hard copies could be available for manual completion. 
However this is implemented, previous research has shown that implementing any 
change of practice requires use of many different educational techniques, preferably on 
site and should include audit. 
Data on urgency of the referral were collected from 1212 medical notes. Some referral 
letters also included the category of ̀ soon' and this was recorded as `urgent' for data 
analysis. Of the 1212 medical notes accessed, 293 (24.1 %) had no referral letter, 154 
(12.7 %) cases were referred as routine, 477 (39.4 %) cases were referred as urgent and 
for 288 (23.8 %) cases there was no indication given in the referral letter how the GP 
would like the referral to be treated. 
The use of a proforma for referrals would improve the quality of data capture but would 
not address sample bias. To address sample bias in a study of this type, a Scottish audit 
would be required. This would also improve case ascertainment, the employment of a 
dedicated research nurses (as in the NTRAC initiative) may also facilitate high levels of 
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case of ascertainment as they would have access to cases at an earlier stage in their 
journey and would be known to the colorectal cancer team. However there will always 
remain a significant proportion of patients that will be genuinely too sick to be entered 
into a research project. 
Implications for Health Service provision 
Ascertainment and recruitment 
This large population based study which recruited patients from 36 hospitals across 
Scotland and this experience of case ascertainment and recruitment may be valuable for 
other research studies wishing to recruit prospectively large numbers of cancer cases 
from Scottish hospitals. 
Ascertainment was found to be higher in hospitals where a colorectal cancer nurse 
specialist (CCNS) was employed or where the recruiting research nurse was a previous 
member of staff. This suggests that employing a research nurse within each surgical 
cancer team or developing the research knowledge and role of existing staff members 
would facilitate ascertainment and recruitment of cases. Nurse specialists (in all areas of 
health care) can play an important role in epidemiological studies e.g. case /control 
studies and clinical trials that recruit cases in hospital. The CCNS has an explicit 
research function within their role and this research role should to be encouraged and 
developed in order to overcome the types of difficulties experienced with data collection 
in this study. 
It would be advantageous to the NHS to provide further research training to develop a 
minimum level of research awareness and skills for all colorectal cancer nurse specialists, 
particularly as this specialist role demands involvement with local and National research 
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studies. This training would have cost implications for the NHS but could make a 
significant contribution to the success of Scottish cancer research initiatives. 
Family history of colorectal cancer 
Family history is now recognised as an important risk factor for colorectal cancer. 
Despite readily available published guidelines for GPs to assist with assigning a family 
history risk, this study has identified that the assessment of family history in patients 
with colorectal cancer is not routinely carried out by GPs. 
This can have important consequences for the patient with colorectal cancer and their 
close family. If an individual with colorectal cancer is assigned a high risk family history 
risk they can be offered mismatch repair gene analysis and the identification of a 
mismatch repair gene mutation would allows other family members to be tested. Those 
family members without the gene mutation can be reassured and will not require 
surveillance and those that do have the gene mutation can be offered regular 
surveillance with the aim of preventing cancer developing in the future. For patients 
with colorectal cancer the identification of a high -risk family history can reduce the risk 
of developing a metachronous cancer through lifetime surveillance. Individuals with 
colorectal cancer assigned a moderate family history risk can be offered MSI testing and 
first- degree relatives over age 35 are eligible to enter into a colonoscopy surveillance 
programme. 
To improve the service and reduce inequality of access to cancer genetic services for 
individuals with colorectal cancer with a high or moderate family history risk, all health 
professionals in secondary care involved with these individuals should be provided with 
education and training to develop their knowledge and skills. This staff training and 
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development should equip them with the skills to record family history information, 
make a basic assessment of risk and make an appropriate referral to the cancer genetic 
services. 
The study found that only 14 (5 %) of individuals from a potential 280 cases with high 
or moderate family history risk (according to published Scottish guidelines) were 
identified by their GP and were appropriately referred to cancer genetic services. Of 
these, 12 cases had perceived that they had a family history of colorectal cancer and 
discussed their concern with their GP and were then referred to cancer genetic services. 
Only two cases that did not perceive a family history risk were identified by the GP and 
referred to cancer genetic services. 
These results indicate that the publication of guidelines alone is not sufficient to change 
practice, and investment is required to provide innovative methods encouraging the 
implementation of guidelines. In addition, acceptable methods to prompt GPs to 
investigate family history in patients with colorectal cancer should be developed. To 
reduce inequality in access to cancer genetic services it is suggested that, in addition to 
staff training and development, a change in the service provision is required. 
Service development proposal 
Two approaches are discussed below. The first approach aims to improve quality and 
equality of referrals to cancer genetic services and the second approach is to provide a 
more equal service to all colorectal cancer patients. 
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First approach -use of family history proforma 
Following completion of an education programme a practice nurse, GP, hospital nurse 
or doctor at any outpatient appointment clinic or on admission to hospital could 
complete a family history proforma (an example of which can be seen in Appendix 14). 
This family history proforma would gather enough family history information to allow a 
decision to be made on the eligibility of the patient for referral to cancer genetic 
services, giving the patient the option to be referred. 
This may require an increase in the number of cancer genetic counsellors in order to 
deal effectively with the possible increase of referrals. However, the reduction in 
inappropriate referrals may balance the increase of appropriate referrals. 
Second approach- surgical department service 
If the responsibility for identifying individuals with colorectal cancer and a high or 
moderate family history were devolved to the surgical unit, with the support of the 
genetic counsellors, more families would benefit from the cancer genetic services 
currently available. The use of a family history proforma (Appendix 14) could once again 
be used to assist with this task. This study has shown that a high proportion of cases not 
participating in this study were receiving palliative care and were unlikely to ever be well 
enough to attend an appointment at cancer genetic services. Families of the more sick 
patients would be denied access to cancer genetic services and thus inequality in service 
provision is created. Assessing patients within the surgical units is the approach that is 




The introduction of this service would require colorectal cancer patients with a high or 
moderate family history risk to be identified preoperatively. This would enable staff to 
discuss the following options with individuals assessed with a high -risk family history: 
o Discuss MSI testing at the preoperative evaluation; consent could be taken 
for MSI testing on tumour material. 
o The Consultant surgeon will be informed of high -risk status and the need to 
discuss a possible change of surgical procedure. 
o Referral to cancer genetic services at a suitable time, using the family history 
proforma, regardless of MSI test result. 
o Give information in accordance with the guidelines that their first- degree 
relatives aged 30 and over should also be referred to cancer genetic services. 
o Offer the opportunity to have blood taken for DNA storage only. 
Colorectal cancer patients with a moderate risk family history could be offered: 
o Discussion of MSI testing at the preoperative evaluation. Consent could be 
taken for MSI testing on tumour material. Those with MSI- positive tumours 
would then be informed of result and offered referral to cancer genetic 
services for genetic counselling on mismatch repair gene analysis. 
o Information for their first- degree relatives who may be eligible for referral to 
cancer genetic services to discuss family history risk and surveillance, 
regardless of MSI status they should be seen in cancer genetic services. 
o The opportunity to have blood taken for DNA storage only. 
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It is current practice in all Scottish genetic centres to inform the consultand of other 
relatives at risk. This information is offered verbally and in written form and no attempt 
is made to follow this up. 
The main health service implication for implementing this service within the surgical 
units would be funding for staff training and for an increased number of laboratory 
tests. 
Referrals to cancer genetic services in this study were predominantly of cases that had 
the confidence to raise their concerns about family history with their GP. This finding 
further suggests that the health service should invest in the training and staff 
development of relevant health care professionals in assessing family history and making 
management decisions in accordance with published guidelines. 
Knowledge and awareness 
The study found that individuals from the most deprived group reported that they had 
no knowledge of colorectal cancer symptoms more often than individuals from the 
most affluent group, suggesting that future health campaigns should target their 
literature and media campaigns to be inclusive of all socioeconomic groups. 
Presentation with lower gastrointestinal symptoms 
The study found that the most common symptom for which an individual will buy over 
the counter medication before visiting their GP is a change in bowel habit (to loose or 
more frequent stools). It is suggested that this may be due to the widespread media 
advertising of over the counter medication to promptly halt diarrhoea. 
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Although there is conflicting evidence on the association between waiting longer with 
symptoms and stage of disease, extensive waiting time with rectal bleeding and change 
in bowel habit will have an effect on overall health. This could impact on recovery and 
complications if individuals continue to use over the counter medications without 
visiting a GP. Although these medications do give advice in the small print, that a visit 
to a GP is recommended should symptoms persist, the health service should ensure that 
this message should have a more central focus on the packaging, particularly in older 
adults, if other symptoms are present or symptoms are not promptly relieved. 
Referral guidelines for suspected colorectal cancer 
The study found a lack of consistency in the information provided in the GP referral 
letter on the symptoms the patient was experiencing on visiting the GP or the GPs 
findings after examination of the patient's abdomen or rectum. This lack of information 
may affect decisions made by the unit receiving the referral letter. In addition, few 
referral letters gave details on the urgency of the referral. Any future evaluation on the 
value of the referral guidelines for `suspected colorectal cancer' will require a 
functioning and complete Scottish audit system to be in place. This would ensure that 
the biases that were experienced in this study would be minimised. However for this to 
be successful action will also have to be taken to improve capture of the data provided 
by the clinicians referring patients for further investigation. This would best be achieved 
by the development of a referral proforma. This could incorporate the important 
features of the referral guidelines that would act to encourage best practice by GPs. An 
example of a referral proforma is included in Appendix 15. The proforma also has the 
potential to improve the hospital triage service so as to ensure prompt and appropriate 
treatment of patients. 
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Future research 
Research skills of surgical nursing staff 
Before implementation of any training programme to improve research knowledge and 
skills it is necessary to ensure that the training package is tailored to need. A mapping 
study is required to identify the current level of research knowledge and skills of all 
health professionals. This enhanced training and knowledge would provide skills that 
could be utilised to participate in clinical audit. 
Family history of colorectal cancer 
Following the development and implementation of a family history training programme, 
research should be undertaken to evaluate its effectiveness. This would assess the degree 
to which health professionals record family history accurately and make referrals to the 
cancer genetic services appropriately, according to the family history guidelines. 
Further research could also be undertaken to understand how information on risk is 
devolved through families and a quantitative study on the number of relatives from an 
affected individuals attend a genetic counselling appointment and the uptake of 
screening. 
Research could be conducted by the four genetic centres in Scotland to assess the 
patient acceptability of referral to the cancer genetic services, at this stage of their cancer 
journey. This research would include collection of data on the number and quality of the 
referrals and source of referrals and would monitor the number of low risk referrals. 
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Future research should evaluate the acceptability of MSI testing at this stage of the 
colorectal cancer journey and should include an economic study to evaluate the 
economic impact of the introduction of MSI testing. 
Presentation with lower gastrointestinal symptoms 
The result from this study and from other published studies is that cancers with a more 
advanced Dukes' stage at diagnosis are associated with shorter median wait times for the 
majority of symptoms. This finding is counter -intuitive. This suggests that some 
tumours progress faster through the stages and are at a more advanced stage when 
symptoms are first obvious or even before symptoms present. It is also consistent with 
a proportion of patients with Dukes' stage D tumours having waited a particularly long 
time with their symptoms that might have been diagnosed with an earlier staged tumour 
if they had presented earlier. Further analysis of the study results showed that the 
waiting time at the 75th centile of Dukes' stage D tumours was significantly longer than 
any of the other Dukes' stages. Further investigation of this issue might reveal new 
knowledge about tumour aetiology and merits future investigation. 
Alternatively, the reporting of symptoms was inaccurate in the group. 
What this study adds to current literature 
This thesis adds the following to the current literature: 
o Health professionals do not routinely assess the family history risk of 
individuals diagnosed with colorectal cancer and an education programme 
would be necessary to provide the skills and knowledge necessary to carry 
out this task. 
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o Family history guidelines in Scotland require to be updated to reflect changes 
in clinical genetic services. They need to change to highlight to health 
professionals that these guidelines also apply to individuals with colorectal 
cancer with a high or moderate family history risk. 
o Waiting times with lower gastrointestinal symptoms before presenting to a 
GP are not specifically associated with comorbidity or deprivation. The 
waiting time with symptoms, presentation of symptoms and Dukes' staging 
are similar to other published studies and provides data on the Scottish 
colorectal cancer population. 
o The referral letter system practiced in Scotland could be improved by the use 
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This study compared the psychological impact of two models of breast cancer genetics services in South East Scotland. One hundred 
and seventy general practices were randomised to refer patients to the existing standard regional service or the novel community - 
based service. Participants completed postal questionnaires at baseline (n = 373), 4 weeks (n = 276) and 6 months (n = 263) to 
assess perceived risk of breast cancer, subjective and objective understanding of genetics and screening issues, general psychological 
distress, cancer worry and health behaviours. For participants in both arms of the trial, there were improvements in subjective and 
objective understanding up to 4 weeks which were generally sustained up to 6 months. However, improvements in subjective 
understanding for the women at low risk of breast cancer (i.e. not at significantly increased risk) in the standard service arm did not 
reach statistical significance. Cancer worry was significantly reduced at 6 months for participants in both arms of the trial. The two 
models of cancer genetics services tested were generally comparable in terms of the participants' psychological outcomes. Therefore, 
decisions regarding the implementation of the novel community -based service should be based on the resources required and client 
satisfaction with the service. 
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Media attention to scientific developments in cancer genetics has 
resulted in a greatly increased demand for cancer genetics services. 
These services aim to identify individuals who have inherited a 
significantly increased risk of cancer in order to counsel them 
about their risks and to offer appropriate risk management to 
reduce morbidity and mortality. There is a challenge to provide 
this information in ways that the lay public can utilise to inform 
their health-care choices without causing undue psychological 
distress. Individuals who are not at significantly increased risk also 
need appropriate reassurance without precluding an appropriate 
vigilance to symptoms of sporadic cancer. There is also a challenge 
to respond to these new developments within existing health-care 
budgets. Internationally, there is a lack of consensus about how 
best to deliver cancer genetic services (Steel et al, 1999) and an 
urgent need for empirical evidence to inform service development. 
A survey of 22 regional cancer genetics services in the UK in 
1998 reported that the predominant users of these services were 
women with a family history of breast cancer (Wonderling et al, 
2001). Of the women who are diagnosed with breast cancer, about 
10% report having a family history of the disease (Narod, 2002). Of 
these cases, only a small proportion will be due to inherited genetic 
mutations in one of the known susceptibility genes, BRCA1 and 
*Correspondence: Dr H Campbell; E -mail: Hany.Campbell @ed.ac.uk 
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BRCA2. These genetic mutations give rise to increased lifetime 
risks of developing the disease, often at an earlier age than is the 
norm for sporadically occurring cases. 
Brain et al (2000) showed that there was no difference in the 
effectiveness of multidisciplinary cancer genetics teams and breast 
surgeons in terms of psychological outcomes in the management 
of familial breast cancer in Wales. Secondary analysis of the data 
(Brain et al, 2002) showed some significant differences in 
psychological outcomes between groups of women at different 
levels of breast cancer risk. Only those women at low or moderate 
risk showed significant reductions in cancer worry and perceived 
risk of breast cancer. Satisfaction with genetic counselling was 
significantly lower in those women found to be at high risk of 
breast cancer. 
In South East Scotland, a multidisciplinary clinic offering 
specialist cancer genetic risk counselling and screening to women 
with a family history of breast cancer has been held in the regional 
breast screening centre in Edinburgh since 1992. With growing 
waiting lists for the South East of Scotland familial breast cancer 
clinic, more stringent referral criteria were applied. GPs referring 
women judged to be at low risk were sent a letter explaining that 
no appointment could be offered when the criteria were not met. 
Referrals of women at relatively low risk were still accepted where 
the woman's presentation remained a particular cause of concern 
(e.g. high level of anxiety about breast cancer risk which was 
difficult for the GP to manage). 
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An alternative model of cancer genetics services has been 
proposed (Campbell et al, 1995) whereby genetics nurse specialists 
could offer clinics within GP locality areas to carry out risk 
assessment, provide counselling for those whose risk was not 
significantly increased and mediate referral of those at higher risk 
to the specialist service. It was hoped this would provide improved 
support to primary care and better services for those at lower risk 
while encouraging more cost -effective use of specialist resources 
for those at increased risk of developing breast cancer. 
We carried out a cluster randomised trial of this new model of 
service delivery comparing it to the existing multidisciplinary 
specialist service. This paper presents a comparison of the 
psychological outcomes of these two service models and across 
participant's level of breast cancer risk. 
MATERIALS AND METHODS 
Participants 
Ethical approval for the study was obtained from the local ethics 
committee. An invitation to take part in the trial was sent to all 
general practices in Lothian (n = 125), South West Fife (n = 54) 
and Borders (n = 24) Health Boards in South East Scotland. One 
hundred and seventy practices (84 %) agreed to take part, 23 (11 %) 
declined and 10 (5 %) did not reply. This meant that 725 of the 828 
(88 %) GPs in practice across these three Health Boards agreed to 
refer patients into the trial. Practices were randomly assigned to 
either arm of the trial using a minimisation technique (Pocock, 
1983, pp 84 -86) to ensure that the two groups were balanced for 
size of practice, historical referral rate and social deprivation 
index. 
During the period March 1998 to November 1999, any woman 
referred from participating GP practices to the regional clinical 
genetics department for breast cancer genetic risk counselling was 
invited to take part in the trial. To be eligible for the trial, women 
had to live in the region, be able to give informed consent and had 
to complete a baseline questionnaire. Women who were sympto- 
matic or had been diagnosed with breast and /or ovarian cancer 
were excluded from the trial as were those who had previously 
consulted another clinic about their family history of cancer. 
Those who were ineligible to participate were offered the standard 
regional service. 
Procedure 
Potential participants were sent an information sheet and were 
invited to return the consent form to indicate whether they were 
willing to participate in the trial. Those who consented were then 
asked to complete a baseline questionnaire. Reminders were sent 
to all nonresponders after approximately 4 weeks. Only those who 
completed the baseline questionnaire were enrolled in the trial. 
Nonresponders and those who did not consent to participate in the 
trial were offered the standard regional service. The service offered 
to women who returned a completed baseline questionnaire was 
dependent on the arm of the trial to which their GP practice had 
been randomised. 
Standard (regional) service Women were sent a family history 
form and a baseline questionnaire to complete. The family history 
form requested information about first -, second - and third- degree 
relatives. If the family history form was not returned, a letter was 
sent to the woman and to her GP to explain that no consultation 
was possible without this information. A genetics consultant (MS) 
and genetics nurse specialist (JC) assigned categorical risk 
assessments informed by published criteria (Table 1) using the 
information on the completed family history form. If necessary, 
further information and /or confirmation of relatives' diagnoses 
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Table I Criteria for assessing a significantly increased risk of breast 
cancer (Cancer Research Campaign, I 997) 
A woman's risk of developing breast cancer is moderately increased if she has one 
of the following 
A first -degree relative with breast cancer diagnosed under 40 years. 
Two first- or second -degree relatives on the same side of the family with 
breast cancer diagnosed under 60 years or with ovarian cancer. 
Three first- or second -degree relatives on the same side of the family with 
breast or ovarian cancer. 
A first- degree relative with breast cancer in both breasts. 
A first- degree male relative with breast cancer. 
were obtained by a genealogist and from the Scottish Cancer 
Registry. When a woman was assessed as being at `low risk' (i.e. 
not at significantly increased risk), she and her GP were sent a 
letter to explain this. Women assessed as being at `moderate' or 
`high risk', or where an adequate risk assessment could not be 
made from the information available, an appointment at the 
familial breast cancer clinic were offered. The clinic consultation 
offered more detailed discussion with a genetics consultant about 
risk status and with a specialist breast surgeon about options for 
risk management (i.e. breast cancer screening and, for `high -risk' 
women, prophylactic mastectomy or chemoprevention). Clinical 
breast examination and mammography (where appropriate) were 
carried out at this visit. After this appointment, the patient's GP 
was sent a letter to summarise the issues discussed. All women 
were asked to complete a postal follow -up questionnaire 4 weeks 
and 6 months later. 
Novel (community- based) service All women in this arm of the 
trial were sent an initial appointment for one of the community - 
based clinics (held in a GP practice near to where they lived), run 
by a genetics nurse specialist (RC /RT). At the clinic, the genetics 
nurse specialist ascertained the woman's family history of cancer 
and compiled a family tree. This information was compared to 
published criteria (Table 1) to determine whether she was at 
significantly increased risk. When an adequate risk assessment 
could not be made during the appointment, further information 
and /or confirmation of relatives' diagnoses were obtained from the 
patient or medical records, before the patient was informed of 
their risk by letter. Women deemed not to be at significantly 
increased risk (i.e. in the low -risk' category) were offered 
information and reassurance and were discharged from the clinic. 
These patients and their GPs were sent a letter reaffirming their 
low -risk' status and summarising the issues discussed at the 
appointment. Women found to be at increased risk (i.e. in the 
`moderate -risk' or `high -risk' categories) were offered an appoint- 
ment at the regional centre with a geneticist and genetics nurse 
specialist. All women were asked to complete a postal follow -up 
questionnaire 4 weeks and 6 months later. 
Sociodemographic and objective breast cancer risk data 
Women were asked to record their date of birth, marital status and 
educational level on the baseline questionnaire. Information about 
the category of breast cancer risk to which each woman had been 
assigned was derived from the clinical records. 
Psychological measures 
Subjective understanding Women were asked to rate on a 4 -point 
scale from 1 (not at all) to 4 (very much) how well they understood 
each of four issues relevant to breast cancer genetic risk. The issues 
were: 
1. How increased risk of breast cancer is passed on in families. 
2. The significance of their own family history of cancer. 
© 2003 Cancer Research UK 
3. Whether there was anything they could do to reduce their risk 
of developing breast cancer. 
4. What services were available to protect the health of people at 
increased risk of breast cancer. 
Responses were summed to give a composite score for subjective 
understanding ranging from 4 to 16. 
Objective understanding Participants were asked to consider a 
number of factual statements and to respond `true', `false' or `don't 
know'. There were 10 statements about breast cancer genetics (e.g. 
`Only a parent who has had breast cancer can pass on increased 
risk to their children') and 12 statements about issues surrounding 
mammography (e.g. `Mammograms are used to detect early stages 
of breast cancer'). Statements were scored 1 (correct) or 0 
(incorrect /don't know), and the number of correct responses 
combined to give total scores for genetics understanding (range 0 - 
10) and mammography understanding (range 0 -12). 
Perceived risk of breast cancer Although a number of items were 
used to assess perceived risk of breast cancer, the results of one 
item were analysed for the purposes of this report. Participants 
were asked to indicate whether they considered their own level of 
risk to be high, moderate or low. 
Psychological distress 
(i) General Health Questionnaire 30 -item version (GHQ -30) 
(Goldberg and Williams, 1988). This well- validated scale was 
scored using the GHQ method (0, 0, 1, 1) using a threshold of 
6 to screen for `case -level' general psychological distress. 
(ii) Cancer Worry Scale (Watson et al, 1998). This six -item scale 
(adapted from four single items, Lerman et al, 1991a, b) 
assesses concerns about developing cancer and their impact 
on daily functioning. Total scores range from 6 to 24 where a 
higher score indicates higher levels of worry. The psycho- 
metric properties of the scale have been shown to be 
satisfactory (Brain et al, 1999; Hopwood et al, 2001). 
Health behaviours Several ad -hoc items indicated the extent to 
which genetic counselling may have influenced the women's health 
behaviour. Participants at 4 weeks were asked retrospectively 
about their health behaviours prior to counselling (i.e. the 
frequency of breast self -examination, smoking, drinking alcohol, 
trying to lose weight, eating bran and high -fibre foods, avoiding 
fatty foods, eating a balanced diet, taking exercise, looking after 
their health in general). They were asked to rate whether the 
frequency of any of these behaviours had changed since consulting 
genetics services (at 4 weeks) or in the last 6 months (at 6 months) 
on a scale from 1 (much less than before) to 5 (much more than 
before). 
Statistical methods 
Descriptive statistics were generated to describe the study 
participants. Differences between two independent groups were 
analysed with independent samples t -tests (two -tailed), Mann - 
Whitney, , x (two -tailed) or Fisher's exact tests (two -tailed). A 2 
(trial arm) x 2 (objective risk) repeated measures analysis of 
variance (ANOVA) was used to determine between -group 
differences and within -group changes over time (baseline, 4 
weeks, 6 months) in psychological outcomes and possible 
interactions between trial arm, objective risk and time. Significant 
effects were followed up with post -hoc tests (independent samples 
t- tests, paired t- tests, ANOVA). xz (two -tailed), Fisher's exact (two - 
tailed), Cochran's and McNemar tests were used to examine the 
impact of time, trial arm and objective risk on perceived risk and 
the proportion of participants suffering from `case -level' distress. 
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A significance level of 0.05 was used throughout. The data were 
analysed using SPSS for Windows version 10.00 (1999). 
RESULTS 
Participants 
Figure 1 shows the progress of participants through each arm of 
the trial. 
Baseline Over the study period, 574 women, referred for breast 
cancer genetic risk counselling, were invited to participate in the 
trial. Consent forms were returned by 451 women (response rate 
79 %), of whom 428 (75% of those invited) agreed to participate in 
the study. Three hundred and seventy -three of these women (87% 
of those who consented) returned a completed baseline ques- 
tionnaire, 185 of whom were then assigned to the standard service 
arm and 188 to the novel service arm of the trial according to their 
GP practice. 
4 weeks Of the 373 women who completed a baseline ques- 
tionnaire, 276 also completed a 4 week follow -up questionnaire 
(74% of those who were enrolled in the trial), 147 from the 
Invited to participate (n = 574) 
Excluded (n = 201) - refused to participate (n = 23) 
- not responded (n = 123) 
- not returned baseline 
questionnaire (n = 31) 
- administrative reasons (n = 11) 
- protocol violation (n = 13)5 
Consented, comp eted baseline 
questionnaire and randomised 
according to GP practice 
(n= 373) 
Standard service arm (n= 185) 
4 week follow -up (n = 147) 
Excluded (n = 38): 
- lost to follow-up (n = 6) 
- not returned questionnaire 
(n = 15) - withdrew (n = 2) 
- clinical reasons (n = 4)b 
- administrative reasons (n =11) 
6 month follow -up (n = 140)d 
Excluded (n =16): 
- not returned questionnaire 
(n= 14) 
- returned questionnaire blank 
n =1 
-administrative reasons (n = 1) 
Completed trial (n = 131) 
Novel service arm (n = 1 88) 
4 week follow -up (n = 129) 
Excluded(n = 59): 
- lost to follow -up (n = 13) - not returned questionnaire 
(n= 22) 
- withdrew (n = 5) 
- clinical reasons (n = 5)b 
- administrative reasons (n =14) 
6 month follow -up (n = 123)d 
Excluded (n= 16): 
- not returned questionnaire 
(n= 14) 
- withdrew (n = 1) 
- administrative reasons (n = 1) 
Completed trial (n = 113) 
Figure I Progress of participants through the trial. 
For example, the women had received genetic counselling elsewhere or 
had been treated for cancer. 
b For example investigation of breast symptoms. 
` Includes nine women who were excluded at the 4 week assessment due 
to administrative reasons (n = 5) or nonretum of the questionnaire (n = 4). 
d Includes I O women who were excluded at the 4 week assessment due to 
administrative reasons (n = 4) or nonretum of the questionnaire (n = 6). 
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standard service arm and 129 from the novel service arm of the 
trial. 
The characteristics of those for whom only baseline data were 
available (`baseline only group'; n = 97) were compared with those 
of the `4 week group' (n = 276) to check for participation bias. A 
significantly greater number of the `baseline only group' had been 
assigned to the novel service arm than the standard service arm of 
the trial (61 vs 39 %; x2 = 5.70, df = 1, P = 0.018). A higher 
proportion of women in the `baseline only group' were categorised 
as being at low risk (54 vs 32 %; x2= 14.01, df = 1, P <0.000). 
Similarly, a greater proportion of women in this group were 
suffering from `case -level' distress at baseline (43 vs 31 %; x2 = 4.53, 
df = 1, P = 0.043). The `baseline only group' had significantly 
higher scores at baseline on the Cancer Worry Scale 
(mean = 12.18/11.10; s.d. = 3.29/2.98; t = 2.97, df = 367, 
P = 0.003). There were no significant differences between the two 
groups on any of the other sociodemographic or psychological 
variables at baseline. 
6 months Two hundred and sixty -three women completed 6 
month follow -up questionnaires (71% of those who were enrolled 
in the trial), 140 women from the standard service arm and 123 
from the novel service arm of the trial. This includes 19 women 
who were excluded at the 4 week assessment due to administrative 
reasons (n = 9) or nonreturn of the questionnaire (n = 10). The 
baseline characteristics of those for whom the 6 month ques- 
tionnaires were analysed (`6 month group'; n=263) were 
compared with those participants who completed the 4 week 
questionnaire but not the 6 month questionnaire (Not 6 month 
group'; n = 32) to check for participation bias. There were no 
significant differences between the number of women who 
dropped out from either arm of the trial. A greater proportion of 
women in the `Not 6 month' group were classified as being at low 
risk of breast cancer (53 vs 31 %; x2 = 6.41, df = 1, P = 0.016). This 
group scored significantly lower on objective understanding of 
mammography (t = -2.37, df = 270, P = 0.018) and had a tendency 
to have higher scores on the Cancer Worry Scale (t= 1.83, 
df= 290, P = 0.068). There were no significant differences between 
the two groups on any of the other sociodemographic or 
psychological variables (marital status and perceived risk could 
not be analysed due to small numbers in some categories). 
Comparison of trial arms on sociodemographic and 
objective breast cancer risk characteristics 
The sociodemographic characteristics of participants and the 
breast cancer risk category to which they were assigned are shown 
in Table 2. A greater proportion of women at low risk of breast 
cancer were in the novel service arm than the standard service arm 
of the trial at baseline (x2= 11.86, df = 1, P = 0.001), 4 weeks 
(x2 = 10.26, df = 1, P = 0.002) and 6 months (x2= 10.52, df =1, 
P = 0.001). Women with 4 week follow -up data in the novel service 
arm were somewhat older than those in the standard service 
arm (t= -2.51, df = 274, P = 0.013). There were no significant 
differences between the trial arms on any of the other socio- 
demographic variables at the three assessment points. 
Table 2 Sociodemographic, objective breast cancer risk and psychological characteristics of the two trial groups at baseline, 4 weeks and 6 months' 
Baseline (n = 373) 4 weeks (n = 276) 6 months (n = 263) 
Standard service Novel service Standard service Novel service Standard service Novel service 
Variable (n = 185) (n = 188) (n = 147) (n = 129) (n = 140) (n = 123) 
Age (years): mean (s.d.) 37.3 (9.4) 39.1 (9.6) 36.8 (9.4) 39.7 (9.4)* 37.4 (9.5) 39.5 (9) 
Marital status: n ( %) 
Married /cohabiting 130 (7 I) 136 (73) 104 (72) 100 (79) 98 (71) 93 (77) 
Separated /divorced /widowed 24 (13) 24 (I 3) 18 (I 3) 14 (I I) 20 (I 4) 16 (13) 
Never married 28 (15) 26 (14) 22 (15) 13 (I 0) 21 (15) 12 (I 0) 
Education: n ( %) 
To age 16 years 65 (36) 68 (37) 49 (34) 44 (34) 46 (33) 42 (34) 
To age 18 years 30 (17) 28 (15) 23 (16) 19 (15) 23 (17) 15 (12) 
After age 18 years 46 (26) 50 (27) 35 (24) 37 (29) 35 (25) 37 (30) 
University graduate 39 (22) 40 (22) 36 (25) 28 (22) 34 (25) 28 (23) 
Risk of breast cancer. n ( %) 
Objective: 
Low 50 (28)b 8 I (46)* 34 (23) 53 (41)* 3 I (22) 50 (41)* 
Moderate /high 129 (72) 97 (55) 113 (77) 76 (59) 109 (78) 73 (59) 
Perceived: 
Low 5 (3) 7 (4) 12 (8) 10 (8) I I (8) I I (9) 
Moderate /high 179 (97) 180 (96) 134 (92) 117 (92) 127 (92) 108 (9 I ) 
Understanding mean (s.d.) 
Subjective` 9.4 (2.8) 8.9 (2.5) 12 (2.2) 11.7 (2.3) 11.9 (2.2) 11.7 (2.3) 
Objective: 
geneticsd 3.9 (2.5) 3.9 (2.2) 6.3 (2.3) 6 (2.2) 6.3 (2.2) 6 (2.1) 
mammographye 7.3 (I.9) 7.0 (I.8) 8 (I.8) 7.8 (I.7) 7.9 (I.8) 7.9 (I.7) 
GHQ -30: 
Total score: median (IQR) 2 (9) 2 (7.3) I (8) 2 (8.5) 0 (4) 0 (5) 
'Case -level' distress: n ( %)f 66 (36) 58 (31) 32 (21) 27 (22) 29 (21) 28 (23) 
Cancer worry. mean (s.d.) I I.5 (3.2) I I.3 (3.0) 10.3 (2.4) 10.2 (2.7) 9.9 (2.5) 9.7 (2.7) 
'Sample size varies due to missing data. bThe majority of women who were assigned a low breast cancer risk in the standard service arm were informed by letter only. `Possible 
range of scores: 4- 16. dPossible range of scores: 0 -10. ePossible range of scores: 0- 12. 'Scores of ? 6. *P <0.05. 
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Comparison of trial arms on psychological characteristics 
and changes over time (by trial arm and objective breast 
cancer risk) 
Table 2 shows the psychological characteristics of the women in 
the two trial arms at baseline, 4 weeks and 6 months. There were 
no significant differences between the two trial arms on any of 
these variables at the three assessment points. Table 3 presents the 
results of repeated measures ANOVA for the 244 participants (65% 
of those who were enrolled in the trial) who completed the 
baseline, 4 week and 6 month questionnaires. 
Subjective understanding Overall, there was a significant im- 
provement in subjective understanding during the course of the 
study. Further analysis showed that subjective understanding only 
improved to a significant degree between baseline and 4 weeks 
(t=- 14.97, df =231, P <0.000). Scores on subjective under- 
standing were shown to be dependent on objective breast cancer 
risk. Post -hoc analysis revealed that women at moderate/high risk 
had significantly greater scores on subjective understanding than 
those at low risk at 4 weeks (t= -2.69, df = 235, P = 0.008) and 6 
months (t= -2.46, df = 109.214, P= 0.015). The main effects of 
time and objective risk were modified by a significant interaction 
between these two factors. Subjective understanding had signifi- 
cantly improved for both women at moderate/high risk 
(t= -13.70, df =164, P <0.000) and women at low risk 
(t= -6.55, df = 66, P< 0.000) between baseline and 4 weeks. 
However, the improvement was significantly greater in women at 
moderate/high risk than those at low risk (t= -2.51, df =230, 
19= 0.013). In addition, there was a significant interaction between 
trial arm, time and objective risk. Post -hoc analysis indicated that 
differences in subjective understanding between the risk groups 
within the different trial arms were significant only between 
baseline and 4 weeks (F(1, 226) = 5.27, P = 0.023). Between these 
two time points, the moderate/high -risk women in the standard 
service arm (t= -11.64, df= 98, P< 0.000) and low risk (t = -7.32, 
df =41, P <0.000) and moderate/high -risk women (t= -7.58, 
df= 65, P <0.000) in the novel service arm had made significant 
improvements in subjective understanding. There were no 
significant differences in the extent to which subjective under- 
standing had improved between these groups. Although for 
women at low risk in the standard service arm there was an 
improvement in subjective understanding between baseline and 4 
weeks, this did not reach statistical significance. 
Objective understanding There was a significant improvement in 
objective understanding of genetics and mammography across all 
participants during the study period. Post -hoc tests showed that 
scores on these two measures had significantly improved between 
baseline and 4 weeks only (genetics: t = - 14.37, df = 232, P < 0.000; 
mammography: t= -5.56, df = 214, P< 0.000). 
Cancer worry For all participants, there was a significant 
reduction in scores on the Cancer Worry Scale during the course 
of the study. Post -hoc analysis revealed that the greatest reduction 
in scores occurred between baseline and 4 weeks (t = 5.86, 
df= 239, P< 0.000) with a smaller, but nevertheless significant 
reduction between 4 weeks and 6 months (t 3.05, df = 238, 
P=0.003). 
General psychological distress Although there was a significant 
decrease in the overall proportion of participants suffering from 
`case - level' distress over the study period (Cochran's Q = 11.44, 
df= 2, P = 0.003), further investigations showed that the reduction 
was only significant between baseline and 4 weeks (McNemar 
)(2= 8.27, P= 0.004). There were no significant differences in the 
proportion of women suffering from `case -level' distress between 
trial arms or risk groups at the three assessment points. 
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Perceived risk of breast cancer There were significant changes in 
perceived risk of breast cancer across all subjects over the 
study period ( Cochran's Q = 10.5, df = 2, P=0.005). Further 
analysis showed that these changes were only significant between 
baseline and 4 weeks where significantly less women perceived 
their risk as low at 4 weeks (P = 0.011). There were no significant 
differences in perceived risk by trial arm at the three assessment 
points. However, a significantly greater proportion of women at 
low objective risk of breast cancer than those at moderate /high 
objective risk perceived their risk to be low at 4 weeks (z2 = 19.94, 
df =1, P <0.000) and 6 months (X2 - 12.24, df =1, P = 0.002). 
Comparison of trial arms on health behaviours 
At 4 weeks, proportionately more women in the standard service 
arm reported examining their breasts every month as recom- 
mended (32 vs 23%) and proportionately more women in the novel 
service arm reported examining their breasts more frequently than 
once per month (11 vs 4 %; x2 = 9.86, df = 4, P= 0.043). There were 
no significant differences between the two trial arms in the extent 
to which participants reported performing health behaviours prior 
to genetic counselling or reported a change in these behaviours 
after counselling. At 6 months, there were no significant 
differences between the two groups in the proportion of women 
who reported changing any of their health behaviours in the last 6 
months. 
DISCUSSION 
The present study responded to an urgent need for empirical 
evidence to inform the development of cancer genetics services in 
South East Scotland. A novel community -based service to provide 
genetic risk counselling for women with a family history of breast 
cancer was compared to the existing standard regional service. 
The initial response rate to invitations to participate was good 
with 75% of the women invited agreeing to take part in the trial. 
The participation rates at each assessment point were satisfactory 
(baseline: 87 %; 4 weeks: 74%; 6 months: 71%) with 65% of those 
enrolled in the trial completing all three questionnaires. The 
amount of data lost due to administrative reasons was comparable 
across the trial arms. 
Women who dropped out of the study tended to be in the novel 
service arm of the trial or at low risk of breast cancer. The latter 
finding is not unexpected since these women may have been less 
motivated to continuing participating in a study of cancer genetics 
services which they were ineligible to receive. However, the women 
who dropped out of the study had greater levels of psychological 
distress. As these women may have dropped out in an effort to 
reduce their high levels of distress, they could perhaps benefit from 
further psychological intervention. Similar findings have been 
demonstrated by a previous trial of cancer genetics services (i.e. 
Brain et al, 2000). Given these potential participation biases, the 
results should be interpreted with caution in regard to their 
generalisability to a wider population. 
The cluster randomisation strategy resulted in comparable trial 
arms at baseline in terms of sociodemographic and psychological 
characteristics. However, a greater proportion of women in the 
novel service arm were assigned a low risk of breast cancer. 
Further investigation is warranted to determine if this finding is 
due to chance or differences between the trial arms in terms of the 
method of risk assignment or the accuracy of family history details 
reported by participants. 
At baseline, subjectively rated understanding of issues related to 
breast cancer genetic risk was relatively low (mean scores = 9.4 for 
the standard service arm /8.9 for the novel service arm out of a 
possible 16) and this was reflected in the objective assessment of 
understanding. On average, correct responses were given to about 
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Table 3 Repeated measures ANOVA for trial arm x time x objective breast cancer risk on psychological 
characteristics 
Variable Effect F df P 
Subjective understanding Trial arm 0.244 0.622 
Time 107.82 .675 0.000 ** 
Trial arm x time 2.092 .675 0.133 
Risk 3.915 0.049* 
Trial arm x risk 0.032 0.859 
Time x risk 6.705 .675 0.003* 
Trial arm x time x risk 3.234 .675 0.049* 
Objective understanding Genetics Trial arm 0.459 0.499 
Time 105.741 .789 0.000** 
Trial arm x time 0.474 .789 0.60 I 
Risk 3.31 0.07 
Trial arm x risk 0.708 0.401 
Time x risk 0.923 .789 0.389 
Trial arm x time x risk 2.573 .789 0.084 
Objective understanding. Mammography Trial arm 0.909 0.34 I 
Time 17.713 .9 0.000** 
Trial arm x time 2.051 .9 0.133 
Risk 0.857 0.356 
Trial arm x risk 0.068 0.794 
Time x risk 0.894 .9 0.405 
Trial arm x time x risk 1.681 .9 0.189 
Cancer worry Trial arm 0.117 0.733 
Time 36.9 .62 0.000 ** 
Trial arm x time 0.535 .62 0.549 
Risk 0.525 0.47 
Trial arm x risk 0.001 0.97 
Time x risk 0.127 .62 0.838 
Trial arm x time x risk 2.675 .62 0.082 
*P <0.05. * *P <0.001. 
one -third of the breast cancer genetics items and to about two - 
thirds of the mammography items. About one -third of participants 
were suffering from `case -level' distress. This is comparable to the 
findings in other samples of women prior to genetic risk 
counselling using the same measure and threshold (Cull et al, 
1999, 2001) and to published data from the general population 
(Goldberg and Williams, 1988). Mean scores on the Cancer Worry 
Scale were similar to those reported in women prior to genetic risk 
counselling by Watson et al (1998) and Brain et al (2000) and 
slightly lower than those reported by Hopwood et al (2001) and 
Bish et al (2002). 
The findings show that after consulting cancer genetics services, 
many of the short-term improvements in psychological outcomes 
experienced across participants were maintained up to 6 months. All 
participants reported greater subjective understanding of issues 
related to breast cancer risk and these improvements were most 
marked up to 4 weeks and were generally sustained up to 6 months. 
However, for the women at low risk of breast cancer in the standard 
service arm of the trial, unlike all other participant groups, these 
improvements did not reach statistical significance. This may be due 
to the fact that the majority of these women received a letter informing 
them about their low risk and were not offered a face -to -face 
consultation. Improvements in subjective understanding across 
participants were reflected by improvements in objective under- 
standing which were again most evident between baseline and 4 weeks 
and were commonly maintained at a similar level up to 6 months. 
Although participants at low risk of breast cancer in the standard 
service arm did not feel that their subjective understanding had 
improved as much as the other participants, there were no differences 
between trial arms or risk groups in significant improvements on 
objectively assessed understanding. 
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It was reassuring to find that despite improvements in objective 
knowledge, the proportion of women suffering from `case - level' 
distress decreased up to 4 weeks and cancer worry continued to 
decrease up to 6 months. Unlike previous research that found 
significant reductions in cancer worry only for those women at low 
or moderate risk of breast cancer (i.e. Brain et al, 2002), reductions 
in cancer worry in the present study were not dependent on 
objective risk. 
Women's perceptions of their risk of breast cancer were altered 
during the course of the study with significantly fewer women 
overall perceiving their risk as low at 4 weeks, than at baseline. 
More women who were informed about a low risk of breast cancer 
perceived their risk of breast cancer as low following their risk 
assessment, as may be expected. Similar findings have been 
reported elsewhere (Bish et al, 2002). This suggests that the 
accuracy of perceived risk for the low -risk group improved during 
the course of the study. However, given the fact that responses to 
only one of the ad -hoc items were analysed for the purposes of this 
report and the accuracy of participants' risk perceptions was not 
assessed in this study, it is difficult to make any firm conclusions 
from these results. However, there is no evidence to suggest that 
learning that your risk of developing breast cancer is greater than 
you believed prior to genetic risk counselling causes psychological 
distress (Cull et al, 1999; Watson et al, 1999). 
This study has shown that the novel community -based model of 
breast cancer genetics services is generally comparable to the 
existing standard regional service in terms of the psychological 
outcomes experienced by recipients. Therefore, decisions regard- 
ing the implementation of the novel model of services should be 
based on additional factors such as the resources required and 
© 2003 Cancer Research UK 
client satisfaction with the service. These factors have been 
investigated and will be published separately. 
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There is a need to integrate primary- and secondary-care cancer genetic services, but the most appropriate model of service delivery 
remains unclear. This study reports patients' expectations of breast cancer genetic services and a comparison of their satisfaction with 
two service models. In the first model, risk assessment was carried out using mailed family history data. Women estimated as being at 
high /moderate risk were offered an appointment at the familial breast cancer clinic, and those at low risk were sent a letter of 
reassurance. In the second model, all women were seen by a genetic nurse specialist, who assessed risk, referred high /moderate -risk 
women to the above clinic and discharged those at low risk. Over 60% of all women in the study regarded access to breast screening 
by mammogram and regular check -ups as very important. This underlines the demand for a multidisciplinary service providing both 
clinical genetic and surgical services. Satisfaction was high with both models of service, although significantly lower among women not 
at increased cancer risk and thus not offered a clinical check -up and mammography. Increased cancer worry was associated with a 
greater expressed need for information and for reassurance through follow -up clinical checks and mammography. Better targeting of 
counselling to the expressed concerns and needs of these women is required to improve the service offered. GPs and patients 
expressed no clear preference for any specific service location or staffing configuration. The novel community service was less 
expensive in terms of both staff and patient costs. The potential to decrease health staff/patient contact time and to employ nurse 
practitioners with both clinical genetic and oncology training should be explored further. The rapidly rising demand for these services 
suggests that the evaluation of further new models needs to continue to be given priority to guide the development of cancer genetic 
services. 
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Media attention to scientific developments in cancer genetics and 
increased public awareness of the potential importance of a family 
history of cancer has resulted in a greatly increased demand for 
cancer genetic services. These services aim to identify individuals 
who have inherited a significantly increased risk of cancer in order 
to counsel them about their risks and to offer appropriate risk 
management to reduce morbidity and mortality. Genetic counsel- 
ling for patients with a family history of cancer has been shown to 
result in a more accurate perception of risk (Evans et al, 1994) 
without an increase in anxiety (Hopwood et al, 1998). A survey of 
22 regional cancer genetic services in the UK in 1998 reported that 
the predominant users of these services were women with a family 
history of breast cancer (Wonderling et al, 2001). Internationally, 
there is a lack of consensus about how best to deliver cancer 
genetic services (Steel et al, 1999), and an urgent need for 
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empirical evidence to inform service development within the 
existing healthcare budgets. 
A model of cancer genetic services has been proposed (Campbell 
et al, 1995, 2003; Fry et al, 2003), whereby genetic nurse specialists 
could offer clinics within GP locality areas to carry out 
risk assessment, provide counselling for those whose risk 
was not significantly increased and mediate referral of those at 
higher risk to the specialist service. It was hoped that this 
would provide improved support to primary care and better 
services for those not at increased risk, while encouraging 
more cost -effective use of specialist resources for those 
at increased risk of developing breast cancer. We have previously 
reported that the establishment of community-based clinics 
leads to substantially higher rates of annual referral, less evidence 
of inequity of access due to deprivation and improved referral 
practices (Campbell et al, 2003), but not to improved 
patient outcomes (Fry et al, 2003). In this study, we report 
women's expectations of cancer genetic services and the results of 
a trial assessing women's satisfaction with this new model of 
service. 
MATERIALS AND METHODS 
Participants 
Ethical approval for the study was obtained from the local ethics 
committee. An invitation to take part in the trial was sent to all 
general practices in Lothian (n = 125), south -west Fife (n = 54) and 
Borders (n = 24) Health Boards in south -east Scotland. In all, 179 
practices (84 %) agreed to take part, 23 (11 %) declined and 10 (5 %) 
did not reply. This meant that 725 of the 828 (88 %) GPs in practice 
across these three Health Boards agreed to refer patients into the 
trial. Practices were randomly assigned to either arm of the trial 
using a minimisation technique (Pocock, 1983, pp 84 - 86) to 
ensure that the two groups were balanced for: size of practice; 
historical referral rate; and social deprivation index. 
During the period March 1998 to November 1999, any woman 
referred from participating GP practices to the regional clinical 
genetics department for breast cancer genetic risk counselling was 
invited to take part in the trial. To be eligible for the trial, women 
had to live in the region, be able to give informed consent and to 
complete a baseline questionnaire. Women who were symptomatic 
or had been diagnosed with breast and /or ovarian cancer were 
excluded from the trial as were those who had previously consulted 
another clinic about their family history of cancer. Those who were 
ineligible to participate were offered the standard regional service. 
Procedures 
The service offered to women who returned a consent form and a 
completed baseline questionnaire was dependent on the arm of the 
trial to which their GP practice had been randomised. Details of 
the trial procedures have been described in detail (Campbell et al, 
2003; Fry et al, 2003), but briefly the trial groups were: 
Standard (regional) service Women were sent a family history 
form to complete. The family history form requested information 
about first -, second- and third -degree relatives. If the family 
history form was not returned, a letter was sent to the woman and 
to her GP to explain that no consultation was possible without this 
information. The genetic nurse specialist drew a pedigree from the 
information on the family history form, then assigned categorical 
risk assessments together with a genetics consultant using the 
criteria published by the Cancer Research Campaign (Cancer 
Research Campaign, 1997). If necessary, further information and/ 
or confirmation of relatives' diagnoses were obtained from the 
cancer registry. When a woman was assessed as not being at a 
significantly increased risk (i.e. `low' risk), she and her GP were 
sent a letter to explain this. An appointment at the familial breast 
cancer clinic was offered to women assessed as being at `moderate' 
or `high risk', and those for whom an adequate risk assessment 
could not be made from the information available. The clinic 
consultation offered more detailed discussion with a genetics 
consultant about risk status and with a specialist breast surgeon 
about options for risk management. Clinical breast examination 
and mammography (where appropriate) were carried out at this 
visit. After this appointment, the patient's GP was sent a letter to 
summarise the issues discussed. All women were asked to 
complete a postal follow -up questionnaire 4 weeks and 6 months 
later. 
Novel (community- based) service All women in this arm of the 
trial were sent an initial appointment for one of the community - 
based clinics (held in a GP practice near to where they lived), run 
by a genetic nurse specialist. At the clinic, the genetic nurse 
specialist ascertained the woman's family history of cancer and 
compiled a family tree. This information was compared to the 
criteria published by the Cancer Research Campaign (Cancer 
Research Campaign, 1997) to determine whether she was at a 
significantly increased risk. When an adequate risk assessment 
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could not be made during the appointment, further information 
and /or confirmation of relatives' diagnoses were obtained from the 
patient, medical records or the cancer registry before the patient 
was informed of their risk by letter. Women deemed not to be at a 
significantly increased risk (i.e. in the low -risk' category) were 
offered information and reassurance and were discharged from the 
clinic. These women and their GPs were sent a letter reaffirming 
their low -risk' status and summarising the issues discussed at the 
appointment. The women were asked to complete a postal 
questionnaire 4 weeks and 6 months later. Women found to be 
at increased risk (i.e. in the `moderate -risk' or `high -risk' 
categories) were offered an appointment at the regional centre 
with a consultant breast surgeon and a genetic nurse specialist. 
Prior to this consultation, they were sent a questionnaire asking for 
their opinions of the community clinic appointment and what 
further information or services they wished from the regional 
clinic. They were asked to complete a postal follow -up ques- 
tionnaire 4 weeks and 6 months after their clinic appointments. 
Sociodemographic and objective breast cancer risk data 
Women were asked to record their date of birth, marital status and 
educational level on the baseline questionnaire. Information was 
also requested on mode of referral, knowledge of breast cancer and 
its inheritance, psychological status and details of what services 
and information was sought from the consultation. Information 
about the category of breast cancer risk to which each woman had 
been assigned was derived from the clinical records. 
Data relating to the consultation 
Clinic data The details of all clinic consultations were recorded. 
These included duration of consultation, level of risk stated, 
matters discussed, time spent in various clinic activities and 
outcome of the consultation. Matters discussed at the consultation 
were classified under five headings (family history and genetics; 
examination and screening; healthy lifestyles; other matters related 
to breast cancer and other matters unrelated to breast cancer). 
Satisfaction with services received At the 4 -week and 6 -month 
follow -up, satisfaction with the consultations was measured in 
several ways. To assess general satisfaction, women were asked to 
assess a number of items from the Medical Interview Satisfaction 
Scale (MISS) (Wolf et al, 1978; used with permission from the 
author). We used 17 of the 26 original questions in the three 
subscales. The psychometric properties of this scale have been 
investigated in surveys in general practice with a conclusion that 
the MISS represents `a valid and reliable instrument for the 
assessment of patient satisfaction with individual consultations in 
British general practice' (Meakin and Weinmann, 2002). Satisfac- 
tion with three aspects of a consultation were measured: 
The affective aspect (A): The extent to which the respondent 
feels the medical professional (MP) listens, understands and is 
interested. 
The behavioural aspect (B): The respondent's evaluation of the 
MP's competence in the consultation. 
The cognitive aspect (C): Satisfaction with the amount and 
quality of information provided by the MP. 
Each item on the scale was rated on a five -point scale of 
agreement from strongly agree (5) to strongly disagree (1). The 
summed scores were divided by the number of items answered by 
the subject to give mean scores for each aspect of the consultation 
and an overall mean score. An evaluation of the subscales within 
UK general practice has shown that they represent fairly discrete 
but overlapping aspects of satisfaction (Meakin and Weinmann, 
2002). 
392 British Journal of Cancer (2004) 90(3), 582 -589 
583 
Patient satisfaction with cancer genetic services 
S Holloway et al 
584 
I 
We also investigated patients' assessment of the helpfulness of 
the specific information given and services offered at the 
consultation. We asked what additional information /services 
women would have wished to receive and what further action 
they had taken since their attendance at the clinic. We also asked 
about their preferences with respect to the clinic location and 
staffing. 
Other measures Psychological distress and cancer worry were 
measured at baseline by the General Health Questionnaire (GHQ 
30) (Goldberg and Williams, 1988) and the Cancer Worry Scale 
(Watson et al, 1998) as described by Fry et al (2003). 
Relative cost of operating novel and standard service clinics 
(a) Estimate of staff costs: 
We estimated staff time taken for various aspects of the 
consultation (such as pedigree drawing, risk assessment and 
counselling) and travel time to clinics by asking the staff to 
complete a standard form recording these details. We also 
recorded details of women's attendance and nonattendance at 
clinics. Relative costs were based on a medical salary being two 
times that of a clinical genetic nurse specialist (consultant or 
associate specialist annual salary of £50 000 and clinical genetic 
nurse specialist salary of £25 ,000). The estimates also assumed 
that secretarial and administrative staff costs for the novel and 
standard service models were approximately equal, with the 
support for additional clinics in the novel service being offset by 
that for obtaining family history forms from all patients and the 
higher nonattendance rate in the standard service. A further 
assumption was that the efficiency of staff use within the clinics 
could be made approximately equal in the two service models by 
appropriate management of clinic sizes and appointments. 
(b) Estimate of patient time and financial costs: 
Patients were asked to complete a short questionnaire after 
clinic appointments asking them to give details of how they 
reached the clinic, their travel time and costs, details of any other 
costs (such as child care) and any loss of earnings and details of 
normal activities interrupted by the appointment. 
RESULTS 
Participants 
Figure 1 shows the progress of participants through each arm of 
the trial with respect to the completion of questionnaires described 
in this report. 
Baseline Over the study period, 374 women consented to take 
part in the trial and completed a baseline questionnaire. The age of 
the women ranged from 17.5 - 69.6 years with a mean ( ± s.d.) of 
38.5 ±9.5 years. The characteristics of these women are described 
in a related publication (Fry et al, 2003). There were no differences 
in age, sociodemographic or educational factors between the two 
trial groups (Fry et al, 2003). 
Follow -up The completion rates for the follow -up questionnaires 
are presented in Figure 1. A total of 274 (73 %) completed 4 -week 
and 265 (71 %) women completed 6 -month follow -up question- 
naires. There were no significant differences between the ques- 
tionnaire completion rates in the two arms of the trial. 
Clinic consultations 
Information was recorded on 379 clinic consultations. The genetics 
of breast cancer, the significance of the family history and the 
patient's own risk were discussed in almost all first consultations. 
In a large proportion (45 -86 %) of these consultations, there was 
British Journal of Cancer (2004) 90(3), 582 -589 393 
also discussion of risks to children and other relatives and the 
possibility of finding a cancer predisposing gene. Mammography 
was discussed in almost all consultations. Screening for other 
cancers was much more likely to be discussed by the doctors 
seeing women who received the standard (regional) service. Breast 
self -examination and adoption of healthy lifestyles were more 
likely to be discussed by the nurse at the community clinic (novel 
service). 
The length of time in minutes spent on each part of the 
consultation was not normally distributed in any of the consulta- 
tion groups. The median total consultation time was 41 min for the 
community clinic appointment and 12 min for the regional follow - 
up appointment as part of the novel service; and 18 min for the 
regional appointment of the standard service. Women receiving 
the novel service spent more time at their initial community clinic 
appointment discussing each of the five areas of consultation (see 
above) than those receiving the standard service (P <0.01 to 0.001, 
Mann - Whitney test). Some of the increased time taken by the 
novel service was due to the fact that details of the family history 
had to be obtained at the community clinic appointment rather 
than by questionnaire as in the standard service. 
Choice of clinic location and personnel At the 4 -week follow -up, 
107 (96 %) women were satisfied with the length of community 
clinic appointment and 89 - 93% of women with that at the regional 
clinic. In all, 69 (30 %) women did not state any strong preference 
for the location of a familial breast cancer clinic run by specially 
trained staff. There was a tendency for women to prefer the 
location of the clinic they had attended. The most popular choices 
were for a community clinic (selected by 27 (52 %) of low -risk 
women who had received the novel service) and a regional clinic 
(selected by 51 (42%) women who received the standard service). 
Among the women who had attended both community and 
regional clinics, 23 (38 %) preferred a community clinic and 16 
(27 %) a regional clinic. Overall, 115 (50 %) of the women expressed 
no strong preference on the grade and type of staff and 58 (25%) 
preferred a genetic nurse and a consultant breast surgeon. 
Expectations of the breast cancer family clinic 
Information needs In all, 294 (79%) women said that they would 
like as much information as possible about their family history of 
cancer, but a minority of 35 (9%) wanted general information only 
and 43 (12 %) only wished to know if their family was at increased 
risk. Women in the first group had significantly (P <0.05) higher 
cancer worry scores than women in the other two groups 
combined (Mann - Whitney test). 
Women were asked to rate how important it was for them to get 
information about various specific issues. Items of information 
regarded by over 70% of women as very important are given in 
Table 1. Women less than 40 years attached greater importance to 
getting information about their risk than did older women 
(P<0.01). 
Access to specific services Services for which access was regarded 
as very important by over 60% of women are given in Table 1. 
Women who placed great importance on the need for services to 
check their current cancer risk (those who rated the need for 
breast examination, check for current signs of cancer and 
mammography as very important) showed no difference in 
objective cancer risk or anxiety levels compared to those who 
did not. However, these women exhibited significantly greater 
cancer worry (P <0.01, Mann - Whitney test). 
Assessment of services received 
Patient satisfaction with services: overall satisfaction Table 2 
summarises the median patient satisfaction scores by MISS 
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Invited to participate (n = 575) 
Excluded (n = 201) 
refused to participate (n = 23) 
not responded (n = 123) 
not returned baseline 
questionnaire (n = 31) 
administrative reasons (n = 11) 
protocol violation (n =13)a 
Consented, completed baseline 
questionnaire and randomised 
according to GP practice 
(n = 374) 
Standard service arm (n = 185) 
4 -week follow -up (n = 146) 
lost to follow -up (n = 8) 
not returned questionnaire 
(n = 25) 
. clinical reasons (n = 2)b 
administrative reasons (n =4) 
6 -month follow -up (n = 139) 
not returned questionnaire 
(n =34) 
returned questionnaire blank 
(n =1) 
administrative reasons (n = 1) 
Novel service arm (n = 189) 
4 -week follow -up (n = 128) 
lost to follow -up (n = 13) 
. not returned questionnaire 
(n = 33) 
clinical reasons (n = 5)b 
administrative reasons (n =10) 
6 -month follow -up (n = 126) 
not returned questionnaire 
(n = 38) 
withdrew (n = 4) 
administrative reasons (n = 3) 
a For example, the women had received genetic counselling elsewhere or had been treated for cancer. 
b for example, investigation of breast symptoms. 
Figure I Progress of participants through the trial. 
subscale and trial group. There were no significant differences by 
trial group. 
Table 3 details the views of patients on specific aspects of 
satisfaction with services at the 4 -week follow -up. The items are 
listed together with the aspect of the consultation measured and 
the number and percentage of patients who agreed /strongly 
(dis)agreed with the statement. A single satisfaction score was 
constructed as the mean of scores of all 17 questions. Most women 
were satisfied with the consultations in both models of service, 
with responses heavily skewed towards the `satisfied' responses. 
When we considered factors that may have influenced satisfaction, 
no statistically significant correlation (Spearman rank correlation) 
was found between overall score and cancer worry (Cancer Worry 
score), anxiety (GHQ score), age or deprivation score. There was 
no significant difference between satisfaction in different educa- 
tional groups (ANOVA). However, women assessed as `low' risk 
were less satisfied with the services they received (P <0.05, t -test) 
than those assessed at `moderate' or `high' risk, as defined in this 
study. 
Patient satisfaction with services: satisfaction subscales (see 
Table 3) The scores for the affective, behavioural and cognitive 
subscales in the MISS were not significantly correlated (Spearman 
rank correlation) with cancer worry (Cancer Worry score), anxiety 
(GHQ score) or age. There was no significant difference between 
educational groups in any of these scores (Kruskal -Wallis test). 
However, women at `low' risk of breast cancer gave significantly 
lower mean scores for the affective (listening, understanding and 
interest of health staff) and cognitive (amount and quality of 
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information given), but not the behavioural (competence of health 
staff) components of the satisfaction questionnaire (P<0.05, 
Mann- Whitney test). 
Additional services requested by women A greater proportion of 
women who received the novel community service stated at the 4- 
week and 6 -month follow -up that they would have liked additional 
services (Table 4). However, this is confounded by the higher 
proportion of women scored as low risk in the novel service trial 
group. Overall, in both trial groups 37% (24 of the 65) low -risk 
women wished access to other services. Low -risk women receiving 
the novel service noted mammography, breast examination, 
regular check -ups and screening for other cancers most corn - 
monly. Eight (19 %) of these women at 4 weeks and seven (17 %) 
women at 6 months wanted access to mammography. High- and 
moderate -risk women receiving the standard service most 
commonly noted screening for other cancers and genetic testing. 
At the 4 -week follow -up, women who wanted further appointments 
to check their breast cancer status had higher cancer worry scores 
than other women (P < 0.05, Mann - Whitney test). 
Further action since attending clinic(s) Table 5 shows the number 
( %) of women (who completed both the 4 -week and 6 -month 
questionnaires) who stated that they intended to seek and 
had sought further advice about their family history of 
cancer after their clinic appointments. Overall, 42 (20 %) stated 
that they intended to seek further advice and 18 (9 %) actually 
sought further advice within 6 months. Most women simply 
wanted to keep up to date with new research or to find out about 
matters that they had not asked about at the clinic visits. A higher 
proportion of women receiving the standard service than the novel 
service (x2 test, P <0.05) and of women at moderate or high risk 
than low risk (x2 test, P < 0.05) stated that they intended seeking 
such advice. 
Women receiving standard service who did not attend a 
clinic but received a letter only 
Women in the standard service group who were assessed at low 
risk were not offered a clinic appointment but were sent a letter 
explaining that they were not at increased risk of breast cancer. 
Some 22 (73 %) of these women returned a questionnaire at 4 -week 
and at 6 -month follow -up. Although 15 (68 %) found the 
information in the letter quite or very helpful, seven (32 %) found 
it only a little helpful or not at all helpful. 
Six (27 %) and eight (36 %) women, respectively, noted that 
there were other items about which they would have liked 
information at the 4 -week and 6 -month follow -up. Seven (33 %) 
and eight (38 %) women stated that they would have preferred 
a clinic appointment to a letter at the 4 -week and 6 -month 
follow -up, respectively. 
Despite having been informed that their risk was not elevated, a 
large proportion of these women wished to have access to services 
and particularly breast examination (mentioned by eight (36 %) at 
the 4 -week follow -up and 15 (68 %) at the 6 -month follow -up) and 
mammography (mentioned by 14 (64 %) at the 4 -week and 15 
(68 %) at the 6 -month follow -up). At the 4 -week follow -up, only 
five women (23 %) stated that they intended to seek further advice 
(for a variety of reasons) and by the 6 -month follow -up, three 
(14 %) had actually sought further advice. 
Relative cost of operating novel and standard service 
clinics 
Relative levels of staff costs in the two service models Based on the 
duration of appointments, the time taken by staff to carry out 
related duties, staff travel times, patient attendance rates and the 
assumptions detailed in the methods section, the novel service 
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staffing and travel costs were approximately 30% lower than those 
for the standard service. 
Relative levels of patient costs in the two service models Ques- 
tionnaires on time and costs associated with clinic attendance were 
completed by 164 patients attending the regional clinic and by 104 
patients attending a community clinic. The median travel cost for 
attendance at the regional clinic was £1 (interquartile range, £1- 
£2.88) and for attendance at a community clinic was £1.00 
Table I Information and service requirements of patients 
Items of information regarded by over 50% of women as very important 
The significance of their family history 
Their own risk of breast cancer 
Anything they can do in everyday life to reduce their cancer risk 
How to examine their own breasts 
Symptoms of breast cancer to look for 
The pros and cons of breast screening 
Research to find new or better ways to prevent/detect breast cancer 
Breast cancer and its treatment 
Services for which access was regarded as very important by over 60% of women 
Reassurance that they show no signs of cancer now 
Breast screening by mammogram 
Regular check -ups 
(interquartile range, £1.00- £1.00). Travel costs were lower for 
women travelling to a community clinic (P<0.001, Mann - 
Whitney test). The travel time of women attending a community 
clinic was also less, with 15% of women taking over 30 min to 
reach the clinic compared to 50% of women attending the regional 
clinic (P <0.001, f test). In addition, only 2% of women attending 
a community clinic reported having to arrange care for their 
children compared to 12% of women attending the regional clinics. 
DISCUSSION 
There is widespread recognition of the need to integrate primary- 
and secondary/tertiary-care services, but the most appropriate 
model of service delivery remains to be defined (Campbell et al, 
Table 2 Median satisfaction subscale scores (with 25th and 75th 
percentiles) by trial group (modified MISS) 
Affective Behavioural Cognitive 
Patient group (A) scale (B) scale (C) scale 
Novel service: all women 4.0 (3.6 -4.3) 4.2 (3.9 -4.6) 4.0 (4.0 -4.6) 
Standard service: all women 4.0 (3.7 -4.4) 4.4 (4.0 -4.6) 4.0 (4.0 -4.8) 
MISS = Medical Interview Satisfaction Scale. 


















moderate /high -risk 
women 
(a) I was told about my risk of developing 
cancer in words that I could understand 
(b) After the consultation I have a good 
idea of what changes in my health I should 
seek medical advice about. 
(c) At the consultation I was told all I 
wanted to know about my family history of 
breast cancer 
d) The person I saw was very good at 
explaining the reasons for any medical tests 
which may be necessary 
e) I feel I understand pr elly well the plan for 
helping me 
(t) I was given a chance to say what was 
really on my mind 
(g) I really felt I was understood 
(h) After the consultation I felt much better 
about my problems 
(i) I felt the person I saw really knew how 
upset I was about my family history 
(j) I felt free to talk about private thoughts 
(k) 1 felt accepted as a person 
(I) I felt that my problems were not taken 
seriously 
(m) All the problems I mentioned were 
looked into 
(n) I felt the person I saw did not spend 
enough time with me 
(o) I was satisfied with the advice I was 
given about the courses of action I could 
take. 
(p) The person I saw seemed rushed during 
the consultation 
(q) The person I saw gave me too much 


















31 (91.2 %) 77 (98.7 %) 54 (96.4 %) 82 (95.3 %) 
20 (64.6%) 67 (85.9 %) 47 (85.5 %) 65 (82.3 %) 
26 (74.3%) 71 (93.5 %) 47 (84.0 %) 81 (92.0 %) 
22 (81.4%) 67 (95,7 %) 48 (88.9 %) 76 (93.8 %) 
14 (56.0%) 67 (94.4%) 52 (96.3%) 79 (93.0%) 
30 (88.2%) 64 (90.1%) 46 (86.7%) 74 (85.0%) 
22 (64.7%) 63 (87.5%) 43 (82.7%) 69 (84.2%) 
16 (53.3%) 46 (69.7%) 39 (78.0%) 59 (76.6%) 
19 (63.3%) 42 (75.0%) 35 (79.5%) 41 (64.0%) 
23 (71.9%) 46 (70.8%) 37 (77.1%) 48 (64.0%) 
32 (91.4%) 64 (9 I.4%) 50 (92.6%) 74 (93.7%) 
24 (75.0%) 63 (92.7%) 43 (89.6%) 79 (96.3%) 
21 (70.0%) 57 (86.4%) 38 (90.5%) 60 (86.9%) 
32 (94.1%) 74 (94.9%) 54 (96.5%) 79 (94.0%) 
19 (59.4%) 75 (97.4%) 49 (90.8%) 75 (88.2%) 
33 (97.0%) 75 (96.2 %) 54 (96.4%) 80 (94.1%) 
30 (85.7%) 69 (88.5 %) 49 (87.5 %) 82 (94.3 %) 
'or disagreed/strongly disagreed items I, n, p, q. "A= affective aspect (doctor /nurse listens, understands and is interested); B = behavioural aspect (doctor /nurse competence); 
C= cognitive aspect (amount and quality of information provided by doctor /nurse). 
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1995, Donnai et al, 2000). This study reports on a cluster 
randomised trial of a novel model of service delivery and presents 
patients' expectations of cancer genetic services and a comparison 
of patients' satisfaction with two service models. Patient satisfac- 
tion is both an objective and outcome of care, and is therefore an 
important dimension of any consideration of the best configura- 
tion of patient services. In addition, satisfied patients are more 
likely to comply with advice given, which is an important aspect of 
any service in which patient information and advice comprises an 
important element of the intervention (Baker, 1991). 
Expectations of cancer genetic services 
About 80% of women stated that they wanted comprehensive 
information about the implications of their family history of 
cancer. The items about which women were most concerned to get 
information or receive services were those connected with their 
own risk and its possible reduction and early detection of breast 
cancer. Over 60% of women wanted a breast examination/ 
mammography to have reassurance that they did not have breast 
cancer and regarded access to breast screening by mammogram 
and regular check -ups as very important. This underlines the 
demand for a multidisciplinary service providing both clinical 
genetic and surgical services, as noted by others (Brain et al, 2000). 
A recognition that increased cancer worry leads to a greater 
expressed need for information and for reassurance from follow - 
up checks is also important to guide clinical practice. 
Assessment of cancer genetic clinics 
Patient satisfaction with services received Levels of satisfaction 
with information given, staff attitudes and length of consultation 
were high. There were no significant differences between the trial 
groups. The lowest levels of satisfaction were found in those 
women with levels of cancer risk that were not significantly above 
population levels, and who were discharged with reassurance only. 
This reinforces the interpretation that many women seek a clinical 
examination to allay fears of current cancer (and possibly to have 
Table 4 Numbers (percentages) of women who stated that they would 
have liked additional services (not offered to them at the clinic 
consultation) 
4 -week 6 -month 
Patient group follow -up follow -up 
Novel service: all women 26/115 (23%) 17/114 (15%) 
Novel service; low -risk women 19/53 (36%) 11/50 (22%) 
Novel service; high /moderate -risk women 7/62 ( I I %) 6/64 (9%) 
Standard service: all women 23/124 (19%) 14/117 (12%) 
Standard service; low -risk women 5/12 (42%) I /8 (13%) 
Standard service; high /moderate -risk women 18/112 (16%) 13/109 (12%) 
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access to future screening such as mammography). It is also 
consistent with the previous finding that genetic counselling has 
less impact on general levels of patient satisfaction than other 
medical procedures, since it rarely `suggests treatment or 
eliminates uncertainties' (Shiloh et al, 1990). 
At the 4 -week follow -up, 14% of the community clinic (novel 
service) group and 25% of the regional clinic (standard service) 
group stated that they intended to seek further advice, although the 
reasons for this were not primarily due to dissatisfaction with the 
service they received. The difference between the two low -risk and 
the two moderate /high -risk groups of women in the trial were not 
statistically significant. At the 6 -month follow -up, only three 
women had actually attended another clinic for advice. Thus, 
provision of a community service staffed by nurses did not lead to 
an increase in the rate of care seeking after the consultation. 
Clinic preferences GPs and patients expressed no clear preference 
for either model of service. Women who had attended a clinic 
consultation were approximately equally divided between expres- 
sing preference for a regional clinic, a community clinic and 
having no preference. One reason for this may be that many 
women are working and so may not find it any easier to get to a 
clinic near their home than to the regional clinic. Similarly, about 
half of the women had no strong preference when asked for their 
choice of clinic personnel. Among those who expressed a 
preference, the combination of being seen by a genetic nurse 
and consultant breast surgeon was the most popular. 
Consultation times were greater when women were seen by a 
nurse at a community clinic (novel service). This is largely due to 
the time taken to document the woman's family history, but may 
also be because women feel more relaxed talking to a nurse or feel 
reluctant to take up the doctor's time. However, despite the shorter 
consultation times at the regional clinics, most women were highly 
satisfied with the duration of all consultations. 
Management of women with a family history of breast 
cancer, but who do not have an increased risk 
In all, 36% of women included in the study were not significantly 
above population levels of cancer risk. These women were less 
satisfied with the service received than women with a higher cancer 
risk. Most of these women were satisfied with the consultation. 
However, the novel service group was less satisfied than other 
groups of women with the amount and quality of information 
given. A relationship between patient satisfaction and rating of 
comprehension of the information received has been reported 
(Kincey et al, 1975), and failure to reassure has been linked to a 
failure to provide explanations at women's level of understanding. 
(Grande et al, 2002) It is possible, therefore, that the lower 
satisfaction reflects explanation and reassurance that is not 
targeted at the major concerns of these women which are a 
perceived need for examination for current (and future) cancer 
rather than principally a need for information about genetic risk. 
There is a need to tailor the explanation /reassurance by health staff 
Table 5 Numbers (percentages) of women who intended to and had sought further advice 
Patient group Intending to seek further advice Had sought advice 
Novel service: all women 
Novel service; low -risk women (n=42) 
Novel service; high /moderate -risk women (n=57) 
Standard service: all women 
Standard service; low -risk women (n=8) 
Standard service; high /moderate -risk women (n =103) 
14/ 99 (14 
5(12 
9 (16 
%) 7/99 (7 %) 
%) 4(10 %) 
%) 3 (5 %) 
28/ 1 1 1 (25%) I I / I I I (10%) 
0 0 
28 (27%) I I ( I I%) 
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to the background understanding and concerns of these women in 
order to improve services for these women. 
More than a third of low -risk women who attended the 
community but not the regional clinic stated that they wished 
access to other services (most often mammography, breast 
examination, regular check -ups and screening for other cancers) 
at the 4 -week follow -up, although this fell to 22% by the time of the 
6 -month follow -up. Thus, although most low -risk women were 
satisfied with being seen by a nurse at a community clinic, many 
still preferred to have the choice of accessing other services, even 
after being reassured that their risk is low. 
Although most of the low -risk women, who received a letter of 
reassurance and advice but not a clinic appointment, found the 
letter quite or very helpful, about a third found it, at most, only a 
little helpful. A similar percentage said there were other items 
about which they would have liked information. In all, 50% stated 
that they wanted a check that they did not have current cancer, 
64% that they wanted mammography and 77% that they wanted 
regular check -ups. At the four -week follow -up, 23% of this group 
said they intended to seek further advice and at the 6 -month 
follow -up, 14% had actually done so. 
Relative costs associated with the two service models 
Since GPs (Campbell et al, 2003) and patients expressed no clear 
preference for any specific service location or staffing configura- 
tion, cost is likely to be a major determinant of the nature of these 
services in the near future. A preliminary comparison of staff time 
and travel costs in the two trial groups revealed that the novel 
(community) service was associated with approximately 30% lower 
staff costs with the assumptions given above. The staff costs of the 
novel service could be further reduced if the medium/high -risk 
women were referred to a specialist nurse for breast examination/ 
mammography and did not have a second genetic counselling 
consultation (since new issues were rarely raised for discussion at 
this second appointment). 
The costs of the standard service could be reduced if the 
moderate/high -risk patients were assessed at the regional clinic by 
nurse practitioners who were dually trained in genetics and 
oncology rather than by a medical consultant or associate 
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Referrals of women with a family history of breast cancer from 
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As part of a cluster randomised trial to assess an altemative model of cancer genetics services, we gathered data on all referrals from 
general practitioners (GPs) to cancer genetics services in South East Scotland over a 4 -year period. The referral rate per 1000 
patients rose by 48% from 0.21 in the 2 -year period before the trial to 0.31 during the trial. This increase was much greater in the trial 
group offered the GP clinic service (64% increase compared to a 38% increase in those referred to the regional service). Thus, the 
offer of a more local service appeared to have a marked effect on GP management of these women. Referral rates to cancer genetics 
services from general practices varied widely with higher referral rates from practices with more female partners. There was a 
negative correlation between referral rates and predice area deprivation scores. However, this was not found during the trial in the 
group which offered clinics in general practice, the provision of clinic appointments nearer to the homes of more socially deprived 
women resulting in improved access to women from deprived areas. The interaction with the GP appears to be associated with an 
inappropriate level of interest in and expectation of the appropriateness of genetic testing. The provision of the clinics within general 
practice did not result in higher levels of confidence among GPs in managing these women. 
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UK genetic services are based on a network of regional centres 
offering specialist services (diagnosis, risk assessment, counselling, 
surveillance and support) to families at high risk of serious genetic 
disorders. While links with secondary and tertiary specialists are 
established in most centres, links with primary care are in the 
process of development (Donnai and Elles, 2001). 
Family history is known be a significant risk factor for breast 
cancer. Awareness of the genetic component of certain forms of 
cancer and therefore the potential importance of a family history is 
increasing among the population. This, in turn, has resulted in an 
increasing number of self -referrals to general practitioners (GPs), 
and subsequently to clinical genetics services (Campbell et al, 
1995). A survey of 22 regional cancer genetics services in the UK in 
1998 reported that the predominant users of these services were 
women with a family history of breast cancer (Wonderling et al, 
2001). 
Of women who are diagnosed with breast cancer, about 10% 
report of having a family history of the disease. We have recently 
found, in a large population -based survey of family history of 
breast cancer, that 52% of adult women have at least one first- or 
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second -degree relative with breast cancer. Thus, all GPs will have 
many patients with first- degree relatives with breast cancer and 
many of these patients are likely to seek counselling and advice 
regarding their level of risk. 
The aims and objectives of genetics services responding to the 
increasing public recognition of family history of cancer have been 
described in detail (Ponder, 1994). The provision of cancer 
genetics services has been seen as one of a number of cancer - 
control strategies located in primary care (Austoker, 1994). In 
South East Scotland, a multidisciplinary clinic offering specialist 
cancer genetic risk counselling and screening to women with a 
family history of breast cancer has been held in the regional breast - 
screening centre in Edinburgh since 1992. This clinic accepted 
direct referrals from GPs or other hospital consultants. 
We had previously proposed an alternative model of cancer 
genetics services (Campbell et al, 1995), whereby genetics nurse 
specialists could offer risk estimation based on an assessment of 
the family history of cancer within clinics held in GP locality areas. 
This would be accompanied by appropriate counselling for those 
whose empiric risk was not significantly increased and by 
immediate referral to regional specialist services for those at 
higher risk. It was hoped that this would provide improved 
support to primary care and more appropriate services for those at 
lower risk while encouraging more cost -effective use of specialist 
resources for those at increased risk of developing breast cancer. 
We carried out a cluster randomised trial of this new model of 
service delivery comparing it to the existing multidisciplinary 
specialist service. As part of the data collection for this trial, we 
gathered structured data on all GP referrals to cancer genetics 
services in the South East of Scotland over a 4 -year period. In this 
report, we present data on rates of referral of women to regional 
cancer genetics services for further assessment of their family 
history of breast or breast /ovarian cancer before and during the 
period of the trial. We identify and discuss factors that influence 
these referral rates and report the views of GPs about their role in 
the management of women with a family history of breast cancer 
and their attitudes to the services available to them. 
METHODS 
Referral by GPs to cancer genetics services 
We defined a study population as the patients registered with 
general practices within the catchment region of the SE Scotland 
Cancer Genetics and Breast services. We calculated the total 
number of referrals from all 203 general practices in this region, 
which were approached to take part in the study during a 24- 
month period before the trial started and the 21 -month period of 
the trial. The total number of patients on the lists of all these 
general practices was 1 221 261 at the beginning of the trial. The 
referral rate was estimated by 
(total referrals per year) x 1000 /(total list size for all general practices). 
Thus, the referral rates to cancer genetics services before and 
during the trial were taken as the number of women referred per 
1000 patients on the general practice lists during the periods from 
1 May 1995 until 30 April 1997 and from 1 March 1998 until 30 
November 1999, respectively. Referral rates for individual general 
practices were calculated in a similar fashion. 
The Carstairs deprivation score that is based on postcode of 
residence was used as a measure of social deprivation of patients 
registered with general practices (Carstairs and Morris, 1990) with 
high positive deprivation scores being indicative of greater 
deprivation. For general practices in Lothian Region, deprivation 
scores for all patients registered with each practice were averaged 
to give a mean score for each practice. For general practices in Fife 
and Borders regions, individual scores were not available so we 
adopted the score for the postcode of the surgery address to 
represent the practice. 
In order to assess whether differences in referral rates might be 
in part due to less selective referral criteria used by practices with 
higher referral rates (resulting in a greater proportion of women 
with a low risk of developing breast cancer), we classified general 
practices into four groups according to their referral rate during 
the trial. In each of these four groups, we calculated the proportion 
of referrals that were estimated to be at high, moderate and low 
risk based on an assessment of family history information given in 
the GP referral letter, thus reflecting the information available to 
the GP at the time of referral. In a few cases, the information in the 
GP letter was insufficient for an accurate risk assignment and so 
these women were omitted. 
Women were asked if they had taken the first step by asking to 
be referred or if this had been suggested to them by their GP, a 
hospital doctor or another medical professional. Those who said 
that they had taken the initiative themselves were asked if this was 
because of their own concern, the suggestion of another family 
member, because of something in the press or for another reason. 
Summary of the conduct of the trial 
Ethical approval for the study was obtained from the local research 
ethics committee. An invitation to take part in the trial was sent to 
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all general practices in Lothian (n = 125), South West Fife (n = 54) 
and Borders (n = 24) National Health Service (NHS) Boards in 
South East Scotland. A total of 170 practices (84 %) agreed to take 
part, 23 (11%) declined and 10 (5 %) did not reply. This meant that 
725 of the 828 (88 %) GPs in practice across these three NHS Board 
areas agreed to refer patients into the trial. Practices were 
randomly assigned to either arm of the trial using a minimisation 
technique (Pocock, 1983) to ensure that the two groups were 
balanced for size of practice, historical referral rate to cancer 
genetics services and social deprivation index. 
During the period from March 1998 to November 1999, any 
woman referred from participating GP practices to the regional 
clinical genetics department for breast cancer genetic risk 
estimation and counselling was invited to take part in the trial. 
To be eligible for the trial, women had to live in the region, be able 
to give informed consent and to complete a baseline questionnaire. 
Women were asked to record their date of birth, marital status and 
educational level on the baseline questionnaire. Information about 
the category of risk to which each woman had been assigned was 
derived from the clinical records. 
Women who were symptomatic or had been diagnosed with 
breast and /or ovarian cancer or who had previously consulted 
another clinic about their family history of cancer were excluded 
from the trial. Those who were ineligible to participate, 
nonresponders and those who did not consent to participate in 
the trial were offered an appointment by the regional genetics 
service. The service offered to women who were enrolled in the 
trial was dependent on the arm of the trial to which their GP 
practice had been randomised. 
Women referred by the first (`regional clinic') group completed 
a family history form and those considered to be at increased 
genetic risk (i.e. in the `moderate -risk' or `high -risk' categories) 
received the existing service that comprised an appointment to see 
a consultant geneticist and breast surgeon at a regional centre. 
Women referred by the second (`community clinic') group were 
seen at one of several clinics held in a community setting relatively 
near the woman's own general practice. 
At the community clinic, the genetics nurse specialist ascer- 
tained the woman's family history of cancer and compiled a family 
tree. This information was compared to published criteria to 
determine whether she was at increased risk. When an adequate 
risk assessment could not be made during the appointment, 
further information and /or confirmation of relatives' diagnoses 
were obtained from the woman or medical records or from cancer 
registry data, before the woman was informed of their risk by 
letter. Women whose risk of breast cancer was estimated not to be 
increased over that of women of a similar age in the general 
population (i.e. in the low -risk' category) were offered informa- 
tion and reassurance and were discharged from the clinic. These 
women and their GPs were sent a letter reaffirming their low -risk 
status and summarising the issues discussed at the appointment. 
Women whose risk was estimated to be increased over that of 
women of a similar age in the general population were offered an 
appointment at the regional centre with a consultant breast 
surgeon and genetics nurse specialist. Further details of the trial 
interventions are given in a related publication (Fry et al, 2003). 
Psychological distress and cancer worry were measured by the 
general health questionnaire (GHQ 30) (Goldberg and Williams, 
1988) and the Cancer Worry Scale (Watson et al, 1998) as 
described by Fry et al (2003). 
Questionnaire survey of general practices who participated 
in the trial 
All GPs who referred women during the study period received a 
questionnaire asking their views about various aspects of the 
management of women with a family history of breast cancer. 
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Statistical methods 
x2 tests were used to compare the distribution of sources of referral 
before and during the trial, the risk statuses of women who were 
referred by practices with different referral rates, and the responses 
of women who had or had not been given information by their 
GPs. Comparisons were made between referral rates within trial 
groups using the paired t -test. Comparisons of the number of 
practice members and female practice members were made using 
the Spearman rank correlation coefficient since these were not 
normally distributed. Pearson's correlation coefficients were 
calculated between locality (Carstairs) deprivation scores and 
referral rates before and during the trial for all Lothian practices. 
RESULTS 
Referral rates to cancer genetics services 
General practices approached to take part in the study A total of 
203 practices in the Lothian, Borders and South-West Fife regions 
of Scotland were approached to take part in the study. Some 170 
(84 %) agreed to take part, 23 (11%) refused and 10 (5 %) did not 
reply. 
Changes in referral rates to cancer genetics services over time The 
referral rate (and 95% confidence interval) per 1000 patients on the 
GP lists rose from 0.21 (0.19 - 0.24) in the 2 -year period before the 
trial to 0.31 (0.28 -0.34) during the trial. Thus, there was a 48% 
increase in referral rate over this period of approximately 2.5 years, 
a highly significant difference (P < 0.001). 
Change in referral behaviour of GPs Prior to the study, many 
asymptomatic women with a positive family history were referred 
to the Edinburgh Breast Unit (symptomatic breast clinic) and then 
referred on, after receiving a mammogram and an appointment 
with a breast surgeon, to the cancer genetics clinic. In order to 
assess if there had been a change in this pattern of referral during 
the period of the study, we compared the referral sources of this 
group of asymptomatic women (with a positive family history of 
breast cancer) before and during the trial. The letter sent out at the 
start of the trial to all GPs requesting that referrals be directed to 
cancer genetics services rather than to symptomatic breast services 
was successful, with the proportion of referrals from the 
symptomatic breast service falling from 24.6% before the trial to 
14.5% during the trial. There was a highly significant difference 
between the sources of referral before and during the trial (P< 
ranging from 0.05 to 1.66 per 1000 registered patients. The 
proportions of referrals that were estimated to be at high, 
moderate or low risk (based on information in the GP referral 
letter since this was the information available to the GP at that 
time) by four strata of general practice referral rates are given in 
Table 1. This shows that although general practices with the lowest 
referral rates referred a smaller percentage of low -risk women, 
there was no statistically significant trend in the proportions of 
risk classifications across the referral rate strata. Thus, we found 
no strong evidence that higher referral rates reflect the use of less 
selective referral criteria by these general practices. 
Relationship between referral rates and number and sexes of 
partners in the practice Of the practices that had agreed to take 
part in the study, 15% had no female partners, 67% had one to two 
female partners and 19% had three or more. Neither referral rate 
before nor during the trial was correlated with the number of 
partners or the number of male partners in the practice. However, 
there is a small but significant correlation between both referral 
rates and the number (Spearman rank correlation coefficient 0.24, 
P <0.002; 0.23, P <0.003) and proportion (Spearman rank 
correlation coefficient 0.22, P < 0.005; 0.17, P <0.02) of female 
partners in the practice before and during the trial, respectively. 
Comparison between referral rates in the two trial groups Table 2 
gives the mean referral rates before and during the trial -by -trial 
group. There was a statistically significant increase in referral rate 
between the two time periods in both trial groups (regional group 
P <0.01; community group P <0.001). This increase was greater in 
the community clinic trial group (64% increase compared to a 38% 
increase in the regional group over rates before the trial). 
Relationship between referral rates and locality deprivation scores 
of general practices We calculated the correlation between the 
locality (Carstairs) deprivation score and referral rates before and 
during the trial for all Lothian practices (whether or not induded 
in the trial) to investigate whether general practices serving women 
who were more socially deprived would have lower referral rates 
than those serving less socially deprived women. The correlation 
coefficients were -0.26 (P <0.01) with referral rates before the 
Table 2 General practitioner (GP) referral rates (per 1000 patients on 
GP list per year) to cancer genetics services before and during the trial 
(mean and 95% confidence limits) 
0.001). 
Relationship between referral rate and risks of women referred Of 
the general practices that agreed to take part in the study, 30 
referred no women during the study period. Annual referral rates 
during the trial for other practices varied by more than 30 -fold, 
GP group 
Before trial 
mean (95% CI) 
During trial 






0.21 (0.I7 -0.26) 
0.22 (0.17 -0.26) 
0.29 (0.23 -0.34) 
0.36 (0.29 -0.43) 
38.1 
63.6 
Table I Numbers (percentages) of referrals classified as high, moderate and low risk of breast cancer (due to family history based on national criteria) by 
practice groups with differing referral rates (annual rate per 1000 women on general practitioner list) 
Referral rate during trial Number of general practices 
Risk classification following national guidelines 
High risk Moderate risk Low risk Total referrals 
50.19 41 7 (11.1%) 48 (76.2%) 8 (12.7%) 63 
020-0.33 28 I I (13.3%) 55 (66.3%) I7 (20.5%) 83 
0.34-0.54 39 26 (12.1%) 133 (62.1%) 55 (25.7%) 214 
0.55 31 23 (12.8%) 116 (64.8%) 40 (22.3%) 179 
Total 139 67 352 120 539 
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trial and -0.13 (not statistically significant) with referral rates 
during the trial, suggesting that the tendency for practices serving 
less deprived areas to have higher referral rates was reduced 
during the time of the trial. Table 3 shows that the relationship 
between referral rate and locality deprivation score in general 
practices is influenced by the provision of community clinics. 
There was a negative correlation between referral rate and locality 
deprivation score both before and during the trial in the regional 
trial group. This indicates that practices in areas of lower social 
deprivation had higher referral rates. The same was true of the 
community trial group before the trial but during the trial the 
correlation was almost zero. Although the difference in referral 
rates between the two groups did not reach statistical significance, 
the lack of change in the regional but not the community trial 
group is striking (Table 3). 
Patient's role in the referral by the GP In all, 43% of women 
indicated that they had asked to be referred (in contrast to the 
others for whom referral was suggested to them by their GP or 
another medical professional). Two -thirds of these women noted 
that this was based on their own concern with the others 
requesting referral at the suggestion of another family member. 
Younger women were more likely to have taken the initiative to 
request referral (50% of women under 40 years compared to 31% 
of those 40 years or over, P = 0.001, y2 test). 
Of those that stated that their GP (or other medical professional) 
had initiated the referral, only a third stated that they had 
specifically enquired about their family history of cancer; for over 
one -half the suggestion of referral had taken place when they had 
seen the doctor about another matter. There was no significant 
difference in educational status, perceived level of risk or cancer 
worry between the two referral groups. 
Women's views of information given to them by their GP 
prior to referral 
Women enrolled in the trial were asked questions about whether 
any information had been given to them by their GP about their 
Table 3 Correlations between general practitioner -referral rates and 
locality (Carstairs) deprivation scores (higher score in more deprived areas) 
by trial group 
Trial group 
Correlation with 
referral rate before 
trial 
Correlation with 
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family history of cancer prior to the referral. About 40% of women 
had received no such information. In total, 50% of those who had 
received information reported that they found it to be very helpful 
or helpful. Women were then classified into two groups according 
to whether or not they had received information. 
The only statistically significant difference between the two trial 
groups (after correcting for the number of comparisons made (by 
the Bonferroni method) related to views on genetic testing. In all, 
90% of those who had received information from their GP thought 
that it was very important or quite important to have genetic 
testing compared with 73% of those who had not received 
information from their GP (P <0.01). Similarly, 71% of the group 
who had received information from their GP stated any informa- 
tion from a genetic test would be very important compared with 
56% of those who had not received information from their GP, but 
this difference was not statistically significant. 
General practitioners' views about the management of 
women presenting with a family history of breast cancer 
All GPs who referred women during the period of the trial received 
a questionnaire asking their views about various aspects of the 
management of women with a family history of breast cancer. 
Completed questionnaires were received from a total of 129 GPs in 
the regional group and 115 GPs in the community group. 
General practitioners' confidence in fulfilling their role in cancer 
genetics services Table 4 shows the percentages of GPs having 
various degrees of confidence in handling various aspects of the 
management of these women. General practitioners in both groups 
were most confident about taking a family history, providing 
emotional follow -up support and regular clinical examination and 
teaching breast self -examination. They were much less confident 
about calculating the risk and counselling on the basis of this and 
less confident about discussing the need for mammographic 
screening and deciding about whether a patient should be referred 
to the genetic clinic. There were no marked differences between the 
two trial groups suggesting that the limited number of contacts 
between the GPs and the genetics nurses who staffed the 
community clinics was insufficient to alter GP confidence in the 
management of these women. There was little evidence of GPs 
taking advantage of the presence of the nurse within the practice to 
discuss genetics issues. 
General practitioners' attitudes to genetic counselling and active 
screening for family history of breast cancer Over 90% of GPs 
agreed or strongly agreed that cancer genetic counselling has a 
useful role for women with a family history of breast cancer, and 
over 85% agreed or strongly agreed that mammography has a 
useful role for those at increased risk. In contrast, however, only 
Table 4 Percentages of general practitioners expressing their degree of confidence in fulfilling various roles in the management of women presenting with 
a family history of breast cancer 
Not confident or a little confident Moderately confident Confident or very confident 
Regional Community Regional Community Regional Community 
Taking detailed family history 25.6 21.8 38.8 35.7 34.9 42.6 
Calculating the risk 89.9 87.8 10.1 10.4 0 0.9 
Counselling on risk 83.0 75.7 13.2 20.9 3.9 2.6 
Providing emotional follow -up support 17.1 23.5 42.6 39.1 40.3 37.4 
Providing regular clinical examination 29.4 21.8 37.2 40.9 33.4 37.4 
Teaching breast self -examination 14.0 13.9 33.3 33.0 52.8 53.0 
Discussing need for mammography /colonoscopy 28.7 33.0 42.6 41.7 28.7 25.2 
Deciding whether patient should be referred to 
regional genetic clinic 
41.1 45.3 50.4 38.3 8.5 15.7 
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Table 5 Percentages of general practitioners' stating views on the usefulness of various forms of support for the management of women with a family 
history of breast cancer 
Not useful or a little useful Quite useful Very useful 
Regional Community Regional Community Regional Community 
Interactive computer program 34.1 37.4 47.3 36.5 17.1 22.6 
Referral guidelines 9.3 6.1 45.0 43.5 45.7 48.7 
Local clinics offering genetic counselling 27.2 20.9 44.2 42.6 28.7 33.9 
Direct access to medical genetic screening 36.4 38.2 41.9 38.3 20.2 19.1 
Training for yourself in genetic counselling 57.4 56.5 29.5 30.4 13.2 10.4 
Training for other primary care staff in genetic counselling 64.3 56.6 27.9 30.4 7.0 11.3 
30% agreed or strongly agreed that GPs should actively identify 
those from their lists who might be eligible for genetic counselling. 
General practitioners' views on their information and training 
needs General practitioners' views on the potential utility of 
various forms of support from regional clinical genetics services in 
helping them deal with their increased workload are given in 
Table 5. Referral guidelines were considered to be the most useful 
support, with over 90% of GPs regarding them as useful or very 
useful. Local clinics offering genetic counselling were regarded by 
one -third as very useful. There was less enthusiasm for interactive 
computer programs or direct access to screening. Over 50% of GPs 
stated that training in genetic counselling for themselves or other 
practice staff would be not at all useful or only a little useful. It is 
possible, however, that this was due to their interpretation of the 
term `genetic counselling' and that a higher proportion of GPs 
would favour some form of training to improve their skills. There 
were no differences in responses between GPs in the two trial 
groups. 
General practitioners' views on trial interventions 
About two -thirds of GPs (62% of regional group GPs and 65% of 
community group GPs) noted that they were confident or very 
confident about their women being seen by a genetic nurse 
specialist or genetic associate rather than by a consultant 
geneticist. A similar proportion (61% of regional group GPs and 
64% of community group GPs) noted that they were positive or 
very positive about having genetic clinics in the community. When 
asked whether they would prefer community clinics run by nurse 
specialists or regional hospital -based genetic clinics about one - 
third (36% of regional group GPs and 34% of community group 
GPs) favoured the former and one -half (51% of regional group GPs 
and 50% of community group GPs) the latter, the remainder being 
undecided. 
General practitioners found the structured summary letter the 
most useful aspect of the service followed by the provision of local 
community-based clinics (rated as useful or very useful by 44.4 
and 37.4 %, respectively). Other items (practice talks given by 
genetics nurse specialists and telephone advice) were rated as 
useful or very useful by less than a quarter of the GPs. General 
comments made by GPs included that they had made little use of 
the service and that women were less likely to default from 
appointments at community clinics. 
DISCUSSION 
Specialist outreach clinics 
Specialist outreach dinics in general practice increased throughout 
the mid- 1990s, reflecting a desire within the National Health 
Service to move towards closer integration of primary and 
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secondary care services (Bailey et al, 1994). Within clinical 
genetics, it is recognised that this has the potential to lead to 
improved equity of access to high -quality regional services 
(Donnai and Elles, 2001), although this has not been formally 
evaluated. Within primary care, there has been a call to develop 
strong links with regional genetics centres. This has stressed the 
need to provide accurate information and support for the primary 
care team and to undertake some genetic risk assessment and 
counselling and facilitate appropriate referral within primary care 
(Kinmonth et al, 1998). 
There have only been a limited number of thorough evaluations 
of outreach services across various disciplines. These have 
reported improved waiting times, patient satisfaction and con- 
venience to patients but have noted less efficient use of specialist 
time, limited interaction between primary care and specialist staff 
and concerns about access to these services not being uniform 
throughout a region (Bowling et al, 1997). 
Prevalence of family history of breast cancer and referral 
rates to cancer genetics services 
We recently carried out a large cross -sectional survey of 13 155 
patients registered with GPs in Scotland (Wallace E et al, personal 
communication). This found that a GP with an average caseload of 
1700 patients would have 140 patients with a family history of 
breast, colorectal or breast/ovarian cancer, and of these 10 would 
meet national criteria for referral for risk assessment. Reported 
referrals to regional services for consultation regarding a family 
history of breast cancer suggested a referral rate of about 0.25 
referrals per 1000 patients per year, consistent with the referral 
rates found in this study. This is based on referral of patients who 
presented spontaneously to their GP and not on any form of active 
surveillance by GPs of family history of cancer within their practice 
population. 
During the study, there was nearly a 50% increase in 
referral rate, compared with 1 -3 years prior to the study and 
a greater proportion of referrals came directly from GPs. At the 
start of the study period, local protocols, based on UK 
recommended guidelines for the primary care management of 
people with a family history of breast cancer, were developed 
together with GP representatives and Health Board guidelines 
groups. These local protocols were disseminated to all GPs 
in South East Scotland. In addition, all GPs received a biannual 
genetics update newsletter during the course of the study. 
These factors are likely to have contributed to the increase in 
referral rate. 
A striking finding was the substantially greater increase in 
referral rates from pretrial levels in the community clinic trial 
group compared to the regional group (64% increase compared to 
a 38% increase). Thus, in addition to the underlying general 
increase in referral rates, the establishment of community clinics 
resulted in a change in referral behaviour that resulted in a further 
increase in referral. 
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Despite the increase in referral rates that we recorded over this 
3 -year period, these rates are considerably lower than those (15 out 
of 1000 adult women /year) at which women reportedly raise 
concerns about family history of breast cancer with their GP 
(Kinmonth, 2001) suggesting that the GP `gatekeeper' role is an 
important one. 
There was a very wide (more than 30 -fold) variation in the 
annual referral rates. The reasons for this are not clear, but there 
was a small but significant correlation between referral rates 
during the trial and the number and proportion of female partners 
in the practice. Referral rates were greater from those practices 
with a greater number of female partners and this could be because 
women with a family history are more likely to seek the advice of a 
GP, if the GP is female. Thus, if the patient belongs to a practice 
where it is impossible or more difficult to see a woman, they may 
be less likely to seek advice. Alternatively, it could be that female 
GPs are more likely to refer women for genetic counselling about 
breast cancer risk than male GPs. 
We postulated that higher referral rates may reflect the use of 
less rigorous selection criteria by some GPs. For example, this 
might have occurred because of their knowledge that selection, 
according to risk, for referral to the breast -screening service would 
be performed subsequently by the genetic nurse who interviewed 
the woman at the locality clinic. However, we found no evidence 
that this had occurred. 
We interpret our finding as follows. Family history of breast 
cancer is common and many women consulting their GP may 
mention this at the time of consultation (Kinmonth, 2001). We 
found that younger women are more likely than older women to 
raise this concern and request referral to specialist services. 
General practitioners are operating at different thresholds at which 
they take action on these concerns. We have already shown that 
about 10% of women with a family history of breast cancer had 
been referred to a specialist service by their GP (Wallace E et al, 
personal communication). Once the decision to respond to this 
concern is made by the GP, similar referral criteria are applied. 
Currently, a more active surveillance of family history of cancer in 
primary care (which would result in a much higher referral rate) is 
not recommended in national cancer genetics guidelines nor is it 
supported by GPs (in this survey only 30% agreed that GPs should 
actively identify those from their lists who might be eligible for 
genetic counselling). 
Relationship between deprivation and referral rates to 
cancer genetics services 
There is an extensive literature that confirms that people from 
different socioeconomic groupings consume health care in 
different ways. This almost invariably shows that more deprived 
people have worse health and have greater need for health care 
(Balarajan et al, 1992; Eachus et al, 1996). It has been found that 
15 - 20% of the overall variation seen in the overall GP referral 
rates (to all services) can be explained by deprivation (Hippisley- 
Cox et al, 1997). Disadvantaged groups have also been shown to be 
less likely to attend for breast and cervical screening preventive 
services (Eachus et al, 1996). 
Provision of health care should be primarily determined by 
need. However, access to secondary care has been reported to be 
selectively poorer in deprived groups (Chaturvedi and Ben - 
Shlomo, 1995). In this study, the correlation coefficient between 
deprivation score and referral rate remained unchanged in the 
regional group: -0.26 before the trial and -0.28 during the trial. 
Thus, prior to and during the study in the regional group, there 
was a tendency for practices serving less deprived areas to have 
higher referral rates. The differential use of cancer genetics 
services across deprivation groups may be influenced by factors 
such as perceived risk and financial considerations (Eachus et al, 
1996) or by health behavioural factors involving knowledge of 
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importance of family history, how personal risk is perceived and 
what action is taken to seek counselling for a personal assessment 
of high risk and the ability to articulate need to health service staff. 
However, this relationship changed in the community group 
with the establishment of new community clinics with the 
correlation between deprivation score and referral rate before 
the trial ( -0.23) falling to -0.01 during the trial. Thus, the 
tendency for practices serving less deprived areas to have higher 
referral rates was no longer found where community clinics were 
held This is consistent with an interpretation that the provision of 
clinic appointments nearer to the homes of more socially deprived 
women and staffed by nurses results in GPs more likely to refer 
and /or women being more willing to attend these clinics than more 
distant regional clinics staffed by consultants. In addition, GPs 
commented that women were less likely to default from appoint- 
ments at community clinics. 
Genetic testing We found that the interaction with the GP was 
associated with an inappropriate level of interest in and 
expectation of the appropriateness of genetic testing, with 90% 
of those who had received information from their GP considering 
it important or very important compared to 73% of those who had 
not received information from their GP. While it is possible that 
this was due to recall bias, we consider this unlikely and suggest 
that this is worthy of further investigation. Since genetic testing is 
only appropriate to a very small percentage of women with very 
high familial risk, it is important that GPs do not foster this level of 
expectation. 
This mismatch in perception about the role of molecular testing 
between those running cancer genetics clinics and women 
attending them may need to be addressed specifically in the way 
clinics are organised in the future and in postgraduate training of 
GPs. 
Views of GPs on new services and on their role in cancer 
genetics 
In general, GPs were confident about taking a family history, 
clinical examination and offering emotional support. They 
were less confident about risk assessment and deciding if 
mammographic screening was necessary, and most did not 
see it as their role to identify those from their lists who might 
be eligible for genetic counselling. Several commented that they 
and their staff did not have time to take on additional work of this 
nature. 
There were no marked differences between the two trial groups 
suggesting that the limited number of contacts between the GPs 
and the genetics nurses who staffed the community clinics were 
insufficient to alter GP confidence in the management of these 
women. This was reinforced by the written comments of a number 
of GPs on the survey questionnaire that they had made little use of 
the service (the average referral rate was 0.5 referrals per GP per 
year). It has been noted previously that the limited interaction 
between primary care and specialist staff jeopardises achievement 
of one of the central aims of these initiatives - to facilitate 
integration and overcome barriers between primary and second- 
ary/tertiary care (Bailey et al, 1994). 
In general, GPs were positive about their patients being seen by 
genetic nurse specialists and about genetic clinics in the 
community. However, one -half still favoured hospital -based rather 
than locality clinics. General practitioners found the structured 
summary letter the most useful aspect followed by the provision of 
local community -based clinics. Most GPs regarded the referral 
guidelines provided by the study as useful. Other items (practice 
talks given by genetics nurse specialists, telephone advice and trial 
newsletters) were rated as useful or very useful by less than a third 
of the GPs. 
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A cross -sectional survey to estimate the prevalence of family 
history of colorectal, breast and ovarian cancer in a Scottish 
general practice population 
E Wallace, A Hinds', H Campbell, J Mackay3, R Cetnarskyj4 and MEM Porteous*'4 
Public Health Department Fife NHS Board, Springfield House, Cupar, Fife, Scotland; 2Community Health Sciences, University of Edinburgh, Teviot Place, 
Edinburgh, Scotland; 3The Genetics Unit Institute of Child Health, 30 Guilford St London WC I N I EH, UK; 4South East Scotland Genetic Service, Western 
General Hospital, Crewe Road, South Edinburgh, EH4 2XU, Scotland 
A cross -sectional survey of all patients aged 30 -65 in four general practices within one Local Health Care Co- operative in Fife, 
Scotland was undertaken to measure the prevalence of family history of colorectal, breast and ovarian cancer. A total of 7619 
patients aged 30 -65 responded to a postal questionnaire (response rate 59 %). In all, 17% of respondents (1324, 95% CI 16-18%) 
reported a relative affected by colorectal, breast or ovarian cancer. Of those, 6% (78, 95% CI 5 -7 %) met the Scottish guidelines for 
referral for genetics counselling. In all, 2% (24, 95% CI I -3 %) of all individuals with an affected relative had received genetic 
counselling and risk assessment. Of these, 25% (6, 95% CI 8 -42 %) met the moderate- or high -risk criteria for developing a cancer. In 
conclusion, the number of patients who are at a significantly increased risk of cancer on the basis of a family history is small 
(approximately 10 per General Practitioner (GP) list). It is therefore unrealistic to expect GPs to develop expertise in genetic risk 
estimation. A simple family history chart or pedigree is one way that a GP can, within the constraints of a GP consultation, determine 
which patients should be reassured and which referred to the local cancer genetic clinic. 
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Cancer is one of the three health priorities of the National Health 
Service in Scotland (NHSiS) (Scottish Office, 1998). Local Health 
Care Co- operatives (LHCCs) were created in Scotland in 1998 to 
provide local management of services, and are made up of 
representatives of local general practices and local service groups 
and patient groups (Scottish Office, 1998). They have been charged 
with measuring health needs within their communities to reflect 
the clinical priorities for the area and to support the development 
of population -wide approaches to health improvement and disease 
prevention (Scottish Office, 1997). 
Cancer genetics is the fastest growing area of clinical genetics 
(Wonderling et al, 2001). In Scotland, the four Regional Genetic 
Centres co- ordinate accurate risk assessment to ensure that 
individuals referred for screening investigations such as mammo- 
graphy and colonoscopy fulfil the national criteria laid down by 
the Cancer Genetic subgroup of the Scottish Cancer Group 
(Table 1). The lifetime risks for breast, colon and ovarian cancers 
in the general population are approximately one in 10, one in 60 
and one in 90, respectively (ISD, 1998). All general practitioners 
(GPs) will, therefore, have patients with a relative with one of these 
cancers. An unknown proportion of these patients are likely to 
seek counselling and advice regarding their risk of developing 
cancer (Biesecker et al, 1993). The relative risk associated with a 
*Correspondence: Dr MEM Porteous; 
E -mail: mary.porteous@ed.ac.uk 
Received 28 July 2003; revised 22 July 2004; accepted 29 July 2004; 
published online 21 September 2004 
family history of these cancers has been widely reported (St John 
et al, 1993; Slattery and Kerber, 1994; Pharoah et al, 1997). The 
challenge is to identify the minority at significantly increased 
genetic risk of developing cancer while reassuring the majority 
whose family history does not indicate a likely increased cancer 
risk above that of the general population. 
A major problem in planning cancer genetic services is that it is 
not known as to what proportion of the population fit into the 
various cancer genetic risk categories. The Scottish Office report 
`Cancer Genetics Services in Scotland' ( Haites, 2000) recognised 
that `at present there is no means of identifying the total 
population who have a family history which places them at a 
significantly increased risk of developing breast, colorectal or 
ovarian cancer'. The report also noted that the uncertainty of these 
estimates makes it impossible to predict future costs for the 
provision of a risk estimation and screening service. 
Risk estimation is based on the number of affected individuals 
within the family, the pattern of cancers and the age of onset of 
cancer. It is therefore necessary for the clinician to take a careful 
family history. This process is time- consuming and many GPs are 
unsure of their ability to obtain an accurate family tree and assess 
genetic risk (Fry et al, 1999). Pre -clinical family history 
questionnaires have been used extensively by genetic departments. 
This study was designed to evaluate how a similar questionnaire 
would be addressed by a general practice population and whether 
such a questionnaire might provide data in a form to facilitate GP 
cancer genetic risk estimation. 
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Table 1 The Cancer Genetic Sub -committee family history criteria for enrolment in a screening programme for breast, ovarian or colorectal cancer 
Breast 
Moderate risk 
One first- degree relative with bilateral breast cancer 
One first- degree relative with breast cancer diagnosed under age 40 years or one first- degree male relative with breast cancer diagnosed at any age 
Two first- or first- and second -degree relatives with breast cancer diagnosed under age 60 years and /or ovarian cancer at any age on the same side of the family 
Three first- or second -degree relatives with breast or ovarian cancer on the same side of the family (always one first -degree relative unless history is via father) 
High risk 
An individual with BRCA I or BRCA2 mutations or other known predisposing gene mutations or the untested first- degree relative of a mutation carrier 
One first -degree relative (or second -degree relative via intervening male relative) in a family with four or more relatives affected with breast cancer or ovarian cancer 
in three generations 
One first- degree relative (or second degree via father) with breast and ovarian cancer 
Ovarian 
Moderate risk 
Two or more first- or first- and second -degree relatives with ovarian cancer 
Two first- or first- and second -degree relatives with ovarian cancer at any age and breast cancer diagnosed under 50 years 
One ovarian cancer and two breast cancers diagnosed less than 60 years on the same side of the family in first -degree relatives or second degree via a male 
Two first- or second -degree relatives with colorectal cancer and /or endometrial cancer and one with ovarian cancer one affected relative with ovarian cancer and 
HNPCC family history 
High risk 
An individual with BRCA I or BRCA2 mutations or other known predisposing gene mutations or her untested female relatives. 
First- degree relative with breast and ovarian cancer 
Bowel 
Moderate risk 
One first -degree relative with colorectal cancer under age 45 years 
Two individuals affected with colorectal cancer (one less than 55 years) who are first -degree relatives of each other and one a first- degree relative of the consultant 
Three affected family members with colorectal or endometrial cancer who are first- degree relatives of each other and one a first- degree relative of the consultant 
High risk 
An individual with a mutation in one of the mismatch repair genes or their untested first -degree relatives 
A family history compatible with HNPCC according to Amsterdam or modified Amsterdam criteria 
Individuals are judged to be at low risk if their family history does not meet the moderate risk criteria for screening. 
We report the results of a cross -sectional survey conducted 
between May 1999 and October 2000 of patients in General 
Practice aged between 30 and 65 years to assess the prevalence of a 
significant family history of colorectal, breast, or ovarian cancer 
and to identify the number of individuals with a family history that 
had been referred onto the Clinical Genetic Service. Ethical 
approval for the study was granted by the Fife Local Research 
Ethics Committee. 
PARTICIPANTS AND METHODS 
A postal survey of all patients aged 30 -65 years from four general 
medical practices covering over 99% of the population within one 
LHCC in Fife, Scotland was undertaken using a cancer family 
history questionnaire that had been developed and evaluated by a 
Cambridge -based research team (Leggat et al, 1999). The 
questionnaire was adapted to determine whether the patients 
had any concerns regarding their own risk of developing cancer 
and, if so, whether they had ever been referred to a cancer genetic 
specialist or had received any form of genetic counselling 
(questionnaire available online at http: //137.195.14.43/cgi -bin/ 
WebObjects /genisys.woa /wa /showDoc ?docid = 208). 
Patients were asked if they had any family members (grand- 
parents, aunts, uncles, father, mother, brothers, sisters and 
children) who had had colorectal, breast or ovarian cancer and 
the age at which these cancers were diagnosed. Those with no 
affected relatives were requested to return the questionnaire at this 
point. Those with a family member affected were asked to 
complete a detailed family history including relationship to the 
affected individual, site of cancer and age at and date of diagnosis. 
In all, 305 randomly selected participants reporting a family 
history of cancer (23% of total) were interviewed by telephone 
(n = 254) or in person by a genetic nurse (n = 51) to check the 
consistency of the information collected via the postal survey. A 
British Joumal of Cancer (2004) 9 I (8), 1575-1579 409 
fieldworker telephoned 101 of those reporting no family history to 
confirm that there was no family history of colorectal breast or 
ovarian cancer in their families. 
RESULTS 
A total of 13 155 questionnaires were mailed, of which 5535 were 
excluded from the study; 281 were returned address unknown and 
5254 were not returned by the patient. In all, 7620 (3386 males, 
4234 females) were completed and returned (Figure 1). The overall 
response rate was 59 %. A total of 1396 (18 %, 95% CI 17-19%) 
responders reported a family history of cancer. When checked by a 
genetics nurse, 72 questionnaires reported relatives with a history 
of cancers at other sites and were excluded from any further 
analysis. In all, 17% of respondents (1324, 95% Cl 16- 18%) 
therefore identified themselves as having a history of colorectal, 
breast, or ovarian cancer in a first- or second -degree relative. Of 
these, 918 were females and 375 males. Some respondents reported 
a family history of more than one of these cancers. In total, 78 
respondents with a family history were classified as being at 
medium or high risk of developing colorectal, breast, or ovarian 
cancer, and thus met the guidelines for referral to cancer genetics 
services in Scotland for risk assessment (Haites, 2000). This 
represents approximately 6% (95% CI 5 -7 %) of all respondents 
reporting a family history of cancer. 
Colorectal cancer 
In all, 31 respondents reporting a family history of colorectal 
cancer met the national guidelines for referral for risk assessment, 
11 males and 20 females, that is, 5% (95% CI 3 -7 %) of those 
reporting a family history of colorectal cancer and 2% (95% CI 1 - 
3%) reporting a history of any of the three cancers or 0.41% (95% 
CI 0.26 - 0.55 %) of the population surveyed. 
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Questionnaires sent out (n = 13,155) 
Excluded (n = 5535) 
I - Returned address unknown (n = 281) 
- No reply (n = 5254) 
Completed questionnaires (n = 7620) 
Positive family history of cancer 
reported (n = 1396 families) 
Excluded (n = 72) 
- Cancer site other than breast, bowel or colorectal 
Number of relevant cancers reported 
(n = 1666) 
Colorectal cancer any 
relative (n = 689) 
Colorectal cancer first 
or second degree 
relative (n = 603) 
l 
High risk (n = 4) 
Moderate risk (n = 27) 
Low risk (n = 572) 
Breast cancer any 
relative (n = 735) 
Breast cancer first or 
second degree 
relative (n = 689) 
1 
High risk (n = 12) 
Moderate risk (n = 33) 
Low risk (n = 644) 
Ovarian cancer any 
relative (n = 242) 
1 
Ovarian cancer first or 
second degree 
relative (n = 213) 
l 
High risk (n = 10) 
Moderate risk (n = 10) 
Low risk (n = 193) 
* Some respondents reported more than one relevant cancer 
** Risk to the responder of developing cancer according to the Cancer Genetic Sub -committee 
guidelines. A total of, 18 women at moderate or high risk of breast and ovarian cancer are represented 
in both categories 
Figure I Flow diagram of response and results of a survey to estimate the prevalence of a family history of selected cancers in a Scottish population 
surveyed in 1999 -2000. 
Breast cancer 
In all, 27 of the female respondents met national guidelines for 
referral for risk assessment for breast cancer only, that is, 3% (95% 
CI 2 -4 %) of all female respondents reporting a family history of 
cancer or 0.64% (95% CI 0.40 - 0.88%) of the total female 
population surveyed. 
Ovarian cancer 
Two female respondents met the national guidelines for referral 
for risk assessment for ovarian cancer only, that is, 0.2% (95% 
CI 0 -0.5 %) of all females reporting a family history of cancer 
or 0.05% (95% CI 0 -0.1 %) of the total female population 
surveyed. 
Breast and ovarian cancer 
In all, 18 female respondents met the national guidelines for 
referral for risk assessment, that is, 2% (95% CI 1 -3%) of 
all female respondents reporting a family history of cancer or 
0.43% (95% CI 0.22 - 0.62 %) of the total female population 
surveyed. 
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Interviews of re- contacted participants 
A validation study was undertaken in order to assess the 
consistency of this information. In all, 352 patients reporting a 
family history of cancer were randomly selected and asked to 
discuss their history with a genetic nurse either face to face or by 
telephone. Of these, 305 (87 %) responded and their family history 
was verbally confirmed. Of these, 17 (6%, 95% CI 3 - 8%) were 
assessed to be at a moderate to high risk of developing colorectal 
cancer and thus met the national criteria for referral for risk 
assessment, 28 (9 %, 98% CI 6 -12%) met the referral criteria for 
breast cancer and three (1 %, 95% CI 0 -2 %) for ovarian cancer. 
As a result of this group being interviewed by the genetic nurse, 
the risk of 21 (7%, 95% CI 4 -10 %) of the respondents was altered. 
The estimated risk of one or more of the three cancers was 
increased for 16 of the respondents, although in six cases it was 
difficult to verify the risk due to incomplete information, for 
example, age of diagnosis of cancer in relative. For five 
respondents, the estimated risk of cancer was reduced. Only four 
(4 %, 95% CI 0.2 - 8%) of the 101 respondents who originally 
reported no family history of breast, ovarian or colorectal cancer 
in the family history form subsequently mentioned a family history 
on interview with a fieldworker. All four were assessed to be at low 
risk of developing cancer. 
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Contact with health services 
In all, 15% of respondents who reported a positive family history 
of these cancers had discussed their concerns with their GP, 
the great majority during the last 3 years. Out of these respondents, 
86% (and 87% of the 30 respondents found to be at moderate 
or high risk) had raised the issue themselves (rather than their 
GP asking them about the family history of cancer). In all, 10% 
of respondents reporting any family history of cancer (and 22% 
of those at moderate /high risk) had been referred to a 
specialist to discuss their risk of cancer and 2% (25% of those 
at moderate /high risk) had received genetic counselling in the 
past. 
Workload implications for GPs and cancer genetics clinics 
Using these results to estimate workload for GPs and cancer 
genetic clinics in the rest of Scotland, the following figures are 
obtained: 
Average caseload of a Scottish GP - 1700 patients 
Average number of patients aged 30 -65 years - 830 patients 
Number with any positive family history (estimate) - 140 patients 
Number who had discussed family history with GP - 21 patients 
Number meeting referral guidelines (estimate) -- 10 patients 
Potentially, only one in 14 patients attending a GP with a 
positive family history of cancer needs to be referred to regional 
cancer genetics services for further risk assessment. 
DISCUSSION 
A valid response rate of 59% was achieved for the postal 
questionnaire used in this study. This is considerably higher than 
that in a previously published study using a similar questionnaire 
where the response rate was 29% (Leggat et al, 1999). Possible 
explanations for this high response rate to the questionnaire 
include: the study was led by the principal GP of one of 
the participating general practices and was thus well known to 
most patients; a press release publicising the study was issued 
prior to mailing; one reminder was sent out to nonresponders 2 
weeks after mailing the questionnaire; and a colorectal cancer 
screening study had recently been undertaken in one of the four 
participating GP practices. When compared with the nonrespon- 
ders, the responders were significantly older (mean age 48 years vs 
44 years), similar to that reported in the previous study which 
evaluated the family history of cancer questionnaire.9 The study 
made no allowance for multiple sampling of the same family, but 
the aim was to assess the burden of cancer genetics in a GP 
practice. Males with a family history of breast or ovarian cancer 
were assessed as low risk, as no clinical screening is indicated for 
them. 
We have recently shown in Scotland that such reports of a 
positive family history of cancer are rarely incorrect but may 
substantially underestimate the true prevalence of a history of 
cancer in relatives, especially among second - degree relatives, when 
compared to cancer registry records (Mitchell et al, 2004). We only 
attempted to `validate' a sample of positive reports of family 
history of cancer in this study. It is likely that a study which also 
involved an analysis of cancer registry records of all relatives 
would yield a higher estimate for the family history of cancer. 
Thus, the prevalence of family history of cancer in this study can 
be considered to represent a minimum estimate. Nevertheless, 
patients make decisions about seeking advice about their cancer 
risk based on their family history as they perceive it and so that 
data presented in this report are important in seeking to plan 
services for these patients. 
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It is interesting to note the higher incidence of moderate- or 
high -risk family histories in the subgroup of participants that 
agreed to be interviewed. This may reflect a greater interest in 
discussing their situation in the moderate- and high -risk groups. 
Prior to the study, it was anticipated that some respondents 
might experience anxiety concerning their own risk of cancer as a 
result of completing the family history questionnaire. Participants 
were invited to voice their anxieties by phone with the study team 
who could then arrange an appointment with a genetic nurse. 
However, it was only necessary for the genetic nurse to contact 
two respondents in relation to this issue and she was able to 
provide advice and reassurance in both cases. Discussion with 
GPs in the practices involved revealed no contact with patients 
worried by the results of the study. Many of the respondents 
did admit to worries about their family history when interviewed, 
but had not taken advantage of genetic counselling. In fact, those 
at the greatest risk were the ones who reported least use of the 
service. 
The majority of questionnaires were completed correctly and 
many respondents included a great deal of information about their 
family history of cancer, sometimes involving obtaining details 
from family members living abroad. For GPs faced with patients 
consulting with concerns about their family history, a suitable 
response would therefore be to ask the patient to complete a 
similar family history form and to rely on this in making a decision 
as to whether or not to refer the patient to the local cancer genetics 
clinic. 
Cancer genetics referral guidelines are quite complex. Therefore, 
computer programmes have been developed based on referral 
guidelines to support the decision -making by GPs. However, as 
GPs will see only a few patients a year, acquiring all of the skills 
necessary for genetic counselling or to operate such programmes 
may be unlikely to be accorded a high priority. In addition, newly 
acquired skills following training are likely to degrade over time 
without frequent reinforcement. We suggest that GPs could 
use a questionnaire to collect information and then pass it on to 
the local genetic nurse, primary care genetic clinician or cancer 
centre for a rapid assessment as to whether further action should 
be taken. 
The number of patients seeking genetic counselling has 
increased sharply over the last few years (Wonderling et al, 
2001). This study has shown that only about one in 14 patients 
attending a GP with a positive family history of cancer needs to be 
referred to regional cancer genetics services for further risk 
assessment. The importance of the gate- keeping role of the GP is 
likely to increase in future. Our experience gained during the 
course of this study suggests that this role might be facilitated by 
the use of a self -completion family history form in general practice. 
Information collected by this means tallies closely with that 
obtained from interviews with trained genetic nurses and permit 
accurate risk assessments which can guide referral decisions. 
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Abstract 
The discovery that genetic factors are involved in the aetiology of colorectal cancer, has prompted many relatives of 
affected individuals to seek genetic counselling and screening. This paper describes the demand for genetic services 
by families with colorectal cancer in south -east Scotland, their expectations and views of the service offered. The 
annual referral rate over the 21 -month study period, for patients with a family history of colorectal cancer, was 0.11 
per 1000 patients on general practitioner lists. This is one third of the rate for patients with a family history of breast 
cancer and in comparison with the breast cancer group, relatives of colorectal cancer patients were significantly 
older and less socially deprived. Approximately one third were referred via a hospital specialist unit. One hundred 
patients were included in the study. Mean (± standard deviation) age was 43 (f 10.7 years), 75 were female and 31 
were self referrals. Before the consultation, almost half the patients had an inflated perception of their risk and there 
was little change at follow -up. There was an improvement in objective understanding after counselling which was 
sustained up to 6 months but only two thirds remembered their objective risk accurately. Most patients were 
satisfied with the consultation. Our findings suggest the need to educate individuals, in particular men, younger 
people and the more socially deprived, about the relevance of a family history of colorectal cancer and to facilitate 
patients' comprehension of their risk status. 
Introduction 
Both genetic and environmental factors e.g. diet and 
exercise, influence the probability that an individual will 
develop colorectal cancer (CRC). A significant minority 
of CRC cases result from two autosomal dominant 
syndromes - familial adenomatous polyposis (FAP) and 
hereditary non -polyposis colon cancer (HNPCC). Other 
less understood genetic factors are also likely to be 
involved in CRC and may account for 15% of cases [1]. 
Media attention to these discoveries has led many 
individuals with a family history of CRC to seek genetic 
counselling and advice about screening. Petersen et al. 
[2] and Trimbath and Giardiello [1] have stressed 
the importance of providing genetic counselling for 
individuals in families with CRC who wish risk assess- 
ment. They list the main components of the counselling 
session e.g. construction of a family pedigree, education 
of the patient and family about medical aspects of the 
disorder, risk and screening and exploration of psycho- 
logical factors such as specific issues related to the family 
history and experience of the disorder. 
Wonderling et al. [3] found that in Scotland the 
annual referral rate to cancer genetics services was 278 
per million population. In the whole of the UK 18% of 
these referrals had a family history of CRC. Several 
studies have been made of genetic services offered to 
relatives of CRC patients but these have often been 
focussed on attitudes to and outcomes of genetic testing 
[e.g. 4, 5, 6, 7]. There have been few studies evaluating 
other aspects of familial CRC services. Amongst these 
Collins et al. [8, 9] assessed a familial CRC clinic and 
Correspondence to: Harry Campbell, Department of Public Health Sciences, University of Edinburgh Medical School, Teviot Place, Edinburgh 
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Julian -Reynier et al. [10] and Nordin et al. [11] assessed 
clinics for patients with a family history of CRC or other 
cancers. 
We therefore carried out a survey of patients pre- 
senting with a family history of CRC in Scotland in 
order to inform the development of appropriate services. 
We investigated the referral rate to the Clinical Genetics 
Service and patients' referral pathways. We also studied 
sociodemographic and psychological characteristics of 
patients, their knowledge and information requirements. 
Finally, we measured patient satisfaction with the 
service received, information retained and further action 
taken by patients after the consultation. 
We have recently reported our experience in managing 
patients with a family history of breast cancer [ 12, 13, 14] 
and these results will be compared with current findings. 
Materials and methods 
Procedure 
Ethical approval for the study was obtained from the 
local ethics committee. A total of 203 GP practices in 
south -east Scotland (Lothian, Borders and south -west 
Fife regions) were invited, by letter, to take part in the 
study. Some 170 (84 %) agreed, 23 (11 %) declined and 
10 (5 %) did not reply. 
During the study period (1 March 1998 to 30 
November 1999), referrals of patients with a family 
history of CRC, from participating practices, were sent 
to the regional Clinical Genetics Service at the Western 
General Hospital. Some referrals were sent directly by 
the GP and others were sent to a hospital gastro- 
intestinal unit and re- referred from there. Patients 
resident outside south -east Scotland and those known 
to be symptomatic or to have been diagnosed with CRC 
were excluded from the study. Those known to have 
previously consulted another clinic about their family 
history of cancer or whose family was already known to 
the Clinical Genetics Service, were also excluded. 
All eligible patients were sent a letter giving details of 
the study and were asked to complete a consent form. 
Those who agreed to take part in the study were sent a 
baseline questionnaire. On receipt of the completed 
baseline questionnaire all patients were offered a clinic 
appointment with a consultant geneticist /specialist reg- 
istrar or a specialist genetic nurse. Patients were seen 
either in one of four hospital outpatient departments or 
in a community clinic based in a general practitioner 
(GP) surgery. At the clinic appointment details of the 
family history were obtained. Amsterdam II criteria [1] 
were used to identify patients at high risk, in families 
with HNPCC. Patients were estimated to be at moderate 
risk if their family history satisfied published criteria 
[15]: i.e. one first degree relative diagnosed with CRC 
under 45 years or two first degree relatives with CRC on 
the same side of the family. Patients not in the high or 
moderate risk categories were considered to be at low 
risk: defined as the same or slightly higher than the 
general population risk. Patients at low risk were 
reassured that no screening was necessary and dis- 
charged. Patients at high and moderate risk were referred 
for colonoscopy if appropriate. Immediately after the 
consultation patients were sent a letter summarising the 
matters discussed. Follow -up questionnaires were sent 
to all patients 4 weeks and 6 months after the appoint- 
ment. For the purpose of the present study we did not 
collect data relating to patient management, following 
referral to other hospitals for possible colonoscopy. 
Patients who were excluded or who did not consent to 
take part received the same service as those in the study 
but did not receive any questionnaires. 
Referrals 
The total number of referrals of patients with a family 
history of CRC, from all 203 practices invited to take part, 
during the 21 month period of the study was recorded. 
The total number of patients on the lists of all these 
practices was 1,221,261 at the beginning of the study 
period. The absolute annual referral rate was estimated as: 
(total referrals per year) x 1000 /(total list size for 
all practices) 
Age, gender and source of referral were recorded 
for all patients from participating GP practices. The 
Carstairs deprivation score (CDS), which is based on 
postcode of residence, was used as a measure of social 
deprivation [16]. The range of this score for all post- 
codes in Scotland was -7.54 -12.87 with higher positive 
scores indicating greater social deprivation. 
Participants 
Sociodemographic characteristics 
Several sociodemographic characteristics of patients 
were assessed at baseline including age, gender, marital 
status, education and CDS. 
Mode of referral 
Patients were asked if they had taken the first step in 
asking to be referred (self referrals) or if this had been 
suggested to them by a medical professional (other 
referrals). 
Psychological measures 
Perceived risk of CRC. Patients were asked to state 
whether they considered their risk to be high, moderate 
or low. They were also asked to categorise their risk in 
terms of the general population risk (lower, same, 
slightly higher, much higher) and the number of times 
their risk of ever developing CRC was greater than that 
of the average person. 
Cancer Worry Scale (CWS) (Watson et al. [17]). This 6 
item, self -report scale (adapted from 4 single items, 
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Lerman et al. [18, 19]) assesses concerns about develop- 
ing cancer and their impact on daily functioning. Total 
scores range from 6 to 24 where a higher score indicates 
higher levels of worry. The psychometric properties of 
the scale have been shown to be satisfactory [20, 21]. 
Subjective understanding. Patients were asked to rate on 
a 4 -point scale from 1 (not at all) to 4 (very well) how 
well they understood each of 4 issues relating to CRC 
genetic risk. The issues were: 
1. How increased risk of developing CRC can be passed 
on in families. 
2. The significance of their own family history of cancer. 
3. Whether there is anything people can do for them- 
selves to reduce their risk of developing CRC. 
4. What services may be offered to protect the health of 
people at increased risk of developing CRC. 
Responses were summed to give a composite score for 
subjective understanding ranging from 4 to 16. 
Objective understanding. Patients were asked to consider 
a number of factual statements and to respond `true', 
`false' or `don't know'. There were 10 statements about 
CRC genetics (e.g. most cases of CRC are caused by 
inheriting a faulty gene) and 10 about issues to do with 
CRC symptoms and screening (e.g. symptoms which may 
be associated with early CRC are blood in the stools). A 
correct response was scored as '1' and `incorrect' or `don't 
know' as zero to give total scores for objective under- 
standing of genetics and of CRC /screening from I -10. 
Information and services required 
Patients were asked at baseline how detailed was the 
information they required from the consultation. They 
were also asked to rate how important it was for them to 
get information about specific items such as risks, 
prevention, screening and treatment. Questions were 
also asked about their desire for access to various forms 
of screening. 
Clinic consultation 
Details of all clinic consultations were recorded. These 
included matters discussed, duration of consultation, 
level of stated risk, and outcome of the consultation. 
General satisfaction 
At the 4 -week and 6 -month follow -up, satisfaction with 
the consultations was measured in several ways. To 
assess general satisfaction, patients were asked to state 
their views on a number of aspects of the service which 
were derived or adapted from the Medical Interview 
Satisfaction Scale (MISS) (Wolf et al. [22]). Satisfaction 
with three aspects of a consultation was measured: 
1. The affective aspect (A) - the extent to which patients 
felt that the medical professional listened, understood 
and was interested. 
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2. The behavioural aspect (B) - the patient's evaluation 
of the medical professional's competence in the con- 
sultation. 
3. The cognitive aspect (C) - satisfaction with the 
amount and quality of information provided by the 
medical professional. 
Each item on the scale was rated on a five point scale 
of agreement from 5 (strongly agree) to 1 (strongly 
disagree). Items I, n, p and q (see Table 3) were scored in 
the reverse direction. 
For those patients who responded to all the items in a 
group (A, B or C) a mean score was calculated for the 
group of items. An overall mean satisfaction score was 
also calculated for those who had responded to all 17 
questions. 
Specific satisfaction 
We investigated patients' assessment of the helpfulness 
of specific information given about genetic risks, symp- 
toms of CRC, screening and treatment and of services 
offered for screening and treatment. 
Recall of risk 
Four weeks and 6- months after counselling, patients 
were asked to state their level of risk of developing 
CRC, given at the clinic appointment. This was com- 
pared with the objective risk stated by the medical 
professional. 
Additional information /services 
Patients were asked if there were other topics they would 
have liked to have discussed at the clinic or other 
services they would have liked to have been offered. We 
also investigated whether patients intended to or had 
sought further information after their clinic appoint- 
ment from any source. 
Statistical methods 
Descriptive statistics were generated to describe the 
study population. Differences between two independent 
groups were analysed, with parametric or non paramet- 
ric tests as appropriate, using the independent samples 
t -test (2 tailed), Mann - Whitney (2 tailed), chi -squared (2 
tailed) or Fisher's exact test (2 tailed). The Kruskal- 
Wallis test was used to test for differences between more 
than two independent group. Differences between pairs 
of observations in the same group were analysed using 
the paired t -test (2 tailed). The Pearson correlation 
coefficient or the Spearman -Rank correlation coefficient 
was used to test for associations between two variables. 
When multiple comparisons were made between 
groups the Bonferroni correction was used when assess- 
ing statistical significance. 
If one or more scores on a scale were missing the total 
score for that patient was not included in any statistical 
analysis. When considering information required from 
the consultation and helpfulness of information given, 
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patients with different categories of response were 
combined into one group if numbers were small. 
A significance level of 0.05 was used throughout. The 
data was analysed using SPSS for Windows, version 9. 
Results 
Referrals 
The absolute annual referral rate (and 95% confidence 
interval) per 1000 patients on the GP lists was 0.11 
(0.09 -0.13) during the study period. 
A total of 150 patients, over a 21 -month period, were 
invited to participate. Of these, 93 (62 %) were referred 
directly by their GP and 52 (35 %) via a hospital gastro- 
intestinal unit. The remaining 5 patients were referred 
from a variety of sources. A total of 107 (71%) were 
female and 43 male. The mean (standard deviation) of 
age and CDS were 42.1 years (11.0 years) and -1.9 
(3.0), respectively. 
Participants 
Figure 1 shows patient participation and completion of 
questionnaires. A total of 100 (67 %) patients were 
included in the study. No significant differences in sex 
Invited to participate n =150 
distribution, age or CDS were found between these 
patients and the 50 who did not take part. Of patients 
sent the 4 week questionnaire a total of 79 (92 %) 
completed it. The corresponding figure for the 6 -month 
questionnaire was 78 (87 %). 
Sociodemographic characteristics 
Sociodemographic characteristics of patients who com- 
pleted the baseline, 4 -week and 6 -month questionnaires 
are summarised in Table 1. There were no significant 
differences in sociodemographic characteristics or base- 
line psychological measures between the patients who 
did /did not complete the 4 -week or the 6 -month 
questionnaires. 
Mode of referral 
Thirty -one (31.3%) patients who responded said they 
were self referrals. Of these, 17 (63%) who responded 
indicated it was their own concern and almost all the 
others requested referral at the suggestion of another 
family member. Of those who stated that they were 
`other referrals' (n = 68), the number of patients stating 
that they had specifically enquired about their family 
history of cancer was 37 (57 %). For 19 (28 %) the 
suggestion of referral had taken place when they had 
seen the doctor about another matter. 
Excluded (n =50):- 
Refused to participate (n =8) 
Did not respond (n =17) 
Did not return baseline questionnaire 
(n =8) 
Administrative reasons (n =13) 
Protocol violations (n=4) 
Consented, completed baseline 
questionnaire (n =100) 
4 week follow-up: - 
Questionnaires returned (n =79) 
Excluded (n =10):- 
Did not attend clinic (n =9) 
Lost to follow -up (n =1) 
6 month follow -up b:- 
Questionnaires returned (n =78) 
Excluded (n =11):- 
Not sent -administrative reasons 
(n=4) 
Did not return Questionnaire 
(n =7) 
Excluded (n =12):- 
Did not return questionnaire 
(n =12) 
Figure 1. Progress of participants through the study. 
'E.g. the patient had received genetic counselling elsewhere or had been treated for cancer. 
bSeven patients who were excluded in the 4 -week follow -up were included at the 6 -month follow -up. 
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Table 1. Sociodemographic and psychological characteristics of patients at baseline and 4 -week and 6 -month follow -up. 
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Variable Baseline (n = 100) 4 Weeks (n = 79) 6 Months (n = 78) 
Sex: n ( %) 
Male 25 (25) 22 (28) 19 (24) 
Female 75 (75) 57 (72) 59 (76) 
Marital status: n ( %) 
Married /cohabiting 76 (76) 60 (76) 58 (74) 
Separated /divorced /widowed 8 (8) 6 (8) 7 (9) 
Never married 16 (16) 13 (16) 13 (17) 
Education: n ( %) 
To age 16 years 31 (31) 25 (32) 24 (31) 
To age 18 years 10 (10) 8 (10) 7 (9) 
After age 18 years 22 (22) 17 (21) 16 (20) 
University graduate 37 (37) 29 (37) 31 (40) 
Age (years): mean (s.d.) 43.0 (10.7) 43.7 (10.6) 44.1 (11.2) 
Carstairs deprivation score: mean (s.d.) -2.2 (2.9) -2.2 (2.8) -2.3 (2.8) 
Risk of CRC: n ( %) 
Objective: 
Low 45 (47) 38 (48) 35 (45) 
Moderate 44 (45) 34 (43) 35 (45) 
High 8 (8) 7 (9) 8 (10) 
Perceived: 
Low 5 (5) 8 (11) 9 (14) 
Moderate 59 (60) 56 (76) 46 (71) 
High 35 (35) 10 (13) 10 (15) 
Understanding: median (inter -quartile range) 
Subjective 9 (7 -11) 12 (11 -15) 12 (11 -14) 
Objective: 
Genetics 4 (2 -7) 7 (5-8) 7 (5-8) 
Symptoms /screening 6 (4-8) 8 (6-9) 9 (8 -9) 
Cancer worry scale: mean (s.d.) 10.8 (3.0) 9.9 (2.7) 10.1 (2.9) 
There were no statistically significant relationships 
between mode of referral (self /other) and age or sex. 
Similarly there were no significant differences between 
the proportions with different modes of referral in the 4 
educational classes. However there was a greater ten- 
dency for those with more education to be self referrals. 
Of those who had left school at 16 years, 19% were self 
referrals, compared with 44% of University graduates. 
There was a highly significant (P < 0.001) difference in 
deprivation as measured by CDS (P < 0.001) between 
patients in the self and other referral groups. Only 20% 
of the more deprived patients (CDS >_ overall mean) 
were self referrals compared with 43% of the less 
deprived patients (CDS < overall mean). 
Psychological characteristics 
Perceived risk of CRC. At baseline 95% patients per- 
ceived their risk of developing CRC to be high /moderate 
(Table 1). By the 6 -month follow -up the percentage had 
reduced to 86 %. Considering only the 56 patients who 
had completed all 3 questionnaires, 29 (52 %) were at 
high /moderate objective risk and the percentages who 
perceived their risk to be high /moderate were 91%, 86% 
and 86% at baseline, 4 -week follow -up and 6 -month 
follow -up, respectively. 
Amongst patients who perceived their risk to be 
high /moderate 56 (62 %) at baseline, 33 (50 %) at the 
4 -week follow -up and 28 (49 %) at the 6 -month follow - 
up considered that their risk of developing CRC was at 
least 5 times greater than the average person. However, 
the majority [65 (94 %) at baseline, 58 (87 %) at the 
4 -week follow -up and 48 (83 %) at the 6 -month follow - 
up] of patients who considered their risk to be the same 
or slightly higher than the general population perceived 
their risk to be high /moderate. 
Cancer Worry Scale. Mean scores on the Cancer Worry 
Scale at the different time periods are given in Table 1. 
Changes in the scores over time were measured in the 59 
patients for whom there was a baseline, 4 -week and 6- 
month measurement. There was a highly significant 
(P < 0.001) decrease in score between baseline and the 
4 -week questionnaire but not between the 4 -week and 6- 
month questionnaire. The results were identical when 
patients at high /moderate (n = 32) and low risk 
(n = 27) were compared separately. 
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Subjective and objective understanding. Baseline: When 
patients were asked how well they understood the 4 
issues relating to subjective understanding, the responses 
to questions 1 -3 were similar with 11 -15% stating they 
had no knowledge, 43-49% saying they had a little 
knowledge and 36-46% saying they had more than this. 
Patients had less knowledge of the services which could 
be offered to at risk individuals (question 4) with 36 
(36 %) stating that they had no knowledge and 36 (36 %) 
that they had a little knowledge. 
Median total scores for subjective and objective 
understanding are given in Table 1. There were signif- 
icant correlations of 0.34 (P < 0.01) between sub- 
jective understanding and objective understanding of 
genetics, 0.35 (P < 0.01) between subjective under- 
standing and objective understanding of CRC /screen- 
ing and 0.54 (P < 0.001) between objective 
understanding of genetics and objective understanding 
of CRC /screening. 
There were no significant differences in subjective 
understanding or objective understanding of genetics 
between patients of different sexes, age groups 
( < 40 years, >_ 40 years), mode of referral (self and 
other) groups and educational groups. At baseline 
there was one significant difference in objective 
understanding of CRC /screening with female patients 
having more knowledge than male patients 
(P < 0.01). 
Changes over time: Changes in each of these scores 
were measured in the 56 patients for whom there was a 
baseline, 4 -week and 6 -month measurement. There were 
highly significant (P < 0.001) increases in subjective 
understanding and objective understanding of both 
genetics and of symptoms /screening, between baseline 
and the 4 -week questionnaire but not between the 4 
week and 6 -month questionnaire. The results were 
identical when patients at high /moderate (n=29) and 
low (n = 27) objective risk were compared separately. 
Information and services required 
Seventy -seven percent of patients said they would like as 
much information as possible but 8 patients (8 %) 
wanted general information only and 14 patients 
(14 %) only wished to know if their family was at 
increased risk. Patients in the first group had signifi- 
cantly higher scores on the Cancer Worry Scale than 
patients in the other two groups combined (P < 0.05). 
Items of information which over 70% patients 
regarded as very important included their own risk of 
CRC, symptoms of CRC to look for and the pros and 
cons of colonoscopy. Services, which over 60% of 
patients regarded as very important included reassur- 
ance that they show no signs of cancer now, regular 
check -ups and the opportunity to take part in research 
to improve services for the future. 
Clinic consultations 
Of the 100 patients who were entered into the study, 9 
did not attend their clinic appointments and for another 
7 no record was kept of their appointment in error. 
Details were available for the other 84 consultations. 
Matters discussed and duration of the consultation 
Matters discussed at the consultation were classified 
under 4 headings: 
1. Family history and genetics; 
2. Examination and screening; 
3. Healthy lifestyles; 
4. Other matters related to bowel cancer. 
The genetics of CRC, the significance of their family 
history and the patient's own risk, were discussed in 
over 95% of all consultations. In a large proportion (43- 
75%) of consultations there was also discussion of risks 
to children and other relatives, the possibility of finding 
a cancer predisposing gene and the risks of developing 
any other cancer. 
Colonoscopy was discussed in 94% consultations. 
Screening by looking for blood in the stools (FOB test) 
and removal of bowel growths was discussed in 79% of 
consultations. 
With regard to healthy lifestyles: dietary factors were 
discussed in 92% of consultations. Symptoms, which may 
be related to CRC, were discussed at 87% of consultations. 
The median time for the whole consultation was 
42 min with almost half of this time being taken up with 
a discussion of the family history and genetics. 
Risk of developing CRC and outcome of consultation 
Of the 82 patients in whom CRC risk was estimated, 45 
(55 %) were at high or moderate risk of developing CRC 
and 37 (45 %) were at the same or slightly higher than 
the general population risk (low risk group). Amongst 
the high /moderate risk group colonoscopy was sug- 
gested for 93%. Over half of the low risk patients were 
advised of the possibility of FOB testing if they required 
further reassurance. 
Given an annual referral rate of 0.11 per 1000 
patients on GP lists and assuming that the risk distri- 
bution of all patients referred is the same as for the 
above 82 patients, we can estimate that there will be 0.06 
new patients, per 1000 population in south -east Scot- 
land, requiring colonoscopy surveillance per year. 
General satisfaction 
For all consultations, patient responses to the MISS 
items were heavily skewed towards the `satisfied'. In 
Table 2, the views of all patients at the 4 -week and 
6 -month follow -up are given. The items are listed along 
with the aspect of the consultation measured and the 
number and percentage of patients who agreed /strongly 
agreed with the statement (or disagreed /strongly dis- 
agreed -items 1, n, p, q). Patients who did not respond to 
the question or who stated that the item was not 
applicable were not included. In general, most patients 
were satisfied with the consultations. 
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Table 2. Satisfaction with cancer genetics services: numbers and percentages of patients who agreed /strongly agreeda with various statements 
concerning their appointments at the 4 -week and 6 -month follow -up. 
Statement 
a) I was told about my risk of developing 
cancer in words that I could understand 
b) After the consultation I have a good idea 
of what changes in my health I should seek medical advice about. 
c) At the consultation I was told all I wanted 
to know about my family history of CRC 
d) The person I saw was very good at 
explaining the reasons for any medical tests which may be necessary 
e) I feel I understand pretty well the plan for helping me 
f) I was given a chance to say what was really on my mind 
g) I really felt I was understood 
h) After the consultation I felt much better about my problems 
i) I felt the person I saw really knew 
how upset I was about my family history 
j) I felt free to talk about private thoughts 
k) I felt accepted as a person 
I) I felt that my problems were not taken seriously 
m) All the problems I mentioned were looked into 
n) I felt the person I saw did not spend enough time with me 
o) I was satisfied with the advice I was given 
about the courses of action I could take. 
p) The person I saw seemed rushed during the consultation 
q) The person I saw gave me too much information too quickly 
Aspecto of 
consultation 
4 -Week follow -up 
n =79 
6 -Month follow -up 
n =78 
C 69 (95.9 %) 72 (93.6 %) 
C 59 (86.8 %) 63 (85.1 %) 
C 58 (80.5 %) 56 (74.7 %) 
C 67 (94.4 %) 63 (88.7 %) 
C 59 (89.4 %) 58 (81.7 %) 
A 67 (93.0 %) 66 (86.9 %) 
A 61 (85.9 %) 61 (81.4 %) 
A 48 (73.9 %) 50 (68.5 %) 
A 34 (66.7 %) 40 (67.8 %) 
A 56 (83.6 %) 59 (83.1%) 
A 63 (91.3 %) 66 (94.3 %) 
A 59 (89.4 %) 64 (86.4 %) 
B 49 (83.0 %) 58 (87.9 %) 
B 66 (91.6 %) 72 (92.3 %) 
B 60 (85.7 %) 65 (85.5 %) 
B 67 (91.8%) 73 (93.6%) 
B 68 (93.1%) 66 (84.6%) 
aDisagreed /strongly disagreed items 1, n, p, q. 
bAspect of consultation: A - The affective aspect - the extent to which patients felt that the medical professional listened, understood and was 
interested; B - the behavioural aspect - the patient's evaluation of the medical professional's competence in the consultation; C - the cognitive 
aspect - satisfaction with the amount and quality of information provided by the medical professional. 
Mean scores for items in groups A, B, and C and 
overall satisfaction scores at the 4 -week and 6 -month 
follow up are given in Table 3. There were no 
significant differences between the mean A, B, and C 
scores at the 4 -week follow -up. However at the 6 -month 
follow -up the B scores were found to be significantly 
greater than the A scores (P < 0.05). The magnitude of 
the difference was small but suggests a greater satisfac- 
tion with the medical professional's competence than 
their ability to empathise. 
There was no significant difference in overall satis- 
faction score by sex, objective risk, education level, 
referral method or level of information requested by the 
patient. There was no significant correlation between 
overall satisfaction score at the 4 -week follow -up and 
age or CDS. 
Specific satisfaction 
At the 4 -week follow -up, over 85% of patients rated the 
information on the genetics of bowel cancer, the signif- 
icance of the family history, their own risk and the pros 
and cons of colonoscopy as quite or very helpful. At the 
6 -month follow -up information on strategies to reduce 
cancer risk in everyday life, and symptoms of bowel 
cancer to look for were also rated in this way. 
Recall of risk 
Amongst the 71 patients who completed both question- 
naires 37 (52 %) were estimated to be at high or 
moderate risk of developing CRC and 34 (48 %) to be 
at low risk. Table 4 gives the numbers and percentages of 
patients by level of risk recalled 4 weeks and 6 months 
after counselling. Only two thirds remembered their 
level of risk accurately. 
Additional informationlservices 
Only a minority (10 %) of patients at follow -up reported 
that there were other topics which they would have liked 
to discuss at the clinic. At the 4 -week follow -up 16 (20 %) 
patients suggested additional services that they would 
Table 3. Satisfaction with cancer genetics services (mean scores (+ SD) for different aspects of the consultation at the 4 -week and 6 -month 
follow -up. 
Score 4 -Week follow -up 6 -Month follow -up 
Group A (affective) 4.04 ± 0.72 4.05 ± 0.66 
Group B (behavioural) 4.24 ± 0.57 4.19 ± 0.50 
Group C (cognitive) 4.22 ± 0.64 4.11 ± 0.59 
Overall satisfaction 4.07 ± 0.62 4.13 f 0.54 
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Table 4. Recall of risk 4 -weeks and 6- months post counselling. 
Risk recalled 
High /moderate risk group (n = 37) 
Time interval 
4 -Week follow -up 
6 -Month follow -up 
Low risk group (n = 34) 
Time interval 
4 -Week follow -up 
6 -Month follow -up 
Correct 
22(59 %) 
26 (70 %) 
Correct 
22(65 %) 
21 (62 %) 
Low risk 
8 (22 %) 
7 (19 %) 
High /moderate risk 
9 (26 %) 
10 (29 %) 
Could not remember 
7 (19 %) 
4 (11 %) 
Could not remember 
3 (9 %) 
3 (9 %) 
like to receive. Nine of these patients noted their interest 
in genetic testing. There was no significant difference in 
the overall satisfaction score of the patients who wished 
further check -ups regarding their CRC status and 
patients who wanted other /no services. At the 6 -month 
follow -up 18 (23%) patients suggested additional ser- 
vices. Six patients noted screening for other cancers, five 
screening by the FOB test and five genetic testing. 
Further action since attending clinic(s) 
At the 4 -week follow -up 24 (34 %) patients said they 
intended to seek further advice about their family 
history of cancer. At the 6 -month follow -up only 10 
(14 %) had actually sought further information. There 
were no significant differences in overall satisfaction 
scores at the 4 -week follow -up between patients who 
intended /did not intend to seek further advice or those 
who had /had not sought further information. 
Discussion 
The present study was carried out to assist in the 
development of genetic services for relatives of patients 
with CRC. We estimated demand for genetic services 
amongst relatives of CRC patients in south -east Scot- 
land. We also considered mode of referral, sociodemo- 
graphic and psychological characteristics of patients 
referred, prior views about the service they wished to 
receive and their satisfaction with the service offered. 
Referrals 
During the study, the annual referral rate for patients 
with a family history of CRC, was approximately one 
third of the referral rate for patients with a family 
history of breast cancer (0.31 per 1000 patients) in the 
same time period [13]. Since this was a population based 
study these figures can be applied to the population of 
south -east Scotland. From data given by Wonderling 
et al. [3] we can estimate that, in their study, the annual 
referral rate in Scotland of patients with a family history 
of CRC was 0.05 per 1000 population. This referral rate 
is less than half that found in the present study but 
assumes that the percentage of referrals with a family 
history of CRC was the same in Scotland as in the rest 
of the UK. In a recent study carried out in Scotland [23], 
8% of participants reported a family history of CRC in 
at least one first or second degree relative whereas 52% 
of women had at least one first or second degree relative 
with breast cancer. Taking patients of both sexes 
together the ratio of those reporting a family history 
of breast cancer to those reporting a family history of 
CRC was 3 : 1. Therefore the ratio of referral rates 
which we found is in agreement with expectation. 
However as shown by Mitchell et al. [24] this ratio 
does not represent the true ratio of patients with a 
positive family history of these cancers since sensitivity 
of reporting a positive family history is much greater in 
breast than colorectal cancer. 
One third of patients were referred via a hospital 
specialist unit compared with only 14.5% of patients 
seeking counselling regarding a family history of breast 
cancer [13]. Thus GPs are less likely to refer asymptom- 
atic patients with a family history of CRC direct to 
cancer genetic services than those with a family history 
of breast cancer. At the start of the study GPs were 
issued with referral guidelines for patients with a family 
history of breast cancer and CRC. They also received 
biannual genetics update newsletters during the course 
of the study. However, after the study was completed 
over 40% of GPs who had taken part were at most only 
a little confident about deciding whether patients with a 
family history of breast cancer or CRC should be 
referred to genetic services [13]. This is probably also the 
explanation for the large proportion (47 %) of CRC 
patients in the study who were at low risk. 
Over two thirds of patients invited to participate were 
female. Wonderling et al. [3] found the same proportion 
amongst bowel cancer referrals to UK cancer genetic 
services. It was felt that this was due to the fact that men 
generally underuse health services. 
The mean age of patients invited to participate was 
higher and the mean deprivation score lower than for 
patients referred with a family history of breast cancer in 
the same time period. This indicates that younger and 
more socially deprived individuals are less likely to be 
referred regarding a family history of CRC than that of 
breast cancer. This may be because fewer socially 
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deprived relatives of CRC patients seek advice and also 
because of ignorance of diagnoses of CRC in relatives. 
One third of patients invited to take part did not do 
so. One half of these failed to return their consent form 
or baseline questionnaire. There was no evidence that 
these patients differed from those who took part in age, 
sex or social deprivation. 
Participants 
The mean age of patients included in the study was 
43 years, 5 years older than for patients seen in the same 
time period with a family history of breast cancer [14]. 
This was probably due to greater media publicity 
regarding the risks associated with a positive family 
history of breast cancer compared to that for CRC. 
Women in the group with a positive family history of 
breast cancer were more likely to be self referrals who 
were younger than those referred by a medical profes- 
sional [13]. In three other studies of patients attending 
cancer genetics clinics [8, 10, 11] a similar mean age was 
found to that in the present study. 
Thirty one percent of participants were self referrals 
in contrast to 43% in the case of breast cancer [13]. Self 
referral rates were higher in less deprived and better 
educated groups. This is in contrast to the patients with 
a family history of breast cancer for whom no difference 
in deprivation score (CDS) was found between referral 
groups. 
At baseline almost all the patients in the study 
perceived their risk of developing CRC to be moderate 
or high. Collins et al. [8] also found that many were 
coming to the clinic with inflated perceptions of their 
own risk. 
Most patients stated at baseline that they had at least 
a little knowledge of CRC risk and preventive measures. 
Over one third had no knowledge of services which 
could be offered to protect the health of people at 
increased risk. However, the correlations between base- 
line subjective and objective understanding were rela- 
tively low suggesting that their perceived level of 
knowledge was often inaccurate. There was a suggestion 
that patients with more education had a better under- 
standing of genetics and females had more knowledge of 
CRC and screening than males. Collins et al. [8] also 
found that increased education was associated with 
increased knowledge. 
We found that over three quarters of the patients 
wanted to obtain as much information as possible at 
their consultation. These patients had higher baseline 
scores on the Cancer Worry Scale. Nordin et al. [11] 
found that patients they referred to as `monitors', who 
sought more information, also had higher levels of 
cancer worry on a numerical 1 -7 scale with end points 
defined as no worry at all and worst possible worry. 
The items about which patients in our study were 
most concerned to get information were those concerned 
with their own risk and its possible reduction and early 
detection of CRC. Collins et al. [8] found that their 
patients were most concerned to find out if there was a 
gene for cancer in their family. This was not a major 
concern for patients in this study. 
Many of our patients wanted to have an opportunity 
to take part in research. Collins et al. [8] found that 
helping research or science was an important motivation 
for attendance for over half of their participants. 
Consultation 
Almost half the patients were informed, at the consul- 
tation, that their risk was at most slightly higher than 
that in the general population. However, at follow -up 
the majority of patients perceived their risk to be high/ 
moderate. 
Most patients were satisfied with the consultation in 
general with satisfaction scores being very similar to 
those found for the breast cancer group [14]. We found 
no difference in satisfaction between certain patient 
groups. Collins et al. [9] found that older age group and 
lack of worry about CRC were associated with a high 
level of satisfaction. Nordin et al. [11] found that 
monitors were less satisfied with the information aspects 
of counselling compared with non monitors. 
At follow -up only 60-70% patients estimated to be at 
high /moderate risk of developing CRC remembered 
their objective risk correctly and about 20% considered 
their risk to be low. Amongst the patients estimated to 
be at low risk 62-65% remembered their objective risk 
correctly but 26-29% recalled their risk to be high or 
moderate. There were similar findings in the study of 
Nordin et al. [11] where after counselling 25% overes- 
timated their risk and 18% underestimated their risk. 
This indicates that some patients may not have under- 
stood the information about risk given to them at the 
clinic appointment and doctors /nurses may need to take 
more time to ensure patients understand their risk status 
and the resulting options open to them. Accuracy of 
recall of risk was unrelated to age, sex education or 
baseline cancer worry. 
However, despite the above results, when asked 
about their perception of their risk over 85% patients 
stated it to be high /moderate at baseline and at the 2 
follow -up times. This suggests that although some 
patients accept that their objective risk is low they still 
perceive themselves to be at higher risk. Similar results 
were found for relatives of breast cancer patients referred 
during the same time period [ 12]. This is in contrast to the 
results of Collins et al. [8], who found close agreement 
between subjective and objective risk after counselling. 
There were, however, highly significant increases in 
subjective and objective understanding after genetic 
counselling. Patients with a family history of breast 
cancer showed similar increases in understanding [12]. 
There was a reduction in score on the Cancer 
Worry Scale after counselling as was also found for 
relatives of breast cancer patients [12]. Other workers 
[17, 21, 25] have used the same Cancer Worry Scale as in 
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the present paper in studies of patients with a family 
history of breast cancer. These workers found very 
similar scores at baseline to those in the present study. In 
two of the studies [17, 25] there was a reduction in score 
after counselling as in the present study. Hopwood et al. 
[21] found no change and pointed out that it is important 
to identify those patients for whom such worries are 
intrusive and impair their day to day functioning rather 
than assume that all cancer worry is pathologic. 
About 20% patients said they would have liked to have 
been offered access to services not offered to them at the 
clinic consultation. At the 4 -week follow -up 34% patients 
said they intended to seek further advice about their 
family history of cancer but less than half this percentage 
had actually done so at the 6 -month follow -up. 
Limitations of the study 
The results of this study are based on a relatively 
small number of patients all from the same region 
of south -east Scotland so should be treated with caution. 
Patients who did not consent to take part in the study 
did not differ from others in age sex or social deprivation 
but we did not have data on psychological characteris- 
tics Nevertheless, where it is possible to compare our 
results with those of others, as discussed above, the 
findings are very similar. Our patients were followed up 
for a comparatively short period of time and it would be 
interesting to investigate their views and actions over a 
longer period since their appointments. 
Clinical /research implications 
Our results would suggest the need to give GPs more 
information about the service offered to CRC families 
and to encourage them to refer directly to genetic 
services. There is also the need to encourage patients 
with CRC to inform relatives of the diagnosis, so that 
they can be offered screening if appropriate. At present 
male relatives and those from socially deprived areas are 
less likely to come forward for counselling and screening. 
There is a need to make counselling and screening more 
accessible to these relatives e.g. through the provision of 
clinics in GP surgeries [ 13]. Patient recall and perception 
of risk after counselling was poor and this suggests the 
need for some reinforcement of the information given as 
this is likely to influence attitudes to screening. 
Conclusions 
This study shows that families with CRC in south -east 
Scotland are generally satisfied with the service 
received. Although many patients did not remember 
or had an inaccurate perception of their level of risk 
up to 6- months after counselling, there was an 
increase in objective understanding and a decrease in 
cancer worry, after counselling. Our results indicate a 
need to target certain groups to educate them about 
the possibility of risk assessment and screening for 
CRC. 
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Appendix 6 
Modified Duke Staging System 
Duke A The tumour penetrates into the mucosa of the bowel wall but no further 
Duke B 
Duke C 
B1: tumour penetrates into, but not through the muscularis propria (the muscular 
layer) of the bowel wall. 
B2: tumour penetrates into and through the muscularis propria of the bowel wall. 
Cl: tumour penetrates into, but not through the muscularis propria of the bowel 
wall; there is pathologic evidence of colon cancer in the lymph nodes. 
C2: tumour penetrates into and through the muscularis propria of the bowel wall; 
there is pathologic evidence of colon cancer in the lymph nodes. 
Duke D The tumour, which has spread beyond the confines of the lymph nodes (to 
organs such as the liver, lung or bone). 
TNM Staging System (Tumour, Node, Metastasis) 
Tumour 
Ti: Tumour invades submucosa. 
T2: Tumour invades muscularis propria 
T3: Tumour invades through the muscularis propria into the subserosa, or into the pericolic 
or perirectal tissues. 
T4: Tumour directly invades other organs or structures, and /or perforates. 
Node 
NO: No regional lymph node metastasis. 
N1: Metastasis in 1 to 3 regional lymph nodes. 
N2: Metastasis in 4 or more regional lymph nodes. 
The corresponding Dukes' classification ofa tumour to the TNM classification. 
TNM Classification (American joint 
commission on cancer) 
Dukes' 
classification 
Stages T N M Stages 
Stage 0 Tis NO MO - 
Stage 1 T1 NO MO A 
T2 NO MO B1 
Stage 11 T3 NO MO B2 
T4 NO MO B2 
Stage 111 T1, T2, N1 or N2 MO Cl 
T3, T4 N1 or N2 MO C2 
Stage 1V Any T Any N M1 D 
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MRC SCOTTISH COLORECTAL CANCER STUDY 
CASE SYMPTOM INTERVIEW 
It is important to us to hear about your symptoms and your experience before your diagnosis. 
Elective Emergency 
Which symptom prompted you to discuss it with your GP? 
FOB Study 
2. Was this the reason you visited your GP? 
2a. 
Yes 
If NO, did it come up in an appointment for another reason? 




What did your GP think about your symptoms on this visit? 
Please mark with an 'X' what the patient feels was the FIRST SYMPTOM to appear First symptom 
(Office use) 
Before you went to your GP / had FOB test / How long did you have symptoms 
or were admitted as an emergency, did you before you discussed with GP? 
have any of the following symptoms: ENTER No. of DAYS ONLY 
4. Change of bowel habit? 
a If YES, frequency? 
b. Increased - no. motions daily? 
c. Decreased - no. days with NO motion? 
d. Consistency? Looser /Harder 
e. Timing? Persistent/Intermittent 
Once Normal habit, per day? 
Rectal Bleeding? 
h. Weight loss? 

















More than twice Other? (Specify) 
Section 4 continued 
Excess wind & bloating? 
Loss of appetite? 
Mucus in stools? 
Tenismus? 
Abdominal discomfort? 
Please specify site 
Before you went to your GP / had FOB test / How long did you have 
or were admitted as an emergency, did you symptoms before you discussed 
have any of the following symptoms: with GP? 
ENTER No. of DAYS ONLY 
'(i) Was it associated with eating? 
iii) Was it every time you ate? 
Pain? 
Please specify site 
(i) Was it associated with eating? 
Iii) Was it every time you ate? 
Any other symptoms? 
Please specify 
Nausea? 
(i) Was it associated with eating? 
'Iii) Was it every time you ate? 
Vomiting? 
(i) Was it associated with eating? 



















Change of bowel habit? 
If YES, frequency? 
After visit to GP & before 
hospital appointment did 
you develop any of these 
symptoms? 
Inc 
Increased - no. motions daily? 
Decreased - no. days with NO motion? 
Consistency? Looser /Harder 
Timing? Persistent/Episodic 
Normal habit, per day? Once 
Rectal Bleeding? 
. Weight loss? 
Loss of energy/ tiredness? 
Excess wind & bloating? 
Loss of appetite? 
Mucus in stools? 
Tenismus? 
n. Abdominal discomfort? 

















(i) Was it associated with eating? 
(ii) Was it every time you ate? 
p. Pain? 
q. Please specify site 
How long didyou have any Did you report your 
new symptoms before new symptoms to 
your hospital appointment? your GP? 
ENTER No. of DAYS ONLY 
N/A 





H Yes No 
I Yes No 






















(i) Was it associated with eating? Yes No Yes No 
(ii) Was it every time you ate? Yes No Yes No 
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After visit to GP & before 
hospital appointment did 
you develop any of these 
symptoms? 
How long didyou have any Did you report your 
new symptoms before new symptoms to 
your hospital appointment? your GP? 
ENTER No. of DAYS ONLY 
Any other symptoms? Yes No Yes No 
Please specify 
Nausea? Yes No Yes No 
(i) Was it associated with eating? Yes No Yes No 
(ii) Was it every time you ate? Yes No Yes No 
Vomiting? Yes No Yes No 
(i) Was it associated with eating? Yes No Yes No 
(ii) Was it every time you ate? Yes No Yes No 
If you had bleeding when going to the toilet, was it? (Tick all that apply) 
Bright red Dark red Mixed in stool 
N/A 
Coating stool I On toilet paper I Large volume 
5a. Did you experience any symptoms in your bottom (anal region)? 
EYES, which of the following? (Tick all that apply) 
Soreness Itching Lumps n Discomfort 
Did you self medicate for any of these symptoms before visiting your GP? 
!!EYES, which symptoms? 
For how long? 
n Yes No 
Pain n Prolapse 
Yes No 
I Before visiting your GP, did you talk to anyone about your symptoms? 
IVES, who did you speak to? 
THERE WERE SYMPTOMS OF ANY KIND FOR 4 WEEKS OR MORE, ASK QUESTION 7 
Yes No 




After telling your GP about your symptoms did you have any of the followg: 
8a. Request for sample of stool? Yes I I No 
If YES, was it tested 
i) For blood? 
ii) For infection? Yes 
iii) Were you given the result? 
Yes I No Don't know 
(I 
No U Don't know 
Yes No 
If you were given the result, what did the GP say to you? 
8b. Rectal examination? 
If YES, what did the GP say ? 
Yes No 
If NO at first visit, did you have a rectal examination from GP at any time before hospital 
appointment? n Yes n No 
Result? 
8c. Abdominal examination? I Yes No 
What did GP say? 
8d. Blood test? Yes No 
If YES, what results were you given? 
How many times did you visit your GP with any of the symptoms before you were referred to the hospital? 
Pi Once 2 or 3 times 4 or 5 times n > 5 times 
No 
IQ. Before your diagnosis, when you went to the toilet did you: 
Look at the contents of the toilet before you flushed it? n Yes 
If YES, how often? 
10a. Every time I I Once a week n Once a month n Sometimes I Never 
10b. Look at the toilet paper? n Yes No 
If YES, how often? 
10c. Every time Once a week n Once a month Sometimes Never 
11. Before your diagnosis, how would you describe your knowledge of bowel (colorectal) cancer symptoms? 
None A little I I Good 
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Very good I I Expert 
Before your diagnosis, did you consider the possibility of having cancer? 
If YES, when did you first think this: (TICK ONLY ONE BOX) 
Before visit to GP? 
After tests? 
On referral to hospital? 
Other? 
If NO, what did you think was wrong? 
Specify 
Yes No 




Would you say you have a family history of cancer? 
Have you ever discussed this with your GP? 
Were you referred to a genetic department? 
In the past two years have you had any other admissions to hospital? ( I Yes I I No 
IfYES, please give details: 
Reason for admission? 
Yes I No I I Don't know 






Please give details 
Reason for admission? 
Mth Yr 
Please give details 
Reason for admission? 
Mth Yr 
Please give details 
Version 1 
27 May 2002 
Did you have surgery? Yes No 
Did you have surgery? n Yes I J No 





Consent to access Medical Records 
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MRC 
Medical Research Council 
MRC Scottish Colorectal Cancer Study 
Consent for Access to Medical Notes 
Name 
Date of Birth 
Address 
Postcode 
I give permission for my medical notes and information from them to be 
released to the Principal Investigators and the research staff of the Scottish 
Colorectal team. 
I also give permission to photocopy all or any reports and /or notes relevant 
to my case, including access to clinical information held on electronic format 
and databases. 
This permission is extended to duration time of the study. My notes may be 
requested on several occasions during this study. 
Signed Date 
study id number: 
MRC Scottish Colorectal Cancer Study 
0017 Consent to access medical notes version 3 
4 February 2002 
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Appendix 12 
Medical Extraction form with Chanson Comorbidity Index 
442 
Medical Record Extraction Form and Comorbidity Index 
Case ID «CaselD» 
1, Is there a referral letter? FOB Study Yes No 
2. If No, date of first letter? 2 0 
3. If Yes, who from? 
4. Type of referral? Routine 
Urgent 
Not indicated 
5. Date of referral letter? 2 






7, Did referral letter or first letter 
indicate diagnosis? 
Yes No 
8. If Yes, what was it? 
9. Admission? Elective 
Emergency 






Please specify, Other (1) 
Other (2) 
L 
MRC Scottish Colorectal Cancer Study 
orliral Rornrrl Fvtrartinn Fnrm t R Marrh ,nnd 
IIF 
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11. Any symptoms indicated on Yes 
referral letter or first letter? 




Intermittent diarrhoea and constipation? 
Weight loss? 
Loss of appetite? 
Mucus in stool? 
Nausea? 
Abdominal pain? 
If Yes, location of abdominal pain 
No N/A On admission 
Diarrhoea? 
Change in bowel habit? 
More frequent stools? 
Loss of energy /tiredness? 
Excess wind and bloating? 
Vomiting? 
Palpable abdominal mass? 
Abdominal discomfort? 











13. Were any tests carried out by GP 
before referral or at open access clinic? 
Yes Don't know 
14. If Yes, what were they? 
15. Date 1st appointment at hospital / / 2 
16. What was the appointment for? 
MRC Scottish Colorectal Cancer Study 
Marlira! Pornrrl Fvtrart-inn Fn rm i fi Marrh 7nna. 
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Abdominal CT scan 




Date of surgery? 
If no surgery, date of pathology? 








20. Earliest Hb recording? (Date) 
21. Result? 
MRC Scottish Colorectal Cancer Study 
MoriIra! I?arnrri Fvtrartinn Fnrm i (+ Marrh 7nnd 
Yes No 
/ 2 0 
/ 2 0 Office use only 
A B C Cl C2 D N/A 
1 
Yes 
2 3 4 
No 
Yes No 
A B C Cl C2 D N/A 





/ / 0 
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Details of other site? 















Local Excision of Rectal Tumour 
Total Mesorectal Excision of Rectum 
MRC Scottish Colorectal Cancer Study 





24. Reason for operation? Curative 
Palliative 
25. Was there anastomotic leak? Yes No Don't know 
26. Was tumour fixed? Yes No Don't know 
27. If Yes, was adjacent organ resectioned? Yes No Don't know 
28. If Yes, which organs? 
29. Comorbidity ASA (Circle) 1 2 3 4 N/A 
30. Date of death if applicable? 2 
MRC Scottish Colorectal Cancer Study 




Case ID «CaseiD» 
Tick box if recorded in notes 























Moderate to severe 
Liver 
Mild 

















MRC Scottish Colorectal Cancer Study 
MArliral Rerryri Fvtrartjnn Form 1 fi Marrh 7nn4 
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Appendix 13 
Satisfaction Study Report 
1 
449 
Assessment ® participants views on consent procedures 
We carried out a cross sectional postal questionnaire survey (questionnaire attached 
on CD) among SOCCS participants from three defined regions. We approached 120 
cases and 117 controls with an invitation to take part. The survey received local 
ethical research committee approval. Responses were received from 157 (66 %) 
participants. A full report is available should this be desired. In summary:- 
Response rates were slightly higher in younger age groups and among participants 
who took part in the SOCCS study in the past 12 months. Otherwise there were no 
statistically significant differences between responders and non -responders. 
Information sheet 
92% thought the detail in the information sheet was "just right "; 5% thought it "too 
detailed" and 3% "not detailed enough" 
91% thought that is was completely clear and easy to understand 
72% found it "very helpful ", 23% "quite helpful" and 5% "not helpful" in helping to 
decide whether to participate. Some (10/42) of those who did not find it very helpful 
noted that this was because they had already decided to take part. 
Many aspects of the information sheet were considered to be important by >90% of 
the respondents. Aspects which seemed least important were: 
Who else is participating (noted by only 45 %) 
Who funded the study (noted by 52 %) 
Consent form (which followed the MRC template and required multiple aspects to be 
consented to individually 
96% of respondents did not find the consent form too complicated. Despite this 84% 
noted that they would have preferred to have given a single general consent to take 
part to all aspects noted in the information sheet and consent form. There was a trend 
for a lower proportion to prefer this option with increasing time since recruitment to 
the study, suggesting that views on this change over time. 
97% felt they had sufficient time to read through the consent form. However, 77% 
would have preferred the consent form to be mailed to them prior to seeing the nurse. 
52% noted that they decided to take part immediately, 27% after a few hours and 21% 
after a day or more. Cases took less time to decide to take part than controls. Younger 
and respondents and those from less deprived areas also took less time to decide to 
take part. 
Role of interview with the research nurse 
77% of respondents felt that this was a necessary part of the consent process. 75 
(63 %) respondents gave reasons for this opinion. The most commonly stated reason 
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was that it aided understanding and gave opportunity to clarify points. Feeling on this 
issue was quite strong, particularly among cases. An illustrative quote is 
"the interview helped me to clarify and reinforce the reasons for the study" 
Reasons for taking part 
The most common categories of reasons were: 
results may improve treatments for future sufferers of bowel cancer 88% 
to contribute towards medical research 79% 
just wanted to help 68% 
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Appendix 14 
Sample Genetic Referral Proforma 
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Family History Ascertainment Form 
To help you ascertain if this patient needs a referral to cancer genetic services. Please 
ask the following questions 
CIRCLE AS APPROPRIATE 
Have you ever had a diagnosis of cancer? YES NO 
Have any of your children ever had a diagnosis of cancer? YES NO 
Have any of your brothers or sisters ever had a diagnosis of cancer? 
YES NO 
Has your mother ever had a diagnosis of cancer? YES NO 
YES NO Has your father ever had a diagnosis of cancer? 
mplete if one or more answers are YES. 







Use reverse for more details 
At least one first -degree relative with colorectal cancer diagnosed under age 45 
Or 
Two relatives with colorectal cancer that are first -degree to each other and one 
diagnosed under age 55. 
Or 
Several relatives with cancer including; colorectal cancer, ovarian or endometrial cancer. 
Or 
Many varied cancers (excluding lung cancer and cervical cancer) 
Patients meeting any one of the above criteria please refer patient to cancer genetics and 
give a leaflet to patient about the cancer genetic services. 
Sent referral to clinical genetics on Date 
Information leaflet on family history and cancer genetic services given 
YES NO 
Please apply patient ID label. 
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Copy should be 
filed in medical 
Appendix 15 
Sample Urgent Referral Proforma for Patients with lower 
gastrointestinal symptoms meeting high -risk criteria 
454 
Urgent referral form for suspected colorectal cancer 
Name 
Address 
Postcode Telephone number 
D.O.B 
I would like this patient of mine to be sent an urgent appointment. 
Mr does /does not meet the criteria for urgent referral. 
Symptom referral guidelines 
Age 
Rectal bleeding WITH a change in bowel habit to looser All ages 
stools and /or increased frequency of defecation persistent 
for 6 weeks 
A definite palpable right -sided abdominal mass. All ages 
A definite palpable rectal (not pelvic) mass All ages 
Rectal bleeding persistently WITHOUT anal symptoms 50 
Change of bowel habit to looser stools and /or increased Over 60yrs 
frequency of defecation, WITHOUT rectal bleeding and 
persistent for six weeks. 
Iron deficiency anaemia WITHOUT an obvious cause 
(Hb < 11 g /dl in men or < 10 g /dl in postmenopausal 
women). 
Circle as appropriate 
I have carried out a rectal examination Yes 
Tick box or 




I have carried out an abdominal examination Yes No 
Findings (including location of mass) 
I have checked Haemoglobin levels Yes No 
Result 
Comments and family history on reverse 
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Yes No 
Pease record reason for patient to be seen URGENTLY, if they do 
nod meet the referral guidelines. 
Please give any further informai lon you feel is necessary for the 
care of this patient. 
Please rec,rd ffamlly history of colorectal cancer in family. Note 
rcelat onsriqp to your patient and age at diagnoss. 
Comments 
GP stamp 
456 
